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Background— Cardiovascular diseases (CVD) remains the leading cause of death globally, with a rising 
prevalence of individual risk factors such as obesity and insulin resistance. Furthermore, diabetic patients 
are particularly at risk for developing ischemic heart disease and strokes. In patient suffering an ischemic 
event, most of the myocardial damage incurred happens once blood flow is restored – a phenomena known 
as reperfusion injury. Mitochondrial ROS production is implicated as one of the major contributors to cell 
death in the reperfused heart and the importance of mitophagic processes (mitochondrial housekeeping) 
could be a potential therapeutic target to prevent ischemia/reperfusion injury (I/R-I). Aspalathus linearis 
(commonly known as rooibos) is an indigenous South African plant grown exclusively in the Western Cape 
fynbos region. Rooibos is rich in bioactive phenolic compounds, including aspalathin, a C-linked 
dihydrochalcone glucoside unique to rooibos, known for its hypoglycemic and strong antioxidant potential.  
Methods— The present study made use of 300 Wistar rats randomly allocated into controls and rats 
receiving a 16-week high-fat, high-caloric diet (HCD). After 10 weeks on the respective diets, half of each 
group received 60 mg/kg/day Afriplex green rooibos extract (GRT), containing 12% aspalathin, for 6 weeks. 
The primary aim was to investigate its therapeutic potential in treating 20 min global ischemia/reperfusion 
injury (I/R-I) in rats with increased susceptibility for CVD, as well as determine the mitochondrial oxidative 
phosphorylation (OxPhos) during four stages of I/R-I. The secondary aim was to elucidate GRT’s effect on 
cardiac signaling and mitophagy with regards to I/R-I.  
Results—  HCD over 16 weeks resulted in daily increased food intake (22.30±1.27 g vs 18.00±0.54 g = ↑24%; 
p<0.001), decreased daily water intake (19.55±0.58 mL vs 29.74±0.74 mL = ↓34%; p<0.001), leading to 
increased body weight (403.9±5.1 vs373.6±4.8 g = ↑8%; p<0.001) and increased intraperitoneal fat 
(23.69±0.89 vs 13.98±0.43 g = ↑69%; p<0.001) compared to age-matched controls. Furthermore, HCD 
increased fasting blood glucose (5.75±0.16 vs 5.21±0.16 mM = ↑10%; p<0.05), fasting blood insulin (6.20±0.57 
vs 4.31±0.54 ng/mL = ↑44%; p<0.05) and insulin resistance through raised HOMA-IR (3.52±0.35 vs 2.30±0.28 
= ↑53%; p<0.05) compared to age-matched controls. GRT supplementation for 6 weeks had no significant 
effect on biometric parameters in either controls or HCD. Pre-ischemia, HCD rats presented with worse 
functional heart parameters, such as diastolic and systolic pressure, aortic output (AO), cardiac output (CO) 
and total work (WT) (10.69±0.14 vs 12.6±0.19 mW = ↓15%; p<0.001) compared to controls, while GRT 
supplementation was able to significantly improve these parameters in both controls (13.91±0.23 mW = ↑10%; 
p<0.001) and HCD (11.98±0.20 mW = ↑12%; p<0.001). GRT administration also lowered the heart rate during 
stabilization in both control and HCD by an average 10 bpms (p<0.05). Post-ischemia, HCD hearts were 
weaker than controls and had a lower WT recovery (55.51±2.28 vs 64.8±2.04% = ↓14%; p<0.01), while GRT 
restored WT recovery in HCD (63.35±2.49% = ↑14%; p<0.05). HCD rats also had a greater infarct size 
compared to controls (34.99±11.56 vs 16.42±8.71% = ↑113%; p<0.01) following a 35 min regional ischemia 
protocol. GRT supplementation led to a remarkable reduction in infarct size (13.22±6.66% = ↓62%; p<0.001), 
while conferring no added protection to controls (14.58±5.43%). Regarding cardiac and mitochondrial 
signaling, prior to ischemia HCD heart had a decreased dependence on insulin-dependent AMPK and 
increased inflammation via upregulated p38, whereas GRT treatment presented with decreased insulin-
dependent PKB and AS160 signaling (together with increased FA OxPhos compared to carbohydrates, 
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however showed more mitochondrial uncoupling, decreasing basal metabolic rate and thereby potentially less 
ROS production), inhibited GSK3β and conferred an anti-inflammatory effect by significantly reducing p38 
activation. HCD also had higher mitophagy rates through Parkin and LC3 signaling. After 20 min ischemia, in 
HCD, ATM and AMPK were upregulated and insulin-dependent PKB downregulated with GSK3β. Mitophagy 
signals, such as PINK1 and p62 were elevated, but autophagic flux remained low during ischemia in all groups. 
GRT supplementation resulted in an opposite profile with AMPK downregulated and showing inhibition of 
ERK1/2. In early reperfusion, all protective signaling were downregulated in HCD including AMPK, PKB, 
AS160, GSK3b and ATM. Mitophagy was also activated through Parkin, p62 and LC3 while having increased 
OxPhos potential in FA compared to carbohydrates. GRT supplementation reduced oxidative stress and 
inflammation through downregulation of JNK1/2 and p38, and initiated mitophagy through an AMPK-
dependent mechanism and Parkin. GRT supplementation also inhibited mitochondrial OxPhos after 
reperfusion culminating in a potentially decreased ROS production.  
Conclusion— This study showed the cardioprotective effect of Afriplex GRT supplementation by improving 
functional heart recovery and reducing infarct size post-ischemia in rats with elevated risk for CVD. Another 
novel find is the reduction in heart rate induced by GRT treatment through inhibition of pacemaking cells. This 
could have potential therapeutic application in patients suffering from ischemic heart disease. GRT ilicits a 
cardiotonic effect in I/R-I through anti-inflammatory mechanisms pre- and post-ischemia. In early reperfusion, 
GRT treatment resulted in decreased oxidative stress, inhibition of mitochondrial OxPhos and enabled AMPK-
dependent mitophagy. GRT shows promise as a strong antioxidant and anti-inflammatory agent in managing 
adverse outcomes in patients at risk for CVD.  
 
  





Agtergrond- Kardiovaskulêre siektes (CVD) is steeds die wêreld se nommer een oorsaak van sterftes. Die 
teenwoordigheid hiervan kan grotendeels toegeskryf word aan ‘n toenemende voorkoms van individuele 
risikofaktore, insluitende vetsug en insulienweerstandigheid. Verder, diabetiese pasiënte in besonder dra 
hoë risiko vir die ontwikkeling van iskemiese hartsiektes en beroertes. In pasiënte wat 'n iskemiese 
gebeurtenis ly, word die meeste van die myokardiale skade eers opgedoen wanneer bloedvloei herstel word 
- 'n verskynsel bekend as reperfusiebesering. Mitochondriale reaktiewe oksidant spesie (ROS)-produksie 
word geïmpliseer as een van die belangrikste bydraers tot seldood tydens reperfusie en die belangrikheid 
van mitofagiese prosesse (mitochondriale huishouding) kan 'n potensiële terapeutiese doelwit dien in 
voorkoming van iskemie/reperfusiebesering (I/R-I). Aspalathus linearis (algemeen bekend as rooibos) is 'n 
inheemse Suid-Afrikaanse plant wat uitsluitlik in die Wes-Kaapse fynbosstreek gegroei word. Rooibos is ryk 
aan bioaktiewe fenoliese verbindings, insluitende aspalatien, 'n C-gekoppelde dihidrochalcoon-glukosied, 
uniek aan rooibos, en bekend vir sy sterk anti-inflammatoriese antioksidant en vermoë om bloedsuiker te 
verlaag. 
Metodes- In die teenwoordigende studie het ons gebruik gemaak van 300 Wistar-rotte wat lukraak verdeel is 
in ‘n 16-week hoë-vet, hoë-kalorie-dieet (HCD) groep, en ‘n ouderdom-gekontroleerde beheergroep wat 
slegs standard rotkos ontvang het. Na 10 weke op die onderskeie diëte het die helfte van elke groep vir 6 
weke 60 mg / kg / dag Afriplex Green Rooibos Extract (GRT), wat 12% aspalatien bevat, ontvang. Die 
primêre doel was om die terapeutiese potensiaal as behandeling van 20 min globale ischemie / 
reperfusiebesering (I /R-I) te ondersoek in rotte met verhoogde vatbaarheid vir KVS, asook om die 
mitochondriale oksidatiewe fosforilering (OxPhos) tydens vier stadiums van I/R-I te bepaal. Die sekondêre 
doelwit was om GRT se effek op hart seintransduksie en mitofagie met betrekking tot I/R-I te verduidelik. 
Resultate-HCD administrasie, teenoor kontrole dieet, vir 16 weke het gelei tot verhoogde daaglikse 
voedselinname (22,30±1,27 g teenoor 18,00±0,54 g = ↑ 24%; p<0.001) en verhoogde daaglikse 
waterinname (19.55±0.58 mL vs 29.74±0.74 mL = ↓ 34%; p<0.001) wat gelei het tot verhoogde 
liggaamsgewig (403.9±5.1 vs 373.6±4.8g = ↑ 8%; p<0.001) en verhoogde intraperitoneale vet (23.69±0.89 
teenoor 13.98±0.43g = ↑ 69%; p<0.001). Daarbenewens het HCD ook verhoogde vastende bloedglukose 
(5.75±0.16 vs 5.21±0.16 mM = ↑10%; p<0.05), vastende bloedinsulien (6.20±0.57 vs 4.31±0.54 ng / mL = 
↑44%; p<0.05) en insulienweerstandigheid deur verhoogde HOMA-IR (3.52±0.35 vs 2.30± 0.28 = ↑53%; 
p<0.05) in vergelyking met ouderdom-gekontroleerde kontrole groepe. GRT-aanvulling vir 6 weke het geen 
beduidende effek gehad op biometriese parameters in beide die kontroles en HCD nie. Tydens stabilisering 
van die geïsoleerde harte, het dié van HCD-rotte verswakkende funksionele hartparameters getoon, soos 
diastoliese en sistoliese druk, aorta-uitset (AO), hartuitset (CO) en totale werk (WT) (10.69±0.14 teenoor 
12.6±0.19 mW = ↓15%; p<0.001) in vergelyking met kontroles, terwyl GRT-aanvulling hierdie parameters 
aansienlik kon verbeter in beide kontroles (13.91±0.23 mW = ↑10%; p<0.001) en HCD (11.98±0.20 mW = 
↑12%; p<0.001). GRT-administrasie het ook die hartklop verlaag tydens stabilisering met 'n gemiddelde 10 
hartkloppens per minuut in beide beheer en HCD groepe (p<0.05). Tydens reperfusie het HCD harte 
swakker gevaar as kontroles met 'n verlaagde WT herstelling (55.51±2.28 teenoor 64.8±2.04% = ↓14%; 
p<0.01), terwyl GRT WT kon herstel in HCD (63.35±2.49% = ↑14%; p<0.05). HCD-rotte het ook groter 
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infarkt-groottes gehad in vergelyking met beheer groepe (34,99±11,56 teenoor 16,42±8,71% = ↑113%; 
p<0.01) na aanleiding van 'n 35 min streeks-ischemie protokol. GRT-aanvulling het gelei tot 'n merkwaardige 
vermindering in infarkt-grootte (13.22±6.66% = ↓62%; p<0.001), terwyl dit geen ekstra beskerming aan 
kontroles verleen het nie (14.58±5,43%). Met betrekking tot die hart- en mitochondriale seintransduksie het 
die HCD-hart 'n afname in afhanklikheid van insulien-afhanklike AMPK en toename van inflammasie via 
opgereguleerde p38 getoon. GRT-behandeling het ‘n beduidende verlaging van insulien-afhanklike PKB- en 
AS160-sein geïnduseer (saam met verhoogde vetsuur teenoor koolhidraat oksidatiewe fosforilasie (OxPhos) 
vertoning, maar terselfdertyd verhoogde mitochondriale ontkoppeling wat gevolglik ‘n stadiger basale 
metaboliese tempo tot volg het en moontlik minder reaktiewe oksidante spesie (ROS)-produseer). GRT-
behandeling het ook GSK3β geïnhibeer en 'n anti-inflammatoriese effek toegedien deur die p38-aktivering 
aansienlik te verminder. HCD het ook hoër mitofagiese prosesse getoon deur Parkin- en LC3-seine te 
opreguleer. Na 20 min van iskemie in HCD harte is ATM en AMPK opgereguleer en insulien-afhanklike PKB 
is afgereguleer saam met GSK3β. Mitofagiese seine, soos PINK1 en P62, was verhef, maar autofagie as ‘n 
geheel was laag gedurende ischemie in alle groepe. GRT aanvulling het gelei tot 'n teenoorgestelde profiel 
met ‘n afname in AMPK aktivering asook inhibisie van ERK1/2. Tydens vroeë reperfusie is alle beskermende 
seinwerk in HCD afgestel, insluitende AMPK, PKB, AS160, GSK3β en ATM. Mitofagie is ook geaktiveer deur 
Parkin, P62 en LC3, terwyl OxPhos potensiaal toegeneem het in vetsure in vergelyking met koolhidrate. 
GRT-aanvulling het verder oksidatiewe stres en inflammasie verminder deur JNK1/2 en p38 af te reguleer, 
en verhoging in mitofagie teweeg gebring deur middel van 'n AMPK-afhanklike meganisme en Parkin. GRT-
aanvulling het ook mitochondriale OxPhos geïnhibeer na reperfusie wat 'n potensiële verlaagde ROS-
produksie tot volg gehad het. 
Gevolgtrekking - Hierdie studie het die hartbeskermende effek van Afriplex GRT-aanvulling getoon deur die 
verbetering van funksionele hartherstel en die vermindering van infarkt-grootte na ‘n ischemiese episode uit 
te wys in pre-diabetiese rotte met verhoogde risiko vir CVD. Nog 'n nuwe bevinding is die verlaging in 
hartklop geïnduseer deur GRT behandeling deur inhibisie van pasaangee selle en kan potensiële 
terapeutiese toediening hê by pasiënte wat aan iskemiese hartsiektes ly. GRT gee 'n kardiotoniese effek in 
I/R-I deur middel van anti-inflammatoriese meganismes voor- en na-ischemie. In vroeë reperfusie het GRT-
behandeling gelei tot verminderde oksidatiewe stres, inhibisie van mitochondriese OxPhos en AMPK-
afhanklike mitofagie. GRT toon belowende effekte as 'n sterk antioksidant en anti-inflammatoriese middel in 









Holy Bible : New Living Translation 
1 Corinthians 13:1 - 13 
Love Is the Greatest 
“1If I could speak all the languages of earth and of angels, but didn’t love others, I would only be a noisy 
gong or a clanging cymbal. 2 If I had the gift of prophecy, and if I understood all of God’s secret plans and 
possessed all knowledge, and if I had such faith that I could move mountains, but didn’t love others, I 
would be nothing. 3 If I gave everything I have to the poor and even sacrificed my body, I could boast about 
it; but if I didn’t love others, I would have gained nothing. 
4 Love is patient and kind. Love is not jealous or boastful or proud 5 or rude. It does not demand its own way. 
It is not irritable, and it keeps no record of being wronged. 6 It does not rejoice about injustice but rejoices 
whenever the truth wins out. 7 Love never gives up, never loses faith, is always hopeful, and endures through 
every circumstance. 
8 Prophecy and speaking in unknown languages and special knowledge will become useless. But love will 
last forever! 9 Now our knowledge is partial and incomplete, and even the gift of prophecy reveals only 
part of the whole picture! 10 But when the time of perfection comes, these partial things will become 
useless. 
11 When I was a child, I spoke and thought and reasoned as a child. But when I grew up, I put away childish 
things. 12 Now we see things imperfectly, like puzzling reflections in a mirror, but then we will see everything 
with perfect clarity. All that I know now is partial and incomplete, but then I will know everything 
completely, just as God now knows me completely. 
13 Three things will last forever—faith, hope, and love—and the greatest of these is love.” 
- Paul, the Apostle of Jesus Christ 
 
My thanks be to God for blessing me with opportunity to study, to advance my career, to enquire into things 
I’m curious about, to grant me with favour so I can focus on completing the task at hand - all while I’m 
searching for my place in the Kingdom and learning to submit to His Will. My God is an awesome God. His 
Name is Jesus. He is Worthy of All Praise! And I will sing of His Love Forever. Amen!! Thank you, Jesus, for 
saving me from my brokenness and my addictions. And for filling me with life!! That I may testify of Your 
Name. I pray that whoever read this, may they know that in my own strength this thesis would’ve been 
incoherent scribbles and half a completed diagram. When I had 2 months to go, a Literature Review to finish 
writing, a conference to attend abroad, and an ENTIRE results and discussion section to complete – God 
took my hand, slapped the cigarettes and alcohol and grass out of my hand, and taught me how to 
persevere to finish a job. God is Good. And He is open to show anyone who seek Him how much He loves 
you. He is in the game of miracles and He WILL meet you at your expectation! Therefore, ALL the Thanks 
and Praise be to YOU, Jesus!  
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“The Heartfelt Truth” 
Cardiovascular diseases (CVD) are the leading cause of death worldwide, constituting 31% of all annual global 
deaths (17.7 million people) (“WHO | Cardiovascular diseases”, 2018). The two major contributing factors are 
obesity (excessive energy storage) and insulin resistance (reduced glucose clearance). Under normal 
physiological conditions, the heart’s contractile function enables circulation of nutrient rich blood through the 
arteries and veins of the entire body. The heart also relies on these nutrients, including glucose and free fatty 
acids (FFA), as energy substrates for its contracting cardiomyocytes. The rate at which nutrients are 
transported into all cells and used as substrates is primarily dependent on the action of the hormone, insulin. 
Insulin induces anabolic processes through activating energy consumption, while simultaneously 
counterbalancing blood glucose levels. However, in diseased conditions, such as type 2 diabetes (T2D), 
various complications start to arise hindering the heart’s performance. Ineffective clearing of blood glucose, 
primes the pancreas to increase insulin production in order to compensate for elevated blood glucose levels, 
and when this state progresses, insulin receptors become so desensitized that the pancreas cannot maintain 
sufficient insulin levels (Shanik et al., 2008). The effect of a decreased potential to effectively utilize insulin in 
peripheral insulin sensitive organs, such as the muscle, heart, fat and liver, and is collectively known as insulin 
resistance (InsR). According to Kannel and McGee (1979), a prolonged insulin desensitized state leads to a 
4-fold increase for the risk of developing ischemic heart disease (IHD), also known as coronary heart disease, 
and strokes. Furthermore, as a direct consequence of obesity, or excess fat mass, higher levels of circulating 
FFA and cholesterol are also present in the blood potentially resulting in a plaque build-up inside arteries, and 
thereby narrowing or completely blocking blood flow (Kwan et al., 2014). Understandably, the slightest 
reduction in blood flow to the heart is severely detrimental to the heart’s function. Therefore, effective 
cardioprotective therapies remains one of the most clinically relevant research fields in cardiology today 
(Fuster, 2014). 
 
1.2 THE HEART 
“The Conductor” 
1.2.1 Overview of the Heart 
The heart is the conductor of all human beings. It sets the tempo for the entire circulatory system, transporting 
nutrients, oxygen (O2), waste, heat, hormones, and immune cells throughout the body – over, and over. The 
heart beats an average 100,000 times per day, pumping 10,000 liters of blood through 95,000 km of veins and 
arteries (Raff, 2003; Watson, 2009). It is as big as a human fist and constitute only 0.5% of our entire body 
weight, averaging 280 g in men and 230 g in women (“The Normal Size of the Heart Muscle Weight”, 1951). 
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From a mechanical point of view, the heart’s only function is to maintain blood pressure. This is achieved by 
generating high hydrostatic pressure to pump blood out of the heart, while also creating low pressure to bring 
it back. This gradient of force is known as blood pressure, also defined as the amount of strain put on the 
arteries by flowing blood. The amount of blood circulated per minute can be increased as much as 6-fold during 
exercise (Baggish & Wood, 2011), and heart rate can range from 40 beats per minute (bpm) at rest to more 
than 200 bpm (Uusitalo et al., 1998) depending on genetics and age (Jose & Collison, 1970).  
Even though regular exercise is strongly associated with good health, it does not exclude cardiovascular 
complications, as is evident from pro-athletic patients with CVD, stemming from various structural and 
functional heart abnormalities (Baggish & Wood, 2011). Furthermore, overexertion can lead to an overload of 
cardiovascular pressure and increased blood volume which can result in acute heart failure, or trigger a pre-
existing heart condition (Carbone et al., 2017).  
 
Interestingly, heart cells can regenerate, albeit at a renewal rate of 1% of all heart cells per year from age 20, 
declining to as little as 0.3% by age 75 - effectively equating to less than 50% turnover of heart cells during an 
entire lifespan (Bergmann et al., 2009). Understandably, any damage inflicted to this organ, albeit via damage 
to the heart’s chambers, veins or valves, or in the circulatory system via occlusions, constrictions, or loss of 
blood, forces the system to overcompensate to maintain the body’s functional demand for nutrient rich blood. 
Once all else fails, heart transplantation remains the final therapeutic option for heart failure (Wilhelm, 2015), 
with the latest available global statistics in 2008 indicating 5,400 heart transplants performed annually (“WHO 
| GKT1  Activity and Practices”, 2013).  
 
1.3 OBESITY 
“Energy can never be created or destroyed – it only changes form”. 
1.3.1 Overview of Obesity 
The human body constitutes the same materials found in food, albeit in different proportions according to 
genetics and lifestyle choices. The average healthy lean man comprises of 62% water, 16% fat, 16% protein, 
6% minerals and less than 1% carbohydrate, with women having 6% more fat and slightly less of the rest 
(Carpenter et al., 2018). A body fat percentage of at least 3-5% in men and 12-15% in women is considered 
essential for healthy functioning (Kang, 2012). In particular, stored adipose tissue play a significant role during 
pregnancy and facilitates the regulation of hormones (Kotecki, 2011). Excess fat not only serve as extra energy 
storage but can also protect internal organs from impact trauma and help regulate body temperature through 
heat generation in response to cold and overfeeding (Stanford et al., 2012). Furthermore, adipose tissue is 
also a metabolically active endocrine organ and produces biologically active substances, including pro-
inflammatory cytokines, angiotensin II, leptin, resistin and adiponectin (Kershaw & Flier, 2004).  
 
Obesity and overweight are defined as abnormal or excessive fat accumulation that presents a risk to health 
(“WHO | Obesity”, 2014). These two related conditions can severely alter metabolism and contribute to a 
cluster of pathophysiological conditions, collectively called the metabolic syndrome (Grundy, 2004). 
Furthermore, as obesity increases, the risk for IHD, ischemic stroke, T2D and cancer also rise (Chamie et al., 
2013; Eckel, 1997; Saboor Aftab et al., 2014).  
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1.3.2 Cause of Obesity 
The law of conservation of energy states that energy can never be created or destroyed – it can only change 
forms. The process of metabolism involves the conversion of energy, either through catabolism (breaking down 
molecules and releasing energy), or anabolism (constructing new molecules and consuming energy). All the 
energy from foods consumed will either be released or stored within the body. Maintaining a healthy body 
weight range is subject to balancing energy intake (consumption of food and O2) and energy output (dissipation 
through body heat, motility and energy storage). The basal metabolic rate, defined as the energy required in a 
resting condition, accounts for 60-70% of total energy expenditure in most individuals (Merghani et al., 2015). 
Persistently consuming more calories (energy) than your daily metabolic demand results in excess fat storage 
contributing to body weight gain and eventually obesity (Heymsfield et al., 2002). Baseline metabolism rate 
also decreases with age, gender (women < men), ethnicity and increased free fat mass (obese < non-obese) 
further complicating the obesity epidemic (Mcmurray et al., 2015). Moreover, lower consumption of O2, through 
not partaking in regular aerobic exercise, also leads to a decrease in basal metabolic rate (Mcmurray et al., 
2015). Broadly speaking, factors that contribute to the obesity epidemic encompass a decrease in physical 
activity, unhealthy diet, lack of sleep, as well as certain medical conditions, such as pregnancy and medications 
with known lipid dystrophy side-effects. 
1.3.3 Assessment 
Health experts use body mass index (BMI) together with body proportions and percentage body fat to classify 
obesity. BMI is a crude calculation through which a person’s weight (in kg) is divided by the square of their 
height (in meters) (Global Diabetes Community, 2015). A BMI between 25 and 30 kg/m2 is considered 
overweight, whereas a BMI of above 30 kg/m2 is classified as obese (Figure 1.1). 
  
 
Figure 1.1 Body mass index classification according to metric height and weight. Obtained from Global 
Diabetes Community (2015). 
 
However, BMI cannot discriminate between fat and lean body mass (muscles, bones, organs and blood) and 
is therefore unreliable in diagnosing obesity in young people, pregnant women and muscular patients. 
Additionally, the following measures can be implemented:  
• waist circumference (circumference of natural waist) 
• waist-to-hip ratio (waist circumference divided by hip circumference) (Noble, 2001) 
• skinfold thickness (measure subcutaneous fat using calipers) (Gray et al., 1990) 
• underwater weighing (body density measurement) (Kotecki, 2011) 
• bio-electrical impedance (total body fat resistance measured by electrical current) (Gray et al., 1990). 
BMI (kg/m2) Weight Status 
Below 18.5 Underweight 
18.5-24.9 Normal 
25.0-29.9 Overweight 
30.0-34.9 Obese (Class I) 
35.0-39.9 Obese (Class II) 
40.0+ Morbidly Obese (Class III) 
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• dual energy X-ray absorptiometry (DEXA) (measure fat-free mass, fat mass and bone mineral density) 
• computerized tomography (CT) (cross-sectional and three-dimensional imaging of internal organs and 
structures)  
• magnetic resonance imaging (MRI) (construct three-dimensional image of entire body composition) 
(Hu, 2008). 
To date, the most accurate assessment of body composition is given by DEXA and Rapid-MRI scans (Borga 
et al., 2018). 
1.3.4 Epidemiology 
Annually, 2.8 million people die as a consequence of being overweight or obese (“WHO | Obesity”, 2015). 
Even though being underweight places you at a higher risk for early death (Anjana et al., 2018), obesity is still 
associated with a higher prevalence of deaths world-wide. In 2016, 1.9 billion (39%) adults over the age of 18 
were overweight, and an estimated 650 million (13%) were obese (“WHO | Obesity and overweight”, 2018), of 
which 11% were male and 15% female (Figure 1.2). Furthermore, the prevalence of obesity has nearly tripled 
over the past 40 years.  
1.3.4.1 Children and Adolescents 
Annually, more children and adolescents are becoming obese. The global prevalence of overweight and obese 
infants and young children (0 to 5 years old) has increased from 32 million to 41 million between 1990 and 
2016 (“WHO | Obesity and overweight”, 2018). In developing African nations, the prevalence of overweight 
and obesity in young children have doubled, from 4 million to 9 million children. In developed countries, 
childhood obesity (6 – 11 years old) increased from 7% to 18% between 1980 and 2012, while adolescent 
obesity (12 – 19 years old) also increased from 5% to 21% in this period. According to literature, an estimated 
third of American children and adolescents are overweight or obese (Ogden et al., 2014). No current data 
exists for the developing world, but regardless, without therapeutic intervention, obesity will likely proceed into 
childhood, adolescence and adulthood.  
1.3.4.2 Socio-economic Status 
In a study done by Pampel and colleagues (2012) they found that a country’s socio-economic status influences 
the prevalence of obesity. They found that the higher the country’s income level, the higher the prevalence of 
raised BMI’s. Higher income countries had an overweight prevalence of more than double that of lower income 
countries. For obesity, the prevalence more than triples from 7% obesity in low-income countries to 24% in 
high-income countries. Obesity was also twice as prevalent in women in low-income countries compared to 
men, whereas it was similar in high-income countries.  
 
Furthermore, an increase in overweight individuals negatively impact the overall health of a country as these 
individuals present with chronic conditions and are more prone to premature death. This trend is also becoming 
more prominent in the developing countries (Popkin, 2009). Socio-economic development results in better 
health management, but at the same time also results in new problems such as the gradual replacement of 
malnutrition with overconsumption (Pampel et al., 2012). Arguably, the group to be most severely impacted by 
this growing trend of obesity, will be those least financially advantaged.  
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Figure 1.2 Global prevalence of obesity and overweight in male and female populations. Note that Polynesian countries have similar prevalence of overweight 
and obesity in males and females. 
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1.4 INSULIN RESISTANCE 
“Use it or Lose it” 
1.4.1 Overview of Insulin Resistance 
Insulin resistance (InsR) describes a state of decreased insulin sensitivity experienced by insulin-hardened 
tissue – effectively resulting in poorer glucose utilization (Beale, 2013). As a result, glucose accumulates in 
the blood instead of being taken up by the muscles, fat and liver. Chronic hyperglycemia  would result in 
augmented insulin production by the pancreatic β-cells to increase glucose clearance (Leibiger et al., 2008). 
However, this progresses to hyperinsulinemia and the inability of insulin to decrease high circulating blood 
glucose  (DeFronzo & Tripathy, 2009). Thus, hyperinsulinemia is both a response and a contributor to InsR 
(Cavaghan et al., 2000a). When left untreated, prolonged InsR can overburden β-cells and result in T2D and 
increase the risk for CVD (Cavaghan et al., 2000b).  
1.4.2 Overview of Insulin 
Insulin is a peptide hormone that plays a crucial role in tissue development, growth and maintaining energy 
homeostasis (Sesti, 2006). Insulin is produced within the pancreatic β-cells and housed in mature secretory 
granules. After consuming a meal, blood glucose spikes, which stimulates the release of insulin into the 
systemic circulation. Insulin secretion can also be induced by various other factors, ranging from amino acids 
(such as leucine and arginine) and lipids (non-esterified fatty acids (FA)) (Fu et al., 2013) to gastrointestinal 
hormones called incretins (Baggio & Drucker, 2007) and other hormones (growth hormone, glucagon, secretin, 
cholecystokinin, gastrin, vasoactive intestinal peptide (VIP), gastrin-releasing peptide) (Wilcox, 2005), as well 
as in response to vagal nerve stimulation (Ahrén & Taborsky, 1986). 
• Insulin Function 
Insulin plays a multifunctional role within the body, eliciting a specific response for each organ or tissue target 
(Benito, 2011). Primarily, it facilitates the absorption of glucose into muscle, fat and liver cells, through 
promoting glucose transporter 4/2 (GLUT4/2) translocation from an intracellular reservoir compartment to the 
plasma membrane (Bertrand et al., 2008) lowering blood glucose levels (Wilcox, 2005). Alternatively, it aids in 
the conversion of glucose to glycogen (glycogenesis) in muscle tissues and liver, and also prevents the 
production of endogenous glucose (gluconegogenesis) within the liver (Bazotte et al., 2014). All three of these 
mechanisms result in lowered blood glucose. Other than glucose, insulin also influences lipid metabolism by 
regulating lipid synthesis in liver cells and adipocytes and inhibiting the breakdown of FA in adipose tissue 
(Sesti, 2006). In the heart, insulin is mainly responsible for substrate utilization but can furthermore augment 
cardiomyocyte contraction, influence myocardial relaxation, promote angiogenesis and cell survival, 
downregulate apoptosis, enhance myocardial microcirculation and reduce coronary artery resistance, which 
improves blood perfusion of the myocardium (Iliadis et al., 2011). 
1.4.3 Assessment 
InsR can be assessed by either measuring the blood insulin levels or the blood glucose response to insulin 
(Bray & Hamman, 2015). The first test, known as a hyperglycemic clamp, requires keeping blood glucose 
levels constantly elevated through hyperinfusion of glucose and measuring the response of pancreatic β-cells 
to produce insulin. The second test, known as an euglycemic clamp, consists of intravenously infusing high 
levels of insulin into a patient’s blood, while simultaneously measuring the fluctuating blood glucose levels for 
up to 24 h  (Heise et al., 2016). The euglycemic clamp is the gold standard in human trials and 
pharmacodynamic studies of drug interactions in diabetes patients (Bray & Hamman, 2015). However, the test 
is too costly and impractical to be used for clinical assessment of diabetes pathology. Rather, blood tests such 
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as fasting lipograms and glycohemoglobin tests are performed to determine the likely presence of insulin 
resistance, a strong indicator for prediabetes.  
1.4.3.1 Fasting Plasma Glucose Test 
Measuring fasting blood glucose in people who have not eaten for at least 8 h, can serve as a strong indicator 
of prediabetes (Jeon et al., 2013). Normal fasting blood sugar is considered between 2.8-5.6 mmol/L (50 and 
100mg/dL), whereas 5.6-6.9 mmol/L (100 and 125 mg/dL) is indicative of prediabetes - known as impaired 
fasting glucose – and a fasting blood glucose exceeding 7 mmol/L (126 mg/dl) is considered diabetic (Mayo 
Foundation for Medical Education and Research, 2018). The test is most reliable when performed in the 
morning hours following sleeping and fasting. In a study done by a Chinese group led by Wang and colleauges 
(2010) they analysed the fasting blood glucose of 500 Wistar rats, specifically comparing the method (glucose 
oxidation method vs glucose strips), fasting vs non-fasting blood glucose, the site of blood glucose collection 
and the duration of fasting (5h vs 11h). They found that the rats averaged fasting 3.95 mmol/L vs 5.65 mmol/L 
non-fasting, the difference between 5h vs 11h was 0.8 mmol/L and blood glucose taken from the abdominal 
aorta was up to 40% higher than in the tail. Furthermore, they found the glucose oxidation method to be more 
reliable, whereas glucose strips potentially show erroneous readings, which need to be double-checked when 
suspicious readings are monitored. In conclusion, they found that the criteria for using blood glucose as 
indicator for diabetes in rats are similar to that of humans. 
1.4.3.2 Oral Glucose Tolerance Test 
Similar to the fasting plasma glucose test, the oral glucose tolerance test (OGTT) also entails 8 h of fasting, 
but additionally, at the start of the test, a person receives glucose bolus to consume, succeeded by follow-up 
blood glucose tests to determine how quickly the blood glucose is cleared (Bray & Hamman, 2015). 
Traditionally, prediabetes have been diagnosed in patients showing impaired glucose tolerance after a 2h 
OGTT (American Diabetes Association, 2014). However, prediabetes does not always result in T2D, and 
similarly, people without prediabetes can also spontaneously develop T2D (Unwin et al., 2002). As such, it has 
been shown that blood glucose levels 1h post OGTT can be a stronger indicator of future diabetic complications 
and mortality (Pareek et al., 2018). 
1.4.3.3 Lipograms 
Various components of the lipogram is linked to InsR and consequent CVD risk, however they are not always 
well understood (Bertsch & Merchant, 2015). For instance, a high triglyceride to high-density lipoprotein 
cholesterol (HDL-C) ratio greater than 3.0 has been correlated to 64% sensitivity for InsR and 68% specificity 
for InsR compared to euglycemic clamp established InsR (McLaughlin et al., 2003). On the contrary, it used 
to be postulated for over half a century that high concentrations of low-density lipoprotein cholesterol (LDL-C) 
was associated with CVD (Ravnskov et al., 2018). However, this statement has only recently been deemed 
incorrect and was verified in a study done by Bertsch & Merchant (2015) who found no corrolation between 
CVD risk and LDL-C levels in an 8-year follow-up of 103,646 non-CVD and non-T2D members between the 
age of 50 to 75 years old. 
1.4.3.4 Hemoglobin A1c 
Hemoglobin A1c (HbA1c), or glycohemoglobin, is used as an indicator of average blood glucose over the past 
3 months (Nam et al., 2018). The test is based on binding of glucose to hemoglobin, the O2 -carrier protein 
present in red blood cells, which typically have a lifespan of 3 months. The percentage of bound HbA1c can 
be used to determine a person’s diabetic status. A percentage between 5.7 and 6.4 is considered prediabetic. 
It is the most reliable test to date, but not always the most sensitive to recent developments in prediabetes and 
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diagnosing prediabetes in people of African, Mediterranean or Southeast Asian descent, as well as people 
having a known familial history of sickle cell anemia, due to possessing a hemoglobin variant that interferes 
with the results of the HbA1c test.  
1.4.4 Insulin-resistant Conditions 
1.4.4.1 Metabolic Syndrome 
Metabolic syndrome (or insulin resistance syndrome) is defined as a range of characteristics prevalent in 
overweight and obese individuals resulting in increased CVD and T2D prevalence, and all-cause mortality 
(Kaur, 2014). These conditions include at least 3 of the following:  
• large waist size (≥102 cm for men, ≥89 cm for women)  
• elevated blood triglycerides (≥150 mg/dL) 
• abnormal blood cholesterol (HDL cholesterol of ≤40 mg/dL for men or ≤50 mg/dL for women)  
• high blood pressure (≥130/85)  
• high blood glucose levels (fasting blood glucose level ≥100 mg/dL or ≥5.6 mmol/L)  
 
Although many of these abnormalities can also occur in non-InsR subjects (McLaughlin et al., 2004), they are 
closely related to obesity (Cornier et al., 2008) and are strongly associated with increased risk for cardiac 
diseases and lowered life expectancy (Vella et al., 2013). The mechanism underlying InsR is still not 
completely understood. One of the major indicators of InsR is an inhibition of glycogen synthesis (Bonadonna 
et al., 1993). Glycogen synthesis results in almost 80% of glucose clearance entering skeletal muscles under 
normal conditions and understandably any decrease in this rate can detrimentally influence blood glucose 
levels (DeFronzo & Tripathy, 2009). Furthermore, a sustained positive or surplus energy balance leads to 
expanded adipose tissue (obesity) and obesity-related disorders, which are commonly associated with InsR in 
41% of patients even in the absence of diabetes (Tewari et al., 2015). Adipose tissue not only stores additional 
calories, but as an endocrine organ, also secretes pro-inflammatory cytokines, such as tumour necrosis factor 
alpha (TNFα), interleukin-1-beta (IL-1β) and monocyte chemoattractant protein-1 (MCP1) (Wieser et al., 2013). 
In the case of obesity, adipose tissue undergoes a phenotypical change which attracts more macrophages 
that can account for up to 40% of the total cells in adipose tissue (Kang et al., 2016; Xu et al., 2003), which 
further increases pro-inflammatory cytokine secretion, resulting in chronic inflammation, and has been 
implicated in InsR (Olefsky & Glass, 2010). Lastly, fat cell lipolysis (the process of adipocyte triacylglycerol 
breakdown into FA and glycerol resulting in elevated blood triglyceride) is also elevated in obesity and 
associated with InsR (Morigny et al., 2016). 
1.4.4.2 Ischemic Heart Disease and Strokes 
Increasing obesity poses a rising risk to ischemic heart disease (IHD) – the leading cause of CVD (Gregory et 
al., 2017). IHD is the result of sustained plaque build-up due to cholesterol deposits in the coronary arteries – 
normally supplying the heart with O2 -rich blood (National Institute of Health, 2009). The narrowing of coronary 
arteries results in reduced blood flow to the heart causing chest discomfort and when completely blocked 
triggers a heart attack. Finally, a plaque region can also rupture or dislodge and form blood clots anywhere 
within in the vascular system, called an embolism. Most notably, a blood clot resulting in complete blockage 
of blood flow to the brain is known as a brain embolism or stroke, causing irreversible damage and potential 
premature death. Strokes are the second leading cause of death worldwide, and approximately 240 new cases 
are identified daily in South Africa, often resulting in lingering disabilities (Akinrinmade et al., 2017). 
Furthermore, the relationship between lipid displacement, InsR and the subsequent development of serious 
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disorders including T2D, hypertension, dyslipidemia and disorders of coagulation and fibrinolysis are well 
established and can lead to CVD (Boden, 2011). 
1.4.4.3 Diabetes 
• Diabetes Overview 
Diabetes mellitus is the most common metabolic disease worldwide with an estimated 425 million diabetic 
adults (1 in 11 adults), an additional 352 million having impaired glucose tolerance, and an estimated 212 
million still undiagnosed (“International Diabetes Foundation”, 2018). Consequently, $727 billion (12% of global 
health expenditure) is spent on diabetes – equivalent to the entire gross domestic product of either Switzerland 
or Saudi Arabia (“World Economic Outlook”, 2018). 
 
Diabetes can be divided into three distinct forms, namely Type 1, Type 2 or gestational diabetes. Type 1 
diabetes (T1D) is characterised by selective autoimmune destruction of pancreatic β-cells responsible for 
insulin secretion, thereby detrimentally affecting insulin secretion required for normal energy metabolism. T2D 
in contrast, is the result of acquired insulin insensitivity in the liver, adipose tissue and muscle cells, initially 
resulting in overexpression of insulin which overexerts β-cell function, and eventually becomes a full blown 
inability to effectively clear blood glucose (DeFronzo, 1999). It was first proposed that diabetic patients present 
with InsR only, as opposed to insulin deficiency (Himsworth, 1936), however it is now recognized that both 
conditions are essential in the disease progression of T2D. Gestational diabetes is also an acquired form of 
diabetes prevalent in 7% of all pregnancies (especially during the 24th to 28th week of gestation) and presents 
with a degree of glucose intolerance that can result in T2D post-pregnancy (Association American Diabetes, 
2003; Metzger & Coustan, 1998). T2D has a much higher incidence (about 95% of all cases of diabetes) and 
obesity is the most common risk factor for developing of T2D (Ghasemi & Jeddi, 2017), resulting in elevated 
serum triglycerides, hypertension and InsR. T1D is primarily diagnosed in younger individuals, whereas T2D 
used to be considered a disease of the aged. However, in recent years there has been an upward trend of 
younger people also presenting with T2D (Huang et al., 2009). Genetics have also been shown to be involved 
in diabetic development, as the disease is often dependent on genetic changes, especially epigenetic changes 
brought upon by environmental factors. In extreme cases (<2%) genetics has shown direct involvement in 
conditions such as maturity-onset diabetes (Fajans et al., 2001) and neonatal diabetes (Støy et al., 2010). 
• Treatment 
The primary agenda in treating diabetes is the maintenance of blood glucose levels within normal physiological 
ranges (Polonsky, 2012). Diet and exercise are effective in the treatment and management of both type 1 and 
2 diabetes (Eiselein et al., 2004), while injectable insulin is also considered as a safe alternative to deal with 
diabetic episodes (McCall, 2012). Additionally, T2D treatments include non-insulin oral anti-diabetic 
medications, comprising of biguanides, sulfonylureas, α-glucosidase inhibitors, and thiazolidinediones. Each 
class of medication has a unique mechanism of action (Figure 1.3):  
o Biguanides (such as metformin) is the most prescribed drug in treating T2D and acts by increasing the 
liver’s insulin sensitivity and restoring its glucose metabolism (Viollet et al., 2012). The molecular action of 
metformin is heavily dependent on the treatment dose and duration, and was initially thought to occur only 
through an AMPK-dependent inhibition of mitochondrial respiration, however AMPK-independent 
mechanisms has now also been implicated (Rena et al., 2017). Metformin is considered to have few side 
effects, but the most common occurrence is gastrointestinal complications in 20-30% of patients resulting 
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in nausea and vomiting (Diabetes Prevention Program Research Group, 2012). Furthermore, patients with 
liver and kidney dysfunction has also shown to be prone to fatal lactic acidosis (Salpeter et al., 2006). 
o Sulfonylureas are the most widely used anti-diabetic drug due to its low cost and acts through increasing 
insulin production by the pancreatic β-cells (Sola et al., 2015). This mechanism occurs through binding to 
a sulphonylurea-specific receptor causing the inhibition of ATP-senstive K+ channels on the pancreatic β-
cells plasma membrane. This inhibition prevents K+ from exciting the cell, leading to a depolarization that 
opens voltage-gated Ca2+ channels (therefore intracellular Ca2+ buildup) triggering more insulin granulae 
fusion with the cell membrane and subsequent insulin secretion (Ashcroft, 1996; Levine & Sobel, 1957). 
Prolonged used has been associated with hypoglycemic episodes and decreased insulin secretion, 
through desensitization of the sulphonylurea-specific receptors (Sola et al., 2015).  
o α-glucosidase inhibitors (such as acarbose) delay the absorption of carbohydrates from the gastro-
intestinal tract (Willms et al., 1991). Through competitive inhibition of α-glucosidases, acarbose delays 
carbohydrate digestion, extending the total carbohydrate digestion time and thereby reduce the rate of 
glucose absorption, subsequently also lowering hyperinsulinemia (Bischoff, 1995). As a secondary effect, 
acorbose also reduces triglyceride uptake into adipose tissue and hepatic lipogenesis, reducing 
triglyceride content. Acarbose was also shown to have a resensitizing effect on GLUT4 (Ledwig et al., 
2002). Due to the inhibition of complex carbohydrate breakdown into glucose, some carbohydrates remain 
undegraded till the colon, where bacterial digestion takes over. This results in gastrointestinal side-effects 
including flatulence (in 78% of patients) and diarrhea (in 14% of patients) (Derosa & Maffioli, 2012). 
Furthermore, there has been reported incidences of liver inflammation whereby treatment had to be 
ceased (Derosa & Maffioli, 2012). 
o Thiazolidinediones (or glitazones) increase insulin sensitivity in peripheral tissues, such as the muscles 
and fat cells (Kahn et al., 2000). They act by binding peroxisome proliferator-activator receptor gamma in 
adipocytes to stimulate peripheral adipogenesis and FA uptake (Greenfield et al., 2004). This reduction of 
circulating FA’s and lipid substrate availability for liver and muscle tissue results in improved insulin 
sensitivity. Furthermore, thiazolidinediones also favourably impact adipocyte hormone secretions, such as 
adiponectin, which also independently aids in insulin resensitization (Achari & Jain, 2017). Given the 
involvement of thiazoledinediones in adipocyte functioning, it is not surprising that the treatment results in 
weight gain and increased peripheral fat mass (but not visceral fat) (Greenfield et al., 2004). Furthermore, 
thiazolidinediones is also not suitable for patients with heart failure as the drug causes fluid retention, 
resulting in increased plasma volume and therefore decreased haemoglobin concentrations causing 
anemia. As blood oxygen is lowered, the heart has to compensate to retain the oxygen demand of 
peripheral tissues (Coats, 2004). 




Figure 1.3 Anti-diabetic therapies and the mode of action. Adapted from Beaser et al. (2015). 
 
The different oral agent classes have different effects on basal insulin and postprandial glucose – effects which 
only become apparent as T2D progresses. The latest drugs available for treating T2D are incretins, such as 
glucagon-like peptide-1 (GLP-1) – a gastrointestinal hormone that increases insulin production in β-cells 
(Kjems et al., 2003). Similarly, dipeptidyl peptidase-4 (DDP-4) inhibitors can be used to delay the breakdown 
of GLP-1 (Dicker, 2011). All of the above have, however, been linked to a variety of serious adverse health 
effects, prompting a search for safer, natural hypoglycemic agents to be used (Patel et al., 2012).  
1.4.5 Summary of Insulin Resistance 
The increased prevalence of obesity in the general population is evident. This burden of disease also 
contributes to a rise in insulin resistant patients. However, insulin resistance is only viewed as an adaptive 
mechanism (to protect cells against acute lipid overload and inflammation) which becomes ineffective and 
leads to multiple metabolic abnormalities in the chronic state (Tsatsoulis et al., 2013).  
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1.5 ISCHEMIA-REPERFUSION INJURY 
“Turning it off and on again”. 
1.5.1 Overview of Ischemia  
During prolonged ischemia, metabolism switches over to anaerobic metabolism and lactate accumulation, 
leading to a decrease in adenosine triphosphate (ATP) levels and intracellular pH (Figure 1.4). Consequently, 
ATPase-dependent ion transport mechanisms cease to work properly, causing a buildup of ROS, intracellular 
and mitochondrial calcium (Ca2+) (a phenomenon known as Ca2+ overload), contributing to the opening of the 
mPTP leading to swelling and rupture of cells, and ultimately cell death through necrotic, necroptosis, apoptotic 
or autophagic mechanisms.  
 
Short durations of ischemia (typically < 5 min) followed by reperfusion activates cell survival signaling cascades 
protecting the heart from the consequences of longer periods of ischemia – a phenomenon known as ischemic 
conditioning. Extending ischemia to 20 min results in myocardial stunning, meaning upon reperfusion 
contractility is impaired, but will eventually improve without resulting in infarction or significant inflammatory 
responses. Prolonged ischemia beyond 20 min results in cell damage which will lead to myocardial infarctions, 
and re-establishing blood flow further aggravates tissue injury through inflammatory signaling. Ischemic 
periods between 5 and 20 minutes induce myocardial stunning (Kalogeris et al., 2017).  
1.5.2 Causes of Ischemic Episodes 
Ischemic episodes can occur in myocardial infarction, stroke, and peripheral vascular disease (Kalogeris et 
al., 2017). The major uncontrollable risk factors for ischemic episodes include advancing age, male gender 
and hereditary factors. Controllable risk factors for myocardial infarction and ischemic stroke include acute 
(and chronic) consumption of 4 or more servings of alcohol per day, smoking of tobacco, hyperlipidemia, 
hypertension, sedentary lifestyle, obesity, metabolic syndrome and diabetes mellitus (Kalogeris et al., 2012). 
The most common underlying cause for ischemic episodes in the western world can be attributed to 
thromboembolic or atherothrombotic vaso-occlusive disease (Kalogeris et al., 2012). Increasingly, studies are 
suggesting that conditions like diabetes, hyperlipidemia and aging can influence the progression of I/R-I 
independent of the vascular aspects (Boengler et al., 2009; Ferdinandy et al., 2007).  
1.5.2.1 Fetal Programming 
The importance of fetal programming is a vital contributor of ischemic disease in later adulthood. Studies have 
reported a “U”-shaped correlation between placental-to-fetal weight ratio and heart disease, which indicates 
that factors inhibiting placental development can severely promote myocardial vulnerabilities later in adulthood 
(Thornburg et al., 2010). It has been found that fetal exposure to a wide variety of environmental triggers, 
including hemodynamic effects, growth factors, cocaine (Meyer & Zhang, 2009) and tobacco smoke exposure, 
hypoxia (Patterson & Zhang, 2010) and nutrient status all contribute towards CVD progression in later age 
(Langley-Evans & McMullen, 2010; Reynolds et al., 2010). Intrauterine stress results in gene-activated 
responses, called fetal programming, and is found to increase risk for CVD. Furthermore, the risk for IHD can 
also be subject to birth weight (Barker, 2007; Reynolds et al., 2010). It was noted that mortality from ischemic 
disease in adults increased as birth weight decreased from 4.1 kg to 2.3 kg, and the same association was 
found for increasing birth weights above 4.3 kg. However, regardless of genetic predisposition, caloric 
restriction and exercise can confer cardioprotection and improve ischemic tolerance even in aged hearts 
(Boengler et al., 2009). 
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Figure 1.4 Changes within cardiomyocyte during ischemia/reperfusion. When O2 supply is ceased to 
myocardial tissue, the metabolism switches from aerobic to anaerobic, causing lactate accumulation and 
lowering of intracellular pH. This drives H+ out of the cell in exchange for a rising intracellular Na+ (facilitated 
by the Na+ / H+ exchanger), which then drives intracellular Na+ to be transported out of the cell in exchange for 
Ca2+ (facilitated by the 2 Na+ / Ca2+ exchanger). During ischemia, Na+ / K+ ATPase loses functionality which 
further exacerbates intracellular Na+ overload. Once blood flow is restored, O2 and aerobic substrates flood 
into ischemic tissue and the electron transport chain (ETC) is restarted, leading to a surge in ROS and 
consequently proinflammatory neutrophils, which worsens ischemic injury. Adapted from Hausenloy & Yellon 
(2013). SR: sarcoplasmic reticulum; mPTP: mitochondrial permeability transition pore; OxPhos: oxidative 
phosphorylation; ROS: reactive oxygen species; MCT1/4: Monocarboxylate transporters 1/4. 
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1.5.3 Overview of Reperfusion Injury 
Ischemia/Reperfusion-Injury (I/R-I) refers to the damage incurred to ischemic tissue upon re-establishing blood 
flow. Myocardial reperfusion is essential in protecting viable myocardium, however it is also the cause for up 
to 50% additional damage done to the susceptible post-ischemic myocardium (Javadov et al., 2018; Yellon & 
Hausenloy, 2007). The severity of the damage to tissues is dependent on the degree of obstruction and the 
duration of ischemia (Heusch & Gersh, 2016). Cell death can still occur 3 days after reperfusion was reinstated 
(Zhao et al., 2000). Therefore, swift restoration of blood flow remains the primary therapeutic approach to all 
incidences of ischemia.  
 
I/R-I is especially prevalent in myocardial infarctions, strokes and peripheral vascular disease. Cardioprotective 
therapies are aimed at targeting myocardial injury to prevent damage done during I/R-I (Rossello & Yellon, 
2016). Interventions performed during ischemia and reperfusion can decrease infarct size by as much as 50% 
(Yellon & Hausenloy, 2007). Improving our understanding of I/R-I enables the development of new therapies 
and would extend the amount of time an organ can remain ischemic without irreversible I/R-I occurring. This 
could potentially implicate our modes of organ transplantation and even aid in performing bloodless operation 
where visual acuity is important (Yellon & Hausenloy, 2007).  
 
The mechanisms involved in I/R-I are complex with the net result being damage to all biomolecules in exposed 
cells and tissues (Kalogeris et al., 2017), with eventual cell death ensuing if left untreated. The fundamental 
characteristics of reperfusion injury entails the release of reactive oxygen species (ROS), cytokines and 
chemokines from surrounding endothelium, macrophages and mast cells, recruitment of neutrophils and 
endothelial dysfunction (Figure 1.4) (Wu et al., 2018). The opening of the mitochondrial permeability transition 
pore (mPTP) induced by ROS from both intracellular and extracellular sources also leads to sarcoplasmic 
reticulum dysfunction resulting in Ca2+ overload, lipid peroxidation of cell membranes, denaturing of enzymes 
and ultimately also DNA damage (Hausenloy & Yellon, 2013). Furthermore, ATP generation also facilitates 
the clearing of accumulated intracellular H+ by flushing out lactic acid through the monocarboxylate 
transporters 1 and 4 (MCT1/4) and through the 2 Na+ / Ca2+ exchanger – however, this has also shown to be 
detrimental (Zhu et al., 2013). Hours after reperfusion, neutrophils are still attracted in response to ROS from 
the infarcted myocardium (Wu et al., 2018) 
 
Relevant to this study, focus will remain on the following key mechanisms present in cardiac I/R-I: Oxidative 
stress, Ca2+ overload, mPTP opening and pronounced inflammatory responses resulting in cell death. 
1.5.4 Oxidative Stress 
As necessary as reoxygenation is for re-establishing aerobic ATP production, it also gives rise to an increase 
in ROS generation. ROS is highly reactive to all surrounding biomolecules and paradoxically induces cell 
dysfunction. This state of elevated ROS signaling has been deemed oxidative stress – an imbalance between 
pro-oxidants and antioxidants, in favor of the former – and is an important contributory factor to I/R-I induced 
damage (Zhou, Prather, et al., 2018). Many conditions linked to CVD are associated with excessive pro-oxidant 
production and/or depression of endogenous antioxidant status, including diabetes, hyperlipidemia, 
hypertension, and obesity. 
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ROS is generated in multiple compartments and by multiple enzymes within the cell, such as NADPH oxidase 
at the plasma membrane, lipid oxidation within peroxisomes, oxidative phosphorylation (OxPhos) within 
mitochondria, and various cyclooxygenases and xanthine oxidase in the cytoplasm (Goszcz et al., 2015). 
Although these sources contribute to the overall oxidative burden, the majority of ROS are produced during 
OxPhos and ATP generation within the mitochondria. Mitochondrial ROS might attack various mitochondrial 
constituents, causing mitochondrial DNA mutations and oxidative damage to respiratory enzymes (Goszcz et 
al., 2015). Furthermore, a defect in mitochondrial respiratory enzymes would increase mitochondrial production 
of ROS, causing further mitochondrial damage and dysfunction (Kalogeris et al., 2017). 
 
The major ROS radical formed during I/R-I is superoxide anion (O2•) by reduction of molecular O2 (Granger, 
1988). Furthermore, all other reactive species is either directly or indirectly derived from O2• through its 
dismutation or interaction with other related reactive species further inducing tissue damage. O2• is generated 
by various cytosolic and membrane enzymes as well as by the ETC, and capable of directly oxidizing enzymes 
with iron-sulfur cores, including aconitase, fumarase, NADH dehydrogenase, creatine kinase and calcineurin 
(Raedschelders et al., 2012). Under normal physiological conditions, O2• spontaneously converts into hydrogen 
peroxide (H2O2) – a reaction that can be accelerated up to 10,000 times by superoxide dismutase (SOD) 
(Kalogeris et al., 2012). However, in low pH conditions, such as during ischemia, O2• can spontaneously 
convert to its conjugate acid, the strong oxidant hydroperoxyl radical (HO2•).  
• p22phox 
p22phox, also known as the human neutrophil cytochrome b light chain, is a crucial constituent of the plasma 
membrane enzyme NADPH-oxidase (Dinauer et al., 1990). NADPH-oxidase, consists of 5 isoforms (Nox1-5) 
and facilitates the transfer of one electron (e-) from NADH or NADPH to O2 to produce O2•, with p22phox being 
the final e- transporter in the chain (Xu, Yuan, et al., 2014). This can be useful as in the case of phagocytes 
which kills foreign microbes by trapping them in a high ROS compartment (Dahlgren & Karlsson, 1999). 
However, during cardiac I/R-I, NADPH-oxidase has been identified as a major source of O2• overproduction 
(Nediani et al., 2007). It has been found that increased p22phox levels are related to lipid peroxidation after 
acute myocardial infarction in rats (Fukui et al., 2001). 
1.5.5 Calcium Overload 
Under ischemic conditions, cells need to resort to anaerobic glycolysis to meet their demand for ATP. This 
results in a buildup of lactate, H+ and NAD+ reducing cytosolic pH levels. To counter-balance, cells exchange 
H+ for Na+ by means of the plasmalemmal Na+ / H+ exchanger (Murphy & Steenbergen, 2007), which is then 
in turn exchanged for Ca2+ via the plasmalemmal Na+ / Ca2+ exchanger. Upon reperfusion, the buildup of Ca2+ 
is worsened as H+ removal increases the H+ gradient across the plasmalemma and effectively speeds up 
Na+/H+ exchanger action (Sanada et al., 2011). Furthermore, Ca2+ reuptake into the sarcoplasmic reticulum is 
also impaired during I/R-I further contributing to the lethality of elevated intracellular Ca2+. This results in 
cardiomyocyte hypercontracture causing sarcolemmal rupture and eventually cell death through contraction 
band necrosis (Miyazaki et al., 1987).   
 
Lethal increases in Ca2+ is normally dealt with by mitochondrial Ca2+ uptake via a Ca2+ uniporter – a 
transmembrane protein that makes use of the negative mitochondrial membrane potential (Δψm) compared to 
the cytosol to attract positively charged Ca2+ (Contreras et al., 2010). However, once the Ca2+ is too 
overwhelming it can trigger the mPTP opening response. Furthermore, ischemic Ca2+ buildup can also result 
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in overactivation of Ca2+ / calmodulin-dependent protein kinases which can contribute to cell death. Increased 
intracellular Ca2+ can also signal the activation of inflammasomes, which mediate increased cytokine 
production, including IL-1β and TNFα, giving rise to an entire cytokine and chemokine cascade complicating 
I/R-I injury (Slegtenhorst et al., 2014).  
1.5.6 Mitochondrial Permeability Transition Pore Opening 
I/R-I induces the opening of the mPTP, a common end-effector (Figure 1.4). Normally, the mPTP serve as a 
highly conductive pore permeable to molecules smaller than ±1.5 kDa in size, including H+, but remains closed 
during ischemia in the presence of low pH (Hausenloy & Yellon, 2013). However, reperfusion causes dramatic 
increases in mitochondrial Ca2+ and ROS inducing the opening of the mPTP (Ong & Gustafsson, 2012), and 
whilst open allows H+ to move freely between the inner mitochondrial membrane and the matrix, effectively 
dissipating the Δψm, uncoupling ETC and inhibiting ATP synthesis (Halestrap, 2010). Additionally, the increase 
in intramitochondrial H+ also draws water inside, causing the mitochondria to swell and rupture. When 
mitochondria are  destroyed, necrosis of the cardiomyocyte will occur (Cohen & Downey, 2015). The molecular 
makeup of the mPTP still remains unknown (Javadov et al., 2018), but it has been shown to entail the protein 
complexes adenine translocase, mitochondrial phosphate carrier, and most prominently cyclophilin-D. This 
composition led to the discovery of chemical inhibitors for cyclophilin-D, such as cyclosporine-A, sanglifehrin-
A, and Debio-025, which have shown to protect against I/R-I-induced cell death in various organs, including 
the heart (Clarke et al., 2002; Di Lisa et al., 2009). Cardioprotective therapies are thus aimed at keeping the 
mPTP closed. Mitochondrial dysfunction and signaling is discussed in more detail in Chapter 2 (Section 2.3). 
1.5.7 Mechanisms of Cell Death 
Signal transduction is crucial for maintaining cellular processes in response to I/R-I with various kinases 
displaying critical involvement in I/R-I pathogenesis (Vassalli et al., 2012). In the past, cell death associated 
with I/R-I has been attributed to reduced energy supply, inflammation and a buildup of toxic molecules and 
mechanical injury inducing necrosis (Kalogeris et al., 2012). Necrosis refers to a form of cell death resulting 
from extensive cell damage, characterised by disruption of organelles and membrane rupture independent of 
ATP supply (Konstantinidis et al., 2012). However, cell death in I/R-I can also occur through various other 
mechanisms, each with their own mode of action (Kalogeris et al., 2017) (See Figure 1.5). As part of this 
review we will only focus on necrosis and necroptosis, apoptosis and autophagy.  
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Figure 1. 5 Different modes of cell death known to date. Taken from Kalogeris et al. (2017) to illustrate 
the complexity of cell death mechanisms. In this review we only focus on necrosis, necroptosis, apoptosis 
and autophagy. 
 
1.5.7.1 Necrosis and necroptosis 
Necrosis is characterized by dysfunctional ion transport mechanisms causing the swelling of cells and 
organelles, mitochondrial dysfunction, lack of nuclear fragmentation, plasma membrane rupture and leakage 
of intracellular contents in the extracellular space (Kalogeris et al., 2017). Necrosis was initially thought to be 
the random consequence of overwhelming stress resulting in cell death. However, likewise to apoptosis and 
autophagy, necrosis can also be programmed, especially in response to I/R-I, in a process referred to as 
necroptosis. In this regard, extreme cellular stress or the activation of death receptors recruits a group of 
serine/threonine kinases called receptor-interacting proteins (RIP), which target the opening of the mPTP 
(Karch et al., 2015). Activation of RIP1 and RIP3 also results in increased ROS production via NADPH 
oxidases (Morgan et al., 2008) or through mitochondrial complex I (Vandenabeele et al., 2010). 
1.5.7.2 Apoptosis 
Apoptosis is an ATP-dependent programmed cell death, which causes cell shrinkage and condensing of the 
cytosol and nucleus to form apoptotic bodies. It is characterised by both cytochrome-c release from damaged 
mitochondria, or autocoid (localized hormones) cell-surface receptor (Fas ligand) activation, resulting in 
downstream signaling via caspases and other signaling proteins which cause non-selective pore formation on 
the outer membrane of the mitochondria, the opening of the mPTP, DNA cleavage and nuclear degradation 
(Konstantinidis et al., 2012). Apoptosis, unlike necrosis, does not release cellular content into the extracellular 
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space as the apoptotic bodies are surrounded by cell membranes. This also enable apoptotic bodies to be 
digested by phagocytes without creating an inflammatory response (Kalogeris et al., 2012).   
 
Apoptosis can result through extrinsic or intrinsic mechanisms (Whelan et al., 2010). The extrinsic pathway 
occurs through activation of the Fas, TNFα and TRAIL receptors, which recruit death domain-containing 
proteins to the receptor complex. The formation of this death-inducing signaling complex activates protease 
caspase-8, resulting in activation of caspase-3. Caspase-3 serves as a protein slayer within cells lysing various 
cellular proteins (Whelan et al., 2010). The intrinsic pathway, or mitochondrial apoptotic pathways, is activated 
in response to cytotoxic stimuli by I/R-I or oxidative stress, resulting in translocation and integration of the cell 
death regulator, B-cell lymphoma 2 (Bcl2), which can either result in apoptosis inhibition or induction by 
recruiting Bcl2-like protein 4 (Bax), Bcl2 homologous antagonist/killer (Bak), BH3 interacting-domain death 
agonist (Bid), p53 upregulated modulator of apoptosis (Puma) and Bcl2 nineteen kilodalton interacting protein 
(BNIP3) into the outer mitochondrial membrane (Whelan et al., 2010). Ischemia by itself is not sufficient to 
activate the redox sensitive Bcl2 proteins and requires reperfusion. Once these proteins have permeabilized 
the outer membrane they signal the release of various pro-apoptotic proteins, such as cytochrome c, from the 
intermembrane space. Cytochrome c attaches to the cytosolic protein, apoptosis protease activating factor 1, 
resulting in an apoptosome which further activates the caspase-3, caspase-9 system (Whelan et al., 2010).  
 
Cardioprotective research is aimed at finding pro-apoptotic proteins and signals which can be targeted during 
I/R-I to possibly salvage cardiomyocytes destined for degradation. It has been demonstrated that inhibiting 
caspases during reperfusion can decrease infarct size in animal models (Mocanu et al., 2000). However, in 
Bcl2 knockout mice, they found greater damage in response to I/R-I occurring in the absence of pro-apoptotic 
proteins than simply induced by apoptosis. This reaffirms that these proteins are not just involved in apoptosis, 
but their role in regulating normal cell function, such as their role in Ca2+ homeostasis, is of greater importance 
than initially realized (Scorrano et al., 2003).  
1.5.7.3 Autophagy 
Autophagy is the cell’s mechanism of housekeeping which disposes of old and damaged proteins and 
organelles. It can also be protective in response to cellular stress induced by starvation, hypoxia, mitochondrial 
dysfunction and infection, by recycling amino acids and FA’s from damaged organelles and removing 
intracellular pathogens (Kalogeris et al., 2017). Autophagy is thus considered a cell survival mechanism rather 
than a mechanism of cell death. However, uncontrollable autophagy can result in cell death and potentially 
exacerbate I/R-I (Kalogeris et al., 2012).  
 
The morphology of autophagy starts with a phagophore, an expanding isolation membrane which starts to 
surround a cell organelle or compartment to be processed (Gottlieb & Mentzer, 2010). Once the contents are 
completely engulfed it is known as an autophagosome, which will go on to fuse with a lysosome to degrade all 
the enclosed material, additionally also inducing an inflammatory cascade (Kalogeris et al., 2017). This process 
is narrowly regulated by the mammalian target of rapamycin (mTOR) protein which inhibits autophagy. 
However, in response to a decreased nutritional status or stress, mTOR can be inactivated, resulting in 
autophagy activation (Gottlieb & Mentzer, 2010). This activates the kinase autophagy-related protein 1 (Atg1), 
which recruits Atg13 and Atg17 to start the phagophore formation. Another complex comprising of the class III 
PI3-Kinases vps34, vps15, and Beclin-1 then continues phagophore formation and recruits Atg12, Atg5 and 
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Atg8 (also called LC-3) which is essential for phagophore elongation and autophagosome completion. Once 
completed, fusion of the autophagosome to the lysosome is facilitated by the small GTPase Rab7 and the 
lysosomal membrane protein, LAMP2A (Gottlieb & Mentzer, 2010).  
 
Autophagy is essential during ischemia, however its role in reperfusion remains uncertain (Ma et al., 2015; 
Sciarretta et al., 2011). The general consensus during I/R-I, is that inhibition of autophagy results in 
aggravated tissue damage (Jiang et al., 2010), whereas activation of autophagy can confer cardioprotection 
(Carloni et al., 2010). However, contrastingly it has been shown that AMPK upregulation during prolonged 
I/R-I can result in mTOR inhibition and thereby upregulate autophagy which resulted in a harmful response 
(Takagi et al., 2007). To the contrary again, suppression of autophagy during reperfusion by administration 
of autophagosome formation inhibitor, 3-MA, or a Beclin1 inhibitor, urocortin, has shown to reduce neonatal 
and adult rat cardiomyocyte cell death following I/R-I (Valentim et al., 2006). It thus remains that more 
research is needed to identify the appropriate status for autophagy during the critical events of reperfusion 
injury. 
1.5.8 Mechanisms of Cell Protection 
1.5.8.1 RISK Pathway 
Reducing cell death in ischemic and reperfused myocardium can be accomplished through activation of growth 
factors, or pro-survival proteins, such as the upstream PKB activator, PI3K, and ERK1/2 (Baxter et al., 2001; 
Yellon & Baxter, 1999). Protection relying on these two key protein cascades was coined the “Reperfusion 
injury salvage kinase (RISK) pathway”, first described by Schulman and colleagues (2002). They made use of 
the growth factor urocortin, which when administered during reperfusion upregulated ERK1/2 and decreased 
myocardial infarct size. When urocortin was co-treated with an ERK1/2 inhibitor, the protection was completely 
abolished. Since then, the importance of the RISK pathway has been thoroughly investigated by testing the 
protective effect of various cardioprotective therapies. The RISK-pathway can be summarised as a group of 
pro-survival protein kinases able to be cardioprotective when activated from the point of reperfusion 
(Hausenloy et al., 2005). 
 
The efficacy of the RISK pathway can be summarized in three characteristics:  
 
Early kinase activation is Protective 
It has been shown that, in response to ischemic pre-conditioning, the RISK pathway is activated at 2 distinct 
time points: 
1) The “Trigger phase” - upon administration of the preconditioning cycles just before the ischemic episode, 
2) Early reperfusion – at the onset of reperfusion (Rossello & Yellon, 2016) 
 
It is speculated that closing the mPTP in the first 15 min of reperfusion is the main target for intervention in 
reducing cardiac I/R-I (Hausenloy et al., 2003). This link between the RISK pathway and the mPTP has also 
been shown in rat myocytes before (Davidson et al., 2006). Also, when the mPTP inhibitors, such as 
cyclosporin, sanglifehrin or insulin, is administered more than 15 min into reperfusion the protection is lost 
(Hausenloy et al., 2003; Jonassen et al., 2001).  
 
Temporary kinase activation is Protective 
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Pro-survival kinases are only beneficial when acutely activated, whereas chronic activation of growth factors 
is considered harmful. Chronic activation of the PI3K-PKB cascade induces cardiac hypertrophy (Nagoshi et 
al., 2005). Clinically it has been shown that ERK and PKB is chronically activated in a failing heart (Haq et al., 
2001). The heart can control phosphorylation of ERK and PKB through activation of PTEN – an important 
trigger for switching growth-induced pathways on and off (Rossello et al., 2017). Clinically, this is an ideal 
treatment for a patient with acute myocardial infarction as it would only require inhibitory intervention prior to 
reperfusion, to prevent severe I/R-I (Rossello et al., 2017). 
 
Common cardioprotective pathway 
The RISK pathway is not solely activated during ischemic conditioning but can also be activated in response 
to various pharmacological agents including insulin, bradykinin adenosine or statins (Rossello & Yellon, 2016). 
Our understanding of the RISK pathway has mostly been acquired from work done on small rodent models of 
acute myocardial infarction, but its role in larger animals, including humans still need to be better established 
(Rossello & Yellon, 2018). RISK has clearly been shown to be involved in cardioprotection in rats and rabbits 
but is of lesser importance in pigs (Hausenloy & Yellon, 2004; Hausenloy et al., 2005; Skyschally et al., 2009). 
The link between ischemic preconditioning and RISK activation has been shown in human atrial trabeculae, 
but remote conditioning still needs to be clearly established in large animals and humans (Heusch et al., 2012). 
The MAPK pathway cooperates with the PI3K/PKB pathway to control cell proliferation. MAPK’s consists of 3 
groups of serine threonine kinases: extracellular signal-regulated kinases (ERK1/2/3), c-Jun amino-terminal 
kinase/stress-activated protein kinases (JNK), and p38 MAPK’s. Depending on the extracellular stimuli, these 
kinases can initiate a network of cell signaling cascades with various responses. The different isoforms of ERK, 
JNK, and the p38 MAPK’s are expressed in nearly all types of tissues and cells (Deng et al., 2012). 
There exist numerous downstream targets induced by pro-death kinases capable of contributing to I/R-I. JNK 
and p38 activation results in a surge of inflammatory cytokines, including TNFα and IL-1 shown to be key 
players in the damage incurred during I/R-I (King et al., 2009). Furthermore, p38, and JNK, along with PKC, 
have shown to translocate to the mitochondria and increase complex I ROS production by up to 80% 
(Chambers & LoGrasso, 2011) making it more prone to mitophagy. p38 and JNK’s exact role in apoptosis 
remain unclear, as they have both shown to inactivate anti-apoptotic Bcl2 proteins (De Chiara et al., 2006; Fan 
et al., 2000) and also activate pro-death Bcl2 proteins (Bright et al., 2004; Metukuri et al., 2009).   
1.5.8.2 Insulin-Dependent Mechanisms 
Insulin signaling is well established to be cardioprotective in insulin resistance and CVD (Ji et al., 2010). The 
PI3K/PKB pathway is the primary signaling cascade mediating metabolic effects induced by insulin. Once the 
insulin receptor is activated, tyrosine phosphorylation of insulin receptor substrates (IRS) 1-4 occurs, resulting 
in PI3K activation at it’s p85 regulator subunit. PI3K then activates the membrane-bound phosphatidylinositol 
phosphate, PIP2, transforming it to PIP3 resulting in downstream activation of phosphoinositide-dependent 
kinase-1 (PDK1) and recruitment of PKB/Akt – responsible for insulin’s metabolic effects.  
• PKB 
Protein Kinase B (PKB) or Akt is a serine/threonine kinase which plays a diverse cellular signaling role in 
especially insulin metabolism. 3 major isoforms have been identified, namely PKB1, PKB2 and PKB3, all of 
which are activated after PI3K recruitment. PKB1 is the most researched isoform, whereas it is known that 
PKB2 is highly expressed in the heart, and PKB3 is severely upregulated in a stressed heart (Altomare et al., 
1995; Taniyama et al., 2005; Walsh, 2006). When PI3K is inhibited through pharmacological inhibition by 
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wortmannin for instance, PKB activation is also inhibited (Burgering & Coffer, 1995). In the heart, PKB is 
upregulated in response to insulin and nutritional status (Shiojima et al., 2002), exercise training (Konhilas et 
al., 2005), pressure overload (Naga Prasad et al., 2000) and advanced heart disease (Taniyama et al., 2005). 
PKB1 furthermore plays a protective role in the myocardium of both acute and chronic cardiac ischemic injuries 
(Fujio et al., 2000). PKB’s prominence as a multipurpose pro-survival protein signal has made it a prominent 
therapeutic target in treating cancer, diabetes, strokes and neurodegenerative diseases. 
• ERK 
ERK (extracellular-signal-regulated kinases) are intracellular protein kinases which play a diverse role in cell 
differentiation and cell division. The ERK pathway is activated in response to a multitude of extracellular 
effectors, including growth factors, cytokines, viral infections, transforming agents, GPCR ligands and 
carcinogens (Shaul & Seger, 2007). The best understood MAPKs are ERK1 (p44 MAPK) and ERK2 (p42 
MAPK) which are distributed in all tissue types. ERK p42/p44 are MAPK subtypes that mediate the mitogenic 
and the pro-inflammatory effects of insulin (Sasaoka et al., 2006). Once resting cells are stimulated, ERK1/2 
first accumulates in the nucleus through active and passive processes to phosphorylate nuclear transcription 
factors involved in early gene responses. The activation of the ERK cascade is mediated by upstream mitogen-
activated protein kinase kinase 1/2 (MEK1/2). Once activated, ERK1/2 also phosphorylate hundreds of other 
substrates, such as the membrane proteins, CD120a, Syk and calnexin, the nuclear substrates, SRC-1, Pax-
6, Elk-1, MEF2, c-Fos, c-Myc and STAT3, several MAPK-activating protein kinases (MK’s), MAPK-interacting 
(MNK’s) and cytoskeletal proteins (Roskoski, 2012). Due to the magnitude of influence of the ERK pathway, it 
has been seen to play conflicting roles in cellular processing, including proliferation, differentiation, metabolism, 
morphology, survival and programmed cell death (Deng et al., 2012). The ERK cascade consists of Ras, Rafs, 
MEK1/2, ERK1/2 and the MAPKAPK’s (MAPK-activating protein kinases), Elk-1, Sap1a and c-Fos. 
1.5.8.3 Insulin-Independent Mechanisms 
• AMPK 
AMP-activated protein kinase (AMPK) plays a key role as a master regulator of cellular energy homeostasis 
(Hardie et al., 2006). The kinase is activated in response to stresses that deplete cellular ATP supplies such 
as low glucose, hypoxia (Mungai et al., 2011), ischemia, and heat shock (Frederich & Balschi, 2002). AMPK 
is a heterotrimeric protein that contains a catalytic subunit (α) and two regulatory subunits (β and γ). AMPKα2 
is most commonly expressed in liver, skeletal muscle and heart tissues (Hardie & Carling, 1997). Binding of 
AMP to the γ subunit allosterically activates the complex, making it a more attractive substrate for its major 
(but not sole) upstream AMPK kinase, liver kinase B1 (LKB1) (Woods et al., 2003). Increased intracellular Ca2+ 
concentration leads to the activation of Ca2+-calmodulin-dependent kinase kinase β (CaMKKβ) which 
phosphorylates and activates AMPK (Woods, 2003). Activation of AMPK in response to Ca2+ fluxes provide a 
mechanism for cells to anticipate the increased demand for ATP. In contrast, insulin inhibits AMPK activation 
in response to an excess of nutrients. Insulin promotes glycogen, triglyceride and protein synthesis, while 
AMPK inhibits these energy consuming processes (Towler & Hardie, 2007). However, AMPK can play a 
protective role in cardiac ischemia as an energy generator in response to fat-cell derived hormones such as 
adiponectin and leptin (Shibata et al., 2005).   
 
AMP-activated protein kinase has been shown to directly stimulate glucose uptake in skeletal muscle, thereby 
improving insulin insensitivity (Fisher et al., 2002). Activation of AMPK enhances both the transcription and 
translocation of GLUT4, resulting in an increase in otherwise insulin-stimulated glucose uptake. In addition, it 
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also stimulates catabolic processes such as FA oxidation and glycolysis via inhibition of acetyl-CoA 
carboxylase and activation of phosphofructokinase 2 in the heart (Hopkins et al., 2003). AMPK negatively 
regulates several proteins central to ATP consuming processes such as, glycogen synthase, HMG-CoA 
reductase, glycerol-3-phosphate acyltransferase and elongation factor 2, resulting in the down-regulation or 
inhibition of gluconeogenesis, glycogen, lipid and protein synthesis.  
 
Due to its role as a central regulator of both lipid and glucose metabolism, AMPK is considered a key 
therapeutic target for the treatment of obesity, T2D, myocardial I/R-I and atherosclerosis (Li, Zhong, et al., 
2017). 
• AS160 
Both insulin-dependent (PKB) and insulin-independent (AMPK) signaling can result in PKB substrate of 
160kDa (AS160) activation. Typically, insulin signaling leads to the activation of PKB, which in turn 
phosphorylates AS160 on 5 suggested sites, of which the Ser588 and Thr642 are the most prominent 
(Manning & Cantley, 2007), resulting in stimulation of GLUT4 translocation to the cell membrane. Mutations at 
these two sites significantly inhibit insulin-induced GLUT4 translocation (Sano et al., 2003). Currently, the 
mechanism proposed for PKB-AS160 mediation of GLUT4 translocation, states that PKB activation on the 
various binding sites of AS160 inhibits GTPase-activating protein (GAP) activity, requiring a Rab-family 
GTPase to become GTP loaded. Rabs are small G-proteins that in their GTP-bound form can participate in 
vesicle movement and fusion (Mîinea et al., 2005). Upon stimulation, GLUT4 vesicles translocate to the plasma 
membrane and facilitate the uptake of glucose from the blood stream (Mîinea, 2005) (Figure 2.11). 
Alternatively, AMPK has also been found to phosphorylate AS160 independent of insulin at its Ser473 site, 
which results in the same downstream activation and recruitment of GLUT4 (Treebak et al., 2006). 
1.5.8.4 Stress Sensing 
• JNK 
JNK (c-Jun N-terminal kinases) or SAPK (Stress-activated protein kinases) are kinases that form part of the 
MAPK family and are activated in response to cytokines and cellular stress. The JNK family comprises 3 
different isoforms, JNK1, JNK2 and JNK3, also known as SAPKγ, SAPKα and SAPKβ respectively. JNK1 and 
2 can be found in all tissue types, but JNK3 is mainly a brain protein (Bode & Dong, 2007). JNK can be 
activated in response to inflammatory cytokines or I/R-I (Deng et al., 2012), via upstream MAPK kinase (MKK4 
and MKK7) phosphorylation at its Ser63 and Ser73 residues, resulting in downstream signaling leading to 
inflammation (Ip & Davis, 1998). Alternatively, JNK can also be inhibited via Ser/Thr or Tyr protein 
phosphatases. Selective JNK inhibition have shown to be cardioprotective in I/R-I in kidneys and lungs (Wang 
et al., 2007; Wolf et al., 2008), however the same effect could not be mimicked in hearts and resulted in 
aggravated damage (Jang & Javadov, 2014; Shvedova et al., 2018). The current trend argues that JNK1 and 
2 is essential in I/R-I prevention, while an ongoing search for selective JNK3 inhibitors are underway 
(Shvedova et al., 2018). 
1.5.8.5 Inflammation Markers 
• p38  
p38’s, also called CSBP (cytokinin specific binding proteins), is a class of MAPK’s sensitive to cytokines and 
stress signals. They play a role in cell differentiation, apoptosis and autophagy. The p38 family has 4 different 
isoforms, p38α, p38, p38γ and p38δ, of which p38α and p38γ are most abundant in the heart (Deng et al., 
2012). Similar to JNK, the p38 cascade can be activated in response to inflammatory cytokines and I/R-I 
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(Harding et al., 2010), starting with the upstream MAPK kinase (MEKK3 and MKK3/4/6) phosphorylation of 
p38 in turn activates MK2/3/5, Elk-1, CHOP, ATF2 and MEF2A (Deng et al., 2012).  
 
Within the isolated-perfused rat heart, p38 have been shown to double in kinase activity following 20 min of 
ischemia and 15 min of reperfusion, which proved to be detrimental (Milano et al., 2007). In our own labs, we 
have also demonstrated that preconditioning in an isolated rat heart model resulted in attenuated p38 activation 
levels following reperfusion, which resulted in increased heart function (Marais et al., 2001).  Similarly, an in 
vivo I/R-I in rat hearts found p38 activation can abolish insulin’s cardioprotective effect (Chai et al., 2008). 
Furthermore, p38 activation in I/R-I exacerbates TNFα-induced tissue damage in response to elevated ROS, 
such as H2O2 (Meldrum et al., 1998). p38 MAPK inhibition in I/R-I mouse hearts led to a decrease infarct size 
(Gao et al., 2002). 
1.5.8.6 Auxiliary Metabolic Regulation 
• GSK-3  
GSK-3 (glycogen synthase kinase-3) is a protein kinase responsible for glycogen synthase regulation and 
plays a prominent role in glucose homeostasis (Ali et al., 2001). Cardiac GSK-3 consists of two isoforms, GSK-
3α (51 kDa) and GSK-3β (37 kDa) (Woodgett, 1990). GSK-3 plays a multifunctional role in cell signaling 
involved in proliferation, migration, inflammatory responses, glucose transport, glycogen synthesis, apoptosis 
and muscle contractility (Huisamen & Flepisi, 2014; Huisamen & Lochner, 2010). In response to insulin 
stimulation, PI3K and PKB are activated which in turn inactivates GSK-3 via phosphorylation of the Ser21 site 
in GSK-3α and Ser9 site in GSK-3β (Cohen et al., 1997). Inactivation of GSK-3 resulting in the activation of 
glycogen synthase and inhibiting the mPTP formation. This has made GSK-3 β inhibitors attractive targets in 
ischemic preconditioning (Förster et al., 2006). In contrast, GSK-3 activation through casein kinase 2 signaling 
(Rayasam et al., 2009), results in IRS-1 and -2 phosphorylation at their Ser307 and Ser332 sites resulting in 
an inhibition of these signals and subsequently inhibits PI3K (Eldar-Finkelman & Krebs, 1997). This has 
negatively implicated GSK-3 as a glucose uptake inhibitor and a contributor to insulin resistance (Aguirre et 
al., 2000; Flepisi et al., 2013).  
• ATM 
Ataxia-telangiectasia mutated kinase (ATM) is a key regulator of several signaling pathways in response to 
DNA damage, leading to cell cycle arrest, DNA repair or apoptosis (Smith et al., 1999). ATM is denoted after 
the symptoms experienced when ATM is deficient (the AT-syndrome: “poor coordination” and “small dilated 
blood vessels”) (Lee & Paull, 2007). Interestingly, lack of PKB function in vivo presents with phenotypical 
similarities to the AT-syndrome. ATM has also been shown to mediate PKB’s insulin stimulated response 
(Viniegra et al., 2005). Furthermore, ATM also plays a crucial role in the heart by controlling myocardial fibrosis 
and preventing myocyte hypertrophy (Foster et al., 2012). In ATM-knockout mice, no activation of pro-apoptotic 
factors such as p53 and JNKs were observed, however a decrease in the anti-apoptotic factor, PKB, resulted 
in increased myocyte apoptosis (Foster et al., 2012). Cardiac ATM have been shown to be upregulated in 
response to acute ischemic damage and reperfusion incurred during cardiopulmonary bypass surgery 
(Corbucci et al., 2004). 
 
Stellenbosch University  https://scholar.sun.ac.za
24 
 
Figure 1.6 Proposed cell signaling mechanisms involved in cardioprotection.  Cell signaling is narrowly regulated by a network of proteins working together to 
to resolve homeostatic imbalances in response to extracellular stresses and metabolic status.  To investigate the efficacy of novel cardioprotective therapies aimed 
at improving I/R-I, it is important to have a clear understanding of the phosphorylation and expression state of key proteins as I/R-I progress. These proteins undergo 
state changes in response to varying levels of cellular stress, such as induced during ischemia, upon reperfusion and during prolonged reperfusion. 
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1.5.8.7 Alternative Pathways 
• SAFE Pathway 
Alternative pathways not investigated in this dissertation have been suggested to be in part responsible for 
mediating ischemic preconditioning-induced cardioprotective effect, including the survivor activating factor 
enhancement (SAFE), and the NO/PKG pathway. It has been shown that administration of TNFα before 
ischemia can be cardioprotective without activation of the RISK pathway (Lecour et al., 2005). This alternative 
pathway was coined 4 years later as the SAFE pathway and has been linked to preconditioning (Lecour, 2009). 
The SAFE pathway has been identified in rodent and porcine hearts (Bhatt et al., 2013; Lecour, 2009; Lecour 
et al., 2005). Individual steps have been identified but not nearly as thorough as the RISK pathway. As such, 
evidence supporting the involvement of the SAFE pathway is very fragmented, and wholly not as compelling 
yet (Cohen & Downey, 2015). The pathway provides a mechanism by which extracellular factors control gene 
expression (O’Shea et al., 2015). Briefly, once engaged with a ligand (TNFα, interleukin-6 (IL-6) or growth 
factors), receptor-associated Janus Kinases (JAK) are activated and induce a functional change in the cytokine 
receptor allowing the cytoplasmic transcription factor, signal transducers and activators of transcription-3 
(STAT-3) to be phosphorylated on its tyrosine residues. Activated STAT-3 forms a dimer that translocates to 
the nucleus and in turn regulate gene expression and targets the inhibition of the mPTP opening (Lecour, 
2009; O’Shea et al., 2013). 
 
  







“Power from Within” 
Mitochondria was coined from the Greek ‘mitos’ (“thread-like”) and ‘khondrion’ (“granule-like”) according to 
their appearance. A mitochondrion is enclosed by two membranes containing specialized proteins, dividing 
the organelle into a narrow intermembrane space and a broader internal matrix. The outer membrane contains 
various channels made by the protein porin, and acts as the first barrier to large molecules entering the 
mitochondrion, while the highly convoluted inner membrane, containing specific transport proteins, further 
limits only selected molecules from entering the internal matrix. The inner mitochondrial membrane also has a 
unique folding-configuration (called cristae), which aligns oxidative phosphorylation complexes in close 
proximity to each other (Youle & van der Bliek, 2012). The number of mitochondria in a cell type is dependent 
on the metabolic demand and can range from a single mitochondrion to thousands. Within cardiac tissue, 
mitochondria comprise 40% of the cell weight (Papadopoulou et al., 1999) and cell volume (Murphy & 
Steenbergen, 2007), but accounts for 90% of ATP generation – enabling the cell to generate 15 times more 
ATP than it would have otherwise (Davidson, 2015). Mitochondria are quite flexible and have been shown to 
rapidly change shape and remain in constant motion throughout the cell. They are thought to be moved by 
motor proteins along the microtubule networks within cells and appear as a mixture of fragmented and tube-
like structures within specific cell-types. For instance, in neurons they form mitochondrial networks throughout 
the cytosol, while in cardiomyocytes they form populations within intermyofibrillar or subsarcolemmal 
compartments (Appendix A1) (Ong & Hausenloy, 2010). Mitochondria also contains its own circular DNA 
(different from its host) (Gray et al., 1998), comprising about 1% of the total cellular DNA (Trifunovic, 2006) 
and can reproduce independently of the cell and translate its own proteins. Mitochondria are primarily inherited 
from the maternal lineage, as the only mitochondria present in sperm is situated in the mid-section of the sperm 
tail (used to fuel the journey to the egg), but once fertilization is successful the tail falls off (Appendix A2). 
Therefore, all mitochondria prevalent in the development of the new organism comes from the mother’s egg. 
This makes mitochondrial DNA different from nuclear DNA, which is shuffled every generation. Mitochondrial 
DNA has been shown to be involved in various genetic diseases, including Alzheimer’s disease and diabetes 
(Davidson, 2015).  
 
2.2 ENERGY METABOLISM 
“The heart is all about non-stop energy”.  
2.2.1 Overview of Myocardial Energy Metabolism 
The heart consists of specialized muscle cells and has the unique feature of uninterrupted contraction and 
relaxation (An & Rodrigues, 2006). This also makes the heart the most metabolically active organ in the body 
(Neubauer, 2007), needing a high supply of energy equating to 6 kg of adenosine triphosphate (ATP) (1/8th of 
total requirement per day) (Kühlbrandt, 2015) to sustain cellular maintenance and contractile function (Shah & 
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Shannon, 2003). The heart has very little stored ATP content (5 mol/g of wet weight) and therefore a high 
turnover of ATP (~30 mol/g of wet weight per minute at rest) allowing the entire pool of ATP to be recycled 
every 10 sec (Bing et al., 1954; Opie, 1968, 1969a). The heart can utilize various substrates for energy 
generation (An & Rodrigues, 2006), but the most prominent are FA’s, which account for 60-90% of ATP 
production (Lopaschuk, Ussher, et al., 2010). The remaining energy is derived from glucose, amino acids, 
lactate and ketones. The heart switches between these substrates to facilitate optimal energy production 
during different physiological (post-prandial and fasted) or pathological conditions (Abdurrachim et al., 2015). 
These conditions can influence the demand for energy, the amount of O2 supplied to the heart, the amount of 
fatty acid supplied to the heart and the prevalence of the competing substrates, as well as change the 
mechanisms of substrate uptake and utilization within the cell (Lopaschuk, Folmes, et al., 2010).  
2.2.2 ATP 
Food molecules, such as carbohydrates, fat and protein are metabolized through stepwise oxidation to produce 
the chemical energy molecule ATP. ATP is the main molecular energy source used to support contractile 
proteins, facilitate ion transport and enable enzymes to be functional. It is majorily generated when phosphate 
ions are linked to adenosine diphosphate (ADP) by the enzyme, ATP synthase (Lodish, 2000). However, it is 
also important to mention that ATP can be produced by direct transfer of a high-energy phosphate group to 
ADP during catabolic breakdown of high-energy transfer compounds during glycolysis and aerobic respiration 
(Lambeth, 2006). Therefore, ATP can either be produced through anaerobic metabolism of carbohydrates (in 
the cytoplasm), or via aerobic metabolism of fats, carbohydrates and proteins (in the mitochondria). Aerobic 
metabolism in the heart account for up to 95% of total ATP yield (Nsiah-Sefaa & McKenzie, 2016) due to its 
high density of mitochondria (Berg et al., 2002). Metabolism can also be broken up into three separate stages, 
which all proceed in series: The first process is either glycolysis (in the cytosol) or fatty acid β-oxidation (in the 
mitochondrial matrix), followed by the citric acid cycle (CAC) (in the mitochondrial matrix), and ending in 
oxidative phosphorylation (on the inner mitochondrial membrane). 
2.2.3 Glucose Metabolism 
Glucose, a monosaccharide carbohydrate, is one of the major fuels utilized by the heart under normal 
physiological conditions. Glucose can either be derived from carbohydrates, such as sugars and starches after 
being processed by the digestive tract, or endogenously made by the body through breakdown of muscle and 
liver glycogen, or by de novo synthesis from lactate, glycerol, alanine and glutamine (Newsholme et al., 2003). 
It enters cells through 14 different glucose transporters (GLUT’s) depending on the tissue type (Augustin, 
2010), and within the heart GLUT4 is the most prominent transporter of glucose intake. The rate at which 
glucose can be used is always limited by the rate of uptake, rather than the processing of glucose (Manchester 
et al., 1994). Once inside the heart cell, glucose can be metabolised via glycolysis (in the cytosol) and glucose 
oxidation (in the mitochondria) or stored as glycogen in small quantities.  
• Glycolysis 
The initial stage of glucose metabolism, known as glycolysis, occurs in the absence of O2 in the cytosol of 
cells. The first step in glycolysis is the phosphorylation of glucose to glucose-6-phosphate (G-6-P) by 
hexokinase, leaving a negative charge and effectively trapping G-6-P inside the cell (Reddy & Reddy, 2015). 
Under physiological conditions, an estimated two-thirds of G-6-P is converted to glycogen (DeFronzo & 
Tripathy, 2009), whereas the rest enters glycolytic pathways to generate ATP. Each glucose molecule 
produces 2 ATP and 2 three-carbon pyruvate compounds, to be used subsequently in the CAC (Figure 2.1).  




Figure 2.1 Energy metabolism pathways involved in generating ATP from either glucose or fatty-acid substrate in mitochondria
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• Citric Acid Cycle 
CAC, also known as the tricarboxylic cycle or the Krebs cycle, is the metabolic junction between carbohydrates, 
fat and protein (Yang et al., 2014). After glycolysis, pyruvate and FA’s are redirected to the mitochondria for 
conversion to acetyl CoA. The CAC oxidizes about 66% of all acetyl-CoA to produce CO2 as waste product, 
and NADH and FADH2 which passes electrons to the ETC to facilitate ATP production during OxPhos (Nsiah-
Sefaa & McKenzie, 2016). The CAC does not directly require O2 to cycle, but it is reliant on O2 to recycle NAD+ 
by accepting e- from NADH. However, the 2-carbon acetyl group is not oxidized directly but transferred to the 
4-carbon oxaloacetate to form a 6-carbon, citric acid – from where the name for the cycle is derived. This is 
followed by the gradual oxidation of citric acid to produce energy-rich activated carrier molecules, such as 
NADH and FADH2, to be used for ATP production during OxPhos. The first step is the synthesis of citrate by 
citrate synthase from acetyl-CoA and oxaloacetate. Oxidising citrate produces ‘reducing equivalents’ NADH 
and FADH2 to drive ATP production during OxPhos. During the cycle, carbon is also released in the form of 
CO2, which further facilitates the replenishing of oxaloacetate. Carbon-containing CAC intermediates, such as 
oxaloacetate and a-ketoglutarate can also be used as alternative sources of energy or transported back into 
the cytosol to serve as precursors for amino biosynthesis (Owen et al., 2002). This creates a higher demand 
for oxaloacetate which becomes a rate-limiting step, unless produced from an alternative pathway not derived 
from mitochondrial citrate. These alternative pathways are known as anaplerosis, allowing the CAC cycle to 
function as both a bioenergetic and biosynthetic pathway (Owen et al., 2002). At the end of the cycle 
oxaloacetate is reproduced and the cycle can start again. In the end, the majority of glucose (80 – 90%) 
undergoing glycolysis is converted to 34 ATP molecules, carbon dioxide and water, while the remainder is 
converted to lactate (DeFronzo & Tripathy, 2009) 
• Glutamate 
Glutamate is a major precursor for oxaloacetate, a CAC intermediate, important in citrate synthesis (Bhatti et 
al., 2017). Glutamate is either derived from glutamine via glutaminase, producing also nitrogen containing 
ammonia, or by nitrogen-donating reactions involved in nucleotide synthesis (Matés et al., 2013). Glutamate 
is then converted to α-ketoglutarate by one of two reactions: 
o Under high-glucose conditions, transaminases transfer the amino group from glutamate to ketoacid, 
resulting in α-ketoglutarate and an amino acid (Yang et al., 2014).  
o Under glucose-starved conditions (and impaired PKB signaling), glutamate dehydrogenase 
deaminates glutamate resulting in ammonia and α-ketoglutarate (Yang et al., 2009) 
• Malate 
During OxPhos, pyruvate, glutamate and aspartate can all be derived from glutamine via glutaminolysis, which 
replenish the metabolic substrates of the CAC and support the synthesis of alanine and NADPH (DeBerardinis 
et al., 2007). However, using glutamate or pyruvate in isolation can result in lower O2 consumption rates 
(Puchowicz et al., 2004). In the absence of malate, acetyl CoA accumulation inhibits pyruvate dehydrogenase 
via feedback inhibition and can also result in a decrease in CAC intermediates through dicarboxylate carriers 
(Salabei et al., 2014). Therefore, when investigating mitochondrial oxidative phosphorylation, the addition of 
malate removes feedback inhibition by increasing oxaloacetate production thereby clearing acetyl CoA - 
essential for normal pyruvate dehydrogenase functioning.  
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2.2.4 Fatty Acid Metabolism 
In the heart, utilizing FA for energy metabolism is very dynamic and can account for nearly 100% of total 
energy requirements or feature only in a minor capacity (Bing et al., 1954; Opie, 1968, 1969b). FA’s reach the 
heart in one of two forms: FFA’s bound to albumin or FA’s released from triacylglycerol (TAG) found in 
chylomicrons or very-low-density lipoproteins (VLDL) (Van Der Vusse et al., 2000). Furthermore, excess body 
fat can be broken down and release as FFA’s to meet energy requirements - one kg body fat contains 7,740 
calories of potential energy (Jennings & Lesser, 2012), which is double the amount of energy stored in equal 
amounts of glycogen (Kotecki, 2011). Furthermore, interestingly, for every 10 kg of fat broken down into energy 
in the presence of O2, 8.4 kg is exhaled as a CO2 byproduct through the lungs, and only 1.6 kg turns to H2O 
which may be excreted in urine, faeces, sweat, breath, tears and other bodily fluids (Meerman & Brown, 2014). 
The rate of utilization is largely dependent on a variety of factors; ranging from the specific demand for energy, 
the availability of energy substrates, the type of FA’s available and its transport into the cell and mitochondria, 
the amount of O2 supplied, the rate at which FA’s can be esterified to Coenzyme A (an essential step to prime 
FA;s for lipid oxidation), the health of mitochondria and the rate at which new enzymes involved in FA’s 
metabolism can be generated (Lopaschuk, Folmes, et al., 2010).  
• Fatty Acid β-Oxidation 
Beta-oxidation is the breakdown process through which FA’s are converted into substrate products in the 
mitochondria to be used for energy generation. FFA’s are negatively charged, making it impossible to diffuse 
across cell membranes without specific transport proteins. Once inside the cell, FA’s need to be transported 
into the mitochondrial matrix for β-oxidation to occur. Products formed in this process include NADH and 
FADH2, co-enzymes involved in ETC, and acetyl-CoA - a type of acetate whereby most of the useful energy 
stored in sugars, fats and amino acids is extracted from. 
• Oxidative Phosphorylation 
OxPhos is the final step in cellular respiration and refers to the phosphorylation of ADP to ATP while oxidizing 
an energy substrate. It is the only step in substrate metabolism that directly requires atmospheric O2 derived 
from water to process acetyl into CO2. OxPhos comprises two closely connected components – the ETC and 
chemiosmosis. ETC drives the majority of ATP synthesis in most cells. NADH and FADH2 transfer the e- 
generated from the previous oxidation steps to the ETC located on the inner membrane of the mitochondrion. 
As e- pass through this long chain of specialized e- acceptors and donor molecules, the overall energy state is 
gradually lowered. The released energy is used to create a H+ gradient, by pumping H+ out of the mitochondrial 
matrix into the intermembrane space. This gradient can, in turn, be used to store potential energy (likened to 
a battery) to drive energy-requiring reactions – such as the phosphorylation of ADP to generate ATP. The last 
step in the ETC is the transfer of e- to O2 gas molecules (having diffused into the mitochondrion), which 
combines with the excess H+ in solution to produce a water molecule. With this action, the e- reach their lowest 
energy state, and no more energy can be extracted from the oxidized food molecule. The complete oxidation 
of a glucose molecule to H2O and CO2 results in 34 molecules of ATP produced. Of the 30, only 2 molecules 
of ATP are produced in the absence of O2 during glycolysis (Lodish, 2000). ETC is the final step in metabolism 
of food molecules, and the site where the most chemical energy is generated.  
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2.2.5 Lactate Metabolism 
• Cori Cycle 
During prolonged contraction of skeletal muscles, O2 supply grows limited, inhibiting complete oxidation of 
glucose. In this scenario, glucose is fermented to two molecules of ATP and lactic acid, rather than pyruvate 
(Lodish, 2000). Lactic acid accumulates in skeletal muscle (arguably contributing to muscle and joint aches 
(Miles & Clarkson, 1994) until it is cleared by secretion into the blood. Once in circulation, it is either taken up 
by the heart or liver, where it can be reprocessed to pyruvate and further metabolized to ATP and CO2 or 
converted back to glucose (Lodish, 2000). Monocarboxylates, such as pyruvate, lactate and ketone bodies are 
transported across the cell and organelle membranes via H+ -linked monocarboxylate transporters (Halestrap 
& Wilson, 2012). 
2.2.6 Ketone Metabolism 
Technically, heart muscle prefers acetoacetate as energy substrate over glucose (Berg et al., 2002). During 
periods of fasting or strenuous exercise, acetoacetate is produced in the liver, along with other ketone bodies 
to be used as energy substrate within organs.  
2.2.7 Glycogen Metabolism 
The heart contains very limited supplies of glycogen reserves, comprising about 2% of the adult heart cell 
volume (Berg et al., 2002), and 30% of fetal and newborn cardiomyocytes (Shelley, 1961). Cardiac glycogen 
concentration can vary based on training status, exercise and diet (Depre et al., 1998). In contrast to liver and 
skeletal muscle cells, cardiomyocytes produce glycogen during fasting (Schneider et al., 1991). In times of 
fasting, fatty acids become the predominant fuel for the heart, whilst glucose uptake and glycolysis are 
decreased. This leads to a repurposing of glucose for glycogen synthesis. Glycogen stores can be further 
expanded in response to insulin, which simultaneously stimulates glucose transport and glycogen synthase 
activity (Moule & Denton, 1997). Glycogen synthesis is also upregulated when lactate is used as the primary 
fuel for the heart (Laughlin & Taylor, 1994). Furthermore, heart glycogen can also be broken down in response 
to adrenaline or O2 deprivation to produce glucose (Morgan & Parmeggiani, 1964). 
 
2.3 MITOCHONDRIAL DYSFUNCTION 
“Load-shedding…” 
The role of mitochondria in human health have been extensively studied for the past 60 years (Calvo & Mootha, 
2010), yet new questions resulting in new insights are still being raised. As mentioned in the previous section, 
mitochondria are involved in energy-production (ATP, NADH and GTP) and bio-synthesis (amino acids, heme 
groups, iron sulfur clusters), but also play an important role in membrane biogenesis (phospholipid 
construction) (Kühlbrandt, 2015), cellular signaling (Ca2+) (Chandel, 2014; Rizzuto et al., 2012) and cellular 
stress (Pellegrino & Haynes, 2015). Thus, retaining mitochondrial quality is essential as dysfunctional 
mitochondria cause an array of pathological effects. Mitochondrial quality control revolves around a cycle of 
fission, fusion, mitophagy and biogenesis (Anzell et al., 2018). Stressful conditions such as acute I/R-I 
influence mitochondrial structural integrity (through swelling or disruption of cristae), ideally resulting in 
mitophagy of dysfunctional mitochondria (Anzell et al., 2018).  
2.3.1 Mitochondrial Fission and Fusion 
Mitochondria are often pictured as rigid, inflexible structures, but they form intercommunicating networks linked 
to the cytoskeleton which are constantly undertaking fission (division) and fusion (joining) subject to 
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intracellular stresses (Chen & Knowlton, 2010; Wong et al., 2000). Mitochondrial fission and fusion maintain 
mitochondrial homeostasis, by regulating turnover of new mitochondria or recycling of old (Seo et al., 2010), 
re-establishing electrical and biochemical connectivity, and preserving mitochondrial DNA (Youle & van der 
Bliek, 2012). Regardless of which cell-type, the balance between fission and fusion is induced by cellular stress 
and energy requirements (Ong & Gustafsson, 2012). Alterations in mitochondrial morphology occurs when too 
much fusion gives way to giant networks of clumped mitochondria, or too much fission results in tiny, 
mitochondrial pieces (Song et al., 2015). During I/R-I, low ATP levels and elevated mitochondrial ROS 
production causes upregulation of fission inducing extrinsic apoptosis, resulting in increased post-ischemic cell 
death. Inhibiting mitochondrial fission during I/R-I reduced mitochondrial fragmentation and presented 
cardioprotective properties by inhibiting the mPTP opening (Ong & Hausenloy, 2010). These findings have 
implicated mitochondrial fission and fusion regulation as a promising therapeutic target in I/R-I.  
2.3.2 Mitophagy 
Obesity and insulin resistance are associated with changes in cardiac mitochondrial function, including 
reduced OxPhos and therefore decreased ATP synthesis (Essop et al., 2009). To deal with these added 
stressors, cells undergo mitophagy, a specialized form of autophagy responsible for elimination of 
mitochondria in response to starvation and other forms of metabolic stress (Dolman et al., 2013). Two distinct 
mitophagy pathways are known which can be categorized into either Parkin-independent or Parkin-dependent 
pathways. Parkin-dependent mitophagy results from a loss in Δψm leading to rapid attenuation of the 
proteolysis of PTEN-induced putative kinase 1 (PINK1), increasing PINK1 accumulation on the surface of 
damaged mitochondria (Figure 1.6). In turn, PINK1 promotes phosphorylation of Parkin (PARK2), which then 
ubiquitinates SQSTM1 (p62) resulting in proteosomal degradation of p62 (Song et al., 2015). P62 serve as the 
link between tagging of the damaged mitochondria and ligation of the autophagy-specific adaptor protein 
MAP1LC3 (LC3) – targeting mitochondria for degradation by autophagosomal fusion with lysosomes. 
Alternatively, independent of parkin (as is evident in Parkinson’s Disease where Parkin-signaling is disrupted), 
mitophagy can also occur through either the BNIP3/Nix or FUNDC1 pathway (Novak et al., 2010). For instance, 
Nix (BNIP3L), located on the outer membrane of mitochondria, can serve as an autophagy receptor by binding 
LC3, which then recruits mitochondria to the autophagosome (Novak & Dikic, 2011). BNIP3L’s homolog, 
BNIP3 (in addition to FUNDC1 and NIX) can also localize to the mitochondria to mediate non-apoptotic cell 
death, leading to mitophagy (Campello et al., 2014). As these pathways can be programmed individually, yet 
often influence each other’s actions (Zorzano, 2017), it is safe to say that a lot more research is needed to 
improve our understanding of when specific mitophagy pathways are favoured.  
2.3.3 Mitochondrial ROS production 
Mitochondria are the single biggest source of intracellular O2• (Perrelli et al., 2011). The ECT reduces over 
90% of O2 entering cells to water, while 1-2% is reduced to O2• due to e- leakage at Complex I and Complex 
III, normally neutralized by SOD. However, mitochondrial ROS generation is elevated in I/R-I, partly due to a 
decrease in endogenous mitochondrial antioxidant potential (Stowe & Camara, 2009). These results were 
confirmed using specific inhibitors of various steps in the ETC, selective targeting of antioxidants to the 
mitochondria, and transgenic overexpression of mitochondrial versus cytosol-specific isoforms of antioxidant 
enzymes (e.g., MnSOD vs CuZnSOD) (Perrelli et al., 2011). In other studies, pharmacological protection 
against I/R-I-induced vascular dysfunction and tissue injury have been found to dependent on inhibition of 
mitochondrial ROS production (Perrelli et al., 2011). 
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2.3.4 Alterations in Diseased Conditions 
• Obesity (Elevated FAO) 
Under normal physiological conditions, excess supply of energy not utilized for immediate energy needs, are 
stored in the form of triacylglycerols (TAG) in adipocytes, as ATP is too unstable to use for stockpiling energy. 
FFA’s usually circulate at concentrations between 0.2 and 0.6 mM and the release of FFA’s is acutely regulated 
to meet the energy requirements (Kurien & Oliver, 1971). When this balance is disturbed through mechanisms 
such as persistent overconsumption of food, adipose hypertrophy and hyperplasia, leading to greater release 
of FFA into circulation at concentrations above 2 mM in diabetes (Boden, 2008; Kurien & Oliver, 1971). 
Elevated FFA in circulation leads to increased VLDL-TAG synthesis in the liver, further exacerbating 
hyperlipidemia. In both experimental animals and humans, elevated circulating FA’s and TAG induced by 
obesity and insulin resistance are important contributors to high rates of FA uptake and β-oxidation in the heart 
(Alberts et al., 2002; Koutsari & Jensen, 2006; Lopaschuk, Folmes, et al., 2010). Myocardial triglyceride 
content has been found to proportionally increase with BMI (Szczepaniak et al., 2003) and is a strong indicator 
of cardiac dysfunction and heart failure (Sharma et al., 2004). In diabetic patients without heart disease, an 
increase in FA circulation has also been correlated with a decrease in heart metabolism and diastolic 
functioning (stiff heart muscles leading to slower filling of the ventricles after a contractile cycle) (Leichman et 
al., 2006; Lopaschuk, Folmes, et al., 2010), and decreasing glucose oxidation can result in lower cardiac 
mechanical efficiency (How et al., 2006). As a therapeutic option it has been shown that pharmacologically 
inhibiting fatty acid metabolism and activating glucose metabolism can result in improved heart function in 
diabetic patients (Stanley, 1997). 
• Insulin Resistance 
In a failing heart, metabolism switches to glucose as the preferred substrate due to the efficiency of glucose 
oxidation in the generation of high-energy phosphates (Shah & Shannon, 2003). Increasing the amount of 
energy derived from glucose requires the upregulation of glucose transport and glucose oxidation. However, 
in the case of insulin resistance, glucose uptake and oxidation are both impaired, leading to less ATP 
generated from glucose. In diseased conditions, cells need to make use of alternative energy sources, 
including amino acids and fatty acid, to meet their metabolic demand. In this regard, glutamate and carnitoyl-
L-palmitate are potential metabolic fuels used to investigate OxPhos potential in isolated cardiac mitochondria.  
• Ischemia 
Without O2, mitochondrial OxPhos ceases and greater emphasis is placed on glycolysis to maintain cellular 
ATP demand. Initially, the glycolytic rate increases for the first 60 to 120 sec, after which it slows down to a 
steady state for up to 90 min, depending on the severity of ischemia (Jennings & Reimer, 1981). If ischemia 
persists beyond this point, all remaining ATP levels will be spent resulting in compromised transmembrane ion 
gradients which will trigger cell death. Electron flow through the respiratory chain is mediated by the presence 
of O2 and thus inhibited during ischemia. Therefore, F1F0 ATP synthase is unable to phosphorylate ADP to 
produce ATP (Di Lisa et al., 2009). Secondly, to maintain the Δψm, ATP synthase runs in the opposite direction 
and starts to hydrolyze the remaining ATP (Di Lisa et al., 2009). This quickly depletes ATP levels in the 
presence of ischemia. It has been shown that inhibiting ATP synthase during ischemia can effectively prevent 
ATP loss and prevent cell death in isolated rat hearts (Grover et al., 2004). However, OxPhos inhibition during 
ischemia can also inhibit fatty acid breakdown, resulting in a toxic intracellular buildup of fatty acids, recruiting 
inflammatory metabolites and stimulating the mPTP opening (Di Paola & Lorusso, 2006). Mitochondrial 
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dysfunction has also been associated with heart failure (Rosca et al., 2008). In mitochondria isolated from 
these hearts, OxPhos was severely decreased. As the individual activities of ETC enzymes remained normal, 
this dysfunction was attributed to a decrease in supermolecular assembly of ETC components (respirasomes) 
– dimerization of Complex I and Complex III assembled to Complex IV (Rosca et al., 2008).  
• Summary 
Mitochondria dysfunction is synonymous with a change in substrate oxidation. Impaired oxidation of energy 
substrates, especially FA, result in lipid accumulation and deposition of lipid mediators such as diacylglycerol 
and ceramides, both of which have shown to reduce insulin signaling. Insulin resistance increases 
susceptibility to cell death following I/R-I, as the anaerobic metabolism is firstly compromised during ischemia 
due to a decrease in glucose oxidation. This results in a decreased ability to maintain homeostasis at the onset 
of reperfusion while myocardial stunning prevails. After reperfusion, cardiac cells become overburdened by 
ROS and calcium, which can lead to dysregulated autophagic mechanisms. As impaired autophagy results in 
a failure to clear abnormal mitochondria, dysfunctional mitochondria proceed to open the mPTP leading to cell 
death. Therefore, therapies aimed at improving substrate utilization, supressing ROS production and 
preventing lethal calcium increases can effectively block the mPTP from opening and thereby prevent 
reperfusion-induced cell death.  
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“THE PURPOSE OF POLYPHENOLS”  
Nature is the master craftsman of molecules used in drug development. In drug discovery, natural products 
remain an inexhaustible resource of therapeutic potential with an estimated 35,000-70,000 plant species 
having been screened for their medicinal use to date (Veeresham, 2012). Interestingly, the first purely natural 
therapeutic product was morphine in 1826, marketed by Merck, whereas the first semi-synthetic pure drug was 
aspirin (isolated from Salix alba) in 1899 by Bayer (Veeresham, 2012). Surprisingly, today only 11% of the 252 
drugs listed as essential by the WHO and only 50% of cancer drugs used in the past 30 years are either directly 
or indirectly derived from natural products (Veeresham, 2012). This while even the most popular anti-diabetic 
medication, metformin, finds its origins in the French lilac or goat's rue (Galega officinalis), a plant that has 
been used for its medicinal properties since 1,500 B.C. (Witters, 2001). The search for novel synthetic 
chemicals, defined as compounds produced by man whereas natural products are made by nature, has often 
led us down a path of uncertainty and minor improvements at best as was asserted by Olfson & Marcus (2013) 
who compared the effect size of novel treatments published in 4 of the top journals around the world between 
1966 and 2010. This is not to say that these research avenues should be stopped, but it is refreshing to know 
that the simpler way can often be more effective. Furthermore, up to 80% of the world’s population still rely on 
natural medicines to treat ailments due to their time trialed safety and efficacy (Ekor, 2014). In search of more 
effective therapies in managing CVD progression, polyphenols and related phenolic compounds have been 
identified as prominent targets (Pandey & Rizvi, 2009). Polyphenolic compounds are abundant in plants and 
are readily found in fruit and vegetables. In addition, they are important components of herbs and spices and 
are likely to be critical ingredients in most Chinese medicines (Goszcz et al., 2015). There are three major 
mechanisms by which polyphenols might impact on CVD, acting as antioxidants, anti-inflammatory agents, 
and/or anti-thrombotic agents. Together with their antioxidant properties, they can also generate ROS. The 
pro-oxidant effects of polyphenols can also be beneficial, since, by imposing a mild degree of oxidative stress, 
they can induce endogenous antioxidant defense mechanisms and serve as a means of preconditioning 
(Goszcz et al., 2015). This can be thought of as how small bouts of exercise, followed by periods of rest, can 
increase your endurance and strengthen muscles in the long run. Unfortunately, the amount of research on 
the antioxidant potential of polyphenols far overshadows the lesser number of studies on the biological 
implications of their pro-oxidant properties. As a new role player to the field of CVD therapies, we turn our 
attention to the polyphenol-rich Rooibos, a plant exclusively cultivated in South Africa. In recent years Rooibos 
has shown promise as a strong antioxidant, anti-inflammatory and cardioprotective agent when administered 
orally. It is thus worthwhile to explore Rooibos’ potential in treating CVD risk in a model of obesity and insulin 
resistant co-morbidities.  
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3.2 ROOIBOS 
“FROM ROOIBOS TO GREENBOS” 
3.2.1 Overview of Rooibos 
Aspalathus Linearis (from the Latin aspalathus or Greek aspalathos – a scented and spiny bush) (Burm.f.) 
Dahlg. (Fabaceae, Tribe Crotalarieae), is an endemic South African fynbos species cultivated to produce the 
well-known herbal tea, rooibos (Johnson et al., 2018; Quattrocchi, 2012). In the past 100 years, rooibos tea 
went from zero commercial value to being the most sought after herbal tea in at least 37 countries worldwide, 
including Germany, the Netherlands, the United Kingdom, Japan and the United States of America 
representing 86% of the export market in 2010 (Joubert & de Beer, 2012a; Joubert & De Beer, 2011). After 
ordinary black tea (Camellia sinensis), rooibos is reported to be the second most consumed tea beverage in 
the world (Anonymous, 2007). Its caffeine-free and comparatively low tannin status, combined with its potential 
health-promoting properties, most notably antioxidant activity, contributes to its popularity. The use of rooibos 
has also moved beyond herbal tea to intermediate value-added products such as extracts for the beverage, 
food, nutraceutical and cosmetic markets. Traditionally, rooibos has been used as a treatment or ointment for 
alleviating stress-related ailments such as insomnia and anxiety. Rooibos polyphenols also exhibit similar 
properties to the polyphenols of honeybush (Cyclopia intermedia), black and green (Camellia sinensis) teas 
when comparing antioxidant potential and antimutagenicity (van der Merwe et al., 2006). Furthermore, 
increased antioxidant levels in unfermented rooibos compared to fermented rooibos (FRE), led to the 
development of green rooibos (GRE) (Figure 3.1). This has become a prominent product for nutraceutical 
industries isolating rooibos compounds for its anti-oxidant properties.  
3.2.2 Composition 
Rooibos’ potential health benefits are a direct result of its phenolic compounds (Joubert & De Beer, 2011). Of 
therapeutic value, rooibos contains two unique polyphenolic compounds, aspalathin (Koeppen & Roux, 1965), 
a dihydrochalcone C-glucoside and aspalalinin (Shimamura et al., 2006), a cyclic dihydrochalcone – occurring 
exclusively in Aspalathus Linearis. Rooibos also contains nothofagin, a rare dihydrochalcone C-glucoside 
which was first identified in the heartwood of Nothofagus fusca (Hillis & Inoue, 1967) and subsequently in the 
Chinese medicinal plant Schoepfia chinensis (Huang et al., 2008). The remaining major phenolic compounds 
prevalent in rooibos include the flavones (orientin, iso-orientin, vitexin, isovitexin, luteolin and chrysoeriol), the 
flavanones (dihydro-orientin, dihydro-iso-orientin and hemiphlorin, and the flavonols (quercetin, hyperoside, 
isoquercitrin and rutin) (Ferreira et al., 1995; Koeppen et al., 1962; Marais et al., 2000; Rabe et al., 1994; 
Shimamura et al., 2006). Rooibos also contains the phenolic acids, lignans, flavone diglycosides, (+)-catechin, 
a phenylpyruvic acid glycoside, and the coumarins, esculetin and esculin (Beltrán-Debón et al., 2011; Breiter 
et al., 2011; Krafczyk & Glomb, 2008; Marais, C., Steenkamp, J.A., Ferreira, 1996; Shimamura et al., 2006). 
3.2.3 Processing 
Commercially, rooibos shoots are shredded and bruised, and left to enzymatically and chemically oxidize. This 
is followed by fermentation and sun drying (Joubert & Schulz, 2006). Finally, the tea is steam pasteurized to 
ensure that the final product is microbiologically safe. However, steam pasteurization significantly reduces the 
soluble solids, total polyphenols, total colour and most importantly, aspalathin contents of rooibos infusions 
(Koch et al., 2013). The polyphenolic content (specific chemical structures with strong anti-oxidant capacity 
occurring naturally in plants) in rooibos extracts, especially the aspalathin and nothofagin content, are 
dependent on the concentration present in the plant (Schulz et al., 2003) and the extent to which the plant 
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material is fermented (Joubert, 1996). Fermenting rooibos plant material to procure oxidized rooibos herbal 
tea results in a significant loss of phenolic composition (Figure 3.1), with 98% loss in aspalathin content 
reported in some cases (Schulz et al., 2003).  
 
Figure 3.1 Reduction in major compounds present in rooibos following fermentation 
 
3.2.4 Bioavailability 
Polyphenols have very low bioavailability with less than 1% ingested reaching the plasma at concentrations 
rarely exceeding 1 M when 10-100 mg of a single polyphenol is ingested (depending on the specific type) 
(Breiter et al., 2011; Goszcz et al., 2015; Scalbert & Williamson, 2000). Polyphenols are firstly metabolized by 
phase I and II liver enzymes, as well as the kidneys, resulting in conjugates forming in the blood plasma and 
urine (McGurk et al., 1998). Peak concentrations in human plasma are usually achieved within 2h of ingesting 
polyphenols and baseline concentration restored within 12h (Scalbert & Williamson, 2000). The biological 
properties of most polyphenolic metabolites remain unknown (Scalbert et al., 2002). Through conjugation, the 
biological effects of the parent compound can be either reduced or completely inhibited (Day et al., 2000). 
Flavonoids bind to proteins, such as albumin, effectively lowering the detectable free flavonoid levels in the 
plasma (Manach et al., 1997), while most flavonoids remain unabsorbed until it reaches the large intestine or 
is broken down by colonic microflora (Thilakarathna & Rupasinghe, 2013). Glucoronidation of aspalathin 
dissipates its antioxidant potential, but it can still elicit other biological properties, as compared with the 
conjugation of another rooibos compound, quercetin (Day et al., 2000; O’Leary et al., 2003). 
 
Aspalathin (2’,3,4,4’,6’-pentahydroxy-3-C-β-D-glucopyranosyldihydrochalcone) is a C-glycosyl dihydro-
chalcone and soluble in water and other polar solvents, but insoluble in non-polar media. It is the primary 
polyphenol and flavonoid present in the leaves of Rooibos or Aspalathus linearis, whilst also biogenetically 
related to other flavonoids isolated from rooibos tea (Koeppen & Roux, 1966). Aspalathin has a very low 
estimated absorption rate between 0.1% and 0.9% in pigs and humans (Courts & Williamson, 2009; Kreuz et 
al., 2008; Stalmach et al., 2009). Unmetabolized aspalathin is also detectable in human plasma (Laue et al., 
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2009). After ingestion of aspalathin, the glycoronyl and sulphate conjugates are present in rat liver extracts 
(Van Der Merwe et al., 2010) and O-linked methyl-, sulphate-, glucoronide-, and O-methyl-O-glucoronide 
derivates in human urine and plasma (Courts & Williamson, 2009; Stalmach et al., 2009). Even though 
polyphenolic conjugation is well recognized, most biological studies still incorporate unmetabolized, natural, 
plant polyphenols. The unconjugated polyphenols as well as the remaining conjugates, could possibly 
aggregate in the body and elicit pharmacological activities (Zhang et al., 2007), especially anti-diabetic effects 
(Sequeira & Poppitt, 2017).  
3.2.5 Safety and Toxicity 
Marnewick and coleagues (2003) treated ten Fisher 344 rats with 2 g/100 ml GRE and FRE for 10 weeks and 
found no adverse effects on body weight, liver, kidney or serum parameters (including aspartate transaminase, 
alanine transaminase (ALT), alkaline phosphatase (ALP), creatinine, bilirubin, total protein, cholesterol and 
iron status). In a follow-up study, they gave 40 volunteers 6 cups of fermented rooibos per day for six weeks 
(essentially ~1.5 L of tea per day) and some individuals presented with minor elevations in liver enzymes, 
albeit not enough to be clinically significant (Marnewick et al., 2011).  
 
In contrast, in 2010, Sinisalo and colleagues (2010) reported a case study on a 42-year-old woman who 
presented with elevated liver enzymes, ALT, ALP and γ-glutamyl transferase, indicators of possible liver 
toxicity after consuming 1L of rooibos tea per day for 2 weeks. As this was an isolated incident it was argued 
that the specific brand of rooibos might’ve been poorly processed or laced with hepatotoxic compounds 
(Sinisalo et al., 2010). Poorly processed rooibos contains high amounts of Salmonella, a gram-negative 
bacteria which can cause severe diarrhea, fever and abdominal cramps in infected patients (Gouws et al., 
2014), which can be avoided through proper processing insuring the tea is microbially safe (Joubert & Schulz, 
2006). Overall, rooibos has been confirmed as safe for human consumption by at least 3 studies (Breet et al., 
2005; Hesseling et al., 1979; Marnewick et al., 2011). 
3.3 ROOIBOS FUNCTION 
“ALL-IN-ONE NATURAL REMEDY” 
Rooibos is gaining more popularity as a dietary antioxidant supplement and drinking merely 2 cups of either 
fermented or unfermented rooibos has the potential to raise plasma anti-oxidant levels in healthy adults (Villaño 
et al., 2010). Furthermore, in adults susceptible to CVD, consuming 6 cups of fermented rooibos infusions per 
day for 6 weeks has been shown to improve lipid profiles and redox status (Marnewick et al., 2011). It is gaining 
increasing popularity in research as a potent anti-oxidant (Dludla et al., 2014; Sinjman et al., 2009), 
cardioprotective agent (Pantsi et al., 2011), stimulant of glucose clearance in muscle and cardiac cells (Muller 
et al., 2012; Smit et al., 2018), regulator of energy metabolism (Kawano et al., 2009; Son et al., 2013) and lipid 
lowering agent (Marnewick et al., 2011). 
3.3.1 Antioxidant Potential 
The balance between internal and external ROS production in response to stress, is at the core of the ageing 
process and many age-related diseases (Liochev, 2013). Under baseline conditions, cells have a natural 
scavenging capacity to balance ROS production through anti-oxidants such as glutathione (GSH). However, 
during diseased conditions such as diabetes or myocardial infarction, there is an increased vulnerability for 
cellular damage and apoptosis due to an imbalance in the antioxidant to oxidative stress ratio. It has repeatedly 
been shown that diets consisting of primarily plant-based foods and beverages can lower the risk of developing 
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chronic diseases (Hu, 2003). Consuming flavonoids reduces the incidence of CVD and cancer (Arts & Hollman, 
2005; Knekt et al., 2002). Also, dietary interventions consisting of polyphenol-rich foods, have shown to 
improve plasma antioxidant capacity and total phenolic content (Lotito & Frei, 2006) Conversely, as shown by 
(Prior et al., 2007), consuming nutrients without anti-oxidants, results in a loss of anti-oxidant potential in the 
blood. Moreover, strong antioxidant polyphenols have been researched in treating diabetic-associated 
complications (Zang et al., 2006). Aspalathin is implicated as one of the main contributors of rooibos’ 
antioxidant potential (Joubert et al., 2009) (Figure 3.2), which is partly due to the relatively high content of 
aspalathin in rooibos, compared to the other compounds, and its radical scavenging activities.  
 
Figure 3.2 Comparison of the aspalathin’s free radical scavenging ability compared to other rooibos 
flavonoids. DPPH•: 2,2-diphenyl-1-picrylhydrazyl free radical, O2•: superoxide radical (Joubert et al., 2006). 
 
• In vitro 
Dludla and colleagues (2014) showed that FRE pretreatment in ischemic cardiomyocytes with a pro-oxidant 
insult (exogenous H2O2) preserved GSH and ATP content, improving anti-oxidant status and thereby reduced 
intracellular ROS and cell death. The protective effect of FRE was also more pronounced than that of vitamin 
E (a strong anti-oxidant used in radiotherapy treatment) (Prasad et al., 2002). Chen and colleagues (2013) 
investigated the protective properties of aspalathin, GRE and FRE in C.elegans - an invertebrate organism 
used for investigating hyperglycemic conditions, ageing and longevity through simulation of a high glucose 
environment. They found that both rooibos and aspalathin prevents damage induced by juglone toxicity (used 
in high dosages to generate intracellular superoxides, O2• and H2O2). Similarly, in RIN-5F cells, GRE and 
aspalathin was able to protect against juglone toxicity by scavenging the O2• radicals (Son et al., 2013). 
Furthermore, aspalathin display greater antioxidant potential than the commercial standard EGCG 
(epigallocatechin gallate), the most abundant catechin in green tea (Snijman et al., 2007).  
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However, high dosages of polyphenols are known to exhibit pro-oxidant, rather than anti-oxidant effects 
(Mennen et al., 2005). This was verified by Dludla and colleagues (2014) as high doses of FRE reduced its 
protective effect against exogenous H2O2.  
• In vivo 
Rats treated with both GRE and FRE displayed increased myocardial total GSH content and reduced oxidative 
stress, which was also associated with improved aortic output recovery after ischemia/reperfusion (Pantsi et 
al., 2011). In a study done on 40 human adults at risk for CVD, consuming 6 cups of fermented rooibos for 6 
weeks improved redox status, lipid profile and elevated plasma GSH levels (Marnewick et al., 2011). Likewise, 
Villaño and colleagues (2010) found that 2 cups of either fermented or unfermented rooibos tea in healthy 
adults increased plasma antioxidant capacity for 1 h similarly to other purported strong antioxidants, such as 
black tea (Widlansky et al., 2005), green tea (Coimbra et al., 2006) and cranberry juice (Duthie et al., 2005). 
Lastly, rats receiving fermented rooibos tea for 7 weeks had increased antioxidant capacity and reduced lipid 
peroxidation, and after I/R-I in the brain, presented with reduced brain oedema and neuronal apoptosis 
compared to controls (Akinrinmade et al., 2017).  
• Synergy between related compounds in rooibos 
Interestingly, Simpson and colleagues (2013) showed that reconstituting an artificial infusion from the two most 
active dihydrochalcones, aspalathin and nothofagin, using the same concentrations had a greater antioxidant 
potential than the sum of either alone, or when compared to natural green and fermented infusions. 
3.3.2 Cardioprotection 
Pretreatment of cardiomyocytes with fermented rooibos prevented damage induced by ischemia, as indicated 
by a reduced amount of high fatty acid binding protein leakage (Dludla et al., 2014). Pantsi and colleagues 
(2011) showed that both GRE and FRE fed to rats for 7 weeks, were able to significantly improve heart function 
following ischemia/reperfusion and decrease poly ADP ribose polymerase (PARP) cleavage (a pro-apoptotic 
protein), while only FRE was able to decrease caspase-3 (also a pro-apoptotic protein) activity, inhibiting 
apoptosis and thereby having a cardioprotective effect. In a lipid toxic H9c2 cardiomyocyte model, established 
by exposure to 33 mM glucose for 48 h, treatment of 1 M aspalathin for 6 h could reverse metabolic 
abnormalities through modulation of lipid metabolism (PPAR and Srebf1/2), inflammation (IL-6/Jak2 pathway) 
and increased Bcl2 expression potentially preventing myocardium apoptosis (Johnson et al., 2017). 
3.3.3 Hypoglycemic agent 
Aspalathin has been found to dose-dependently increase glucose uptake in rat L6 skeletal myotubes at 
concentrations between 1 and 100 M (Kawano et al., 2009; Son et al., 2013). In our previous studies, we 
found that aspalathin had no observable effect on glucose uptake prior to 1.5 h in vitro administration to isolated 
cardiomyocytes, attributable to its role in upregulating gene expression first, resulting in GLUT4 translocation 
to membranes to facilitate glucose uptake into cells (Smit et al., 2018). Aspalathin also suppressed elevated 
fasting blood glucose and improved impaired glucose tolerance in ob/ob mice (Son et al., 2013) and db/db 
mice (Kawano et al., 2009). 
• AMPK-dependent mechanism 
Kawano and colleagues (2009) first showed in RIN-5F pancreatic β-cells that 100 M aspalathin treatment can 
increase insulin secretion, potentially leading to improved glucose homeostasis. Mazibuko and colleagues 
(2013) found that treating palmitate-induced insulin-resistant C2C12 skeletal muscle cells with either FRE or 
GRE enhanced glucose uptake, mitochondrial activity and ATP production, and resulted in the activation of 
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the insulin-independent AMPK pathway which culminated in increased levels of GLUT4. Similarly, Son and 
colleagues (2013) found that ob/ob mice fed a diet substituted with 0.1% aspalathin for 5 weeks (effective 
aspalathin dose 100 mg/kg/day/mouse) suppressed gene expression of enzymes related to gluconeogenesis 
and glycogenolysis, while upregulating glycogenesis in the liver resulting in improved glucose homeostasis. 
This effect was shown to manifest in activated AMPK signaling promoting endogenous GLUT4 translocation 
to the plasma membrane without effecting PKB activation. In C2C12 mouse skeletal muscle cells, Muller et al. 
(2012) also showed aspalathin improved glucose uptake, while this same effect could not be mimicked in 
Chang liver cells, which does not contain GLUT4. This strongly implicates GLUT4 and AMPK as essential role 
players in eliciting rooibos’ response.  
• PKB-dependent mechanism 
The role of rooibos’ flavonoids on PKB signaling remain controversial. In rats supplemented for 7 weeks with 
GRE and FRE, there was little to no significant difference in total cardiac PKB levels (Pantsi et al., 2011). In 
another study done by Son and colleagues (2013), rooibos also did not activate PKB in normal L6 myocytes. 
However, Mazibuko and colleagues (2013) was able to show activation of PKB in insulin resistant C2C12 
myocytes when treated with rooibos. They observed that chronic exposure to saturated FFA, such as 
palmitate, reduces downstream activation of IRS-1 resulting in decreased PKB activation and GLUT4 
translocation, effectively producing more insulin resistant cells (Bhattacharya et al., 2007). However, when 
treated with rooibos, the P-PKB levels of the palmitate treated cells resembled that of normal P-PKB levels 
when stimulated by insulin, suggesting that rooibos can activate downstream insulin signaling.  
• Synergy between related compounds in rooibos 
Muller and colleagues (2012) showed that Streptozotocin (STZ)-induced T1D Wistar rats (STZ used to ablate 
insulin producing pancreatic β-cells) pretreated for 1 h with aspalathin-enriched fractions suppressed blood 
glucose level increases. Purified aspalathin was unable to elicit the same response, but when aspalathin was 
combined with rutin (another prominent flavanoid present in rooibos), blood glucose was effectively 
suppressed for up to 6 h. Furthermore, it’s been shown that GRE has a post-prandial blood glucose lowering 
effect in rats through suppressing intestinal α-glucosidase activity (Mikami et al., 2015). Recently, it’s been 
shown that 200 µg/mL GRE was required to have the same α-glucosidase inhibitory effect as 42 µg/mL of the 
anti-diabetic drug, acarbose (Miller et al., 2018). 
3.3.4 Lipid Profile 
A person’s lipid profile is determined by screening the blood for abnormalities in lipids, including cholesterol 
and triglycerides. In adults at risk for CVD, it was found that 6 cups of fermented rooibos per day for 6 weeks 
improved the lipid profile by lowering the LDL-cholesterol and TAG levels, and increasing the HDL-cholesterol 
(Marnewick et al., 2011). In addition, fermented rooibos reduced lipid peroxidation, by decreasing conjugated 
dienes and thiobarbituric acid reactive substances (TBARS). Furthermore, 0.1% aspalathin administered for 5 
weeks (effective aspalathin dose 100mg/kg/day/mouse) reduced hypertriglyceridemia, serum TBARS and 
adiponectin levels in ob/ob mice (Son et al., 2013). In these mice, aspalathin also suppressed gene expression 
of enzymes related to lipogenesis leading to reduced serum triglyceride levels. In a study done by Najafian 
and colleagues (2016) they found in STZ-induced diabetic rats receiving 5 – 40 mg/kg aspalathin for 21 days 
had dose-dependent improvement in dyslipidemia (and blood glucose levels). Aspalathin also induced weight 
loss and reduced food intake, while also reducing diabetic-induced fluid loss through urine.   
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MOTIVATION FOR RESEARCH 
 
OBESITY AND INSULIN RESISTANCE PREVALENT IN CARDIOVASCULAR DISEASE 
CVD’s are the leading cause of death worldwide, constituting 31% of all annual global deaths (17.5 million 
people) (“WHO | Cardiovascular diseases (CVDs)”, 2018). This figure is in part aggravated by the presence of 
individual risk factors such as obesity and insulin resistance. Furthermore, the risk of cancer, IHD, ischemic 
stroke and T2D also increase as the severity of obesity increases (Abdelaal et al., 2017). Recently, there has 
been a shift towards research into the therapeutic properties of natural products, including plant extracts 
(concentration of active compounds in plants), phytochemicals (isolation of active compounds in plants) and 
microbial metabolites (isolation of microbes present in plants) (Lahlou, 2013). These products are increasingly 
recognized for their potential in treating and preventing the metabolic syndrome, and subsequent T2D and 
CVD.  
ROOIBOS BENEFICIAL FOR CARDIOVASCULAR HEALTH 
Aspalathus linearis (commonly known as rooibos) is a plant indigenous to South Africa’s fynbos area. Rooibos 
has shown to improve antioxidant status, CVD health, lower blood glucose and improve lipid profile (Muller et 
al., 2018). Rooibos contains various bioactive phenolic compounds such as aspalathin, a C-linked 
dihydrochalcone glucoside unique to rooibos, and has been implicated as one of the main contributors of 
therapeutic potential (Johnson et al., 2018).  
EXPAND OUR UNDERSTANDING OF ISCHEMIA-REPERFUSION INJURY 
In view of the significant role of anaerobic glycolysis in the survival of the ischemic myocardium (Opie, 2004), 
GRT could possibly be cardioprotective by contributing to myocardial glucose uptake and metabolism. 
Therefore, the effects of long-term GRT treatment on myocardial glucose metabolism in insulin-resistant, 
obese animals might aid in resensitising metabolism and protecting against I/R-I. In previous studies, rats 
treated with an aqueous unfermented rooibos extract for 7 weeks displayed improved cardiac aortic output 
recovery after I/R-I (Pantsi et al., 2011). However, the role of rooibos in protecting against elevated CVD risk 
is uncertain. Furthermore, investigating the cellular signaling in both early reperfusion (5 mins of reperfusion) 
and late reperfusion (30 mins of reperfusion) will elaborate our understanding of pre- and post-treatment 
intervention feasibility. 
EFFECT OF ROOIBOS ON MITOCHONDRIA 
In view of mitochondria being the major producer of ROS leading to cell death, the importance of mitophagy 
in myocardial I/R-I may lay in sequestering dysfunctional mitochondria to prevent extensive ROS-induced 
damage. Aspalathin-rich rooibos extracts and purified aspalathin have been shown to inhibit the activity of 
xanthine oxidase, an enzyme responsible for generating ROS (Chen et al., 2013). Unfermented rooibos has 
also been shown to protect against mitochondrial dysfunction (Mazibuko et al., 2013). Thus, using GRT as a 
ROS scavenger may have a profound effect on mitophagic processes. This remains unclear as the effect of 
GRT on the mitochondria has not yet been studied in any setting.  Experimental studies provided compelling 
evidence for rooibos extracts as a potential therapeutic tool against obesity and related metabolic 
abnormalities, contributing to the health of South Africans, and the rest of the world.  
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PURPOSE OF RESEARCH 
Thus, the primary aim of the research was to investigate the effect of 6-week Afriplex Green Rooibos Extract 
(GRT), which is good-laboratory-practice certified product containing 12.36% aspalathin (See Certificate in 
Appendix A3) in treating cardiometabolic disease risk factors induced by a 16-week high-fat, high-caloric diet 
(HCD) feeding in rats. Specific focus was placed on GRT’s effect on insulin resistance, obesity, I/R-I 
cardioprotection and oxidative phosphorylation. The secondary aim was to elaborate our understanding of the 
mechanism of action of rooibos polyphenols, and to ensure its effectiveness and safety using rat models. This 
study investigated the signaling molecules possibly involved in Afriplex GRT's beneficial effects by determining 
the expression and activation of proteins known to be involved in cardioprotection as well as mitophagy.  
HYPOTHESES 
• Alternate hypotheses 
We hypothesize that treating obese, insulin resistant rats with GRT, an aspalathin-rich rooibos extract, for 6 
weeks can protect against cardiac I/R-I and mitochondrial dysfunction potentially through cardioprotective, 
anti-inflammatory and anti-oxidant mechanisms. 
• Null hypothesis 
Treating obese, insulin resistant rats with GRT, an aspalathin-rich rooibos extract, for 6 weeks is insufficient 
to protect against cardiac I/R-I and mitochondrial dysfunction. 
RESEARCH AIMS AND OBJECTIVES 
Aim 1: To determine the effects of a 6-week treatment period with GRT on the functional performance of the 
heart by subjecting the isolated heart to a period of ischemia followed by reperfusion. 
(i) Hearts from control (n=50) and HCD (n=50) animals, with half of each group receiving GRT treatment, 
stabilized for 30 min in ex vivo Working Heart Perfusion System followed by 20 min global ischemia and 30 
min reperfusion for functional recovery determination. These hearts are freeze-clamped at the end of 
reperfusion to be analyzed for cellular signaling proteins in objective (ii).  
(ii) In order to analyse the signaling pathways involved, the previously mentioned hearts, along with 
additional C (n=30) and HCD (n=30) hearts, of which half GRT treated, freeze clamped in groups of 5, after 
either 30 min stabilization period, 20 min ischemic period or 5 min into reperfusion. 
(iii) All freeze-clamped hearts analysed for expression and activation of a battery of proteins known to play 
a role in cardioprotection or known for their detrimental role to the heart if activated. This included the following: 
PKB/Akt, ERK, AMPK, ATM, GSK3β, P38MAPK, JNK and AS160.  
 
Aim 2: To determine the effects of a 6-week treatment period with GRT on infarct size induced by regional 
ischemia followed by reperfusion 
(i) Hearts from control (n=20) and HCD (n=20), with half of each group GRT treated, to determine infarct 
size as the golden standard of cardioprotection.  Isolated working hearts subjected to 30 min stabilization, 
followed by 35 min regional ischemia by occluding the left anterior descending coronary artery followed by 1 h 
of reperfusion.  As these hearts are stained with Evan’s Blue after the perfusion period to demarcate live, area 
at risk and dead tissue, they cannot be used for any additional measurements. Infarcted tissue vs live tissue 
determined using tetrazolium chloride (TTC) staining. 
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Aim 3: To determine the effects of a 6-week treatment period with GRT on mitochondrial OxPhos potential of 
the heart, before and after ischemia. 
(i) Control (n=50) and HCD (n=50) animals with half of each group on GRT treatment.  Mitochondrial 
isolations prepared from hearts stabilized for 30 min in ex vivo Working Heart System, after 20 min global 
ischemia and after 30 min reperfusion. Mitochondrial OxPhos potential measured using oxygraph. 
(ii) Lysates prepared from mitochondrial fractions to determine accumulation of mitophagy induced 
proteins PINK1, Parkin, p62/SQSTM1, BNIP3L and LC-3.   
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Chapter 4 
MATERIALS AND METHODS 
 
4.1 MATERIALS 
Abcam Plc., United Kingdom 
Total-(PINK1, Parkin, p62, BNIP3L, LC3I/II) primary antibodies 
Afriplex (Pty) Ltd., South Africa 
Green rooibos extract 
Amersham Biosciences Corp. (GE Healthcare Ltd.), United States 
Enhanced chemiluminescence (ECL) western blotting detection reagents 
Bayer HealthCare Animal Health, South Africa  
Eutha-naze (sodium pentobarbital) 
BDH Chemical Ltd., United Kingdom 
Glycerol, Sodium dithionite 
Bio-Rad Laboratories, Inc., United States  
Bovine Serum Albumin, Clarity Western ECL Substrate, Millipore Immobilon-p Polyvinylidene Fluoride 
(PVDF) microporous membrane, Criterion™ Tris-Tricine Precast Gels, Criterion™ TGX Stain-Free Precast 
gradient (4-15%) Gels 
CAB Foods (Pty) Ltd., South Africa 
Gelatine powder 
Cell Signaling Technology, United States 
Anti-rabbit and anti-mouse IgG HRP-linked secondary antibody, Total-(AMPKα, PKB, AS160, ATM, ERK1/2, 
GSK3β, p38, JNK1/2) primary antibodies, Phospho-(AMPKα (Thr172), PKB (Ser473), AS160 (Thr642), ATM 
(Ser1981), ERK1/2 (Thr202, Tyr204), GSK3β (Ser9), p38 (Thr180/Tyr182), JNK1/2 (Thr183/Tyr185)) primary 
antibodies 
Clover S.A. (Pty) Ltd., South Africa 
Elite fat-free milk powder, Way BetterTM condensed milk 
GlucoPlus Inc., Canada 
Blood glucose meter strips 
Greiner Bio-One International, Germany 
PLAIN serum clot activator vacuettes, pyrogen free Cryo.STm cryotubes 
Hanna Instruments (Pty) Ltd., South Africa 
HI 70300L pH Electrode Storage Solution, HI 7004 and HI 7007 pH Buffer Solution 
Hansatech Instruments (Pty) Ltd., United Kingdom 
Oxygen-permeable membrane 
Hudson & Knight (Pty) Ltd, South Africa 
HolsumTM 
Johnson and Johnson Medical (Pty) Ltd, South Africa 
Ethicon silk suture 
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Lasec SA (Pty) Ltd, South Africa  
Parafilm 
Merck (Pty) Ltd., South Africa  
Na2S2O4, HCl, KCl, KH2PO4, MgSO4, Na2HPO4, Na2SO4, NaCl, NaH2PO4, NaHCO3, Na+K+-Tartrate, NaOH, 
tetra-Na+-pyrophosphate, tris (hydroxymethyl) aminomethane, dimethyl sulfoxide (DMSO), butanol, Folin-
Ciocalteu’s phenol reagent 
Next Advance, Inc., United States 
stainless-steel 1.66 mm diameter beads  
NuChek Prep Inc., United States 
Standard FAME mixture 
Pioneer Foods (Pty) Ltd., South Africa 
Moir’s strawberry jelly 
RayBiotech Inc., United States 
Rat Insulin ELISA Kit 
Roche Products (Pty) Ltd. - Diagnostics, South Africa 
BSA fraction V - fatty acid free, BSA fraction V 
Safeline Pharmaceuticals (Pty) Ltd., South Africa 
Isofor (isoflurane) 
Sigma-Aldrich Life Science, United States  
2-mercaptoethanol (solution), aprotonin, CaCl2, EDTA, EGTA, leupeptin, MgCl2, SDS, TEMED, trypsin-EDTA 
solution, Tween-20, β-glycerophosphate, β-mercaptoethanol, ammonium persulfate (APS), Triton X-100, 2-
mercaptoethanol, phenylmethylsulfonyl fluoride (PMSF), Coomassie Brilliant Blue G, sodium orthovanadate, 
Calbiochem® SignalBoostTM Immunoreaction Enhancer Kit, Ponceau S 
Thermo Fisher Scientific Inc., South Africa 
Fetal Bovine Serum, PageRuler Prestained Protein Ladder (Fermentas Life Sciences), 15/50mL Falcon 
Conical Centrifuge Tubes, 15/50mL SorvallTM tubes, HiMark Pre-Stained Protein Standard 
 
4.2 EQUIPMENT 
Amersham Biosciences Corp. (GE Healthcare Ltd.), United States  
Electrophoresis Power Supply (EPS) 301 
Bante Instruments Ltd., China 
PHS-3BW Digital pH Meter 
Benchmark Scientific Inc., United States 
Incu-Shaker Mini 
Bio-Rad Laboratories, Inc., United States  
ChemiDoc MP System, Image Lab Version 5.0, Mini-PROTEAN Tetra System, PowerPac Basic 
BioTek Instruments Inc., United States  
ELx800 Absorbance Reader 
Corning Inc., United States 
Telfon® pestle, PYREX® Potter-Elvehjem tissue grinder 
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GlucoPlus Inc., Canada 
Blood glucose meter 
Grant Instruments Ltd., United Kingdom 
Water Bath 
GraphPad Software Inc., United States 
GraphPad Prism 7 
Hamilton Company, United States 
Air-tight syringe 
Hansatech Instruments (Pty) Ltd., United Kingdom 
Clark-type oxygen electrode oxygraph, Oxygraph+ software 
Heidolph Instruments (Pty) Ltd., Germany 
Silent Crusher M Polytron 
Lasec SA (Pty) Ltd., South Africa 
Sigma 1-14K Refrigerated Microfuge 
Microsoft Inc., United States 
Powerpoint 365 
Next Advance, Inc., United States 
Bullet Blender 
Orto Alresa, Spain  
Digicen 20 Centrifuge 
Oxford University, United Kingdom 
HOMA2 Calculator 2.2.3 
PZ HTL S.A., Poland 
Discovery Comfort multi-pipette 
Sensor Scientific Inc., United States 
Temperature probe 
SGE International Pty, Australia 
30m capillary column of 0.32 mm internal diameter; BPX70 0.25 um 
Sigma-Aldrich Life Science, United States  
Eppendorff Minispinplus 
Thermo Fisher Scientific Inc., South Africa  
Spectronic 20 Genesys Spectrophotometer, Heraeus™ Megafuge™ 16 Centrifuge Series 
Thermon Electron Corporation, United States 
Finnigan Focus Gas Chromatograph 
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4.3 METHODS 
4.3.1 Introduction 
This section elaborates on the methods and techniques used to conduct the research set out in the study aims. 
Briefly, the research activities will be discussed according to the specific performing work-station as follows: 
• Animal House 
o Animal Care 
o Study Design 
o Feeding 
o Treatment 
o Oral Glucose Tolerance Tests 
o Blood Collection 
• Heart Laboratory 
o Sacrificing and Heart Procurement 
o Isolated Cardiac Perfusions 
o Mitochondrial Isolation 
o Oxygraph 
• Protein Laboratory 
o Lowry Protein Determination 
o Bradford Protein Determination 
o Insulin Assays 
o Western Blot Analysis 
• External Analysis 
o Total Lipid Fatty Acid Composition 
• Statistical Analysis 
 
4.3.2 Animal House 
Laboratory animals were bred, housed and supplied by the Central Research Facility, Faculty of Medicine and 
Health Sciences, Stellenbosch University. 
4.3.2.1 Animal Care  
Age and weight matched male Wistar rats were used in the present study. Four weeks after birth, rats were 
weaned and then allowed free access to standard rat chow and water. Rats were housed in cages (maximum 
5 per cage) in a stable environment of 22 C, 40% humidity and a 12-hour artificial day/night cycle (light from 
06:00 to 18:00) at the Central Research Facility, Stellenbosch University. The experimental procedure was 
revised and approved by the Committee for Ethical Animal Research for the Faculty of Health Sciences, 
University of Stellenbosch (Ethical Clearance: SU-ACUM16-00080). The revised South African National 
Standard for the care and use of laboratory animals for scientific purpose was followed (SABS, SANS 10386, 
2008).  
4.3.2.2 Study design 
Male Wistar rats (Rattus norvegicuss) at 6-8 weeks of age and weighing 190±10 g were randomly allocated 
into two groups for 16 weeks feeding with either standard rat chow (1,272 kJ/100 g) or a high-caloric diet (HCD) 
(1,354 kJ/100 g) consisting of standard chow, supplemented with sucrose, condensed milk and holsum 
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cooking fat. Each group were further subdivided into 2 groups receiving either gelatine-fortified strawberry jelly 
or Afriplex GRT (60 mg/kg body weight (BW)/day, dissolved in gelatine-fortified strawberry jelly) for the last 6 
weeks of the experimental program. Jelly was administered individually to each rat and observation was made 
until the treatment finished – ~20 sec per rat to finish a 1 cm x 1 cm cube of jelly which they were quite fond 
of. All 4 groups had access to ad libitum drinking water. The food and water intake of selected cages were 
monitored daily throughout the study and the animal body weight on a weekly basis. An oral glucose tolerance 
test was performed on selected groups of animals before the onset of the 6 weeks GRT treatment and again 
1 week before sacrifice. This cycle was repeated 4 times over 3 years, consisting of 80 rats twice (to address 
Aim 1), 40 in the 3rd cycle (Aim 2) and finally 100 rats in the final cycle (Aim 3). Additionally, young control rats 
on a standard commercial rat chow diet weighing between 220-300 g were used throughout the study as 
positive controls to verify the validity of experimental protocols. The present investigation was divided into 3 




Figure 4.1 Study design according to the number of animals per aim 
 
4.3.2.3 Feeding 
After random allocation into cages, rats received either ad libitum standard rat chow (C) or ad libitum standard 
rat chow with a high-caloric diet (HCD). The diet compositions are given in Table 4.1 as determined by 
Microchem specialized laboratory services, Cape Town, South Africa (see Appendix A4 and A5 for Diet 
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Analysis Certificates, Microchem Lab Services (Pty) Ltd., RSA). The HCD porridge was prepared weekly from 
standard rat chow softened with sucrose dissolved in boiling water, addition of melted cooking fat, consisting 
of HolsumTM (Hudson & Knight (Pty) Ltd., RSA) and Way BetterTM condensed milk (Clover (Pty) Ltd., RSA), 
supplied to the rats in excess by allocation in bowls and replaced daily. 
 
Table 4.1 Diet Composition of Control and High-Caloric Diet 
HCD: High-Caloric Diet 
 
As given by Andreollo and colleagues (2012), the first 6 weeks of a rat (42.4 days) equates to one human year 
and is referred to as the nursing period. This is followed by the brief prepubescent period at 4.3 days for each 
human year, followed by adolescence ‘years’ every 10.5 days, and the adult years occurring similarly every 
11.8 days. Considering these growth curves, the breakdown of our rat age is rationaled as follows: recruited 
for treatment at 6 weeks old (42 days nursing = 1 human year), and then receiving diet for 10 weeks (8 days 
prepubescent = 2 human years and 62 days adolescent = 6 human years), before receiving treatment for 6 
weeks (42 days adolescent/adult = 4 human years), equating roughly to 13 years at age of sacrifice. This age 
was intentionally chosen as previous research interventions using this setting has been successful (Huisamen 
et al., 2013; Smit et al., 2018), and for the convenience of doing a large scale animal study (300 rats) without 
the added cost of feeding well into late adulthood.   
4.3.2.4 Treatment 
In this research project, the effect of Afriplex Green Rooibos Extract (GRTTM) was investigated for its 
cardioprotective properties when used as a supplement for 6 weeks in a Wistar rat model of diet-induced 
obesity and insulin resistance. The treatment was administered at a dose of 60 mg GRT/kg BW/rat per day. 
The composition of GRT is given by Table 4.2 as determined by the Medical Research Council of South Africa. 
The extract also contained neglible amounts of heavy metals and microbes as was determined by Afriplex 
Pharmaceuticals (See Appendix A3 for Certificate). 
 
  
Diet Control HCD 
Protein (%) 17.1 8.3 
Carbohydrates (%) 34.6 42 
Sugar (g/100 g) 6.6 24.4 
Fat (%) 4.8 11.6 
Saturated Fat (g/100 g) 0.9 7.6 
Mono-unsatured Fat (g/100 g) 1.5 2.9 
Poly-unsaturated Fat (g/100 g) 2.4 1.1 
-3 Polyunsaturated Fat (g/100 g) 0.2 0.1 
-6 Polyunsaturated Fat (g/100 g) 2.2 1.0 
Cholesterol (mg/100 g) 3 13 
Energy (kJ/100 g) 1272 1354 
Average Energy Intake Daily (kJ) ~255 ~320 
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Table 4.2 Compounds present in Afriplex GRT 












SS: Soluble solids 
 
Various considerations were made before elucidating the method of administration, such as ease of 
administration, together with retaining the stability of rooibos flavonoids which are prone to denature in 
response to light exposure, temperature, pH and storage time. 
• Preparation of Treatment 
The standard recipe for a batch of 35 Jelly cubes (35 daily dosages) contained  
- 5.6 g Moir’s Strawberry Jelly (consisting of sugar, gelatine (bovine), acidity regulators (E296, E450), 
ascorbic acid (E300), flavouring, salt, colourants (E122, E124))  
- 5.6g Gelatine (gelatine (bovine), preserved with sulphur dioxide)  
- 35ml boiling distilled water 
- ~735 mg GRT (for rats averaging 350 g). 
For example, to prepare weekly dosages for 5 rats/cage: 60 mg GRT/kg BW per day was divided by average 
rat weight per cage and multiplied by 35 cubes (7 days treatment x 5 rats). This amount of GRT powder was 
added to 5.6 g of Moir’s Strawberry-flavoured Jelly and 5.6 g Gelatin, together with 35 ml boiling water and 
gently stirred at low heat until dissolved. 1mL was then aliquoted into an ice-tray containing 35 molds and 
stored overnight at 4°C covered with foil. The next day, each jelly cube was gently removed with a micro-
spatula, paying attention to time handled at room temperature, before transported for weekly storage at 4°C 
and protected from light, in the animal facility. The nutritional composition of the jelly is given in Table 4.3 and 
the ~2 kJ jelly cube administration is deemed neglible on overall caloric intake (compared to the average daily 
food intake of these rats from Table 4.1). 
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Safe GRT dosage was determined according to the following rationale:  
In a recent study by Son and colleagues (2013), ob/ob mice were gavaged an aspalathin dose of 100 mg/kg 
BW after fasting for 15 h, and furthermore given aspalathin supplementation for 5 weeks at a dose of 100 
mg/kg BW per day. In another study done by Kawano and colleagues (2009), they gavaged an aspalathin 
dose of 18-110 mg/kg BW once. Given that the metabolic rate of a mouse is twice as fast as a rat, a dose of 
100 mg/kg BW for a mouse would extrapolate to 50 mg/kg BW for a rat (Nair & Jacob, 2016). As the GRT 
product contains 12.8% aspalathin, a GRT dose of 60 mg/kg Rat BW, contains an effective aspalathin 
concentration of 7.7 mg/kg BW per rat - far below the safe dosages indicated in mice. 
 
Given that the metabolism of a rat is 6 times as ‘quick’ or efficient as a human, this dose equated to 10 mg 
GRT/kg BW of a human, effectively meaning 700 mg GRT for a 70 kg person, resulting in a dose equivalent 
of 89.6 mg aspalathin. From Bramati and colleagues (2002) - one tea bag (2 g of leaf material) steeped for 10 
min in boiling water would contain on average 1.234 mg aspalathin/g and therefore in one tea bag (2g) = 2.468 
mg aspalathin. Thus, the 89.6 mg aspalathin within a single dose of GRT would contain the equivalent amount 
of aspalathin in ~36 cups of tea. This content within a cup of tea is corroborated by a paper by Joubert & de 
Beer (2012), however they indicated the aspalathin content in 6 cups of tea and, when reduced to one cup, 
the aspalathin content is found to be 1.22 mg aspalathin (which more roughly equates to 1g tea bags – the 
researchers only indicated tea bags were prepared according to standard practice), and therefore a single 
GRT dose would equate to the aspalathin content of ~73 Cups of tea. Regardless of the exact amount of ‘tea 
cups’ the dose equated to, it is safe to say it is not feasible to consume this concentration of aspalathin through 
drinking herbal infusions alone.  
• Light sensitivity 
Phytochemical oxidation experiments performed by Koeppen and Roux (1966) showed that aspalathin 
exposed to direct sun light can denature readily within 3 days of exposure with longer exposure time being 
more detrimental. To prevent oxidation from occurring to the set jelly cubes, the batches were prepared in low-
light and left to set in 1cm x 1cm cube moulds and completely covered with foil until administration. 
• Temperature 
Work done by both Joubert and colleagues (2010) and also De Beer and colleagues (2015) showed that 30 
min pasteurization (96C) of GRE dissolved in water had little to no effect on flavonoid content. Furthermore, 
Koch and colleagues (2013) also demonstrated that steam pasteurization of fermented rooibos leaves for 60 
sec had little effect on the stability of flavonoids, albeit a minor reduction <5% in aspalathin attritubed to an 
Diet Per 100g Per Jelly Cube 
Protein (g)  17.1 26.9 mg 
Carbohydrates (g) 34.6 54.4 mg 
Sugar (g) 6.6 10.4 mg 
Total Fat (g) 4.8 7.5 mg 
Sodium (mg) 26 40.9 ug 
Energy (kJ) 1272 2 kJ 
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acceleration in oxidation. This inferred that rapid addition of boiling water during the preparation of the jelly 
cubes would prevent a significant detrimental effect on GRT flavonoid content.  
• pH 
Aspalathin was also found to be most stable at decreasing pH, including pH = 4 and 5 (De Beer et al., 2012). 
We determined the pH of strawberry jelly together with added gelatine to be acidic at 4.54 with the addition of 
GRT not causing a significant fluctuation in this pH level. 
• Storage 
In research done by De Beer and colleagues (2012) aspalathin in the presence of sugar can result in decreased 
stability occurring after 1 week of storage. Furthermore, the addition of ascorbic acid together with citric acid 
can help in improving stability – both components present in Moir’s Strawberry Jelly. Jelly cubes were made 
weekly as an added measure of preventing oxidation induced over time. The cubes were stored at 4°C covered 
in foil for the duration of the week and administered to the rats daily. During this time, no compositional changes 
were noted in the consistency of the jelly.  
4.3.2.5 Oral Glucose Tolerance Test 
OGTT was used to determine fasting whole-body glucose homeostasis – the efficacy of rats to clear blood 
glucose following oral ingestion of sucrose. At both 10 weeks and 16 weeks of diet (Figure 4.2), a subgroup 
of animals were fasted overnight (with access to drinking water), and the body weights of the animals taken 
prior to moving the animals to a separate theatre within the animal unit. Fasting blood glucose levels were 
established from a tail prick using a standard glucometer (GlucoPlus Inc., Canada), before sedating the rats 
by intraperitoneal injection with a very low dose of sodium pentobarbital (15 mg/kg BW) using a sterile 26-
gauge hypodermic needle. The site of injection was at the lower right quadrant of the abdomen to ensure that 
no damage is done to the urinary bladder, cecum, liver and other abdominal tissues (Zatroch et al., 2016). 
Thereafter, a solution of 50% sucrose, containing a disaccharide bond of glucose and fructose, at a dose of 1 
mg/g BW, was administered by oral gavage and blood glucose levels monitored by a drop of blood obtained 
from a tail prick and subsequent glucometer readings at various time points (3, 5, 10, 15, 20, 25, 30, 45, 60, 
90 and 120 min). After the OGTT, animals recovered for one week from this metabolic insult before being 
sacrificed in other experiments. Relative glucose tolerance was determined by comparing the difference in 
blood glucose for each time point between groups, and by comparing the area under curve (AUC) of each 
individual rat tolerance test between groups. 
4.3.2.6 Blood Collection 
At 10 weeks and 16 weeks of diet (Figure 4.2), a subgroup of rats was fasted overnight, anaesthetized with 
2% (v/v) isoflurane (Isofor, Safeline Pharmaceuticals (Pty) Ltd., RSA) and approximately 2 ml of blood collected 
via the carotid artery and allocated to eppendorf tubes. The blood was kept on ice for 30 min and then spun 
down at 3,000 rpms and the supernatant serum collected.  
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Figure 4.2 Timeline of blood-collection procedures performed on diet rats. OGTT: Oral 
glucose tolerance test. 
 
4.3.3 Heart Laboratory 
The cardiovascular research experiments were conducted in the Division of Medical Physiology, Faculty of 
Medicine and Health Sciences, Stellenbosch University. 
4.3.3.1 Sacrificing and Heart Procurement 
Rats were collected from the animal house a week prior to being used in experiments to reduce the stress of 
handling on the day of experimentation. Rats were anaesthetized with sodium pentobarbital (160 mg/kg BW). 
The rats were weighed and the non-fasting blood glucose (or random blood glucose test) value of the animals 
were determined from a tail prick using a standard glucometer (Figure 4.2). After determining deep 
anaesthesia via an unresponsive foot pinch (pedal reflex) and unresponsive eye reflex on touch (attained <5 
min in most animals), hearts were quickly excised (<1 min after first incision) and arrested in ice cold Krebs-
Henseleit (KH) buffer (Table 4.2).  
• Heart Weight 
Just prior to mounting of the heart onto the perfusion rig, the heart was trimmed of excess fat and tissue 
potentially obstructing the view of the important landmarks needed for cannulation. The heart was also drained 
of residual blood by gently squeezing and rinsing the heart in ice-cold Krebs buffer. The heart was then 
submerged in a weighing boat containing ice-cold Krebs buffer and the weight determined by weight 
displacement using a SF-700 digital Jewelry Scale. This entire procedure happened within 1-2 min after 
isolating the heart and just prior to cannulation of the aorta on the perfusion rig.  
• Blood Collection 
Directly after heart excision, blood was quickly collected from the chest cavity using a pipette and placed into 
plain serum clot activator vacuettes and kept on ice for 30 min, followed by centrifugation at 3,000 rpm for 20 
min at 4°C (Heraeus™ Megafuge™ 16 Centrifuge Series). Thereafter, the supernatant (serum) was carefully 
aspirated and aliquoted into pyrogen free cryotubes and stored at -80 °C for future serum analyses. 
• Intraperitoneal Fat 
The intra-peritoneal fat of the control and HCD animals were dissected out and weighed at an opportune time 
after sacrifice and mounting of the heart onto the perfusion rig. These fat deposits include the visceral adipose 
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tissue surrounding the inner organs and can be clustered into the retroperitoneal, the fat surrounding the 
kidneys and the gonadal or fat attached to the epididymis and testes. 
4.3.3.2 Isolated Cardiac Perfusions 
The perfusion rig, also known as the Neely-Morgan perfusion system (Neely et al., 1967) was set up in 
advance with reservoirs filled with filtered Krebs-Henseleit bicarbonate (KH) Buffer (Table 4.4) receiving 
permanent oxygenation (95%) and carbon dioxynation (5%), to maintain a pH of 7.4 at a temperature of 40°C 
to account for the temperature drop between the reservoirs and the mounted heart as a result of the lower 
ambient room temperature (Figure 4.3). The aorta (at least 5 mm of visible white aortic tissue) was mounted 
using surgical forceps, onto the aortic cannula (Figure 4.4) and retrogradely perfused (Langendorff mode) for 
10 min, initially at lower pressure, and gradually increased to 100 cm H2O hydrostatic pressure. During this 
time, the coronary sinus was pierced to release pressure build-up (a technique known as thebesian drainage) 
and to insert a temperature probe. Furthermore, the pulmonary vein bridging into the left atrium was also 
cannulated and tied down using surgical thread (<4 min of mounting the heart) (Figure 4.4). The water jacket 
around the heart was closed and the coronary temperature kept constant between 36.7°C and 37.0°C, 
especially in response to fluctuating coronary flows from different experiments. At the end of stabilization, the 
flow was changed to antegrade perfusion (working heart mode), with a preload of 15 cm H2O hydrostatic 
pressure and a left ventricle ejection fraction against an afterload of 100 cm H2O and continued for 20 min. 
Functional measurements were obtained.  At 30 min of total perfusion time, two different ischemic protocols 
were followed as described below.  
• Global Ischemia-Reperfusion Protocol 
During global ischemia, all blood supply (substitution buffer) to the heart was ceased to start the ischemic 
protocol. Myocardial temperature was kept constant at 36.5°C for 20 min. After ischemia, reperfusion was 
initiated by Langendorff perfusion for 10 min followed by working heart for 20 min. During this protocol, 
following stabilization, ischemia, 5 min into reperfusion and after 30 min of reperfusion, hearts were either 
freeze-clamped (for subsequent Western Blot analysis of cardiac signaling proteins – described in 
Section 4.3.4.5) or homogenized and mitochondrial isolations made (for subsequent mitochondrial oxidative 
phosphorylation analysis and Western Blot analysis of mitophagy signaling proteins).  
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Figure 4.3 Perfusion system setup (A), protocol (B) and perfusion states (C). AO: Aortic output, PT: 
Pressure transducer, CF: Coronary flow, FC: Freeze-clamp heart, LH: Langendorff perfusion, WH: Working 
heart perfusion, GI: Global ischemia. 
 
• Regional Ischemia-Reperfusion Protocol 
During regional ischemia, the left anterior descending artery was ligated using a silk surgical suture 
(Figure 4.4), while temperature was kept constant at 36.5 °C for 35 min. This ligation effectively reduced 
coronary flow rate to one third of pre-ischemic flow.  After ischemia, the suture was loosened and the hearts 
perfused in Langendorff for 10 min followed by working heart perfusion for 20 min and switched back to 
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Figure 4.4 Different configurations used between the global- and regional-ischemia protocol. 
 
• Myocardial Functional Parameters 
Figure 4.3 contains a graphical illustration of different endpoints that were measured during the perfusion 
protocols. The aortic output (AO) and coronary flow (CF) rates were determined by periodic 10 sec interval 
fluid collections and multiplied by 6 to attain the rate per minute. Cardiac output (CO) was determined as a 
measure of AO and CF. The aortic systolic pressure (SysP) and diastolic pressure (DiaP) in mmHg, and heart 
rate (HR), in beats per minute (bpm), were measured with a Viggo-Spectramed pressure transducer and 
recorded on a computer running PhysiTutor® software. The total work performance indice (WT), a measure of 
the strength of the heart derived from pressure and kinetic power, was determined according to the principles 
set out by Kannengiesser and colleagues (1979) – simplified, it is calculated multiplying CO with SysP and 
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then multiplying this total by 0.002222 to get the total power per gram (W/g) of heart tissue. All measurements 
were performed pre- and post-ischemia at various intervals, and the average of these values used in 
calculations. Functional recovery was expressed as the post-ischemic value’s percentage of the pre-ischemic 
value.  
• Infarct Size Determination 
Myocardial infarct size was determined as previously demonstrated in our laboratory (Huisamen et al., 2013; 
Salie et al., 2014; Webster et al., 2017). After the 60 min of reperfusion described above in the regional 
ischemia protocol, the silk suture was fastened again and 1mL of Evans blue suspension (0.5%) was slowly 
injected through the aortic cannula. The heart was then removed from the perfusion rig and frozen overnight 
at -20ºC. At the end of each week, after all perfusions had been performed, the hearts were cut into 2 mm 
thick slices and stained with 1% w/v triphenyl tetrazolium chloride (TTC) in phosphate buffer (pH 7.4 at 37ºC) 
for 15 min. To increase the contrast between viable and unstained necrotic regions, the tissue was fixed in 
10% v/v formaldehyde solution at ambient temperature. From each heart, 5 ventricular tissue slices were 
mounted on a double transparent mould and scanned into a computer.  
 
Briefly, the work-flow for infarct size graphical analysis is described in Figure 4.6 according to the following 
logic: First, the background was removed from the original image using a magic wand tool from the freeware 
software paint.net 4.1.1, which enable the selective removal of a colour (or colour shade) as required. This 
image was then contrast enhanced to more easily define the colour differences. Next, using ImageJ 1.51n, 
navigating through Image -> Adjust -> Color Theshhold was selected. Colour space was changed to the YUV 
spectra, where Y is luminance, and U and V are arbitrary abbreviations used denote the x and y axes of 
chromaticity space. For instance, U-V planes in a range of [-1, 1] will be the following colour ranges for Y-
values of 0, 0.5 and 1 respectively shown in Figure 4.5. 








Figure 4.5 Luminance spectra illustration for varying Y = 0, 0.5 and 1. 
 
Using this threshold system, we can select very specific colour ranges and consequently summate each colour 
group. Black was chosen as the colour threshold indicator (Figure 4.6) and the sum of all black pixels counted 
separately using the image software. These colour ranges were divided into i) viable tissue (blue-ranges), ii) 
live cells in the area at risk (TTC positive, prominent red-ranges) and iii) non-viable tissue (TTC negative, white, 
yellow, light-red ranges). The total Area at risk (AAR) constitute of both the infarcted area (non-viable tissue) 
as well as the surrounding viable red area and are expressed as a % of the total left ventricular volume. The 
infarct size was calculated as the percentage non-viable tissue to the area at risk.  
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1)  IMAGE AFTER BACKGROUND REMOVAL: 
 
2) IMAGE CONTRAST ENHANCED: 
 
3) THRESHOLD SELECT (“BLACK”) FOR VIABLE TISSUE (“BLUE”): 
 
4) THRESHOLD SELECT (“BLACK”) FOR VIABLE TISSUE IN AREA AT RISK (“RED”): 
 
5) THRESHOLD SELECT (“BLACK”) FOR NON-VIABLE TISSUE (“WHITE”): 
 
Figure 4.6 Infarct size determination work-flow  
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Table 4. 4 Buffer compositions used in perfusion and isolation protocols 
Abbreviations: KH: Krebs-Henseleit bicarbonate, EGTA: ethylene glycol tetraacetic acid, EDTA: 
ethylenediamine tetraacetic acid, PMSF: phenylmethylsulphonyl fluoride 
 
4.3.3.3 Mitochondrial Function 
Mitochondria are dynamic and constantly fusing or dividing, even when isolated (Lackner, 2014; Meeusen et 
al., 2004). Normally, they form tubular networks (See Appendix A1), but once isolated from cells they break 
up into pieces which will reseal again (Kühlbrandt, 2015). Isolated mitochondria maintain their membrane 
structure and membrane potential, and thus retain their ability to undergo OxPhos and synthesize ATP 
(Alexandre et al., 1978). This enable us to investigate mitochondria’s functional integrity in isolated 
mitochondrial fractions obtained from perfused rat hearts.  
• Mitochondrial Isolation 
Following the perfusion protocol described in Section 4.3.3.2, hearts were allocated for mitochondrial isolation 
after 30 min stabilization, 20 min global ischemia, 5 min into reperfusion and after 30 min of reperfusion. The 
isolation protocol was adapted from the methodology outlined by Lanza & Nair (2009). The hearts were cut 
just above the atrium using surgical scissors and placed into a 50 mL SorvallTM tube containing ice-cold KE 
buffer (Table 4.4). The hearts were then further snipped for approximately 20 sec to achieve a size small 
enough <5mm as to not get stuck in the homogenizer. The supernatant was decanted (with the heavier heart 
tissue remaining at the bottom of the SorvallTM tube) and rinsed twice with fresh ice-cold KE buffer. The hearts 
were then transferred to a 15 mL SorvallTM tube, half-filled with KE-buffer and homogenized in five 2 sec bursts 
at 15,000 rpm (Silent Crusher M Polytron, Heidolph Instruments, Germany). The homogenate was transferred 
to a 50 mL SorvallTM tube, topped up with KE-buffer, placed in a SorvallTM SS34 Rotor and centrifuged for 10 
min at 2,500 rpm (755g) at 4°C (SorvallTM RC 6 Plus, Thermofisher Scientific, RSA). The supernatant was then 
gently decanted into a new 50 mL SorvallTM tube, and split halfway into another 50 mL SorvallTM tube, and 
both centrifuged for 10 min at 12,500 rpm (18,800g) at 4°C. The supernatant from both tubes were discarded 
and 250 uL KE-buffer added to the pellet of Tube 1 and 200 uL Lysis buffer added to the pellet of Tube 2. The 
contents of both tubes were separately resuspended using a manual Teflon® pestle and PYREX® Potter-
Elvehjem tissue grinder (Corning Inc., USA) and the resuspensions transferred to Epperdorf tubes. 50 uL of 
resuspension 1 was precipitated in 1 mL 10% trichloroacetic acid (TCA) and refrigerated for subsequent protein 
Solution Composition 
KH Buffer 
(pH = 7.4) 
119 mM NaCl, 24.9 mM NaHCO3, 4.7 mM KCl, 1.2 mM KH2PO4, 0.59 mM 
MgSO4.7H2O, 0.59 mM Na2SO4, 1.25 mM CaCl2.H2O, 10 mM glucose 
KE Buffer  
(pH = 7.4) 
180 mM KCl, 10 mM EDTA, pH set with 2M Tris 
Lysis Buffer 
 
20 mM Tris-HCL EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM β-glycerophosphate, 
2.5 mM tetra-Na+-pirophosphate, 1 mM Na3VO4, 1% Triton X-100, 10 ug/mL 
leupeptin, 10 ug/mL aprotonin, 50 ug/mL PMSF 
Glutamate Media 
(pH = 7.4) 
250 mM sucrose, 10 mM Tris-HCL, 8.5 mM KH2PO4, 2 mM malate, 5 mM glutamate 
Palmitate Media 
(pH = 7.4) 
250 mM sucrose, 10 mM Tris-HCL, 8.5 mM KH2PO4, 2 mM malate, 0.45 mM 
palmitoyl-L-carnitine 
Stellenbosch University  https://scholar.sun.ac.za
61 
    
determination using the Lowry assay (described in Section 4.3.4.6), while the remaining 200 uL was used to 
determine mitochondrial OxPhos described below. The contents of resuspension 2 was stored at -80°C till 
Bradford protein determination (described in Section 4.3.4.3) and subsequent Western Blot analysis of 
mitophagy associated proteins (described in Section 4.3.4.5).  
• Mitochondrial Oxidative Phosphorylation  
In a healthy heart, the rate of OxPhos is exclusively linked to the rate of ATP hydrolysis to ensure constant 
ATP levels even when with varying cardiac power output (Balaban et al., 1986). Mitochondrial OxPhos 
produces ATP via electrons transferred from NADH and FADH2 generated by dehydrogenation of carbon 
substrates primarily in FA-β-oxidation, CAC and least of all pyruvate dehydrogenase and glycosis (See 
Section 2.2, Figure 2.1) (Stanley et al., 2005). When measuring OxPhos, mitochondrial O2 consumption is 
related to the rate of ATP production and can be inferred in the presence of both ADP-independent and ADP-
dependent respiration. Addition of the mitochondria to the FA- or carbohydrate substrate results in baseline 
respiration independent of ADP called State 2 respiration (S2) (Figure 4.8). Addition of ADP to mitochondria 
causes a rapid increase in O2 consumption, known as State 3 respiration (S3), and transcribed as a measure 
of ATP production, known as oxidative phosphorylation rate of State 3 (OxPhos S3) (Lesnefsky et al., 2001). 
OxPhos S3 is primarily a function of ATP turnover and substrate oxidation, dependent on substrate 
metabolism, processing and ETC enzymes, whereas inhibiting any of these steps result in attenuated OxPhos 
S3. As the ATP/ADP ratio equilibrates (ADP depletes), proton re-entry through ATP synthase stops which 
raises the proton motive force (proton gradient responsible for passively driving ATP synthase) across the 
inner mitochondrial membrane, in effect slowing down respiration (Brand & Nicholls, 2011). This is known as 
State 4 respiration (S4), and can also be transcribed to indicate oxidative phosphorylation rate of State 4 
(OxPhos S4) (Lesnefsky et al., 2001). The ratio of S4/S3 describes a measure of mitochondrial function known 
as respiratory control index (RCI). A high RCI indicates a strong capacity of mitrochondria to oxidize substrates 
and produce ATP with low proton leakage. RCI values are usually dependent on the type of substrates used 
and the type of mitochondria isolated and therefore no standard range has been defined to indicate 
mitochondrial dysfunction, however it still remains a valuable to tool to infer relative mitochondrial dysfunction 
(Brand & Nicholls, 2011). The maximum amount of ATP synthesized per atom of oxygen is given by the 
parameter ADP/O, or the proton/oxygen ratio. A decrease in this value indicates mitochondrial uncoupling, and 
therefore a dissipation of the proton gradient driving ATP synthesis, which is also a measure of OxPhos 
efficiency (Brand & Nicholls, 2011). 
 
To determine the OxPhos potential of mitochondria, a polarographic measure of mitochondrial respiration was 
carried out using a Clark-type oxygen electrode oxygraph (Hansatech Instruments Ltd., UK) set up in advance 
(Figure 4.7), as previously described (Boudina et al., 2005). A drop of 50% KCl was placed on the electrodes 
and a small oxygen-permeable membrane fitted into place on top of it and secured with a rubber O-ring by 
means of an applicator shaft. A slightly bigger rubber O-ring was used to seal the electrode disk into the oxygen 
electrode chamber and the entire assembly fastened with a lockring. The oxygraph system was continuously 
temperature regulated at 25 °C using an external water bath, and all the electrode readings relayed to a 
computer running Oxygraph+ software (Hansatech Instruments Ltd., UK). In the current study two oxygraph 
systems were ran simultaneously to compare the mitochondrial OxPhos rates of carbohydrate substrate 
utilization vs FA substrate utilization. The first chamber represented a carbohydrate-rich environment and 
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made use of a Glutamate Medium and the second chamber a FA-rich environment consisting of a Palmitate 
Medium (See Table 4.4 for compositions). First, both chambers were filled with distilled H2O (25 °C) and a 
magnetic stirrer (Speed: 100) and calibrated to ambient oxygen (100%) and 0% oxygen by addition of sodium 
dithionite (BDH Chemicals (Pty) Ltd., UK) to allow the software to be zeroed when oxygen levels dropped to 
levels where insignificant fluctuations were recorded. The chambers were then rinsed with distilled H2O 5 times 
and filled with either 650 uL Glutamate Medium or Palmitate Medium and given sufficient time to reach 100% 
ambient oxygen levels and the set temperature before commencing with experimentation. 100 uL of isolated 
mitochondria suspension in KE-buffer was added to each incubation medium and the chamber sealed with a 
plunger adaptor. Once a steady-state respiration rate was obtained (in presence of substrate but absence of 
ADP), 50 uL ADP (0.35 uM ADP) was injected into the chamber using an air-tight syringe (Hamilton Company, 
USA) to commence S3 (Figure 4.8). Once all the ADP was converted to ATP, S4 respiration commenced 
which is characterized by a slow-down in respiration (in the presence of substrate and ATP). Following a 
steady-state S4 period of approximately 30 sec, 50 uL of 10X ADP concentration (3.5 uM ADP) was injected 
into the chamber to saturate ATP production using oxygen as substrate – leading to a gradual depletion of all 
O2 levels. Once a steady-state zero oxygen was reached, a 20-min anoxia period was ushered in. After this, 
oxygen was manually reintroduced into the chambers by using a plastic Pasteur pipette, and S5 attained. From 
the oxygraph data, together with the protein concentration determined for each sample, we can determine the 
parameters set out in Figure 4.8. 
 
 
Figure 4.7 Oxygraph assembly 
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Figure 4.8 Representative oxygraph 
 
4.3.4 Protein Laboratory 
Insulin ELISA and Westerm blot analysis were conducted under the auspices of the Cardiovascular Research 
Group housed in the Protein Laboratory, Division of Medical Physiology, Faculty of Medicine and Health 
Sciences, Stellenbosch University. 
4.3.4.1 Insulin assay 
Insulin levels were determined in the fasting state and the homeostasis model assessment for insulin 
resistance (HOMA-IR) values calculated as index of glucose homeostasis, insulin resistance and β cell function 
(Antunes et al., 2016). Rat insulin was determined from fasting blood using a rat insulin ELISA kit (RayBiotech 
Inc., USA). This assay consisted of a 96-well microplate coated with rat insulin-specific antibody, a wash buffer, 
rat insulin used in establishing a standard curve, biotinylated anti-rat insulin, HRP-conjugated streptavidin 
(secondary antibody), 3,3,5,5’-tetramethylbenzidine (TMB), 0.2 M sulfuric acid and diluent buffer.  
 
All reagents and blood serum samples were used at room temperature (18 – 25°C), while all standards and 
samples were analyzed in duplicate. Standards were diluted in series to obtain the following concentrations: 
4.69 µIU/mL, 9.38 µIU/mL, 18.75 µIU/mL, 37.5 µIU/mL, 75 µIU/mL, 150 µIU/mL, 300 µIU/mL and 1400 µIU/mL. 
Diluent buffer from the kit (composition unknown – usually a combination of phosphosaline, EDTA, sodium-
(Na)-azide and BSA) was simply used as a blank. All samples were diluted 2-fold with the diluent buffer. First, 
100 µL of each sample, standard and blank was loaded in duplicate into the 96-well plate and then slowly 
agitated at room temperature for 2.5 h. The solution was discarded and each well washed 4X with 300 µL 
Wash buffer using a multi-channel pipette (Discovery Comfort, PZ HTL S.A., Poland). The remaining liquid in 
each well was carefully aspirated using a glass Pasteur pipette coupled to a vacuum. The plate was then 
inverted and blotted dry on paper towel. Next, 100 µL of biotinylated antibody was added to each well, to act 
as a precursor for the secondary antibody to bind to, and gently agitated for 1 h at room temperature. The 
solution was once again discarded and washed 4X with wash buffer and blotted dry. Afterwards, 100 µL of 
HRP-conjugated streptavidin was added to each well and gently agitated for 45 min at room temperature, 
followed by discarding the solution, washing 4X with wash buffer and then blotting dry. Subsequently, 100 uL 
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TMB One-Step Substrate Reagent was added to each well and incubated for 30 min at room temperature at 
30 rpms in a darkened Incu-Shaker Mini (Benchmark Scientific Inc., USA). Finally, 50 µL Stop Solution was 
pipetted into each well. This sulphuric acid solution changed the blue colour to a yellow colour. The intensity 
of the colour was immediately measured within 5 min on the microplate reader at 450 nm. A standard curve 
was set up by plotting the Y-absorbance at 450 nm with standard rat insulin concentrations on the X-axis and 
used to determine the insulin concentrations of unknown serum samples. The homeostasis model assessment 
for insulin resistance (HOMA-IR) index was calculated using the HOMA2 Calculator 2.2.3 software (Oxford 
University, UK), which calculates the product of fasting glucose concentration (mmol/L) multiplied by the fasting 
insulin concentration (μIU/mL) divided by 22.5 (HOMA-IR = [fasting glucose concentration X fasting insulin 
concentration]/22.5), as well as the product of 20 times insulin concentration divided by 3.5 units less than the 
fasting glucose concentration (HOMA-%B = [20 × fasting insulin concentration]/[fasting glucose concentration 
− 3.5]), which corrects for beta cell function (Levy et al., 1998).  
4.3.4.2 Tissue Homogenisation 
Small sections of freeze-clamped heart ventricular tissue (~5x5 mm) were chipped off and pulverized using a 
liquid nitrogen pre-cooled mortar and pestle. Next, 70 mg of pulverized powder was homogenized and lysed 
in Lysis buffer (Table 4.5) containing 6 stainless-steel 1.66 mm diameter beads, using a Bullet Blender (Next 
Advance Inc., USA) at 4 C for three one-minute cycles at Speed 8, and 5 min of rest inbetween each cycle. 
The homogenized samples were rested for an additional 20 min at 4 C, followed by centrifugation at 15,000 
rpm (12,074g) for 20 min at 4 C (Sigma 1-14K Refrigerated Microfuge, Lasec SA (Pty) Ltd., RSA). The 
supernatant was then used in subsequent Bradford protein determination.  
 
4.3.4.3 Bradford Protein Determination 
The Bradford protein determination method was used to determine the protein content of heart tissue and 
mitochondrial lysates (Bradford, 1976). Just prior to protein determination, the BSA stock (5 mg/mL) was 
diluted 1:5 times with dH2O and then serially diluted into duplicate test tubes to generate concentrations 
between 1 and 30 μg in a volume of 100 μL. 5 μL supernatant of the samples generated in the above 
experiments, was diluted 1:10 with dH2O to dilute all detergents that may interfere with the assay. The diluted 
samples were then further diluted 1:20 in test tubes to reach a volume of 100 uL. All standards and samples 
received 900 μL of double filtered Bradford reagent (diluted 1:5 with H2O) (Table 4.5), vortexed and incubated 
for 30 min at room temperature. The absorbance values were measured using a spectrophotometer 
(Spectronic 20 Genesys Spectrophotometer, Thermo Fisher Scientific Inc., RSA) at 595 nm and the protein 
content of the samples determined from the standard curve plotted. Hereafter, the protein concentration for 
each sample was calculated and proceeded to lysate preparation. 
4.3.4.4 Lysate Preparation for Western Blotting 
Lysis buffer was added to the appropriate amount of supernatant to obtain protein concentrations of 50 g/12 
l final solution. Finally, a mix of 850 l 1:2 Laemmli sample buffer (Table 4.5) with 150 l mercaptoethanol 
was made and added to the samples in a volume equal to half of the lysis buffer and sample buffer. The 
samples were boiled for 5 min at 100C and stored at -80 C for future analysis by Western blotting. 
  
Stellenbosch University  https://scholar.sun.ac.za
65 
    
Table 4.5 Buffer and gel compositions used in western blot protocol 
Solution Composition 
Lysis Buffer 20 mM Tris-HCl, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 1 mM β-
glycerophosphate, 2.5 mM tetra-Na+-pirophosphate, 1 mM Na3VO4, 1% Triton 
X-100, 10 g/ml Leupeptin, 10 g/ml Aprotinin, 50 g/ml PMSF 
Laemmli Sample 
Buffer 
62.5 mM Tris-HCl (pH 6.8), 4% SDS, 10% glycerol, 0.03% bromophenol blue, 
5% β-mercaptoethanol 
Bradford Reagent 100 mg Coomassie Brilliant Blue G-250, 50 ml 95% Ethanol, 100 ml 85% 
(w/v) Phosphoric Acid, 850 ml dH2O 
Running Buffer 25 mM Tris-HCl,192mM Glycine, 0.1% SDS (made up with dH2O)  
Transfer Buffer 25 mM Tris, 192 mM glycine and 20% (v/v) methanol 
Transfer Buffer (ATM) 25 mM Tris, 192 mM glycine and 10% (v/v) methanol 
TBS-Tween Buffer 
(pH 7.6) 
20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20 (diluted with dH2O) 
Ponceau Red  5 mL acetic acid, 0.5 g ponceau S/ 100 mL dH₂O 
 
4.3.4.5 Western Blot Analysis 
Loading and separation of proteins 
In the present study, we made use of either 26-well Criterion™ Tris-Tricine Precast gradient (4-15%) Gels or 
26-well Criterion™ TGX Stain-Free Precast gradient (4-15%) Gels (Bio-Rad Laboratories Inc., USA). The 
gels were placed in a Mini-PROTEAN Tetra System (Bio-Rad Laboratories Inc., USA) and filled with Running 
Buffer (Table 4.5). After boiling the lysates for 5 min, 12 L (50 g) of each sample was loaded onto the gel. 
The first and last lane position on each gel was loaded with 5L PageRuler Prestained Protein Ladder 
(Fermentas Life Sciences, RSA) for proteins of interest smaller than 100 kDa, whereas 7.5 L HiMark Pre-
Stained Protein Standard (Thermo Fisher Scientific Inc., RSA) for proteins of interest larger than 100 kDa, to 
aid with determination of molecular weights of specific bands. The second and third lane was loaded with 30 
min stabilized young controls hearts (for interest sake), the fourth and fifth 30 min stabilized control samples, 
and subsequent lanes contained treated groups. Proteins were then separated using the principle of 
sodiumdodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Gels were run for 10 min at 200 V 
and set current, followed by 50-80 min (depending on definition required) at set 140 V and set current, in 
Running Buffer (Table 4.5).  
Protein transfer and visualization 
Following SDS-PAGE, proteins of interest <100 kDa were electrotransfered to polyvinylidene fluoride (PVDF) 
membranes, using a Mini Trans-Blot® Cell Transfer System (Bio-Rad Laboratories Inc., USA) for 60 min at 
200 mA and set volts, or proteins >100 kDa for 90 min at 200 mA and set volts and packing the Transfer 
System with icepacks to prevent overheating of the transfer sandwich and denaturing of proteins. The 
membranes were then Stain-Free activated and visualized with the ChemiDoc MP System using ImageLab 
Software 5.0 (Bio-Rad Laboratories Inc., USA), and images stored for later use in normalization of samples. 
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Membranes transferred from the 26-well Criterion™ Tris-Tricine Precast Gels were first reversibly stained with 
Ponceau Red (Table 4.5) and then imaged for later normalization.  After washing of the membranes with TBS-
Tween Buffer (Table 4.5), the membranes were blocked in TBS-Tween Buffer with 5% (w/v) fat-free dry milk, 
while gently agitating for 2 hours at room temprature. The membranes were then 3 times washed with TBS-
Tween Buffer for 5 min, followed by incubation overnight at 4C with primary antibody, according to dilutions 
set out in Table 4.6. The membranes were again washed 3 times with TBS-Tween Buffer for 5 min, followed 
by agitation for 1 hour with secondary anti rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP) linked 
whole antibody (Amersham Biosciences, UK, and Dako Cytomation, Denmark) diluted either in 7.5mL TBS-
Tween Buffer, 7.5 mL 5% Milk-TBS-Tween or 7.5 mL SignalBoostTM Immunoreaction Enhancer Kit 
(Calbiochem®) (Table 4.6) at room temperature. Following secondary antibody incubation, membranes were 
washed again with TBS-Tween Buffer and then visualized using Clarity Western ECL Substrate for 5 min and 
exposed with the Bio-Rad Chemidoc MP Imager for a specific time depending on the antibody used 
(Table 4.6). The optical density readings of each band was expressed relative to the average of the two 
stabilized controls present in lane 4 and 5 (as the first proteins are notorious for becoming smudged due to the 
lack of integrity/support from the open lane used for the ladder). Appendix A6, Figure A3 contains a western 
blot work-flow illustrating protein content on the stain-free gels/membrane and how they were used to 
normalize. All visualizations and quantification of protein bands on membranes were analyzed using Image 
Lab 5.0 (Bio-Rad Laboratories).  
4.3.4.6 Lowry Protein determination 
The refrigerated tubes containing 50 uL of resuspension 1 precipitated in 1 mL 10% (TCA) (described in 
Section 4.3.3.3) were centrifuged at 3,000 rpm for 10 min at 4 °C (Heraeus™ Megafuge™ 16 Centrifuge 
Series) and the supernatant decanted. Tubes were set to dry out upside down (pellet precipitated at the bottom 
of the tube) on a paper towel for 30 min and excess TCA still present removed with a cotton swab. 500 uL 1N 
NaOH was aliquoted into each tube and the protein dissolved at 45 °C in warm bath for 5 min. Once dissolved, 
500 uL dH2O was added to each tube, leaving a protein concentration suspended in 0.5 N NaOH effectively 
and the tube vortexed. To determine the protein concentration of mitochondrial samples, 50 μl protein sample, 
3 BSA concentrations (0.161, 0.322 and 0.644 mg/ml 0.5 N NaOH), used as standards and 0.5 N NaOH (used 
as blank) was pipetted into Lucham tubes in triplicates. 1ml reaction buffer, containing 2% Na2CO3, 1% 
CuSO4•5H20 and 2% Na+K+-Tartrate, was added to each tube, vortexed and incubated at room temperature 
for 10 min. Hereafter, 0.1 ml of a 1:3 dH20 diluted Folin Ciocalteus reagent was added to each tube, vortexed 
and incubated for 30 min after which OD values were determined using a spectrophotometer (Spectronic 20 
Genesys Spectrophotometer, Thermo Fisher Scientific Inc., RSA) at 750 nm. A standard curve was produced 
and the protein content of the samples determined. 
 
Under alkaline conditions, cupric ions (Cu2+) chelate with the peptide bonds of a protein resulting in a reduction 
of cupric ions (Cu2+) to cuprous ions (Cu+). Addition of reagents such as Folin Ciocalteu (phosphomolybdic-
phosphotungstic acid) with the Cu+ creates chromogens that give a colour reaction resulting in an increased 
absorbance between 550 nm and 750 nm. Absorbance at the peak wavelength of 750 nm quantitate protein 
concentrations between 1-100 mg/ml, whereas 550 nm is more suitable for quantifying higher protein 
concentrations (Sengupta & Chattopadhyay, 1993). The amount of colour produced can be readily detected 
and is proportional to the amount of peptide bonds, and thus an indication of the amount of protein.   
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Insulin-dependent Metabolic Regulator 
PKB 60 50 1:1000 0% 1:4000 0% 20s 
Insulin-Independent Metabolic Regulator 
AMPKα 62 50 1:1000 0% 1:4000 0% 40s 
AS160 160 50 1:1000 0% 1:4000 0% 70s 
RISK Pathway 
ERK1 44 50 1:1000 0% 1:4000 0% 20s 
ERK2 42 50 1:1000 0% 1:4000 0% 20s 
Stress-Marker 
JNK1 46 50 1:1000 0% 1:4000 0% 20s 
JNK2 54 50 1:1000 0% 1:4000 0% 20s 
Inflammation 
p38 43 50 1:1000 0% 1:4000 0% 20s 
Autophagy Marker 
LC3-I 18 50 1:1000 0% 1:4000 0% 10s 
LC3-II 16 50 1:1000 0% 1:4000 0% 10s 
Auxiliary Metabolic Regulation 
GSK3β 46 50 1:1000 0% 1:4000 0% 20s 







PINK1 63 50 1:1000 0% 1:4000 5% 300s 
Parkin 52 50 1:1000 0% 1:4000 5% 180s 
p62 62 50 1:1000 0% 1:4000 0% 160s 
BNIP3 30 50 1:1000 0% 1:4000 0% 300s 
LC3-II 62 50 1:1000 0% 1:4000 0% 10s 
Calbiochem® SignalBoostTM Immunoreaction Enhancer Kit (Sigma-Aldrich Life Sciences, USA) 
 
4.3.5 External Analysis 
4.3.5.1 Total Lipid Fatty Acid Composition 
The rat serum total lipid fatty acid composition was determined by means of gas-liquid chromatograpgy (GC) 
performed under supervision of Prof. Paul van Jaarsveld at the Non-Communicable Diseases Research Unit 
of the South African Medical Research Council.  
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Briefly, total lipids were extracted from serum obtained from the fasted rats, described in Section 4.3.2.6, using 
chloroform:methanol (2:1, vol:vol, containing 0.01% butylated hydroxytoluene) extraction in a modified Folch 
et al. (1957) method as described by Hon and colleagues (2009). Lipid extracts were concentrated till dry and 
the fatty acid of the lipids transesterefied using trans-methylation with methanol: sulphuric acid (95:5, vol:vol) 
at  70 °C for 2 hours to yield fatty acid methyl esters (FAMEs). The FAMES were then extracted with water 
and hexane, and the hexane layer evaporated until dry, before resuspended in a small volume of hexane and 
analysed by GC on a Finnigan Focus Gas Chromatograph equipped with flame ionisation detection (Thermo 
Electron Corporation, USA) and a 30m capillary column of 0.32 mm internal diameter; BPX70 0.25 um (SGE 
International Pty, Australia) as described by (Chimhashu et al., 2018). The sample FAMEs were identified 
according to retention times compared to the standard FAME mixture (27 FAMEs, NuChek Prep Inc., USA). 
Relative percentages of FAs were calculated by taking the AUC of a given FAME as percentage of the total 
area count of all FAs identified in the sample.  
4.3.6 Graphical Illustrations 
All of the figures used in this dissertation were self-illustrated in Powerpoint 365 (Microsoft Inc., USA) with the 
help of stock images obtained from http://www.somersault1824.com/resources/. These images are freeware 
and no copyrights are attached to the use thereof.  
4.3.7 Statistical Analysis 
Unless stated otherwise, all results are presented as the means ± standard error of the mean (SEM). For 
comparative studies, statistical analysis was done with a one-way analysis of variance (ANOVA) for multiple 
comparisons followed by Bonferroni post-hoc test (for p<0.05) (marked in black on all graphs) or as an 
additional test, Student’s t-test (unpaired) (for p<0.05 taken as significant, and p<0.10 indicated as points of 
interest for potential future research) (indicated in grey on all graphs) using GraphPad Prism 7 (Graphpad 
Software Inc., USA). P<0.05 was considered as significant. 
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5.1 CHARACTERISTICS OF DIET MODEL WITH AFRIPLEX GREEN ROOIBOS EXTRACT 
5.1.1 Body Weight 
Figure 5.1 shows the average increase in body weight over the 16 weeks of feeding, with week 17 being the 
week of sacrifice. At the start of the treatment in week 11, HCD rats did not weigh significantly more than 
control rats (335.8±6.3 g; n=147 vs. 326.2±4.7 g; n=146). However, at the end of the study (week 17), control 
rats averaged 373.6±4.8 g (n=74) and HCD animals 403.9±5.1 g (n=74), having gained 65.63±2.97 g (n=74) 
vs. the 45.22±2.80 g (n=74) in the treatment span of 6 weeks, equating to a 45.1% increase in weight gain for 
the same duration. HCD resulted in an average higher body weight of 30.3 g or 8.1% (p< 0.001). From 
Figure 5.2 (and Table 5.1), GRT supplementation did not significantly influence weight gain in the control rats 
(382.7±5.5 g; n=72), however the final weight of HCD animals supplemented with GRT was significantly 
increased (423.9±6.0 g; n=73), equating to an average gain of 20 g or 5.0% body weight (p<0.05). 
 
• Average Weekly Body Weight Per Rat 
 
Figure 5.1 Average body weight per week before-, during treatment and at the time of sacrifice 
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• Body Weight of Different Treatment Groups at 16 Weeks 
B o d y  w e ig h t
















































Figure 5.2 Scatterplot of body weight for each rat at the time of sacrifice (17th week of diet). ***p<0.001 
(Control vs HCD), *p<0.05 (HCD vs HCD + GRT). 
 
5.1.2 Intraperitoneal Fat 
Intraperitoneal fat was dissected at the time of sacrifice. From Figure 5.3 (and Table 5.1), HCD rats had 
significantly more intraperitoneal fat, 23.69±0.89 g or 5.79±0.18% of BW (n=73), compared to controls, 
13.98±0.43 g or 3.74±0.10% of BW (n=73), equating to a 41.0% increase in intraperitoneal fat. 
Supplementation with GRT did not significantly increase intraperitoneal fat in controls (13.71±0.55 g or 
3.54±0.12% of BW; n=72) but did approach a significant increase in HCD (26.50±1.19 g or 6.11±0.21% of BW; 
n=73; p=0.0595).  
 
Stellenbosch University  https://scholar.sun.ac.za
71 
    
In tra p e r ito n e a l  F a t




































































































Figure 5.3 Absolute intraperitoneal fat and percentage intraperitoneal fat of total body weight 
 
5.1.3 Food Consumption 
Food intake of selected groups of animals was monitored daily (and divided by the number of rats per cage to 
obtain individual food consumption) from the start of the diet until the week of sacrifice. Figure 5.4 shows a 
scatterplot of the average derived food consumption per rat for selected cages monitored. HCD animals 
consistently ate more food daily (23.41±0.52 g; n=40) than the control chow diet animals (17.62±0.36 g; n=40) 
in the first 10 weeks (Figure 5.5, Table 5.1). Furthermore, during the 6-week treatment period, the HCD 
animals still ate significantly more food daily (21.10±0.92 g; n=20) compared to the control group (17.76±0.44 
g; n=20). The addition of GRT did not significantly influence daily food intake compared to their untreated 
groups in either the control rats (17.10±0.47 g; n=20) or the HCD counterparts (23.80±0.96 g; n=20).  
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• Average Daily Food Consumption Per Rat 
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Figure 5.4 Scatterplot showing the distribution of average daily food intake per rat for each cage 
monitored.  
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Figure 5.5 Average Daily Food Consumption Per Rat Grouped into Pre-Treatment (Week 1 – 10) and 
With-Treatment (Week 11-16).  ***p<0.001 (Control vs HCD at 10 Weeks; Control +/- GRT vs HCD +/- GRT 
at 16 weeks). 
 
5.1.4 Water Consumption 
Water intake of selected cages was monitored daily (and divided by the number of rats per cage to obtain 
individual water consumption) from the start of the diet until the week of sacrifice. Figure 5.6 shows a 
scatterplot of the average derived water intake per rat for each individual cage monitored. HCD animals 
consistently drank less water daily (19.85±0.64 mL; n=40) compared to control animals (29.09±0.90 mL; n=40) 
in the first 10 weeks (Figure 5.7, Table 5.1). During the 6-week treatment period, the HCD animals still drank 
significantly less water daily (20.25±0.76 mL; n=20) compared to the control group (29.76±0.88 mL; n=20). 
The addition of GRT did not influence daily water intake compared to their untreated counterparts in either the 
control rats (28.76±0.48 mL; n=20) or the HCD treated groups (19.60±0.60 mL; n=20).  
 
  
Stellenbosch University  https://scholar.sun.ac.za
74 
    
• Average Daily Water Consumption Per Rat 
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Figure 5.6 Scatterplot showing the average daily water intake per rat for each cage monitored 
 







































Figure 5.7 Average daily water consumption grouped into pre-treatment (week 1 – 10) and with-
treatment (week 11-16). ***p<0.001 (Control vs HCD at 10 Weeks; Control vs HCD, Control +/- GRT vs HCD 
+/- GRT at 16 weeks).  
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5.1.5 Non-Fasting Blood Glucose Levels 
Non-fasting blood glucose levels were obtained just prior to sacrificing rats. Control rats had an average blood 
glucose level of 6.88±0.11 mmol/L (n=63), control with GRT 6.78±0.12 mmol/L (n=62), HCD rats 7.78±0.14 
mmol/L (n=65), and HCD with GRT 7.54±0.13 mmol/L (n=64). Non-fasting blood glucose levels were 13.1% 
higher in HCD rats compared to control rats (p<0.001), and supplementation with GRT did not significantly 
reduce the 11.2% higher blood glucose levels of HCD rats receiving GRT compared to their control 
counterparts. (Figure 5.8, Table 5.1).  































































Figure 5.8 Non-Fasting blood glucose levels taken at time of sacrifice (Week 17) 
 
5.1.6 Fasting Blood Glucose and Oral Glucose Tolerance Test 
To test for initial whole-body insulin resistance after 10 weeks of HCD, an OGTT was performed (Figure 5.9). 
Following overnight fasting, HCD rats had elevated basal blood glucose levels compared to the controls 
(5.63±0.15 (n=26) vs 5.16±0.10 mM (n=26); p<0.05) (Table 5.1). After an oral gavage, the blood glucose levels 
of HCD rats remained significantly elevated for up to 45 min (6.89±0.14 (n=26) compared to controls 
(6.37±0.14 (n=26) mM; p<0.05). AUC analysis of each individual OGTT for both groups also revealed 
significantly increased AUC in HCD compared to the control counterparts (771.8±13.6 (n=26) vs. 715.1±10.6 
(n=26; p<0.01). At 16 weeks, fasting blood glucose levels remained elevated in HCD rats compared to controls 
(5.75±0.16 (n=12) vs 5.21±0.16 mM (n=12); p<0.05) (Table 5.1). After an oral gavage, the blood glucose levels 
of HCD rats remained significantly elevated for up to 60 min (6.81±0.32 (n=12) vs controls, 5.92±0.18 (n=12) 
mM; p<0.05) (Figure 5.10). Furthermore, AUC analysis of each individual OGTT for each group, revealed 
significantly increased AUC in HCD and HCD with GRT compared to the control counterparts (p<0.05 for both) 
(793.3±19.20; n=12 and 849.0±24.90; n=12 respectively for HCD, vs. 732.2±12.38; n=12 and 722.9±13.89; 
n=12 respectively for controls). 
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• Oral Glucose Tolerance at 10 Weeks 
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Figure 5.9 Oral glucose tolerance test performed at 10 weeks (Prior to Treatment). At 60 min, HCD vs 
Control non-significant at p=0.05. 
 
• Oral Glucose Tolerance Test at 16 Weeks 
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Figure 5.10 Oral glucose tolerance test performed at 16 weeks (After 6 weeks of Treatment). HCD: high-
caloric diet; AUC: area under curve.  
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5.1.7 Fasting Serum Insulin Levels 
Fasting insulin levels were obtained from blood collected directly from the carotid artery under anaesthesia. 
From Figure 5.11, 16 Weeks of diet significantly elevated serum insulin compared to 10 Weeks in both diet 
models (4.31±0.54 ng/mL (n=5) vs 2.47±0.27 ng/mL (n=10); p<0.001 for control, and 6.20±0.33 ng/mL (n=5) 
vs 3.10±0.33 ng/mL (n=10); p<0.001 for HCD) (Table 5.1). Furthermore, at 16 weeks HCD rats had signifcantly 
higher fasting serum insulin levels compared to controls rats (6.20±0.33 ng/mL (n=5) vs 4.31±0.54 ng/mL 
(n=5); p<0.05), constituting an increase in serum insulin levels of 43.9%. Supplementation with GRT for 6 








































Figure 5.11 Fasting serum insulin at 10 weeks (pre-treatment) and 16 weeks (6 weeks of treatment). 
HCD: High-caloric diet, GRT: Afriplex green rooibos extract; *p<0.05 (Control vs HCD at 16 weeks), ***p<0.001 
(Fasting serum insulin levels at 10 weeks vs 16 weeks of diet).    
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5.1.8 Major summary of biometric parameters 
Table 5.1 Characteristics of the diet models with GRT treatment 
Parameter 
 
Control Control + GRT HCD 
 
HCD + GRT 
 
Unit MEAN±SEM n MEAN±SEM n MEAN±SEM n MEAN±SEM n 
 
BODY WEIGHT 
Week 10 g 326.2±4.7 146    335.8±6.3 
(n.s.) 
147    





Weight Gain during 
Treatment 












Percentage of BW % 3.74±0.10 73 3.54±0.12 72 5.79±0.18 
(***) 
73 6.11±0.21 73 
 
FOOD per rat/day 
Week 1-10 g 17.62±0.36 40    23.41±0.52 
(***) 
40    





Week 1-16 g 18.00±0.54 20 17.21±0.43 20 22.30±1.27 
(***) 
20 23.24±1.40 20 
 
WATER per rat/day 
Week 1-10 mL 29.09±0.90 40    19.85±0.64 
(***) 
40    





Week 1-16 mL 29.74±0.74 20 28.56±0.68 20 19.55±0.58 
(***) 
20 20.21±0.51 20 
 
NON-FASTING BLOOD GLUCOSE 
Week 16 mM 6.88±0.11 63 6.78±0.12 62 7.78±0.14 
(***) 
65 7.54±0.13 64 
 
FASTING BLOOD GLUCOSE 
Week 10 mM 5.16±0.10 26    5.63±0.15 
(**) 
26    






FASTING SERUM INSULIN 
Week 10 ng/mL 2.47±0.27 10    3.10±0.33 10    
Week 16 ng/mL 4.31±0.54 5 5.43±0.48 5 6.20±0.57 
(*) 
5 6.36±0.66 5 
 
HOMA-IR INDEX 
Week 10 AU 1.31±0.14 10    1.62±0.18 10    
Week 16 AU 2.30±0.28 5 2.89±0.25 5 3.52±0.35 
(*) 
5 3.48±0.34 5 
              
GRT: Afriplex green rooibos extract, HCD: high-caloric diet, HOMA-IR: homeostasis model assessment of 
insulin resistance, AU: arbitrary units, n.s.: no significance, *p<0.05, **p<0.01, ***p<0.001 (HCD vs Control; 
HCD + GRT vs HCD). 
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5.2 PERFUSION PARAMETERS OF 20 MIN GLOBAL ISCHEMIA PROTOCOL 
5.2.1 Heart Weight 
Heart weight was measured just prior to mounting of the heart onto the perfusion rig (Figure 5.12, Table 5.2). 
The average absolute heart weight was greatest in the HCD with GRT group, 1.31±0.02 g or 0.318±0.004% 
of BW (n=55), followed by HCD without GRT, 1.27±0.02 g or 0.322±0.003% of BW (n=61), both of which were 
significantly greater than their control counterparts, with GRT, 1.23±0.02 g or 0.326±0.003% of BW (n=55), 
and without GRT, 1.18±0.01 g or 0.324±0.003% of BW (n=61), respectively. However, when taken as a 
percentage of total body weight, the significance was lost. Thus, heart weight was found to be directly 
proportional to total body weight.  
H e a rt   W e ig h t





















































































Figure 5.12 Absolute heart weight and percentage heart weight of total body weight 
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5.2.2 Heart Rate 
Pre-ischemia (Figure. 5.13), GRT supplementation significantly decreased the heart rate of both controls 
(266.7±3.32 beats/min; n=55, vs. 275.5±3.18 beats/min; n=55; p<0.05) and HCD hearts (260.3±2.80 
beats/min; n=60, vs. 270.6±3.05 beats/min; n=61; p<0.05). Heart rate was also signicantly lower in all groups 
post-global ischemia vs. pre-ischemia (Table 5.2), however there was no significant differences between 
groups in percentage heart rate recovery post-ischemia.  



































































Figure 5.13 Average heart rate rate recorded pre- and post-global ischemia. HCD: High-caloric diet, GRT: 
Afriplex green rooibos extract; *p<0.05 (Control vs Control + GRT, HCD vs HCD + GRT Pre-Ischemia; Control-
, HCD- and HCD + GRT Post-Ischemia vs Pre-Ischemia), **p<0.01 (Control + GRT Post-Ischemia vs Pre-
Ischemia).   
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5.2.3 Coronary Flow 
Pre-ischemia, there was no significant differences in coronary flow between the 4 groups (Figure 5.14, 
Table 5.2). However, post ischemia, coronary flow was significantly lower in hearts from HCD rats compared 
to hearts from control rats (16.22±0.59 mL/min; n=33 vs. 18.67±0.63; n=27, p<0.01), which equated to a 
96.9±2.60% and 105.6±2.63% recovery, respectively; p<0.05).  
C o ro n a r y   F lo w
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Figure 5.14 Coronary flow pre- and post-global ischemia. HCD: High-caloric diet, GRT: Afriplex green 
rooibos extract; **p<0.01 (Control vs HCD Post-Ischemia).   
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5.2.4 Diastolic Pressure 
Pre-ischemia, diastolic pressure was significantly lower in the HCD group compared to controls (72.67±0.48 
mmHg; n=56 vs. 74.27±0.37 mmgHg; n=55; p<0.01) (Figure 5.15, Table 5.2). Furthermore, supplementation 
with GRT increased diastolic pressure in both controls (75.68±0.49 mmHg; n=56; p<0.05) and HCD 
(74.11±0.43 mmHg; n=61; p<0.05) compared to their untreated counterparts. Post-ischemia, diastolic pressure 
was significantly lower in Control (71.74±0.59 mmHg; n=27; p<0.05), Control + GRT (72.37±0.47 mmHg; n=27; 
p<0.001) and HCD + GRT (70.54±0.55 mmHg; n=26; p<0.001) compared to pre-ischemia, while HCD did not 
decrease significantly. These decreases, however, did not result in a significantly different percentage diastolic 
pressure recovery between any of the 4 groups.  
 










































































Figure 5.15 Diastolic pressure pre- and post-global ischemia. HCD: High-caloric diet, GRT: Afriplex green 
rooibos extract; *p<0.05 (Control vs Control + GRT Pre-Ischemia; HCD vs HCD + GRT Pre-Ischemia; Control 
Pre-ischemia vs Post-ischemia), **p<0.01 (Control vs HCD Pre-Ischemia), ***p<0.001 (Control + GRT and 
HCD + GRT Pre- vs Post-ischemia).   
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5.2.5 Systolic Pressure 
Pre-ischemia, systolic pressure was significantly lower in the HCD group compared to controls (92.01±0.28 
mmHg; n=61 vs. 94.24±0.36 mmHg; n=55; p<0.0001) (Figure 5.16, Table 5.2). Supplementation with GRT 
increased systolic pressure in both controls (95.98±0.36 mmHg; n=56; p<0.001) and HCD (94.22±0.36 mmHg; 
n=61; p<0.0001) compared to their untreated counterparts. Post-ischemia, systolic pressure was significantly 
lower in all groups. However, this did not result in a significantly different percentage systolic pressure recovery 
between any of the 4 groups.  







































































*** *** *** ***
 
Figure 5.16 Systolic pressure pre- and post-global ischemia. HCD: High-caloric diet, GRT: Afriplex green 
rooibos extract; **p<0.01 (Control vs Control + GRT Pre-Ischemia), ***p<0.001 (Pre- vs Post-ischemia), 
****p<0.0001 (Control vs HCD Pre-Ischemia, HCD vs HCD + GRT Pre-Ischemia).   
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5.2.6 Aortic Output 
Pre-ischemia, aortic output (AO) was significantly lower in the HCD group compared to controls (34.76±0.45 
mL/min; n=61 vs. 41.79±0.47 mL/min; n=55, p<0.0001) (Figure 5.17). Furthermore, supplementation with GRT 
improved AO in both controls (44.38±0.56 mL/min; n=56; p<0.001) and HCD (37.78±0.58 mL/min; n=60; 
p<0.0001) compared to their untreated counterparts. Post-ischemia, AO was still significantly lower in HCD 
compared to controls (13.07±0.95 mL/min; n=33 vs. 20.33±0.97 mL/min; n=27, p<0.0001), equating to a 
percentage AO recovery of 38.04±2.76% and 51.03±2.29%, p<0.001 respectively (Table 5.2). 
Supplementation with GRT improved post-ischemic AO in HCD hearts (18.15±0.90 mL/min; n=26; p<0.001, 
percentage AO recovery of 49.04±2.20%, p<0.01), equating to a 28.9% improvement in AO recovery 
compared to the untreated HCD hearts. 
. 









































































Figure 5.17 Aortic output pre- and post-global ischemia. HCD: High-caloric diet, GRT: Afriplex green 
rooibos extract; **p<0.01 (Control vs Control + GRT Pre-Ischemia; HCD vs HCD + GRT Post-Ischemia), 
***p<0.001 (HCD vs HCD + GRT Pre-Ischemia), ****p<0.0001 (Control vs HCD Pre- and Post-Ischemia; Pre- 
vs Post-ischemia).   
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5.2.7 Cardiac Output 
Pre-ischemia, cardiac output (CO) was significantly lower in the HCD group compared to controls (52.07±0.58 
mL/min; n=61 vs. 59.97±0.69; n=55, p<0.0001) (Figure 5.18). Furthermore, supplementation with GRT 
improved CO in both controls (63.3±0.85 mL/min; n=56; p<0.01) and HCD (55.88±0.81 mL/min; n=60; 
p<0.001) compared to their untreated counterparts. Post-ischemia, CO was still significantly lower in HCD 
compared to controls (30.2±1.16 mL/min; n=33 vs. 38.84±1.40 mL/min; n=28, p<0.0001), equating to a 
percentage CO recovery of 58.34±2.25% and 68.36±1.87%, p<0.01 respectively (Table 5.2). Supplementation 
with GRT improved post-ischemic CO in hearts from HCD rats (36.38±1.354 mL/min; n=26; p<0.001 
percentage CO recovery of 66.49±2.32%, p<0.05), equating to a 14.0% improvement in CO recovery 
compared to the hearts from untreated HCD rats. 









































































Figure 5.18 Cardiac output pre- and post-global ischemia. HCD: High-caloric diet, GRT: Afriplex green 
rooibos extract; *p<0.05 (Control vs Control + GRT Pre-Ischemia; HCD vs HCD + GRT Post-Ischemia), 
**p<0.01 (HCD vs HCD + GRT Pre-Ischemia), ***p<0.001 (Control vs HCD Post-Ischemia), ****p<0.0001 
(Control vs HCD Pre-Ischemia, Pre-ischemia vs Post-ischemia). 
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5.2.8 Total Work 
Pre-ischemia, total work (WT) was significantly lower in the HCD group compared to controls (10.69±0.14 mW; 
n=61 vs. 12.6±0.19 mW; n=55, p<0.0001) (Figure 5.19). Furthermore, supplementation with GRT improved 
WT in both controls (13.91±0.23 mW; n=56; p<0.0001) and HCD (11.98±0.20 mW; n=60; p<0.0001) compared 
to their untreated counterparts. Post-ischemia, WT was still significantly lower in HCD compared to controls 
(5.91±0.24 mW; n=33 vs. 8.01±0.24 mW; n=26, p<0.0001), equating to a percentage WT recovery of 
64.80±2.04% and 55.51±2.28%, p<0.01 respectively (Figure 5.20). Supplementation with GRT improved post-
ischemic WT in hearts from HCD rats (7.29±0.30 mW; n=26; p<0.001, percentage WT recovery of 
63.35±2.49%, p<0.05), equating to a 14.1% improvement in WT recovery compared to the untreated HCD 
hearts. 
 
Figure 5.19 Total work pre- and post-global ischemia. HCD: High-caloric diet, GRT: Afriplex green rooibos 
extract; **p<0.01 (HCD vs HCD + GRT Post-Ischemia), ****p<0.0001 (Control vs HCD Pre- and Post-Ischemia; 
Control vs Control + GRT Pre-Ischemia; HCD vs HCD + GRT Pre-Ischemia; Pre- vs Post-ischemia).  
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• Total Work Recovery 






















































Figure 5.20 Percentage total work recovery post-global ischemia. HCD: High-caloric diet, GRT: Afriplex 
green rooibos extract; *p<0.05 (Control vs HCD; HCD vs HCD + GRT).   
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5.2.9 Summary of functional heart parameters 
Table 5.2 Summary of functional heart parameters in global ischemia protocol 
  CONTROL CONTROL+GRT HCD HCD+GRT 




1.18±0.01 61 1.23±0.02 55 1.27±0.02 
(**) 
61 1.31±0.02 55 





275.5±3.18 55 266.7±3.32 
(*) 




















17.57±0.37 60 17.98±0.44 58 16.66±0.33 61 17.05±0.42 61 
Post-
Ischemia 
18.67±0.63 27 17.76±0.76 26 16.22±0.59 
(**) 
33 17.72±0.73 26 























27 71.42±0.73 33 70.54±0.55 
(⧫***) 
26 
















































































































HCD: High-caloric diet, GRT: Afriplex green rooibos extract; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
(Control + GRT vs Control; HCD vs Control; HCD + GRT vs HCD; ⧫post-ischemia vs pre-ischemia).   
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5.3 PERFUSION PARAMETERS OF 35 MIN REGIONAL ISCHEMIA PROTOCOL 
5.3.1 Heart Rate 
There were no significant differences in heart rate pre- or post-ischemia for either of the groups during the 
regional ischemia protocol (Table 5.3).  
5.3.2 Coronary Flow Rate 
Pre-ischemia there were no significant differences in coronary flow between the 4 groups, however 
supplementation with GRT did initially increase coronary flow in control groups, albeit non-significantly due the 
low n-value (p=0.063) (19.30±0.51 mL/min; n=10 vs. 17.67±0.64 mL/min; n=9) (Table 5.3). Post regional 
ischemia, there were no major differences in coronary flow rate and with only minor decreases (p=0.056) in 
the percentage coronary flow recovery observed in the GRT supplemented controls (96.92±6.07%; n=10 vs. 
114.3±5.55%; n=9). 
5.3.3 Diastolic and Systolic Pressure 
There were no significant differences in either diastolic or systolic pressure pre- or post-ischemia for either of 
the groups during the regional ischemia protocol (Table 5.3).  
5.3.4 Aortic Output 
Pre-ischemia, AO was significantly lower in the HCD group compared to controls (33.67±1.15 mL/min; n=9 vs. 
39.00±0.85 mL/min; n=9, p<0.05) (Table 5.3). Furthermore, supplementation with GRT improved AO in both 
controls (43.80±1.28 mL/min; n=10; p<0.05) and HCD (37.33±1.21 mL/min; n=9; p<0.05) compared to their 
untreated counterparts. Post-ischemia, AO was lower in HCD compared to controls (13.06±2.34 mL/min; n=9 
vs. 19.13±2.05 mL/min; n=9, p=0.0712), equating to a percentage AO recovery of 32.36±4.93% and 
49.09±5.31%, p<0.05 respectively. Supplementation with GRT improved post-ischemic AO in HCD hearts 
(17.89±1.36 mL/min; n=9; p=0.0865, percentage AO recovery of 47.48±2.38%, p<0.05), equating to a 26.4% 
improvement in AO recovery compared to the untreated HCD heart. 
5.3.5 Cardiac Output 
Pre-ischemia, CO was significantly lower in the HCD group compared to controls (51.39±1.07 mL/min; n=9 vs. 
56.63±1.51; n=9, p<0.05) (Table 5.3). Furthermore, supplementation with GRT improved CO in controls 
(63.10±1.55 mL/min; n=10; p<0.01), but not significantly in HCD (54.89±1.56 mL/min; n=9) compared to their 
untreated counterparts. Post-ischemia, CO was still significantly lower in HCD compared to controls 
(30.44±2.33 mL/min; n=9 vs. 38.19±2.31 mL/min; n=9, p<0.05), equating to a percentage CO recovery of 
58.22±4.39% and 67.39±3.55%, respectively. Supplementation with GRT did not have a significant effect on 
coronary output post-regional ischemia. 
5.3.6 Total Work 
Pre-ischemia, WT was significantly lower in the HCD group compared to controls (10.42±0.27 mW; n=9 vs. 
11.63±0.33 mW; n=9, p<0.05) (Figure 5.21). Furthermore, supplementation with GRT improved WT in controls 
(13.28±0.40 mW; n=10; p<0.01), but not significantly in HCD (11.38±0.38 mW; n=9; p=0.057) compared to 
their untreated counterparts. Post-ischemia, WT was still significantly lower in HCD compared to controls 
(5.70±0.43 mW; n=9 vs. 7.49±0.45 mW; n=9, p<0.05), equating to a percentage total work recovery of 
53.55±4.22% and 64.42±3.51%, respectively (p=0.067) (Figure 5.22). Supplementation with GRT improved 
post-ischemic WT in HCD hearts (7.00±0.35 mW; n=9; p<0.05, percentage total work recovery of 61.46±2.09%, 
p=0.093), equating to a 14.8% improvement in WT recovery compared to the untreated HCD hearts. 
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Figure 5.21 Total work pre- and post-regional ischemia. HCD: High-caloric diet, GRT: Afriplex green 
rooibos extract; *p<0.05 (Control vs Control + GRT and HCD Pre-Ischemia, Control vs HCD Post-Ischemia, 
HCD vs HCD + GRT Post-Ischemia), ⧫p<0.001 (Pre- vs Post-ischemia).       
• Total Work Recovery 
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Figure 5.22 Percentage total work recovery post-regional ischemia. HCD: High-caloric diet, GRT: Afriplex 
green rooibos extract. 
5.3.7 Infarct Size 
%AAR did not differ between the groups (Table 5.3). HCD had the greatest infarct size (34.99±11.56%; n=9 
compared to controls: 16:42±8.71%; n=9; p<0.01), while GRT supplementation completely reversed the infarct 
size (13.22±6.66%; n=9; p<0.001) (Figure 5.23, Figure 5.24). 














































Figure 5.23 Percentage infarct size following regional ischemia and reperfusion. HCD: High-caloric diet, 
GRT: Afriplex green rooibos extract; **p<0.01 (HCD vs Control), ***p<0.001 (HCD + GRT vs HCD). 
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• Representative slices of 4 different groups after staining 
 
Figure 5.24 Representative stained heart slices after ischemia and reperfusion. HCD: High-caloric diet, 
GRT: Afriplex green rooibos extract. Viable area (stained by Evans blue), area at risk (AAR, i.e. area not 
stained by Evans Blue), live cells (TTC positive, i.e. red) and infarcted area (TTC negative, i.e. white).  
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5.3.8 Summary of functional heart parameters 
Table 5.3 Summary of functional heart parameters in regional ischemia protocol 
  CONTROL 
(n = 9) 
 
CONTROL+GRT 
(n = 10) 
HCD 
(n = 9) 
HCD+GRT 
(n = 9) 
Parameter  MEAN±SEM MEAN±SEM MEAN±SEM MEAN±SEM 
Heart Rate 
(beats/min) 
Pre-Ischemia 249.4±6.6 261.8±8.31 262.4±7.2 259.1±5.2 
Post-Ischemia 243.6±10.4 247.9±5.3 252.3±10.22 258.9±9.0 




Pre-Ischemia 17.67±0.64 19.30±0.51 17.72±0.31 17.56±0.72 
Post-Ischemia 19.06±0.99 17.70±0.71 17.38±0.66 18.22±0.98 




Pre-Ischemia 73.55±1.00 75.10±1.18 72.83±1.25 73.44±0.91 
Post-Ischemia 72.75±0.51 72.85±0.87 71.13±0.99 71.89±0.53 




Pre-Ischemia 92.85±1.07 94.6±1.02 91.22±0.84 93.22±0.98 
Post-Ischemia 88.31±0.60 89.90±0.98 88.00±1.10 87.17±0.61 


























% Recovery 67.39±3.55 65.00±4.11 58.22±4.39 65.69±2.16 
Total Work 
(mW) 









% Recovery 64.42±3.51 64.23±3.51 53.55±4.22 61.46±2.09 
Infarct size 
% Area at Risk 50.65±1.71 50.46±1.22 51.29±2.26 49.75±0.72 
% Infarct Size 16.42±8.71 14.58±5.43 34.99±11.56 (**) 13.22±6.66 (***) 
HCD: High-caloric diet, GRT: Afriplex green rooibos extract; *p<0.05, **p<0.01, ***p<0.001 (Control + GRT 
vs Control; HCD vs Control; HCD + GRT vs HCD; ⧫post-ischemia vs pre-ischemia).   
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5.4 CARDIAC PROTEIN SIGNALING 
In order to describe the protein signaling as possible mechanistic explanation for the observed changes, we 
investigated the change in total protein (expression) and phosphorylated protein (referred to as activation) 
relative to the basal control (referred to as C1 - 30 min stabilized control marker) in isolated perfused cardiac 
ventricular tissue freeze-clamped at the following time points (n=5): Stabilization (30 min total perfusion time), 
Ischemia (20 min global-ischemia and 50 min total perfusion time), Early Reperfusion (5 min into reperfusion 
and 55 min total perfusion time) and Late Reperfusion (30 min into reperfusion and 80 min total perfusion 
time).  Additionally, a young control marker (YC) was also placed on the first two lanes to serve as an additional 
positive control and out of interest for future comparative studies. 
5.4.1 PKB 
PKB plays a primary role in insulin-dependent metabolism and is well-recognized to be cardioprotective as 
part of the RISK pathway when activated in early reperfusion (Rossello & Yellon, 2018). 
 
• Stabilization 
GRT supplementation in controls significantly increased PKB activation compared to untreated controls 
(p<0.05), and decreased activation and expression in HCD compared to untreated HCD (p<0.01 for both) 
(Figure 5.25, Table 5.4).  
 
• Ischemia 
HCD significantly decreased PKB activation (p<0.05) and PKB activation/expression ratio (p=0.072) compared 
to controls. GRT supplementation increased PKB expression (p=0.060) and consequently decreased PKB 
activation/expression ratio (p=0.063) in controls.  
 
• Early Reperfusion 
HCD significantly increased PKB expression (p<0.01) but decreased PKB activation (p<0.05), resulting in a 
decreased PKB activation/expression ratio (p=0.075). GRT supplementation in HCD significantly increased 
PKB expression (p<0.001) but not the activation/expression ratio.  
 
• Late Reperfusion 
HCD significantly decreased PKB expression (p<0.001), resulting in an increased PKB activation/expression 
ratio (p<0.001). GRT supplementation increased PKB expression (p=0.051) in HCD, whilst decreasing PKB 
expression in controls (p<0.05). However, GRT supplementation decreased PKB activation in both controls 
(p<0.001) and HCD (p<0.05), simultaneously also decreasing the PKB activation/expression ratio (p<0.01) in 
HCD.  
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Figure 5.25 PKB Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.2 AMPK 
AMPK is considered an insulin-independent metabolic regulator (Xu et al., 2014).  
 
• Stabilization 
HCD significantly increased AMPK expression (p<0.01) and consequently decreased the AMPK 
activation/expression ratio (p<0.05) compared to controls. GRT supplementation increased AMPK activation 
in controls (p<0.001), whilst consequently decreasing the AMPK activation/expression ratio (p=0.060) 
(Figure 5.26, Table 5.4).  
 
• Ischemia 
HCD significantly increased AMPK activation (p<0.05) and activation/expression ratio (p<0.05) compared to 
controls. GRT supplementation increased AMPK activation in controls (p<0.05), resulting in increased 
activation/expression ratio (p=0.09), whilst contrastingly decreasing AMPK activation in HCD (p=0.075). 
 
• Early Reperfusion 
GRT supplementation significantly decreased AMPK expression in HCD (p<0.05), whilst significantly 
increasing AMPK activation (p<0.001) and consequently increasing the AMPK activation/expression ratio 
(p<0.001).  
 
• Late Reperfusion 
HCD significantly decreased AMPK expression (p<001), resulting in an increased AMPK activation/expression 
ratio (p<0.05). GRT supplementation in controls decreased AMPK expression (p=0.01) resulting in an 
increased AMPK activation/expression ratio (p<0.05). In contrast, GRT supplementation in HCD significantly 
increased AMPK expression (p<0.001).  
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Figure 5.26 AMPK Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.3 AS160 
AS160 serve as a precursor to GLUT4 mediated glucose uptake into cells (Mîinea et al., 2005).  
 
• Stabilization 
HCD increased AS160 expression (p=0.065) compared to controls (Figure 5.27, Table 5.4). GRT 
supplementation significantly increased AS160 expression in both controls (p<0.05) and HCD (p<0.01), while 
decreasing AS160 activation in both controls (p<0.01) and HCD (p<0.05) and resulting in decreased AS160 
activation/expression ratio (p=0.097 and p=0.087 respectively).  
 
• Ischemia 
GRT supplementation decreased AS160 expression in both controls (p<0.05) and HCD (p=0.079), and 
significantly increasing the AS160 activation/expression ratio in controls (p<0.001) but not in HCD. 
  
• Early Reperfusion 
HCD significantly decreased the AS160 activation/expression ratio compared to controls (p<0.05).  
 
• Late Reperfusion 
GRT supplementation decreased the AS160 activation/expression ratio in HCD (p=0.086).  
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Figure 5.27 AS160 Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.4 ERK1 
ERK cascade plays a crucial role in multiple cellular processes such as cell proliferation, differentiation, 
adhesion, migration and survival. Therefore, it is essential for many physiological events including 
development, immunity, metabolism, and memory formation (Buscà et al., 2016). Activation of ERK during 
reperfusion is associated with cardioprotection (RISK pathway). 
 
• Stabilization 




GRT supplementation resulted in significant decreased ERK1 expression and in effect increased ERK1 
activation/expression ratio (p<0.05 and p=0.068) compared to HCD. No significant differences were observed 
in controls.  
 
• Early Reperfusion 
GRT supplementation led to a significant decrease in ERK1 activation and in effect decreased ERK1 
activation/expression ratio (p<0.01 for both) compared to HCD. No significant differences were recorded in 
controls.  
 
• Late Reperfusion 
HCD significantly decreased ERK1 activation and expression compared to controls (p<0.05 and p<0.01 
respectively). Likewise, GRT supplementation also decreased ERK1 activation and expression compared to 
controls (p<0.001 for both). There were no significant differences observed in the ERK1 activation/expression 
ratio between the 4 groups.  
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Figure 5.28 ERK1 Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.5 ERK2 
Whether ERK1 and ERK2 specify functional differences or are in contrast functionally redundant, constitutes 
an ongoing debate despite the huge amount of studies performed to date (Buscà et al., 2016). However, for 
the sake of investigating both isoforms were considered for analysis.  
 
• Stabilization 
GRT supplementation significantly increased ERK2 expression in controls (p<0.05), but not HCD (Figure 5.29, 
Table 5.5).  
 
• Ischemia 
GRT supplementation resulted in a significant decreased ERK2 expression and activation (p<0.01 for both) 
and increased ERK2 activation/expression ratio (p=0.075) compared to HCD. No significant differences were 
observed in controls.  
 
• Early Reperfusion 
GRT supplementation significantly increased ERK2 activation and activation/expression ratio in controls 
(p<0.0001 and p<0.001 respectively). GRT supplementation also decreased the ERK2 activation/expression 
ratio (p<0.01) in HCD. 
 
• Late Reperfusion 
HCD had significantly increased ERK2 expression (p<0.05), resulting in increased ERK2 activation/expression 
ratio (p<0.05) compared to controls. GRT supplementation decreased ERK2 expression in controls (p<0.01) 
and decreased the ERK2 activation/expression ratio in HCD (p<0.01).  
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Figure 5.29 ERK2 Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
points (n=5). HCD: High-caloric diet, GRT: Afriplex green rooibos extract.  
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5.4.6 ERK1/ERK2 
ERK1 and ERK2 seem to be expressed ubiquitously and there are no obvious regulatory differences inferred 
from their protein sequences, their regulation or their sub-cellular localization (Buscà et al., 2016). 
 
• Stabilization 
There were no significant differences in ERK1/ERK2 expression or activation ratios for any of the 4 groups 
(Figure 5.30, Table 5.5). 
 
• Ischemia 
GRT supplementation resulted in significantly increased ERK1/ERK2 activation ratio in both control and HCD 
(p<0.001 for both) and increased ERK1/ERK2 expression ratio in HCD (p<0.001).  
 
• Early Reperfusion 
GRT supplementation resulted in significantly decreased ERK1/ERK2 activation ratio in both control and HCD 
(p<0.001 and p<0.05 respectively) and decreased ERK1/ERK2 expression ratio in HCD (p<0.05).  
 
• Late Reperfusion 


















































































































Figure 5.30 Ratio between ERK1 and ERK2 Activation (A) and Expression (B) between the different 
groups and time points (n=5). HCD: High-caloric diet, GRT: Afriplex green rooibos extract. 
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5.4.7 JNK1 
JNK’s are activated in response to inflammatory cytokines and cellular stress but early activation of JNK in 
reperfusion is known to be a pre-requisite for the activation of PKB (Fan, 2017). The latter occurrence is 
recognized as cardioprotective as part of the RISK pathway.  
 
• Stabilization and Ischemia 
JNK1 activation was detectable in either of the groups prior to reperfusion, while expression was also faint in 
comparison to JNK2 (Figure 5.31, Table 5.5). 
 
• Early Reperfusion 
HCD resulted in significantly decreased JNK1 expression and activation (p<0.001 for both), and increased 
JNK1 activation/expression ratio (p<0.001) compared to controls. GRT supplementation resulted in increased 
JNK1 activation, and subsequently JNK1 activation/expression ratio in controls but not in the HCD (p<0.05 
and p<0.001 respectively).  
 
• Late Reperfusion 
HCD had significantly increased JNK1 activation (p<0.001) and increased JNK1 activation/expression ratio 
(p<0.001) compared to controls. GRT supplementation resulted in increased JNK1 activation, and 
subsequently JNK1 activation/expression ratio in controls (p<0.001 for both) but not in the HCD.  
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Figure 5.31 JNK1 Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.8 JNK2 
• Stabilization 
GRT supplementation increased JNK2 expression in controls (p<0.05), but not HCD. No JNK2 activation 
detected prior to reperfusion.  
 
• Ischemia 
No significant differences were observed in JNK2 expression during ischemia, and no JNK2 activation detected 
prior to reperfusion (Figure 5.32, Table 5.5).  
 
• Early Reperfusion 
HCD increased JNK2 expression (p<0.05), but decreased JNK2 activation (p<0.01), resulting in a decrease of 
JNK2 activation/expression vs controls (p<0.001). GRT supplementation significantly increased JNK2 
expression (p<0.05) and activation (p<0.01) in controls. In HCD, GRT supplementation decreased JNK2 
activation and consequently decreased the JNK2 activation/expression ratio (p<0.05 for both). 
 
• Late Reperfusion 
HCD had significantly increased JNK2 activation (p<0.001), resulting in increased JNK2 activation/expression 
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Figure 5.32 JNK2 Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.9 p38 
p38 MAPK is predominately expressed and activated in response to inflammation but is also known to be 




P38 activation was significantly increased in HCD compared to controls (p<0.001), which also led to an 
increased p38 activation/expression ratio (p<0.001) (Figure 5.33, Table 5.6). GRT supplementation in controls 
also led to significantly higher p38 activation (p<0.001) and p38 activation/expression ratio (p<0.01). GRT 
supplementation in HCD decreased p38 activation and expression (p<0.01), but increased p38 
activation/expression ratio compared to untreated HCD (p<0.05). 
 
• Ischemia 
GRT supplementation resulted in increased p38 expression and activation (p<0.01 and p=0.078) in controls, 
but not in HCD.  
 
• Early Reperfusion 
GRT supplementation led to a significant increase in p38 activation in controls (p<0.01) and decrease in p38 
expression in HCD (p<0.05). No significant differences between untreated controls and HCD were recorded.  
 
• Late Reperfusion 
P38 expression and activation was decreased in HCD compared to controls (p<0.01 and 0.074 respectively).    
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Figure 5.33 p38 Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.10 LC3-I and -II 
LC3-A and LC3-B are referred to as LC3-I and LC3-II, respectively. During the activation of autophagy, the 
cytosolic LC3-I (substrate) is converted into the phagophore-bound LC-II (product) – a process termed LC3 
conversion. The LC-II/LC-I ratio thus shows the degree of conversion, and to a certain degree the flux of 
autophagy (Oh et al., 2017).  
 
• Stabilization 
LC3-I and II was significantly elevated in HCD compared to controls (p<0.05 and p<0.01 respectively). LC3-II 
was also significantly elevated in controls supplemented with GRT (p<0.001), which also resulted in an 
elevated LC3-II/LC3-I ratio (p<0.05). No significant differences were noted in HCD supplemented with GRT 
(Figure 5.34, Table 5.6).  
 
• Ischemia 
HCD increased LC3-I (p=0.086), while GRT supplementation in HCD resulted in a significant decrease in LC3-
I (p<0.05). LC3-II/LC3-I ratio was significantly decreased in controls with GRT and HCD compared to 
stabilization (p<0.05 for both).  
 
• Early Reperfusion 
LC3-I and II were significantly increased in HCD groups compared to controls (p<0.01 and p<0.05 
respectively), while GRT supplementation resulted in decreased LC3-I (p<0.01) and therefore increased LC3-
II/I ratio (p<0.05). In controls, GRT supplementation decreased the LC3-II/I ratio (p<0.05). 
 
• Late Reperfusion 
LC3- II was decreased in HCD (p<0.01), thereby decreasing the LC3-II/I ratio (p<0.05). GRT supplementation 
resulted in a decrease in LC3-I (p<0.01) and LC3-II (p<0.05) in control animals, but no effect in HCD animals. 
LC3-II/LC3-I ratio was significantly increased in controls compared to stabilization (p<0.05), in controls, 
controls with GRT and HCD with GRT compared to ischemia (p<0.05 for all), and controls with and without 
GRT compared to early reperfusion (p<0.05 for both).  
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Figure 5.34 LC3-I (C) and II (B) Expression Ratio (A) between the different groups and time points (n=5). 
HCD: High-caloric diet, GRT: Afriplex green rooibos extract. p<0.05 (Stabilization vs Ischemia), p<0.05 
(Stabilization vs Late Reperfusion), ⧫p<0.05 (Late Reperfusion vs Ischemia),  p<0.05 (Late Reperfusion vs 
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5.4.11 GSK3β 
GSK3β plays a prominent role within glucose homeostasis, cardioprotection and the RISK pathway where it is 
seen as the end-effector in the closure of the mPTP (Ghaderi et al., 2017a).  
 
• Stabilization 
HCD elevated the GSK3β phosphorylation/expression ratio (p=0.053) compared to controls. GRT 
supplementation in HCD decreased GSK3β expression (p<0.05) and phosphorylation (p<0.01) compared to 
untreated HCD (Figure 5.35, Table 5.6). 
 
• Ischemia 
HCD significantly decreased GSK3β phosphorylation (p<0.05) and subsequently decreased the GSK3β 
phosphorylation/expression ratio (p<0.05) compared to controls. GRT supplementation had no significant 
effect on GSK3β signaling.  
 
• Early Reperfusion 
HCD significantly decreased GSK3β phosphorylation (p<0.001) and subsequently the GSK3β 
phosphorylation/expression ratio (p<0.001) compared to controls. GRT supplementation had no significant 
effect on GSK3β signaling.  
 
• Late Reperfusion 
No significant differences were recorded in GSK3β signaling for either diet or GRT supplementation.  
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Figure 5.35 GSK3β Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.12 ATM 
ATM is an important cell signaling kinase in response to cell damage. Its activation is postulated to be a 
prerequisite for the activation of both PKB and AMPK (Li, Luo, et al., 2017; Viniegra et al., 2005). 
. 
• Stabilization 
There were no significant differences in ATM expression or activation between the groups (Figure 5.36, 
Table 5.6).  
 
• Ischemia 
HCD significantly increased ATM activation (p<0.05) compared to controls. GRT supplementation in controls 
but not HCD led to increased ATM expression (p=0.081) and activation (p<0.05).  
 
• Early Reperfusion 
HCD decreased ATM activation (p<0.05) compared to controls. GRT supplementation in controls led to 
decreased ATM expression (p<0.05) and ATM activation (p<0.05). 
 
• Late Reperfusion 
HCD decreased ATM expression (p<0.05) and activation (p<0.001), whilst GRT supplementation in controls 
similarly decreased ATM expression (p<0.05) and activation (p<0.001) compared to controls. GRT 
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Figure 5.36 ATM Ratio (A) of Activation (B) to Expression (C) between the different groups and time 
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5.4.13 Summary of western blot parameters 
Table 5.4 Summary of all cardiac western blot parameters 
Parameter Time Point 
CONTROL  CONTROL + GRT  HCD  
 
HCD + GRT 
 
 
MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  
Insulin-dependent Signaling 
T-PKB 
Stabilization 1.49±0.16  1.85±0.18  1.71±0.08  1.30±0.07 (**) ↓ 
Ischemia 0.96±0.08  1.18±0.04(p=0.06) ↑ 0.83±0.06  0.79±0.03  
Early Reperfusion 1.03±0.12  0.85±0.12  1.77±0.45 (**) ↑ 2.84±0.17 (***) ↑ 
Late Reperfusion 0.76±0.03  0.58±0.05 (*) ↓ 0.32±0.02 (****) ↓ 0.43±0.04(p=0.05) ↑ 
P-PKB 
Stabilization 1.04±0.10  1.48±0.13 (*) ↑ 0.95±0.03  0.72±0.03 (**) ↓ 
Ischemia 0.98±0.09  0.97±0.06  0.67±0.02 (*) ↓ 0.60±0.04  
Early Reperfusion 1.92±0.20  1.87±0.10  1.12±0.11 (*) ↓ 0.97±0.06  
Late Reperfusion 2.54±0.35  1.22±0.30 (***) ↓ 2.18±0.35  1.46±0.29 (*) ↓ 
P/T-PKB 
Stabilization 0.72±0.08  0.84±0.13  0.56±0.01  0.55±0.02  
Ischemia 1.02±0.08  0.81±0.02(p=0.06) ↓ 0.82±0.03 (p=0.07) ↓ 0.77±0.07  
Early Reperfusion 2.04±0.40  2.33±0.27  0.93±0.36 (p=0.08) ↓ 0.34±0.04  
Late Reperfusion 3.33±0.46  2.06±0.49  6.63±1.38 (***) ↑ 3.72±1.05 (**) ↓ 
Insulin-independent Signaling 
T-AMPK 
Stabilization 1.14±0.07  1.58±0.03 (***) ↑ 1.39±0.07 (**) ↑ 1.53±0.05  
Ischemia 0.88±0.04  0.90±0.05  0.87±0.03  0.90±0.02  
Early Reperfusion 1.02±0.02  1.05±0.02  0.97±0.01  0.91±0.00 (*) ↓ 
Late Reperfusion 1.25±0.04  1.00±0.05 (**) ↓ 0.93±0.02 (***) ↓ 1.30±0.07 (***) ↑ 
P-AMPK 
Stabilization 0.91±0.06  0.98±0.05  0.72±0.09  0.63±0.03  
Ischemia 0.73±0.03  0.92±0.02 (*) ↑ 0.99±0.07 (*) ↑ 0.82±0.01(p=0.08) ↓ 
Early Reperfusion 0.72±0.02  0.67±0.05  0.76±0.11  1.38±0.13 (***) ↑ 
Late Reperfusion 0.37±0.05  0.42±0.02  0.39±0.04  0.44±0.03  
P/T-AMPK 
Stabilization 0.81±0.07  0.62±0.04(p=0.06) ↓ 0.53±0.09 (*) ↓ 0.41±0.01  
Ischemia 0.83±0.05  1.04±0.09(p=0.09) ↑ 1.14±0.12 (*) ↑ 0.91±0.02  
Early Reperfusion 0.71±0.03  0.63±0.04  0.78±0.12  1.51±0.14 (***) ↑ 
Late Reperfusion 0.29±0.03  0.42±0.01 (*) ↑ 0.42±0.03 (*) ↑ 0.34±0.02  
T-AS160 
Stabilization 1.15±0.14  2.05±0.53 (*) ↑ 1.77±0.23 (p=0.07) ↑ 2.81±0.21 (**) ↑ 
Ischemia 1.36±0.33  0.55±0.04 (*) ↓ 1.30±0.11  0.87±0.17(p=0.08) ↓ 
Early Reperfusion 1.85±0.06  1.98±0.12  2.18±0.27  2.13±0.17  
Late Reperfusion 0.85±0.14  0.85±0.08  0.70±0.07  0.64±0.05  
P-AS160 
Stabilization 1.93±0.49  0.61±0.21 (**) ↓ 1.35±0.54  0.30±0.09 (*) ↓ 
Ischemia 1.74±0.17  2.15±0.20  1.25±0.35  0.74±0.16  
Early Reperfusion 1.85±0.11  1.62±0.21  1.37±0.39  0.70±0.17  
Late Reperfusion 1.13±0.17  0.78±0.23  1.15±0.27  0.62±0.12  
P/T-
AS160 
Stabilization 1.74±0.54  0.52±0.24(p=0.10) ↓ 0.78±0.29  0.10±0.03(p=0.09) ↓ 
Ischemia 1.95±0.77  4.15±0.79 (***) ↑ 0.99±0.28  0.90±0.22  
Early Reperfusion 0.99±0.03  0.82±0.10  0.59±0.12 (*) ↓ 0.36±0.11  
Late Reperfusion 1.41±0.21  0.99±0.33  1.58±0.27  0.93±0.13(p=0.09) ↓ 
HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance and arrow direction 
compared to Control, HCD significance and arrow direction compared to Control, HCD + GRT significance and 
arrow direction compared to HCD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (Control + GRT vs Control; 
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Table 5.5 Summary of all cardiac western blot parameters (continued) 






 HCD  
 





 MEAN±SEM  MEAN±SEM  MEAN±SEM  
RISK Pathway 
T-ERK1 
Stabilization 0.89±0.04  1.15±0.09 (*) ↑ 0.94±0.09  0.82±0.05  
Ischemia 1.38±0.04  1.38±0.03  1.42±0.01  1.28±0.01 (****) ↓ 
Early Reperfusion 0.90±0.06  0.84±0.07  0.99±0.09  1.04±0.05  
Late Reperfusion 1.33±0.01  1.00±0.06 (***) ↓ 1.07±0.03 (**) ↓ 1.12±0.05  
P-ERK1 
Stabilization 1.10±0.14  1.23±0.06  1.23±0.11  1.00±0.01  
Ischemia 1.02±0.07  1.10±0.02  0.86±0.03 (p=0.09) ↓ 0.86±0.02  
Early Reperfusion 1.13±0.08  0.81±0.18  1.09±0.05  0.65±0.10 (**) ↓ 
Late Reperfusion 1.78±0.06  1.26±0.14 (***) ↓ 1.38±0.05 (*) ↓ 1.34±0.07  
P/T-ERK1 
Stabilization 1.23±0.13  1.11±0.13  1.22±0.13  1.22±0.05  
Ischemia 0.74±0.06  0.79±0.01  0.60±0.02  0.67±0.02(p=0.07) ↑ 
Early Reperfusion 1.29±0.18  1.01±0.23  1.13±0.09  0.64±0.11 (**) ↓ 
Late Reperfusion 1.33±0.03  1.24±0.07  1.29±0.02  1.24±0.03  
T-ERK2 
Stabilization 1.03±0.02  1.35±0.10 (*) ↑ 1.22±0.15  1.00±0.05  
Ischemia 1.14±0.08  1.18±0.05  1.05±0.04  0.78±0.01 (**) ↓ 
Early Reperfusion 0.85±0.03  0.77±0.09  0.87±0.02  1.09±0.10  
Late Reperfusion 1.47±0.04  1.08±0.09 (**) ↓ 1.14±0.03 (*) ↑ 1.19±0.06  
P-ERK2 
Stabilization 1.50±0.39  1.97±0.18  1.70±0.16  1.59±0.45  
Ischemia 1.41±0.35  0.75±0.02  0.83±0.06  0.50±0.02 (**) ↓ 
Early Reperfusion 1.49±0.08  2.52±0.08 (****) ↑ 1.42±0.05  1.49±0.08  
Late Reperfusion 6.53±0.55  4.33±1.00 (**) ↓ 6.09±0.20  4.71±0.95  
P/T-ERK2 
Stabilization 1.45±0.37  1.50±0.21  1.50±0.26  1.58±0.17  
Ischemia 1.34±0.40  0.64±0.04  0.80±0.06  0.64±0.03(p=0.08) ↓ 
Early Reperfusion 1.35±0.15  3.43±0.34 (***) ↑ 1.25±0.03  0.64±0.13 (**) ↓ 
Late Reperfusion 4.41±0.26  3.79±0.69  5.33±0.08 (*) ↑ 3.90±0.69 (**) ↓ 
T-ERK1/2 
Stabilization 0.86±0.03  0.84±0.01  0.77±0.03  0.82±0.04  
Ischemia 1.22±0.06  1.18±0.06  1.37±0.06  1.63±0.03 (***) ↑ 
Early Reperfusion 1.06±0.04  1.10±0.03  1.13±0.08  0.97±0.04 (*) ↓ 
Late Reperfusion 0.91±0.02  0.92±0.02  0.93±0.00  0.94±0.03  
P-ERK1/2 
Stabilization 0.81±0.08  0.63±0.04  0.73±0.06  0.65±0.06  
Ischemia 0.92±0.20  1.46±0.04 (***) ↑ 1.04±0.06  1.72±0.10 (***) ↑ 
Early Reperfusion 0.77±0.09  0.31±0.05 (***) ↓ 0.77±0.09  0.43±0.06 (*) ↓ 
Late Reperfusion 0.27±0.02  0.34±0.05  0.22±0.00  0.32±0.05  
Stress-Signaling 
T-JNK1 
Early Reperfusion 1.32±0.11  1.28±0.08  0.83±0.11 (***) ↓ 0.71±0.04  
Late Reperfusion 0.99±0.05  0.99±0.05  1.00±0.08  1.15±0.01  
P-JNK1 
Early Reperfusion 0.90±0.05  1.19±0.08 (***) ↑ 0.64±0.03 (***) ↓ 0.66±0.06  
Late Reperfusion 0.56±0.08  1.06±0.09 (***) ↑ 0.91±0.02 (***) ↑ 0.87±0.02  
P/T-JNK1 
Early Reperfusion 0.70±0.07  0.93±0.05 (*) ↑ 0.83±0.11  0.92±0.08  
Late Reperfusion 0.56±0.08  1.06±0.09 (***) ↑ 0.91±0.02 (***) ↑ 0.87±0.02  
T-JNK2 
Stabilization 0.82±0.03  1.24±0.12 (*) ↑ 0.95±0.16  0.75±0.03  
Ischemia 1.20±0.05  1.38±0.11  1.20±0.04  1.13±0.00  
Early Reperfusion 0.48±0.05  0.86±0.12 (*) ↑ 0.89±0.20 (*) ↑ 0.97±0.09  
Late Reperfusion 1.14±0.05  1.10±0.07  1.03±0.06  1.20±0.07  
P-JNK2 
Early Reperfusion 2.78±0.11  4.13±0.44 (**) ↑ 1.66±0.21 (**) ↓ 0.96±0.15 (*) ↓ 
Late Reperfusion 1.98±0.21  1.99±0.45  3.45±0.65 (***) ↑ 2.46±0.29 (*) ↓ 
P/T-JNK2 
Early Reperfusion 5.92±0.53  5.38±1.19  2.07±0.25 (***) ↓ 1.06±0.21 (*) ↓ 
Late Reperfusion 1.75±0.22  1.75±0.33  3.30±0.56 (*) ↑ 2.15±0.44  
HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance and arrow direction 
compared to Control, HCD significance and arrow direction compared to Control, HCD + GRT significance and 
arrow direction compared to HCD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (Control + GRT vs Control; 
HCD vs Control; HCD + GRT vs HCD); n=5 for all groups.  
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Table 5.6 Summary of all cardiac western blot parameters (continued) 
Parameter Time Point 
CONTROL  CONTROL + GRT  HCD  
 
HCD + GRT 
 
 
MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  
Inflammation 
T-p38 
Stabilization 1.30±0.13  1.30±0.15  1.27±0.07  0.77±0.25 (**) ↓ 
Ischemia 1.79±0.19  2.41±0.06 (**) ↑ 1.58±0.21  1.36±0.06  
Early Reperfusion 1.11±0.08  1.24±0.09  1.27±0.17  0.76±0.14 (*) ↓ 
Late Reperfusion 1.23±0.03  1.32±0.04  0.93±0.05 (**) ↓ 0.95±0.03  
P-p38 
Stabilization 1.20±0.11  2.14±0.11 (***) ↑ 2.70±0.11 (***) ↑ 1.91±0.10 (**) ↓ 
Ischemia 1.26±0.15  1.63±0.06(p=0.08) ↑ 1.18±0.18  1.04±0.07  
Early Reperfusion 1.22±0.15  1.96±0.26 (**) ↑ 1.10±0.24  0.81±0.12  
Late Reperfusion 1.68±0.09  1.30±0.29  1.32±0.14 (p=0.07) ↓ 1.45±0.17  
P/T-p38 
Stabilization 0.93±0.03  1.66±0.12 (**) ↑ 2.01±0.06 (***) ↑ 2.55±0.13 (*) ↑ 
Ischemia 0.70±0.02  0.67±0.02  0.74±0.04  0.76±0.02  
Early Reperfusion 1.41±0.32  1.60±0.19  0.88±0.17  1.16±0.21  
Late Reperfusion 1.18±0.14  0.98±0.20  1.29±0.15  1.45±0.24  
Autophagy 
LC3-I 
Stabilization 1.02±0.08  1.18±0.11  1.48±0.13 (*) ↑ 1.70±0.06  
Ischemia 1.73±0.08  1.79±0.06  2.01±0.10 (p=0.09) ↑ 1.63±0.11 (*) ↓ 
Early Reperfusion 0.77±0.14  1.26±0.21  1.42±0.38 (**) ↑ 0.76±0.08 (**) ↓ 
Late Reperfusion 1.21±0.04  0.95±0.05 (**) ↓ 1.16±0.01  1.21±0.01  
LC3-II 
Stabilization 0.96±0.07  1.85±0.25 (***) ↑ 1.70±0.14 (**) ↑ 1.85±0.15  
Ischemia 1.08±0.07  1.21±0.08  1.11±0.13  1.19±0.14  
Early Reperfusion 0.62±0.04  0.73±0.07  0.99±0.11 (*) ↑ 0.92±0.02  
Late Reperfusion 1.84±0.14  1.22±0.14 (***) ↓ 1.25±0.08 (**) ↓ 1.69±0.24  
LC3-II/I 
Stabilization 0.95±0.10  1.43±0.14 (*) ↑ 1.20±0.16  1.08±0.04  
Ischemia 0.62±0.05  0.67±0.03  0.58±0.08  0.73±0.03  
Early Reperfusion 0.86±0.09  0.62±0.06 (*) ↓ 0.81±0.12  1.19±0.09 (*) ↑ 
Late Reperfusion 1.53±0.12  1.28±0.13  1.08±0.07 (*) ↓ 1.39±0.19  
Auxiliary Metabolic Regulation 
T-GSK3β 
Stabilization 1.06±0.11  1.04±0.08  1.10±0.07  0.86±0.02 (*) ↓ 
Ischemia 0.93±0.06  1.03±0.03  0.82±0.11  0.72±0.01  
Early Reperfusion 1.05±0.04  1.03±0.05  1.18±0.09  1.18±0.03  
Late Reperfusion 1.07±0.07  1.20±0.03  0.92±0.03  1.11±0.03 (**) ↑ 
P-GSK3β 
Stabilization 1.10±0.17  1.06±0.04  1.30±0.06  0.90±0.04 (**) ↓ 
Ischemia 0.87±0.08  0.79±0.02  0.56±0.05 (*) ↓ 0.45±0.01(p=0.09) ↓ 
Early Reperfusion 5.26±1.47  4.33±0.81  1.79±0.57 (***) ↓ 1.90±0.63  
Late Reperfusion 1.02±0.27  0.56±0.16  1.09±0.21  0.64±0.21  
P/T-
GSK3β 
Stabilization 1.01±0.04  1.04±0.05  1.20±0.06 (p=0.05) ↑ 1.05±0.05  
Ischemia 0.93±0.07  0.77±0.00(p=0.10) ↓ 0.70±0.04 (*) ↓ 0.63±0.02  
Early Reperfusion 4.94±1.25  4.15±0.69  1.42±0.36 (***) ↓ 1.57±0.50  
Late Reperfusion 0.93±0.24  0.45±0.12  1.19±0.24  0.59±0.20(p=0.10) ↓ 
T-ATM 
Stabilization 0.92±0.04  1.03±0.08  0.92±0.10  0.91±0.03  
Ischemia 2.20±0.24  2.80±0.15(p=0.08) ↑ 2.50±0.43  2.28±0.11  
Early Reperfusion 2.12±0.12  1.35±0.11 (*) ↓ 1.86±0.31  1.87±0.22  
Late Reperfusion 2.02±0.09  1.21±0.19 (*) ↓ 1.29±0.02 (*) ↓ 1.37±0.06  
P-ATM 
Stabilization 0.96±0.22  0.51±0.09  0.75±0.16  0.91±0.08  
Ischemia 1.43±0.03  1.80±0.04 (***) ↑ 1.72±0.09 (*) ↑ 1.81±0.06  
Early Reperfusion 1.98±0.11  1.42±0.03 (*) ↓ 1.57±0.10 (*) ↓ 1.85±0.11  
Late Reperfusion 2.10±0.14  1.37±0.23 (***) ↓ 1.35±0.11 (***) ↓ 1.61±0.15  
P/T-ATM 
Stabilization 1.04±0.23  0.53±0.11  0.85±0.16  0.98±0.08  
Ischemia 0.67±0.06  0.65±0.03  0.73±0.07  0.79±0.03  
Early Reperfusion 0.95±0.08  1.09±0.12  0.92±0.12  1.02±0.07  
Late Reperfusion 1.06±0.11  1.17±0.14  1.05±0.08  1.18±0.13  
HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance and arrow direction 
compared to Control, HCD significance and arrow direction compared to Control, HCD + GRT significance and 
arrow direction compared to HCD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (Control + GRT vs Control; 
HCD vs Control; HCD + GRT vs HCD); n=5 for all groups.    
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5.5 MITOCHONDRIAL OXPHOS 
5.5.1 ADP/O Ratio 
The ADP/O Ratio, also referred to as the OxPhos efficiency, gives the ratio of ATP production to total oxygen 
utilization during state 3 (nmoles ATP/nAtom of oxygen consumed). The ADP/O ratio is calculated as follows: 
nmoles ADP phosphorylated/nAtoms oxygen utilization during state 3. 
 
• Stabilization 
HCD did not significantly influence the ADP/O ratio in either the glutamate or palmitate medium compared to 
controls. In the glutamate/malate medium, GRT supplementation decreased the ADP/O ratio in controls 
(2.17±0.11 vs 2.53±0.08; p<0.05) and HCD (1.97±0.13 vs 2.33±0.12; p=0.066) compared to their untreated 
counterparts. In the palmitate/malate medium, GRT supplementation also significantly decreased the ADP/O 
ratio in controls (2.37±0.05 vs 2.76±0.01; p<0.001), but not in HCD. (Figure 5.37, Table 5.7, Appendix A7).  
• Ischemia 
In the palmitate medium, GRT supplementation decreased the ADP/O ratio in HCD (2.46±0.07 vs 2.78±0.26; 
p=0.065), but not in controls. 
• Early Reperfusion 
GRT supplementation in HCD resulted in a greater ADP/O ratio of mitochondria in palmitate medium, 
compared to glutamate medium (3.05±0.09 vs 2.32±0.05; p<0.05) – a statistical significance not found in the 
other groups. 
• Late Reperfusion 
Mitochondria from HCD hearts had a significantly increased ADP/O ratio in palmitate medium compared to 















































Figure 5.37 ADP/O ratio in glutamate and palmitate medium between different groups and time points 
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5.5.2 State 3 Respiration 
State 3 respiration (S3) is defined as the mitochondrial respiration in the presence of conversion of ADP to 




There were no significant differences recorded in mitochondrial S3 attributed to diet prior to ischemia 
(Figure 5.38, Table 5.7, Appendix A7). GRT supplementation in controls did significantly increase 
mitochondrial S3 in controls only (358.92±12.71 O-atoms/mg/min vs 313.35±13.09 O-atoms/mg/min; p<0.05). 
• Ischemia 
In the glutamate medium, HCD significantly increased mitochondrial S3 compared to controls (272.81±25.6 
O-atoms/mg/min vs 177.82±21.37 O-atoms/mg/min; p<0.05). In both the glutamate/malate and 
palmitate/malate medium, GRT supplementation resulted in a significant increase in S3 of mitochondria from 
controls (280.45±17.34 O-atoms/mg/min vs 177.82±21.37 O-atoms/mg/min; p<0.01 and 318.09±5 O-
atoms/mg/min vs 245.96±26.73 O-atoms/mg/min, p=0.053 respectively), while no effect was found in the HCD 
group.  
• Early Reperfusion 
In the palmitate/malate medium, HCD resulted in a significant increase in mitochondrial S3 (p<0.05) compared 
to controls (446.68±26.38 O-atoms/mg/min vs 368.84±10.77 O-atoms/mg/min; p<0.05), while GRT 
supplementation significantly decreased mitochondrial S3 in both glutamate medium (275.61±37.77 O-
atoms/mg/min vs 392.34±10.44 O-atoms/mg/min; p<0.05) and palmitate medium (297.88±26.53 O-
atoms/mg/min vs 446.68±26.38 O-atoms/mg/min; p<0.01). 
• Late Reperfusion 
GRT supplementation resulted in a significant decrease in S3 in mitochondria from controls in both glutamate 
medium (227.09±14.49 O-atoms/mg/min vs 305.2±19.03 O-atoms/mg/min; p<0.05) and palmitate medium 



















































Figure 5.38 State 3 respiration in glutamate and palmitate medium between different groups and time 
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5.5.3 Oxphos S3 
Oxidative phosphorylation rate of State 3 (OxPhos S3) indicates the rate at which ATP is produced during 
State 3 and is calculated as State 3 X ADP/O ratio (nmoles ATP produced/mg mitochondrial protein/min). 
 
• Stabilization 
In the palmitate medium, HCD significantly increased mitochondrial OxPhos S3 compared to glutamate 
medium (879.23±101.5 moles ATP/mg/min vs 579.11±106.35 moles ATP/mg/min; p<0.05) (Figure 5.39, 
Table 5.8, Appendix A7).  
• Ischemia 
In the palmitate medium, GRT supplementation in HCD increased mitochondrial OxPhos S3 compared to 
glutamate medium (724.49±41.41 moles ATP/mg/min vs 441.14±38.77 moles ATP/mg/min; p<0.05). In the 
glutamate/malate medium, GRT supplementation in controls resulted in a significant increase in OxPhos S3 
(653.83±58.72 moles ATP/mg/min vs 355±37.38 moles ATP/mg/min; p<0.05), while non-signifantly increasing 
OxPhos S3 in Palmitate medium (830.26±36.8 moles ATP/mg/min vs 578.04±106.03 moles ATP/mg/min; 
p=0.075).  
• Early Reperfusion 
In both the glutamate/malate and palmitate/malate medium, GRT supplementation in HCD decreased 
mitochondrial OxPhos S3 (641.21±92.55 moles ATP/mg/min vs 943.19±28.14 moles ATP/mg/min; p<0.05 and 
913.69±92.23 moles ATP/mg/min vs 1276.93±70.55 moles ATP/mg/min; p<0.05 respectively), while no effect 
was observed in the controls. In palmitate medium, HCD had significantly increased mitochondrial OxPhos S3 
compared to controls (1276.93±70.55 moles ATP/mg/min vs 1007.01±51.39 moles ATP/mg/min; p<0.05) and 
compared to glutamate medium (943.19±28.14 moles ATP/mg/min; p<0.05).  
• Late Reperfusion 
In the glutamate/malate medium, HCD had a decreased mitochondrial OxPhos S3 compared to controls 
(511.31±73.96 moles ATP/mg/min vs 760.98±24.93 moles ATP/mg/min; p<0.05). In the palmitate medium, 
GRT supplementation in controls resulted in a borderline non-signifant decrease in OxPhos S3 (717.37±47.61 



























































Figure 5.39 Oxidative phosphorylation rate of State 3 in glutamate and palmitate medium between 
different groups and time points (n=5). p<0.05 (Palmitate vs Glutamate in HCD), p<0.05 (Palmitate vs 
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5.5.4 State 4 Respiration 
State 4 respiration (S4) follows State 3 respiration and describes the mitochondrial respiration after all ADP 
was converted to ATP as nAtoms oxygen utilized in the absence of ADP/mg mitochondrial protein/min. 
 
• Stabilization 
In the glutamate medium, HCD significantly decreased S4 compared to controls (64.53±8.99 vs 92.81±8.4 O-
atoms/mg/min; p<0.05). In the palmitate medium, GRT supplementation resulted in a significant decrease in 
S4 in HCD (66.67±2.76 O-atoms/mg/min vs 89.38±11.59 O-atoms/mg/min; p<0.05) (Figure 5.40, Table 5.7, 
Appendix A7).  
• Ischemia 
In the glutamate medium, HCD significantly increased S4 compared to controls (64.44±3.64 O-atoms/mg/min 
vs 46.31±5.19 O-atoms/mg/min; p<0.05). In both the glutamate/malate and palmitate/malate medium, GRT 
supplementation resulted in a significant increase in S4 in controls (69.51±5.36 O-atoms/mg/min vs 46.31±5.19 
O-atoms/mg/min; p<0.05 and 87.77±5.69 O-atoms/mg/min vs 65.76±4.98 O-atoms/mg/min; p<0.05 
respectively), while no effect was found in the HCD group. 
• Early Reperfusion 
In the palmitate/malate medium, HCD resulted in an increase in S4 compared to controls (107.27±8.86 O-
atoms/mg/min vs 87.31±3.49 O-atoms/mg/min; p=0.088), while GRT supplementation decreased S4 in both 
glutamate medium (63.46±6.32 O-atoms/mg/min vs 78.31±3.32 O-atoms/mg/min; p=0.083) and palmitate 
medium (76.16±3.37 O-atoms/mg/min vs 107.27±8.86 O-atoms/mg/min; p<0.01). Furthermore, HCD had a 
significantly increased S4 in palmitate compared to glutamate (107.27±8.86 O-atoms/mg/min vs 78.31±3.32 
O-atoms/mg/min; p<0.05).  
• Late Reperfusion 



















































Figure 5.40 State 4 respiration in glutamate and palmitate medium between different groups and time 
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5.5.5 Oxphos S4 
Oxidative phosphorylation rate of State 4 (OxPhos S4): Calculated as State 4 X ADP/O ratio (nmoles ATP 
produced/mg mitochondrial protein/min). 
• Stabilization 
HCD has a significantly increased mitochondrial OxPhos S4 in palmitate medium compared to glutamate 
medium (230.25±29.53 moles ATP/mg/min vs 149.51±20.53 moles ATP/mg/min; p<0.05), while GRT 
supplementation in HCD decreased OxPhos S4 in palmitate medium (163.9±8.02 moles ATP/mg/min vs 
230.25±29.53 moles ATP/mg/min; p=0.088) (Figure 5.41, Table 5.8, Appendix A7).  
• Ischemia 
In both glutamate/malate and palmitate/malate medium, GRT supplementation resulted in an increase in 
OxPhos S4 in controls (163.28±18.76 moles ATP/mg/min vs 112.19±10.48 moles ATP/mg/min; p=0.053 and 
229.65±19.02 moles ATP/mg/min vs 169.86±19.33 moles ATP/mg/min; p=0.059 respectively), while no effect 
was found in the HCD group. In the palmitate medium compared to glutamate medium, OxPhos S4 was 
significantly increased in both HCD (202.41±26.53 moles ATP/mg/min vs 130.03±12.66 moles ATP/mg/min; 
p<0.05) and HCD supplemented with GRT (196.59±20.07 moles ATP/mg/min vs 124.43±7.34 moles 
ATP/mg/min; p<0.05).  
• Early Reperfusion 
In the palmitate/malate medium, OxPhos S4 was significantly increased in HCD compared to control 
(306.79±23.57 moles ATP/mg/min vs 238.03±12.52 moles ATP/mg/min; p<0.05), whereas GRT 
supplementation in HCD resulted in a decreased OxPhos S4 in both palmitate medium (231.53±6.43 moles 
ATP/mg/min vs 306.79±23.57 moles ATP/mg/min; p<0.05) and glutamate medium (147.76±16.14 moles 
ATP/mg/min vs 189.11±12.17 moles ATP/mg/min; p=0.078). Furthermore, both HCD and HCD supplemented 
with GRT had increased OxPhos S4 in palmitate medium compared to glutamate medium (306.79±23.57 
moles ATP/mg/min vs 189.11±12.17 moles ATP/mg/min; p<0.05 and 231.53±6.43 moles ATP/mg/min vs 
147.76±16.14 moles ATP/mg/min; p<0.05 respectively). 
• Late Reperfusion 


























































Figure 5.41 Oxidative phosphorylation rate of State 4 in glutamate and palmitate medium between 
different groups and time points (n=5). p<0.05 (Palmitate vs Glutamate in Control + GRT), p<0.05 
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5.5.6 RCI 




HCD did not significantly alter RCI compared to controls. In the palmitate medium, GRT supplementation in 
controls significantly increased RCI (4.46±0.28 vs 3.55±0.19; p<0.05) (Figure 5.42, Table 5.8, Appendix A7). 
 
• Ischemia 
There were no significant differences between either of the groups in RCI.  
 
• Early Reperfusion 
There were no significant differences between either of the groups in RCI. 
 
• Late Reperfusion 
In both the glutamate and palmitate medium, GRT supplementation in controls significantly decreased RCI 




















































Figure 5.42 Respiratory control index in glutamate and palmitate medium between different groups 
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5.5.7 State 5 Respiration 
State 5 respiration (S5) describes the mitochondrial respiration after a 20 min period of anoxia when oxygen 
is reintroduced into the system (re-oxygenation). It is also a measure of nAtoms oxygen utilized in the presence 
of ADP/mg mitochondrial protein/min. 
 
• Stabilization 
In the palmitate medium, mitochondria from HCD rats had a significant decrease in S5 compared to controls 
(274.1±44 O-atoms/mg/min vs 419.64±22.56 O-atoms/mg/min; p<0.05) and GRT supplementation increased 
S5 in HCD (392.13±17.28 O-atoms/mg/min vs 274.1±44 O-atoms/mg/min; p=0.053). Furthermore, 
mitochondria from controls had higher S5 in palmitate compared to glutamate medium (419.64±22.56 O-
atoms/mg/min vs 255.55±41.43 O-atoms/mg/min; p<0.05) (Figure 5.43, Table 5.7, Appendix A7).   
 
• Ischemia 
In the glutamate/malate medium, HCD had significantly elevated S5 compared to controls (311.04±31.57 O-
atoms/mg/min vs 200.52±33.7 O-atoms/mg/min; p<0.05). Also, GRT supplementation resulted in a significant 
increase in S5 in controls (314.7±26.3 O-atoms/mg/min vs 200.52±33.7 O-atoms/mg/min; p<0.05).  
 
• Early Reperfusion 
In the palmitate/malate medium, GRT supplementation in HCD decreased S5 (352.65±26.72 O-atoms/mg/min 
vs 468.71±9.8 O-atoms/mg/min; p<0.01), while no effect was observed in the controls. 
 
• Late Reperfusion 
In both the glutamate and palmitate medium, GRT supplementation resulted in a decrease in S5 in controls 
(277.88±26.39 O-atoms/mg/min vs 383.46±35.35 O-atoms/mg/min; p<0.05 and 356.74±5.42 O-atoms/mg/min 

















































Figure 5.43 State 5 respiration in glutamate and palmitate medium between different groups and time 
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5.5.8 %Respiration Recovery 
The percentage respiration recovery (%RR) following reoxygenation was also determined to indicate the 




In the glutamate medium, mitochondria from HCD rats had increased %RR compared to controls 
(118.4±11.59% vs 86.07±5.92%; p<0.05), whereas in the palmitate medium, HCD decreased %RR compared 
to controls 89.14±21.44% vs 133.45±2.06%; p<0.05), an effect that was reversed by GRT supplementation 
(134.67±10.32%; p<0.05). GRT supplementation of control rats also resulted in an increase in %RR in 
mitochondria incubated in a glutamate medium (115.6±10.26% vs 86.07±5.92%; p<0.05). Furthermore, %RR 
in mitochondria from controls was significantly greater in the palmitate medium compared to the glutamate 
medium (133.45±2.06% vs 86.07±5.92%; p<0.01) (Figure 5.44, Table 5.8, Appendix A7). 
 
• Ischemia 
There were no other significant differences recorded in %RR during ischemia between either of the 4 groups.  
 
• Early and Late Reperfusion 
There were no other significant differences recorded in %RR during either early or late rerperfusion between 












































Figure 5.44 %Respiratory recovery in glutamate and palmitate medium between different groups and 
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5.5.9 Summary of OxPhos parameters in glutmate and palmitate 
• Stabilization 
 
- Carbohydrate Medium 
Prior to ischemia, cardiac mitochondria from rats on both diets presented with a similar S3 (Table 5.7). 
However, in the glutamate/malate medium, GRT supplementation in animals from both control and HCD 
decreased the mitochondrial ADP/O ratio. Once ADP was depleted, mitochondria from rats on the HCD had a 
significantly decreased S4 compared to animals on the control diet when incubated in the glutamate medium. 
After 20 min of anoxia, mitochondria from animals on the HCD had increased %RR compared to mitochondria 
from controls, while GRT supplementation in controls also resulted in an increase in %RR of the mitochondria. 
- Fatty Acid Medium  
GRT supplementation significantly decreased the ADP/O ratio in palmitate medium in cardiac mitochondria 
prepared from control rats, while having no effect in mitochondria from the HCD rats (Table 5.7). GRT 
supplementation in control animals also increased the mitochondrial OxPhos S3 but resulted in increased RCI. 
HCD resulted in a significantly increased mitochondrial OxPhos S3 and OxPhos S4 in palmitate medium 
compared to glutamate medium, while GRT supplementation significantly decreased mitochondrial S4 in 
hearts from HCD rats. After subjecting the mitochondria to 20 min of anoxia, mitochondria from HCD animals 
had a decrease in S5 in palmitate medium, whereas GRT was able to enhance the %RR. Furthermore, 
mitochondria from the control groups had higher S5 and %RR in the palmitate medium compared to the 
glutamate medium. 
 



















ADP/O Ratio S  ↓  ↓  ↓   
S3  
 
S      ↑   
Oxphos S3 S      ↑ (↑)  
S4 S   ↓     ↓ 
Oxphos S4 S       (↑)  
RCI S      ↑   
S5 S     (↑)  ↓ ↑ 
%RR S  ↑ ↑  (↑)  ↓ ↑ 
S: Stabilization; HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance 
compared to Control, HCD significance compared to Control, HCD + GRT significance compared to HCD; 
⧫p<0.05 (Palmitate vs Glutamate in Control), p<0.05 (Palmitate vs Glutamate in HCD); n=5 for all groups.  
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• Ischemia  
 
- Carbohydrate Medium 
After 20 min of global ischemia, ingestion of the HCD significantly increased mitochondrial S3 compared to 
controls (Table 5.8). GRT supplementation also increased mitochondrial S3 and OxPhos S3 in controls, while 
having no effect in HCD – possibly due to the already elevated ATP production and respiration. Once 
supplemented ADP was depleted, mitochondria from rats on the HCD also presented with increased S4, while 
again GRT supplementation resulted in increased S4 and OxPhos S4 in controls, while having no effect in 
mitochondria from HCD rats. Post 20 min of anoxia, HCD again had elevated S5, while GRT supplementation 
increased S5 in controls.  
- Fatty Acid Medium 
After 20 min of global ischemia, cardiac mitochondria from GRT supplemented rats had significantly increased 
S3 and OxPhos S3 in controls in palmitate medium (Table 5.8). Furthermore, GRT supplemented HCD groups 
had increased OxPhos S3 in palmitate compared to glutamate. In low presence of ADP, both GRT treated and 
untreated HCD had elevated S4 OxPhos in FA compared to carbohydrates. Furthermore, mitochondria from 
control rats supplemented with GRT presented with improved S4 and OxPhos S4, while having no effect in 
animals on the HCD. After 20 additional minutes of anoxia, there were no more significant differences between 
the 4 groups in the palmitate medium.  
 



















ADP/O Ratio I         
S3  
 
I  ↑ ↑   ↑   
Oxphos S3 I  ↑    ↑  (↑) 
S4 I  ↑ ↑   ↑   
Oxphos S4 I  ↑    ↑ (↑) (↑) 
RCI I         
S5 I  ↑ ↑      
%RR I         
I: Ischemia; HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance compared 
to Control, HCD significance compared to Control; p<0.05 (Palmitate vs Glutamate in HCD), p<0.05 
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• Early Reperfusion 
 
- Carbohydrate Medium 
GRT supplementation decreased S3 and OxPhos S3 in mitochondria from HCD rats, while having no effect in 
controls (Table 5.9). Following depletion of supplemented ADP, mitochondria from HCD rats supplemented 
with GRT also presented with decreased OxPhos S4. 
- Fatty Acid Medium 
OxPhos S3 was elevated in HCD in FA compared to carbohydrates (Table 5.9). Furthermore, HCD also had 
significantly increased cardiac mitochondrial S3 and OxPhos S3 compared to controls, an effect that was 
reversible by GRT supplementation which had improved ADP/O ratio in FA compared to carbohydrates. 
OxPhos S4 was elevated in HCD, and GRT supplemented control and HCD mitochondria in FA compared to 
carbohydrates. HCD also increased mitochondrial S4 and OxPhos S4 compared to controls, while GRT 
supplementation on the animals decreased mitochondrial S4 and OxPhos S4. After anoxia, GRT 
supplementation in HCD also decreased S5, while having no effect in controls.  
 



















ADP/O Ratio ER        (↑) 
S3 ER    ↓   ↑ ↓ 
Oxphos S3 ER    ↓   ↑(↑) ↓ 
S4 ER       (↑) ↓ 
Oxphos S4 ER    ↓  (↑) ↑(↑) ↓(↑) 
RCI ER         
S5 ER        ↓ 
%RR ER         
ER: Early Reperfusion; HCD: High-caloric diet, GRT: Afriplex green rooibos extract; HCD significance 
compared to Control, HCD + GRT significance compared to HCD; p<0.05 (Palmitate vs Glutamate in Control 
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• Late Reperfusion 
 
- Carbohydrate Medium 
In late reperfusion, HCD decreased OxPhos S3 in cardiac mitochondria compared to the controls (Table 5.10). 
GRT supplementation of the animals resulted in a significant decrease in cardiac mitochondrial S3 and 
decreased the RCI in controls. GRT supplementation in controls decreased mitochondrial S5 after anoxia. 
- Fatty Acid Medium 
HCD had significantly elevated mitochondrial ADP/O ratio in FA medium compared to carbohydrates (Table 
5.10). GRT supplementation in control rats resulted in mitochondria obtained from the hearts to have 
decreased OxPhos S3 and decreased RCI. GRT supplementation in controls decreased S5 after anoxia. 
 



















ADP/O Ratio LR       (↑)  
S3  
 
LR  ↓    ↓   
Oxphos S3 LR   ↓   ↓   
S4 LR         
Oxphos S4 LR         
RCI LR  ↓    ↓   
S5 LR  ↓    ↓   
%RR LR         
LR: Late Reperfusion; HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance 
compared to Control, HCD significance compared to Control); p<0.05 (Palmitate vs Glutamate in HCD); n=5 
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5.6 Mitophagy SIGNALING 
5.6.1 PINK1 
PINK1 accumulates on the outer membrane of damaged mitochondria. 
 
• Stabilization 
No significant differences were recorded in PINK1 levels between either of the 4 groups (Figure 5.45, 
Table 5.11).  
• Ischemia 
HCD significantly increased mitochondrial PINK1 levels (p<0.05), while supplementing controls with GRT also 
significantly increased PINK1 levels (p<0.05). GRT supplementation in HCD had no significant effect.  
• Early and Late Reperfusion 
No significant differences were recorded in PINK1 levels between either of the 4 groups.  
 
 





























































Figure 5.45 Mitochondrial PINK1 levels between the different groups and time points (n=5). HCD: High-
caloric diet, GRT: Afriplex green rooibos extract. 
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5.6.2 Parkin 
Parkin ubiquitinates outer mitochondrial membrane proteins to trigger selective autophagy. 
 
• Stabilization 
HCD significantly increased Parkin levels (p<0.01), while supplementing controls with GRT also increased 
Parkin levels (p<0.05). GRT supplementation in HCD had no significant effect (Figure 5.46, Table 5.11).  
• Ischemia 
No significant differences were recorded in Parkin levels between either of the 4 groups. 
• Early Reperfusion 
Parkin levels were significantly increased in early reperfusion in all 4 groups. GRT supplementation in HCD 
also led to a significant increase in Parkin levels (p<0.01).  
• Late Reperfusion 
Parkin was significantly reduced towards late reperfusion. GRT supplementation significantly decreased 
Parkin levels in controls (p<0.05), but not in HCD.  
 
 




























































Figure 5.46 Mitochondrial Parkin levels between the different groups and time points (n=5). HCD: High-
caloric diet, GRT: Afriplex green rooibos extract. p<0.05 (Compared to Stabilization), ⧫p<0.05 (Compared to 
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5.6.3 p62 
p62 serve as the link between the damaged mitochondria and LC3 to initiate autophagolysosomal degradation.  
 
• Stabilization  
GRT supplementation significantly reduced p62 levels in controls (p=0.083), but not in HCD (Figure 5.47, 
Table 5.11). 
• Ischemia 
p62 was significantly increased in ischemia compared to stabilization in all groups except GRT supplemented 
HCD. GRT supplementation significantly increased p62 levels in controls (p<0.001) and decreased p62 levels 
in HCD (p=0.058). Untreated HCD had the same p62 levels as untreated controls.  
• Early Reperfusion 
p62 levels were significantly reduced compared to ischemia in GRT supplemented controls and untreated 
HCD. No significant differences were recorded in p62 levels between either of the 4 groups.  
• Late Reperfusion 
Towards late reperfusion, p62 levels were still elevated compared to stabilization in HCD groups. HCD also 
had significantly increased p62 levels (p<0.05) compared to controls, while supplementing controls with GRT 































































Figure 5.47 Mitochondrial p62 levels between the different groups and time points (n=5). HCD: High-
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5.6.4 BNIP3L 
BNIP3L serves as an autophagy receptor which recruits mitochondria to the autophagosome. 
• Stabilization 
HCD significantly reduced mitochondrial BNIP3L levels (p<0.01), while supplementing controls with GRT also 
reduced BNIP3L levels (p<0.05). GRT supplementation in HCD had no significant effect (Figure 5.48, 
Table 5.11).  
• Ischemia 
HCD significantly increased mitochondrial BNIP3L levels (p=0.085), while supplementing controls with GRT 
also significantly increased BNIP3L levels (p<0.001). GRT supplementation in HCD had no significant effect.  
• Early Reperfusion 
No significant differences were recorded in BNIP3L levels between either of the 4 groups. However, HCD, 
together with GRT supplemented controls and HCD maintained elevated BNIP3L levels compared to 
stabilization. 
• Late Reperfusion 
HCD significantly increased BNIP3L levels (p<0.001), while supplementing controls with GRT also significantly 
increased BNIP3L levels (p<0.001) – these two groups remained elevated since ischemia, whereas untreated 
controls saw a significant reduction in BNIP3L content during later reperfusion. GRT supplementation in HCD 






























































Figure 5.48 Mitochondrial BNIP3L levels between the different groups and time points (n=5). HCD: High-
caloric diet, GRT: Afriplex green rooibos extract. p<0.05 (Compared to Stabilization), p<0.05 (Compared 
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5.6.5 LC3-II  
Mitochondria-bound LC3-II is present on the forming phagophore and targets the mitochondria for autophagy. 
It can used as a steady state indicator for mitophagy levels (Oh et al., 2017). 
  
• Stabilization 
No significant differences were recorded in LC3-II levels between either of the 4 groups (Figure 5.49, 
Table 5.11).  
• Ischemia 
HCD significantly decreased LC3-II levels (p<0.01). No other significant differences were noted.  
• Early Reperfusion 
Both treated and untreated HCD animals presented with increased mitochondrial LC3-II levels compared to 
stabilization (p<0.05 for both) and mitochondrial LC3-II level in GRT treated HCD was also significantly 
elevated compared to ischemia (p<0.05). 
• Late Reperfusion 
GRT supplementation significantly increased LC3-II levels in HCD (p<0.05), which also remained elevated 




























































Figure 5.49 Mitochondrial LC3-II levels between the different groups and time points (n=5). HCD: High-
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5.6.6 Summary of mitophagy associated proteins 
Table 5.11 Summary of mitophagy associated proteins 
Parameter Time Point 








0.95±0.09  0.94±0.03  1.07±0.06  0.87±0.21  
Ischemia 
 
1.57±0.26  1.18±0.24  0.77±0.10 (**) ↓ 0.56±0.08  
Early 
Reperfusion 
1.19±0.01  1.40±0.19  1.43±0.18  1.78±0.10  
Late 
Reperfusion 




0.98±0.05  0.62±0.05 (*) ↓ 0.51±0.03 (**) ↓ 0.81±0.15  
Ischemia 
 
0.96±0.13  1.64±0.13 (***) ↑ 1.30±0.09 (p=0085) ↑ 1.08±0.07  
Early 
Reperfusion 
1.28±0.06  1.44±0.11  1.26±0.06  1.40±0.04  
Late 
Reperfusion 




0.96±0.05  1.40±0.14 (*) ↑ 1.33±0.07 (**) ↑ 1.15±0.09  
Ischemia 
 
2.77±0.55  3.68±0.73  1.84±0.38  1.35±0.19  
Early 
Reperfusion 
6.78±1.15  7.84±1.84  7.37±0.87  10.50±0.53 (**) ↑ 
Late 
Reperfusion 




0.99±0.03  0.86±0.05 
(p=0.083) 
↓ 1.01±0.01  1.03±0.13  
Ischemia 
 
1.58±0.21  2.65±0.28 (***) ↑ 1.67±0.13  1.31±0.08(p=0.058) ↓ 
Early 
Reperfusion 
1.09±0.09  1.29±0.16  1.22±0.06  1.14±0.10  
Late 
Reperfusion 




1.16±0.10  1.71±0.30  2.37±1.03  2.23±0.36  
Ischemia 
 
1.37±0.29  2.57±0.35 (*) ↑ 2.62±0.36 (*) ↑ 2.59±0.42  
Early 
Reperfusion 
2.52±1.42  1.41±0.34  2.11±0.21  1.73±0.40  
Late 
Reperfusion 
1.39±0.11  1.46±0.10  1.49±0.10  2.09±0.25(p=0.084) ↑ 
HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance and arrow direction 
compared to Control, HCD significance and arrow direction compared to Control, HCD + GRT significance and 
arrow direction compared to HCD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (Control + GRT vs Control; 
HCD vs Control; HCD + GRT vs HCD); n=5 for all groups.   
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The primary aim of this study was to characterise the effect of 6 weeks Afriplex green rooibos extract treatment 
(aspalathin-rich equating to a daily aspalathin dose of 2 “cups-of-tea” in a rat or 70 “cups-of-tea” in a human) 
on functional heart recovery and infarct size following ischemia reperfusion injury in a pre-diabetic rat model 
with established obesity and insulin resistance vs controls. The secondary objective was to elaborate our 
understanding of the role of Afriplex GRT on cell signaling mechanisms pertaining to cardioprotection, 
inflammation and cardiac stress. The secondary aim was to investigate the mitochondrial oxidative 
phosphorylation potential of these hearts and relate how Afriplex GRT influenced bio-energetics, and to 
correlate these parameters with the mitochondrial mitophagy process.  
 
Our results showed that the pre-diabetic heart had lower mechanical function prior to ischemia, presented with 
impaired mechanical recovery post reperfusion and had increased infarct size. Furthermore, mitochondria 
isolated from these hearts showed elevated beta-oxidation throughout the protocol and elevated OxPhos post-
ischemia, culminating in increased ROS production and, while mitophagy was increased, without added 
antioxidant defence, cell death was inevitable. Administration of GRT treatment improved mechanical heart 
function before and after ischemia, resulting in better heart recovery and decreased infarct size. GRT treatment 
resulted in lessor inflammation signaling and GSK3b inhibition prior to reperfusion, while also increasing 
mitochondrial uncoupling, resulting in a decreased metabolic rate connected to less ROS production. In early 
reperfusion, GRT treated pre-diabetic rats had lower stress and inflammatory signaling, while furthermore 
inhibiting mitochondrial OxPhos, and thereby contributing to less ROS production, without really affecting 
mitophagy. These effects proved to be cardiotonic in the present study, implicating Afriplex GRT’s potential in 
being cardioprotective in a high-caloric diet-induced pre-diabetic rat model.  
6.2 BIOMETRIC PARAMETERS 
Our research made use of two animal models induced by two different diets: a normal rat chow diet (referred 
to as control diet) and a high calorie diet (referred to as the HCD diet). Both these diets were supplied ad 
libitum for a period of 16 weeks to male Wistar rats (aged approximately 6 weeks and weighing approximately 
180 g at baseline) (Pickavance et al., 1999; Salie et al., 2014; Webster et al., 2017).  
6.2.1 Weight gain 
The impact of obesity and its comorbidities are well established to impair quality of life and diminish life 
expectancy (Boden, 2011). It is defined as excessive and abnormal body fat accumulation leading to adverse 
health effects. Obesity poses a threat to an individual’s health and unnecessarily places a financial burden on 
society through diverted capital and increased health care expenditure (Abdelaal et al., 2017). Furthermore, 
obesity is associated with co-morbidities such as T2D and dyslipidemia, which further increases mortality. 
Staying obese should thus be considered as a high-risk lifestyle, or more colloquially ‘living on the edge’. The 
pathology of obesity arises from the inability to control appetite which arises from both environmental factors 
and a genetic susceptibility (Abdelaal et al., 2017). Obesity is underlined by consuming more energy than one 
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expends and is most commonly induced by hyperphagia through hormonal cues either increasing hunger, 
decreasing satiety or both. The first essential hormone in appetite control is ghrelin, secreted by the gut, which 
plays a central role in inducing food intake (increasing hunger) (Klok et al., 2007). Conversely, adipose tissue 
secretes leptin which mediates long-term energy balance by suppressing food intake (increasing satiety) 
resulting in weight loss (Klok et al., 2007). However, consistently overriding leptin signaling by consuming food 
when satisfied, gives rise to a phenomenon called leptin resistance, resulting in decreased satiety from 
average portion meals causing chronic overconsumption and weight gain (Hagan & Niswender, 2012). 
 
Monitoring body weight is an essential diagnostic technique to describe the quality of health in both humans 
and animals. As obesity is a serious risk indicator and narrowly tied to increased energy intake and total body 
weight, the weight of animals was continually monitored from the onset of the study until the time of sacrifice 
(Figure 5.1 and 5.2) Before the onset of treatment, HCD animals did not weigh significantly more than controls 
(Table 5.1). However, 6 more weeks of HCD diet resulted in a significant increase in weight gain for both 
untreated (↑8%) and GRT treated (↑11%) rats compared to their respective controls (Figure 5.2). Increased 
weight gain induced by high-caloric diets compared to control diets have been established previously (Kamau, 
2018; Nduhirabandi et al., 2017; Salie et al., 2014). These studies also reflected similar differences in body 
weight between high-caloric diets and controls following 16 weeks of diet (↑18%, ↑19%, ↑12% respectively). 
GRT supplementation in HCD also led to a 5% increase in body weight compared to the untreated HCD 
(Figure 5.2), albeit having no significant increase in weight gain per se. Interpreting the weekly body weight 
totals of rats from week 11 onwards (Figure 5.1), it is noted that HCD with GRT had an increased average 
body weight since the start of the treatment term. Thus, this elevation in body weight at the time of sacrifice 
could be the effect of random allocation, as these animals were allocated for either GRT treatment or placebo 
since week 1. It is therefore uncertain whether the observed increase in body weight is due to the effect of the 
GRT or random allocation and would require further investigation.   
6.2.2 Visceral fat 
Obesity can also be defined as enlargement of the adipose tissue to store excess energy intake. This 
expansion occurs through both adipocyte hypertrophy (cell size increase) and adipocyte hyperplasia (cell 
number increase) (Jo et al., 2009). Distinction must be made between visceral fat, which wraps around internal 
organs – and is associated with increased risk for metabolic disorders and mortality (Merlotti et al., 2017) - and 
subcutaneous fat, which lies under the skin around the belly, thighs and rear – and carries less risk, and have 
even been associated with cardioprotection in T2D (Golan et al., 2012). Body weight and the inferences made 
through BMI alone are not enough to make a diagnosis of obesity – additional measurements such as body 
adiposity index or the waist to hip circumference ratio is required. This ratio can be used to measure abdominal 
obesity and is an independent risk factor for metabolic disorders such as T2D (Li et al., 2014). As there are no 
such indices for rats, we harvested and weighed the IP fat (or visceral fat) after sacrifice and expressed this 
fat mass as a percentage of total body mass. It must be mentioned that it is possible to distinguish between 
visceral and subcutaneous fat stores, however this requires determining total fat content by DEXA and then 
subtracting the excised IP fat to obtain subcutaneous fat content (Donner et al., 2015). In the present study, 
HCD had significantly higher IP fat and IP fat percentage compared to controls (Table 5.3, Figure 5.7). GRT 
treatment in the present study had no significant effect on body fat accumulation in the control animals but did 
indicate a higher propensity to increasing total intraperitoneal fat in HCD groups. This was surprising as rooibos 
Stellenbosch University  https://scholar.sun.ac.za
140 
    
has recently drawn attention for its potential weight loss effects (Sanderson et al., 2014). The researchers used 
both hot water extracts from infused fermented rooibos and the soluble solids (at a “cup of tea”-strength) to 
treat differentiated 3T3-L1 adipocytes. They found that rooibos significantly inhibited lipid accumulation, 
decreased PPARγ, PPARα, SREBF1 and FASN messenger RNA, impeded glycerol release and decreased 
leptin secretion. Taken together, these results indicated that rooibos can inhibit adipogenesis and thereby 
affect adipocyte metabolism, potentially preventing obesity. In our present study, a dose of roughly 12 times 
this amount of aspalathin had no significant effect on fat accumulation in controls but did show higher 
propensity for IP fat accumulation in HCD animals. However, since weight gain was not significantly different 
between GRT treated and untreated HCD at the time of sacrifice (Table 5.1), the perceived increased in IP fat 
could be due to random chance as these animals were allocated for GRT treatment at 10 weeks without 
discretion given to initial body weight. This phenomenon warrants further investigation. 
6.2.3 Food intake 
Considering the effect of higher energy intake, dietary monitoring was essential in this present study to 
determine its potential contribution on weight gain. HCD animals consistently ate more food than the control 
counterparts before (↑33%) and after the onset of treatment (↑19%) (Table 5.1, Figure 5.4 and 5.5). The 
present findings were in accord with previous studies which also established increased food consumption by 
HCD animals (Kamau, 2018; Nduhirabandi et al., 2017; Pickavance et al., 1999). In all three these studies, 
increased food consumption by HCD Wistar rats compared to standard control-chow fed Wistar rats resulted 
in increased weight gain, elevated serum insulin and blood lipids. As such, the present study can also be 
considered a hyperphagia diet model which can be translated to human conditions with the same underlining 
pathology. Interestingly, food consumption was significantly decreased after introducing the jelly, which was 
not due to a significant effect on calorie intake as the jelly contributed a ~2kJ extra calories (Table 4.3) 
compared to 255 – 320 kJ intake from food (Table 4.1). The HCD animals could have potentially had lower 
activity from week 10 resulting in lower energy expenditure and therefore a lowered energy consumption. This 
phenomena has been found in human children, whereby there is an increase in sedentary downtime from age 
9 to 12 (Janssen et al., 2015). However, to verify such an progression occurring into later rat adolescence daily 
activity measures during the 10 to 16-week period will need to be performed.  
 
GRT supplementation did not influence food intake in the present study. The claim that rooibos can increase 
appetite has long been maintained by individuals (Morton, 1983). However, no direct mechanism has been 
established to confirm this. To the contrary, rooibos is implicated in curbing appetite through indirect measures. 
For instance, in a study performed by Schloms et al. (2014), 80 mg GRE/rat (0.96 mg aspalathin/day) for 10 
days resulted in decreased glucocorticoid (stress hormone) levels. This mechanism has been implicated as a 
means for rooibos to contribute to decreasing appetite and induce weight loss –stemming from curbing stress-
eating and stress-induced hyperphagia (Yau & Potenza, 2013). However, in the present study this mechanism 
had no effect on food intake. 
6.2.4 Water consumption 
Water is deemed to be physiologically essential to regulate body temperature, lubricate and preserve joints, 
protect your spinal cord and other sensitive tissues, and aid in waste removal through improving urination, 
perspiration and bowel movements (Popkin et al., 2010). Water consumption was significantly decreased in 
HCD compared to controls, both before (↓32%) and after (↓32%) treatment (Table 5.1, Figure 5.6 and 5.7). 
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This decrease in water consumption can partly be attributed to the higher moisture content within the HCD 
diet, as food was prepared to have a runny porridge consistency, while the standard rat-chow pellets were 
served dry. However, it cannot be excluded that this might be the effect of an unhealthy diet such as HCD 
leading to worse hydration as well (Popkin et al., 2010). In the present study, GRT treatment had no significant 
effect on water consumption in either control or HCD diets, and GRT thus had no significant influence on 
dehydration or induction of increased fluid loss through symptoms such as nausea or diarrhea.  
6.2.5 Summary 
Taken together, animals on a high-caloric diet had increased energy intake (of a diet more energy dense) 
(Table 4.1) without increased energy expenditure (inferred by similar housing arrangements) resulted in 
increased energy storage (in the form of IP fat – both absolute and as percentage of total body mass), which 
gave rise to increased body mass compared to control diet animals. In a clinical setting, these elevated 
parameters result in a syndrome called metabolic syndrome. As the HCD did not differ significantly in 
micronutrient composition (see Appendix A4 vs A5) compared to the standard rat chow diet, the perceived 
effect can solely be attributed to the increased caloric intake of fat and carbohydrates. 
6.3 SERUM ANALYSES 
The effect of both diet and GRT treatment on blood and serum biochemistry were investigated. These are 
important considerations as alterations in biochemical markers can be early indications for organ dysfunction.  
6.3.1 Hyperglycemia 
One of the first clinical consequences of insulin resistance is a dysregulation in glucose homeostasis - the 
maintenance of blood glucose concentration within very narrow physiological limits (Norris & Rich, 2012). This 
abnormality can be determined by measuring the fasting blood glucose concentration. Fasting blood glucose 
is closely regulated by endogenous glucose production (hepatic glycogenolysis, gluconeogenesis) and 
glucose utilization by insulin-sensitive tissues. In the present study both non-fasting and fasting blood glucose 
levels were measured. HCD animals presented with elevated non-fasting blood glucose levels (or random 
blood glucose levels taken just prior to sacrificing of rats) compared to controls (Table 5.1, Figure 5.8). Fasting 
blood glucose was also elevated in HCD animals before the onset of treatment and one week prior to sacrifice 
(Table 5.1). Furthermore, OGTTs performed on these animals showed that HCD animals had poorer glucose 
tolerance for the first 45 min of the OGTT before treatment (Figure 5.9) and this extended to 60 min after 6 
additional weeks of receiving the HCD diet (Figure 5.10). In both instances blood glucose returned to baseline 
levels at the clinically relevant 2-hour time point. Considering that these rats are only the equivalent of about 
13 years old in human years (See Section 4.3.2.3) the severity of this profile is expected to increase as these 
rats get older. These results replicate previous studies using a similar diet (George et al., 2011; Kamau, 2018; 
Pickavance et al., 1999). 
 
In the present study, GRT supplementation had no effect on fasting blood glucose or glucose tolerance. This 
was unexpected, as various in vitro and in vivo studies have indicated that rooibos has hypoglycemic effects. 
Aspalathin and GRE  dose-dependently increased glucose uptake in rat L6 skeletal myotubes (Kamakura et 
al., 2015; Kawano et al., 2009; Son et al., 2013) and cardiomyocytes isolated from both control and HCD rats 
(Smit et al., 2018), while FRE and GRE enhanced glucose uptake in palmitate-induced insulin-resistant C2C12 
skeletal muscle cells (Mazibuko et al., 2013). Furthermore, in vivo, aspalathin suppressed elevated fasting 
blood glucose and improved impaired glucose tolerance in ob/ob mice (Son et al., 2013) and db/db mice 
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(Kawano et al., 2009), while also suppressing gene expression of enzymes related to gluconeogenesis and 
glycogenolysis, and upregulating glycogenesis in the liver of ob/ob mice, resulting in a reduced blood glucose 
levels (Son et al., 2013).  
 
Two potential reasons will be addressed to explain GRT’s lack of effect on glucose homeostasis: Kamakura 
and colleagues (2015) reported on the hypoglycemic effect of GRE in type 2 diabetic KK-Ay mice fed a control 
diet supplemented with 0.3% GRE (initial 3 weeks) – containing 6.6g aspalathin / 100g GRE. The authors 
however did not disclose the amount of food intake by the mice, and it is therefore uncertain what the exact 
daily dose of rooibos compounds were. The authors showed that 0.3% GRE did not elicit any effect in 
decreasing blood glucose, whilst increasing the dose to 0.6% GRE for an additional two weeks showed a 
significant hypoglycemic effect – an effect that was dissipated once again in the final week. The authors 
attributed the loss in hypoglycemic effect to a ‘chance’ decrease in the diabetic controls, which dissipated the 
statistical significance. The study was subsequently ended, and the authors concluded that a hypoglycemic 
effect had been established. Due to this ‘unfortunate’ termination it is uncertain whether the hypoglycemic 
effect induced by GRE can be sustained for an extended time, or whether it was only effective for one week in 
a mouse model, before it was reversed for unknown limitations used in the model. However, in the present 
study, it could also be possible that GRT induced an initial hypoglycemic effect, which dissipated over time, 
and through hyperphagia by the HCD animals, was overturned.  This is in line with a study done by Mikami 
and colleagues (2015), which found that GRE supplementation in mice receiving glucose, maltose and starch 
had a significant post-prandial blood glucose lowering effect through surpressing intestinal α-glucosidase, an 
enzyme involved in the breakdown of glucose. This α-glucosidase inhibitory effect by rooibos was also 
corroborated in a recent study published by Miller and colleagues (2018). Thus, the glucose lowering of rooibos 
might be a direct consequence of inhibiting glucose metabolism.  
 
Considering the dosage variances between studies, Muller and colleagues (2012) showed that pre-treating for 
1 hour with aspalathin-rich fractions were most effective at surpressing increases in blood glucose at a dose 
of 25 mg GRE/kg BW (equal to 4.61mg aspalathin//kg BW compared to the 7.7 mg aspalathin/kg BW in the 
present study) in STZ-induced T1D Wistar rats, and the combination of aspalathin and rutin also significantly 
suppressed blood glucose for up to 6 hours. They also showed a dose-dependent decrease in efficacy at 
higher doses of rooibos (300mg GRE/kg BW, equal to 55.32 mg aspalathin/kg BW and effectively 16 “cup-of-
tea”-strengths for a 300 g rat) which were not able to surpress glucose beyond 4 hours. Taken together, in the 
present study, ad libitum feeding of HCD animals and only receiving one daily dose of GRT could have 
contributed to the lack of effect on improving glucose homeostasis. To investigate this phenomenon in more 
detail, multiple smaller doses of GRT would have to be administered throughout the day, and OGTTs would 
need to be done one and two weeks after introducing the GRT treatment to confirm that the glucose lowering 
effect can be sustained beyond 3 weeks. This would be an interesting approach for future studies.  
6.3.2 Insulin resistance 
HOMA-IR can be used to measure insulin resistance and β cell function from serum insulin levels and fasting 
blood glucose and has been validated for inference in Wistar rats (Antunes et al., 2016). Furthermore, 
hyperinsulinemia has been independently associated with increased risk for CVD (Libman et al., 2010). Prior 
to the treatment period, there were no significant differences in serum insulin concentrations. However, 
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following 6 additional weeks on diet, serum insulin was significantly elevated in HCD compared to controls 
(Figure 5.11). This, together with the raised fasting blood glucose levels and worse tolerance discussed in the 
previous section, also equated to a significant increase in HOMA-IR in HCD compared to controls (Table 5.1), 
indicating that the HCD animals were insulin resistant – or at least more so than the controls. Previous studies 
using the same diet also reported on increased serum insulin and HOMA-IR (Huisamen et al., 2011; 
Nduhirabandi et al., 2017; Smit et al., 2018). The cardiovascular effects of a 16-week high-sucrose diet without 
high-fat has been well characterised by Huisamen and colleagues (2011). These rats also presented with 
whole-body insulin resistance, as well as myocardial insulin resistance. In an additional study, Nunes and 
colleagues (2013) administered a high-sucrose diet to 16-week old Wistar rats for 9 weeks and found left 
ventricle hypertrophy with no differences in fasting blood glucose between their diet group and controls (~5.6 
mM), but these rats presented with raised fasting blood insulin of 10.83±1.00 ng/mL compared to the 
3.74±1.84 ng/mL of controls. Thus, in establishing a pre-diabetic model, even in the absence of significantly 
raised fasting blood glucose, hyperinsulinemia can be a prominent indicator of CVD risk. GRT supplementation 
had no significant effect on insulin serum levels or insulin resistance. Again, this was surprising as both rooibos 
and its polyphenols have been implicated to play a role in insulin sensitization. Aspalathin has shown to 
upregulate insulin secretion at concentration of 100 M in RIN-5F pancreatic β-cells (Kawano et al., 2009). 
Furthermore, treating insulin-resistant C2C12 skeletal muscle cells with either FRE or GRE enhanced glucose 
uptake, an effect attributed to a resensitization of P-PKB activity, suggesting improvement in insulin signaling 
(Mazibuko et al., 2013). Similarly, in our previous publication (Smit et al., 2018) we found aspalathin action in 
isolated cardiomyocytes to be significantly enhanced when co-treated with insulin. It could thus be that unless 
β-cell function is also improved by an additional treatment (which would result in elevated insulin) that the 
glucose uptake effect of rooibos is dissipated. Thus, supplementary insulin in conjunction with rooibos might 
be needed to improve glucose homeostasis. 
6.3.3 Toxicity 
Currently, the only known studies that showed toxic effects of rooibos were isolated case studies (Engels et 
al., 2013; Sinisalo et al., 2010). In the first instance a 42-year-old woman, receiving treatment for low-grade B-
cell malignancy drank 1 L of rooibos infusions per day and presented with signs of liver toxicity, which stopped 
upon cessation of rooibos. In the second instance, a 52-year old man having a history of hyperlipidemia and 
stage III chronic kidney disease, using daily oral steroids and long-term statins to manage the disease, also 
presented with liver toxicity when consuming daily servings of buchu and rooibos. In the present study, at a 
daily aspalathin dose as found in 60 mg/kg GRT showed that GRT had no toxic effect on biometric parameters 
and did not induce morphological changes in the heart (Table 5.2, Section 6.4.1). Visual inspection of organs 
(liver, kidneys, intestines), also showed no obvious discolouration and rats did not present with any ‘increased’ 
irritation or aggression. Appendix A8 (Table A3) shows the fasting serum lipid markers indicating no adverse 
changes in lipid composition in either the control or HCD diet. From this we can at least deduce that lipid profile 
had not deteriorated in response to GRT treatment, and rooibos is known to improve in lipid profiles in rats 
(Canda et al., 2014) and humans (Marnewick et al., 2011). The safety of the dosage was predetermined and 
compared with previous studies performed on mice which showed no toxic effects (Section 4.3.2.4). One such 
study showed that ob/ob mice gavaged daily with 100 mg/kg BW aspalathin for 5 weeks (compared to the 7.8 
mg/kg BW aspalathin in the present study) presented with decreased hepatic gene expression of 
gluconeogenesis and lipogenesis, considered to be anti-diabetic without toxic side-effects (Son et al., 2013). 
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Granted, contraindications between related polyphenols in the GRT could have had a pro-oxidant effect 
(Goszcz et al., 2015). Thus, the potential toxic effects of daily GRT administration for a period of 6 weeks in a 
control and pre-diabetic Wistar rat model remains to be determined as the current study did not measure liver 
enzymes.  
6.3.4 Summary 
We speculate that the mechanism for insulin resistance development following a high-fat, high-caloric diet is 
due to an increase in adipose tissue which causes elevated circulating FFA levels, altering adipose tissue 
derived factors, such as increasing leptin (responsible for inhibiting appetite) and TNFα (known to induce 
peripheral insulin resistance) and decreasing adiponectin (sensitize insulin action) (Yadav et al., 2013), 
followed by the eventual visceral fat accumulation (Ding et al., 2015; Grundy, 2012). In this regard, an increase 
in plasma FFA may have contributed to the elevated glucose levels as follows: i) inhibition of insulin action 
leading to increased lipolysis in fat cells, (ii) induction of insulin resistance by altering glucose transport, 
phosphorylation of relevant proteins or both (inhibition of insulin-mediated glucose uptake pathways) in cardiac 
muscle and possibly skeletal muscle and adipose tissue, (iii) increasing endogenous glucose production by 
increasing hepatic glucose output (Boden, 2011), (iv) and increased FFA-induced insulin secretion 
exacerbated by the FFA-induced insulin resistance (Boden, 1999).  
 
Taken together, increased fasting blood glucose, fasting serum insulin and HOMA-IR, along with increased 
body weight and IP fat, confirm that the HCD diet was successful in establishing a model of pre-diabetes. 
However, in the present study, GRT supplementation had no significant effect on the biometric parameters in 
either control or pre-diabetic animals. 
6.4 EFFECT OF GRT ON ISCHEMIA/REPERFUSION INJURY 
The basis of all experimentation in this study hinged on the working rat heart model, which generates 
haemodynamic endpoints used to indicate myocardial function. Subsequently these hearts can also be stained 
with TTC to determine the infarcted area present after regional ischemia (35 min of occluded blood supply) or 
the mitochondria can be isolated from ventricular heart tissue after global ischemia (20 min of zero blood 
supply) and mitochondrial function determined by measuring OxPhos. The effects of different protocols of 
ischemia and reperfusion on mechanical recovery post ischemia have been established previously in our 
laboratories, with 20 min global ischemia protocol resulting in partial contractile dysfunction short of complete 
heart failure during reperfusion (Nduhirabandi, 2014), while 35 min regional ischemia has been shown to result 
in significant infarcted areas without completely dissipating contractile function (Webster et al., 2017).  
6.4.1 Heart mass 
Cardiac remodeling are molecular, cellular and interstitial variations that present in altered mass, size, shape 
and function of the heart (Azevedo et al., 2016). This process is narrowly associated with ventricular 
dysfunction and malignant arrhythmias and therefore a strong indicator of a poor prognosis. Thus, it is 
important to investigate the effect of new treatments on these parameters of the heart. In the present study we 
measured the heart mass just prior to mounting the heart. The absolute cardiac mass was significantly 
increased by 8% in HCD compared to controls (Table 5.2, Figure 5.12), however when taken as a percentage 
of total body weight, this significance dissipated. Heart weight is associated with body weight, gender and age, 
(Kumar et al., 2014), but can also be associated with hypertrophy - an independent indicator of CVD (Okwuosa 
et al., 2015), which is also evident by the detrimental function of HCD hearts discussed in Section 6.4.4. In 
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the present study GRT supplementation had no significant effect on heart mass in either the controls or the 
HCD animals. Elevated heart mass had not been reported previously using the same diets (Kamau, 2018; 
Salie et al., 2014). In our study, after weighing the hearts of 232 rats, we found values ranging between 0.876 
and 1.620 g from rats weighing between 271-541 g, which equated to ranges between 0.25 and 0.45% of total 
body mass. However, in a study done by De Carvalho & Thomazini (2014) they reported on the mass of Wistar 
rat hearts ranging between 1.100 and 3.456 grams from rats weighing between 150 - 770 g. This equated to 
a ratio of heart weight to total body mass ranging between 0.5 and 0.7%. The authors of this study stated that 
after dissection of the heart, it was simply weighed immediately. To explain this discrepancy, we stress that 
after dissection of the hearts, residual blood was first squeezed out (to prevent blood clots forming during 
transport) before weighing as these hearts were destined for working heart perfusions. Furthermore, it is well 
established that heart mass increases with body mass (Beznak, 1954). Diet can also be a factor, as showed 
by a study done on Wistar rats receiving low- and high-fat diets, respectively comprising 16.4% and 50.4% of 
total caloric intake, whereby the high-fat diet resulted in increased cardiac mass found to be associated with 
increased triglyceride levels within the heart which resulted in cardiac dysfunction (Ouwens et al., 2005). These 
high-fat diets were especially high in palmitate and oleate. In the present study, no differences were observed 
in serum palmitate levels between controls and HCD, however, HCD did present with elevated serum oleic 
acid (Appendix A8). 
6.4.2 Heart Rate 
In conditions such as angina pectoris, characterized by insufficient myocardial blood supply leading to chest 
pain, a higher heart rate is usually counterintuitive and accelerates the discomfort induced by myocardial 
ischemia (Riccioni, 2009). At baseline, GRT supplementation significantly decreased heart rate in both control 
and HCD animals (Table 5.2, Figure. 5. 13) without compromising heart function (Section 6.4.4). Heart rate 
lowering drugs, such as the benzocycloalkane, Ivabradine, selectively inhibits pacemaker activity (through 
inhibition of If, hyperpolarization-activated pacemaker current, which contributes to action potential generation 
in the sinoatrial node) (Verkerk et al., 2007). It has been shown to dose-dependently lower both resting and 
maximal heart rate during exercise, shown greater efficacy in patients with elevated heart rate and protects 
against excessive bradycardia (Borer & Heuzey, 2008). We propose that GRT could have a similar pacemaker 
inhibitory effect. In humans, only one study has been done on rooibos’ potential heart rate lowering effect. 
Persson and colleagues (2010) investigated the effect of 400 ml of Green, Black and Rooibos tea (“cup-of-tea” 
strength) on health volunteers and found no significant differences in heart rate for up to 3 hours of 
administration. However, in contrast, the present study administered a daily dose of aspalathin-rich extract at 
2 “cup-of -tea” strength to rats and found a significant heart rate lowering effect on baseline perfusion 
measurements. This is a potential avenue for future research and would need further investigation. 
6.4.3 Coronary flow rate and aortic diastolic / systolic pressure 
Healthy coronary circulation is a direct product of coronary blood flow and myocardial-oxygen consumption 
according to the energy requirements of the heart. In humans, coronary perfusion at rest is an estimated 200 
mL/min and can increase up to 1000 mL/min at maximal exercise (Hirasawa et al., 1974). The main parameters 
dictating cardiac oxygen consumption and therefore coronary blood flow are heart rate, cardiac contractility 
(aortic perfusion pressure), and left ventricular wall stress (or afterload – kept constant throughout our 
experiments) (Depre et al., 2011). Interestingly, unlike most other vasculature, the myocardium is perfused 
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mainly during diastole and coronary flow sharply decrease during systole attributed to myocardial compression 
(Depre et al., 2011). 
 
Pre-ischemia there were no significant differences in coronary flow between the 4 groups (Figure 5.14), while 
diastolic and systolic pressure were significantly lower in hearts from the HCD group compared to controls 
(Figure 5.15, Figure 5.16). Post-ischemia, coronary flow was significantly lower (↓13.1%) in HCD hearts 
compared to control hearts (Figure 5.14). Ischemia also significantly lowered diastolic and systolic pressure 
but did not result in inter-group differences (Figure 5.15, Figure 5.16). It has been shown in a study done on 
Zucker Diabetic Fatty rats that as the severity of diabetes progresses, the damage incurred by I/R-I also 
increases and results in decreased coronary flow (Povlsen et al., 2013). Also during myocardial ischemia, left 
ventricular diastolic function deteriorates, which is considered a precursor for systolic dysfunction (Stewart et 
al., 1992). Furthermore, supplementation with GRT increased diastolic and systolic pressure in hearts from 
both controls and HCD rats pre-ischemia, but this effect was lost after ischemia and not significant. Similar to 
the heart rate lowering effect of Ivabradine described in the previous action (Section 6.4.3), this drug also 
showed to selectively induce a positve inotropic effect on cardiac contractility in both mice and humans (Boldt 
et al., 2010).  
6.4.4 Aortic output, total cardiac output and total work 
Myocardial I/R-I contributes to cardiac dysfunction following myocardial ischemia, cardiac surgery or circulatory 
cessation (Frank et al., 2012). Pre- and post-ischemia, AO, CO and WT were significantly reduced in hearts 
from HCD rats compared to controls (Figure 5.17, Figure 5.18, Figure 5.19) and HCD hearts had poorer 
recovery post-ichemia for all three parameters (Table 5.2, Figure 5.20). These findings are characteristic of 
previous data obtained from diet-induced obese (Du Toit et al., 2008), insulin-resistant models (Huisamen et 
al., 2012) and interestingly, also high-fat, low-carb diets (Liu et al., 2014, 2016), which resulted in the same 
biometric morphology as induced in our study by a high-sucrose, high-fat diet.  
 
GRT supplementation significantly improved all three parameters measured pre-ischemia in hearts from 
control and HCD rats, whilst also improving all three parameters post-ischemia in the HCD group, resulting in 
improved aortic and coronary output recovery (Table 5.2) and total work recovery (Figure 5.20). Antioxidant 
pre-treatment is known to reduce myocardial I/R-I (Crouser & Parinandi, 2011). These findings corroborate 
previous studies showing rats treated with either GRE or FRE displayed increased myocardial total GSH 
content (endogenous antioxidant) and reduced oxidative stress, resulting in improved cardioprotection through 
increased aortic output recovery against I/R-I (Pantsi et al., 2011). Furthermore, rats receiving fermented 
rooibos tea for 7 weeks had increased antioxidant capacity and reduced lipid peroxidation, conferring 
neuroprotection against I/R-I in the brain (Akinrinmade et al., 2017). Based on GRT’s effect on increasing heart 
contractility, it can be considered cardiotonic – per definition a substance that favorably effect upon the action 
of the heart. 
6.4.5 Left ventricular infarct size 
It has been illustrated that, without reperfusion, 100% of the area at risk will become an infarct, whereas 
through timely reperfusion about half of the lethal I/R-I can be prevented (Sattur et al., 2015). The addition of 
therapeutic interventions in the form of pre-conditioning or post-conditioning results in salvaging another 
quarter of reversible infarcted area - but even considering the best cardioprotective drug known, 25% damage 
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of the initial theoretical untreated infarct size will remain. In general, the longer the coronary artery is occluded, 
the bigger the infarct size, and the worse the outcome for the patient (Heusch & Gersh, 2016). In the present 
study we determined the effect of GRT following 35 min of regional ischemia/reperfusion. Similar to the global 
ischemia protocol, coronary artery occlusion during the regional ischemia protocol also caused significant 
decreases in all functional heart parameters for each group (Table 5.3, Figure 5.21), signifying the detrimental 
effect of I/R-I on myocardial contractile function. GRT treatment once again showed improvement in functional 
heart recovery, albeit not as profound as for the global ischemia protocol, with some of the previous 
significance lost, such as improvement in both coronary flow, diastolic, systolic pressures and total work 
recovery (Table 5.3, Figure 5.22). Staining these hearts for viable tissue, we saw a significant increase in 
infarct size in HCD compared to controls (Table 5.3, Figure 5.23). It has been shown previously in diet-induced 
obese models using the same ischemic protocol that infarct sizes were grossly increased (Huisamen et al., 
2011; Du Toit et al., 2008). Remarkably, GRT supplementation completely diminished the infarcted area in 
HCD (↓62.2%) to that seen in controls (Figure 5.23, Figure 5.24). This is the first time Afriplex GRT has been 
shown to have a cardioprotective effect on infarct size reduction in vivo. Thus, we speculate that the 
improvement in heart function can be partly attributed to the cardioprotective effect in preventing necrotic tissue 
damage and subsequently preventing additional ROS release and inflammation, ameliorating a necrotic chain 
reaction, which would have exacerbated surrounding cardiomyocyte damage.  
6.5 SIGNALING PROTEINS 
In view of GRT’s cardioprotective effects pertaining to heart function and infarct size reduction discussed in 
the previous section, we aimed to investigate a broad-spectrum of various cellular signaling intermediates 
pertaining to cardioprotection, including the Ras–MAPK signaling pathway such as p38, ERK1/2 and JNK, 
which are precursors of cell stress signaling; and intermediates in the PI3K–PKB–eNOS pathway, which 
results in metabolic modulation and cardiovascular protection.  
 
In aiming to understand the effect of treatment on the progression of T2D, it is essential to recognize two 
points: First, glucose uptake into cells (including heart muscle) can result from two distinct pathways, namely 
insulin-dependent (through PI3K/PKB and contraction-mediated stimulation) (Sriwijitkamol et al., 2007), and 
insulin independent (through AMPK and hypoxia-mediated stimulation) (Jing et al., 2008). Secondly, in the 
progression of T2D, AMPK activation remains largely intact (Jing et al., 2008), whereas PKB and other proteins 
relating to the PI3K pathway becomes dysfunctional (Mackenzie & Elliott, 2014). 
6.5.1 Insulin-Dependent Signaling 
• PKB/Akt  
PKB is a serine/threonine-specific protein kinase that plays an essential role in insulin-stimulated cellular 
processes, including cell growth, survival, proliferation, and metabolism (Gonzalez & McGraw, 2009). Insulin 
binding to insulin receptor on the cell surface results in activation of insulin receptor substrate and recruitment 
of PI3-Kinase and then PKB, which proceeds to activate AS160, likened to AMPK’s action discussed below, 
which then result in GLUT4 translocation to the membrane and glucose uptake (Sakamoto & Holman, 2008). 
Therefore, any reduction in PI3K/PKB/AS160 activation results in suppressed glucose uptake. It has been 
shown that insulin resistant conditions present with downregulation of up- and downstream targets of PKB 
(Mackenzie & Elliott, 2014). Also, PKBβ-knockdown mice (Cho et al., 2001) and PKBβ-mutations in humans 
(George et al., 2004) result in severe insulin resistance and diabetic-like symptoms, implicating PKB as a key 
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role player in maintaining normal blood glucose levels. Prior to ischemia there were no significant differences 
between PKB expression or activation in hearts from control and HCD rats (Figure 5.25, Table 5.4). This was 
surprising as HCD had significantly poorer glucose tolerance and increased insulin resistance, which would 
indicate lower PKB activity. Previous studies using diet-induced obese rats and high-fat diet rats also reported 
no difference in baseline cardiac PKB activation (Salie et al., 2014). Alternatively, it has been shown in mice 
with high-fat diet induced insulin resistance and obesity presenting with high circulating FA that even with 
established systemic insulin resistance, cardiac tissue can remain insulin sensitive (Gupte et al., 2013). 
Similarly, in our present HCD model cardiac tissue could have remained insulin-sensitive, even while 
presenting with systemic insulin resistance (Section 6.3.2) and elevated circulating FA (Appendix A8, 
Table A3). Furthermore, GRT supplementation increased basal PKB activation in hearts from controls, but 
decreased activation and expression in HCD. As both GRT treated groups did not differ significantly in glucose 
tolerance or insulin sensitivity compared to their untreated counterparts, this was also unexpected. In our 
previous study, it was found that 10 M aspalathin treatment could induce glucose uptake in isolated 
cardiomyocytes from insulin-sensitive rats, while the effect was lost in insulin-resistant rats without 
administering additional insulin (Smit et al., 2018). Given that HCD had elevated serum insulin levels compared 
to controls, it would appear that the presence of insulin is not the determining factor in eliciting GRT’s glucose 
uptake response, but rather downstream insulin signaling, such as GLUT4 translocation that is impaired. As a 
possible confounder, it has been shown before by Huisamen & Lochner (2005) that diabetic rats receiving 
exercise had increased cardiomyocyte glucose uptake and normative PKB activation compared to controls. If 
this is the case in our present study, it would point out the disparity between full body insulin resistance (as 
measured: Table 5.1) and cardiac insulin resistance, or alternatively call into question the sedentary lifestyles 
led by our animals, and their potential to be highly active at night (Borbély et al., 1975). 
- ISCHEMIA 
HCD significantly decreased myocardial PKB activation during ischemia compared to controls, whereas GRT 
had no statistically significant effect in reversing or improving these parameters (Figure 5.25, Table 5.4). 
Surprisingly, not much is known about the role of PKB during ischemia. By definition, ischemia and the absence 
of blood flow means no circulating insulin, and therefore no PKB signaling. It has been shown in the isolated 
perfused heart that ischemia inhibits PKB activation through the lowering of pH (Beauloye et al., 2001). 
Consequently, insulin-independent AMPK signaling becomes more important during ischemia (Section 6.5.2 
- Ischemia) (Qi & Young, 2015). 
- REPERFUSION 
Upon reperfusion, PKB activation results in various protective mechanisms sequestering or inactivating pro-
apoptotic proteins such as BAD, BAX and caspase 9 (Bertrand et al., 2008). In early reperfusion, hearts from 
rats on the HCD has significantly decreased PKB activity compared to controls (Figure 5.25A+B, Table 5.4), 
correlating with the poorer heart function and increased infarct size (Section 6.4.4-5). Similarly, it has 
previously been shown in our laboratories in an obese, insulin-resistant rat model, that 15 min of myocardial 
ischemia followed by 10 min of reperfusion resulted in significantly decreased PKB activation in comparison 
to hearts from control animals, also resulting in decreased cardioprotection (Salie et al., 2014). Furthermore, 
HCD animals had significantly elevated PKB expression, with GRT treatment resulting in even higher PKB 
expression (Figure 5.25C). The significance thereof remains unclear as these hearts did not have elevated 
PKB activation. All of the previous work showing Rooibos to stimulate PKB activation occurred in vitro in L6 
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myocytes (Son et al. 2013) and insulin-resistant C2C12 myocytes (Mazibuko et al. 2013). In vivo, isolated 
hearts from a control rat model pre-treated for 7-weeks with GRE, wereubjected to I/R-I in while PKB activation 
remained unchanged after 10 min of reperfusion - even though these hearts also had improved infarct size 
and heart function (Pantsi et al., 2011).  Even in the absence of PKB activation, due to a lack of upstream PI3K 
or insulin-stimulation, these hearts are still protected against subsequent stressors. In the present study we 
did not use insulin in our perfusates as insulin by itself was shown to be cardioprotective in I/R-I (Ji et al., 
2010). During late reperfusion, hearts from rats on the HCD had significantly decreased PKB expression 
(Figure 5.25C, Table 5.4), while GRT supplementation significantly decreased PKB activation in both controls 
and HCD (Figure 5.25B), implicating GRT in switching over metabolism to non-insulin dependent mechanisms 
in extended reperfusion.  
6.5.2 Insulin-Independent Signaling 
• AMPK  
AMPK is a protein serine/threonine kinase and the master energy regulator of cells operating independent of 
insulin-action. It senses the energy status of the cell and responds by restoring energy balance (Hue & Rider, 
2007). As a result, therapies are often aimed at activating AMPK in managing metabolic syndrome (and 
associated) diseases, which include anti-diabetic drugs, such as metformin (Hawley et al., 2002) and 
thiazolidinediones (LeBrasseur et al., 2006), insulin sensitizing adipokine therapies, such as adiponectin (Zhou 
et al., 2009), and exercise (Richter & Ruderman, 2009). The opposite is also true, in that decreased AMPK 
activity has been associated with increased prevalence of metabolic disorders in animals and humans (Xu, 
Valentine, et al., 2014). In the present study, prior to ischemia, HCD decreased myocardial AMPK activity 
compared to controls (Figure 5.26A, Table 5.4) in alignment with the increased metabolic stress experienced 
in this model. GRT supplementation increased myocardial AMPK expression in controls, but not in HCD 
(Figure 5.26B). Rooibos has been shown in previous studies to increase AMPK activation, including in vitro 
in insulin-resistant mouse C2C12 skeletal muscle cells (Mazibuko et al., 2013), and aspalathin treatment in L6 
myocytes and in mice fed aspalathin for 5 weeks (Son et al., 2013). In all three these instances, AMPK 
activation led to GLUT4 translocation, which resulted in glucose uptake. However, it has been shown by Muller 
and colleagues (2012) that aspalathin treatment only resulted in glucose uptake if GLUT4 was present in the 
cell line (C2C12 skeletal muscle cells vs Chang liver cells – a cell line absent of GLUT4). The inference is that 
for rooibos (aspalathin) to induce glucose uptake, altogether AMPK, AS160 and GLUT4 signaling need to be 
sensitized.  
- ISCHEMIA 
Normally, glycolysis only contributes about 5% of ATP production in a normal oxygenated heart (Abozguia et 
al., 2009). However, during ischemia, reduced oxygen delivery results in decreased ATP formation through 
oxidative phosphorylation (Rosano et al., 2008). This results in increased reliance on glycolysis to provide ATP 
production (Depre et al., 1999). During ischemia, AMPK activation is associated with increased glucose 
utilization and ATP production, which serves a critical role in preserving ionic gradients across membranes 
and preserving cell function and viability (Weiss & Hiltbrand, 1985). Glucose uptake by AMPK activation is a 
result of AS160 activation leading to GLUT4 translocation to cell membranes (Samovski et al., 2012). 
Additionally, AMPK upregulates glycolysis in myocardial ischemia through PFK-2 activation (an intermediate 
in the glycolysis pathway) increasing the glycolytic rate-limiting step, PFK-1 (Marsin et al., 2000). Conversely, 
AMPK also suppresses the activity of glycogen synthase, resulting in less glycogen synthesis during stress, 
Stellenbosch University  https://scholar.sun.ac.za
150 
    
and therefore more ATP conservation (Halse et al., 2003). Presently in ischemia, HCD significantly increased 
myocardial AMPK activity compared to hearts from control rats (Figure 5.26A+B, Table 5.4). Likewise, GRT 
supplementation also increased myocardial AMPK activation in control rats, without a significant effect in HCD 
rats. The exact mechanism how an increase in AMPK during ischemia resulted in cardiodamaging outcomes 
in the HCD model, but improved cardioprotection induced by GRT supplementation in controls is uncertain. 
Given that both PKB and AMPK activation did not result in increased glucose uptake, a dysfunctional GLUT4 
translocation or activation can be inferred or that downstream myocardial AMPK signaling is inhibited in the 
HCD animals. This may be at the level of GLUT4 translocation, which was not measured in the current study. 
Alternatively, the response of each model to the effect of acute vs prolonged ischemia needs to be considered. 
It has been found during moderate myocardial ischemia, sustaining glycolysis can be beneficial as maintaining 
ion gradients is potentially essential in optimal diastolic relaxation (Kusuoka & Marban, 1994). However, in 
sustained ischemia, should glucose oxidation not increase parallel to increased glycolysis, it results in 
accumulation of protons and lactate correlated with a poorer outcome in the heart (Vaughan-Jones et al., 
2009).  
- REPERFUSION 
In early reperfusion, GRT supplementation significantly increased myocardial AMPK activation in HCD rats 
(Figure 5.26A+B, Table 5.4). Accumulating research is implicating AMPK activation post-ischemia as a 
protective mechanism in reducing ischemic injury and reducing necrosis (Qi & Young, 2015). For instance, 
high dosages of metformin administration have been shown to activate cardiac AMPK through inhibition of 
mitochondrial complex I and thereby inhibition of mitochondrial ATP production (Hou et al., 2018). This results 
in a protective effect to ischemic damage in both normal and diabetic mice when administered prior to ischemia 
and at the onset of reperfusion (Calvert et al., 2008). This same effect has also been shown to protect against 
acute I/R-I and chronic rejection (a condition whereby antibodies injure the blood vessels and thereby restrict 
blood flow to the heart) following heart transplants in mice (Chin et al., 2011). In late reperfusion there were 
no differences in the specific AMPK activation between the 4 groups. However, HCD significantly decreased 
myocardial AMPK expression, while GRT supplementation increased the AMPK expression (Figure 5.26C, 
Table 5.4). Conversely, in controls, GRT supplementation decreased AMPK expression. The significance of 
difference in AMPK expression levels at this point is considered arbitrary as the initial cardiodamaging or 
protective effects in response to reperfusion had already been incurred. 
• AS160 
AS160 acts as a precursor to GLUT4 mediated glucose uptake into cells. AS160 is a GTPase-activating 
protein, which functions to inhibit the small GTP-binding proteins in control of key intracellular vesicle 
movement steps (Fukuda, 2011). As an insulin-independent mechanism, AMPK-induced activation of AS160 
removes the GAP inhibition on Rab GTPases triggering GLUT4 vesicle translocation to the cell membrane 
(Ishikura et al., 2007). In insulin-sensitive tissues, insulin binding to insulin receptor initiates signaling through 
PKB resulting in GLUT4 translocation and subsequent glucose uptake into the cell (Thorell et al., 1999). 
However, the activity level of intermediates in this signaling cascade, such as PKB, can remain normal under 
various conditions, including fasting (Vendelbo et al., 2012), obesity (Bandyopadhyay et al., 2005) and 
diabetes (Sakamoto & Holman, 2008), thereby implicating the importance of downstream signals relating to 
insulin action. AS160 is currently acknowledged as the most distal signaling step in insulin-mediated glucose 
transport (Consitt et al., 2013). Insulin stimulated activation of AS160 becomes impaired in insulin-resistant 
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conditions (Karlsson et al., 2005) and as a result decreases GLUT4 translocation and consequently decrease 
glucose uptake into cells. Sedentary aging decreases insulin-induced phosphorylation of AS160 in skeletal 
muscles - an effect that can be reversed with exercise training (Consitt et al., 2013). In the present study, pre- 
and during ischemia there were no significant differences in AS160 activation between hearts from controls 
and HCD rats (Figure 5.27B, Table 5.4). As the hearts from the HCD rats were more insulin resistant, we 
expected AS160 activity to also be lower at baseline compared to controls. However, this could be the effect 
of 30 min of insulin-free perfusion, and the levels could potentially have been different if these hearts were 
investigated for AS160 levels before perfusion. Pre-ischemia, GRT supplementation significantly increased 
AS160 expression in hearts from both control and HCD rats (Figure 5.27C) while decreasing AS160 activation 
in both (Figure 5.27B). Without AS160 activation, GLUT4 would also remain indifferent and no glucose 
clearance would take place. AS160 appears to be the primary signal that requires resensitization in order for 
GRT to have any beneficial effect on glucose uptake. To date, no other study has been done on the effect of 
GRT on the signaling of AS160. 
- ISCHEMIA 
In ischemia, GRT supplementation significantly increased the myocardial AS160 activation/expression ratio in 
controls but not in HCD (Figure 5.27A). As previously mentioned, GRT supplementation also improved 
myocardial AMPK activation in controls, while decreasing AMPK activation in HCD. Therefore, AS160 
activation is a direct consequence of an AMPK-dependent mechanism, which is not present during ischemia 
in HCD animals. It has been noted that FA-oxidation can be detrimental in ischemia when preferred over 
glucose-oxidation. In a study done by (Chang et al., 2012) they treated rats for 14 days with 100 mg/kg BW/day 
berberine (a compound present in European barberry) and subjected the isolated hearts to 30 min ischemia 
followed by 120 min of reperfusion. They found that the treatment significantly decreased AMPK activation in 
the ischemic areas of the heart while significantly increasing AMPK activation in the non-ischemic areas. 
Likewise, it is possible that GRT also resulted in improving myocardial AMPK activation resulting in AS160 
activation and higher glucose-oxidation within hearts from control rats and decreased myocardial AMPK 
activation resulting in decreased AS160 activation and decreased glucose oxidation in hearts from HCD rats 
at higher risk for infarct size generation. 
- REPERFUSION 
Upon reperfusion, hearts from HCD had significantly decreased AS160 activation/expression ratio compared 
to controls (Figure 5.27A), as a result of lower upstream myocardial PKB and AMPK activation - which would 
implicate lower glucose uptake and inversely, increased FA-oxidation (Section 6.6.3). Increased FA-oxidation 
rates early into reperfusion has been linked to severe cardiac dysfunction. In a study by Kudo and colleagues 
(1995) they found isolated rat hearts subjected to 30 min ischemia followed by 60 min reperfusion to have 
elevated FA-oxidation compared to pre-ischemia, but these hearts only had a 16% functional recovery. Thus, 
metabolic switching from glucose to FA into reperfusion can be detrimental to at risk heart tissue. Presently, 
GRT had no effect on AS160 expression or activation during late reperfusion (Figure 5.27B+C, Table 5.4).  
6.5.3 RISK 
• ERK 1 / 2  
The ERK cascade has been identified as a key player in cell proliferation, differentiation, adhesion, migration 
and survival (Buscà et al., 2016). Through proteomic screening, ERK has shown to phosphorylate at least 270 
substrates to date (von Kriegsheim et al., 2009). ERKs phosphorylate numerous transcription factors through 
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passive diffusion to the nucleus (Lenormand et al., 1993). The longer and the more pronounced ERK is 
activated, the more substrates are phosphorylated in turn at their respective docking sites (Murphy et al., 
2004). It is still unclear whether ERK1 and ERK2 have functional differences despite the determination of a 
vast amount of studies aimed at answering this question (Buscà et al., 2016). Given that ERK2 is more highly 
expressed than ERK1 in most mammalian cells (Frémin et al., 2015), it is important to consider the relative 
expression and activation level of both to interpret and compare data between studies (Buscà et al., 2016). 
Presently, the only difference in activation over expression ratio for either ERK1 or ERK2 between HCD and 
controls occurred 30 min into reperfusion, when HCD had significantly decreased ERK2 activation/expression 
ratio (Figure 5.28A, Table 5.5). It has been shown that increased ERK1/2 activation is correlated with 
increased cell function and survival following stress stimulation in a rat model of myocardial 
ischemia/reperfusion (Milano et al., 2007). In the present study, GRT had varying effects on both controls and 
HCD, indicating that separate mechanisms are at play in response to the different cellular signaling profiles 
induced by two different diets. During stabilization, GRT supplementation increased ERK1 and 2 expression 
in controls, but not HCD (Figure 5.28C, Figure 5.29C, Table 5.5). Bueno and colleagues (2000) showed that 
transgenic mice over-expressing activated MEK1 (an upstream activator of ERK), resulted in improved cardiac 
function and increased ERK1/2 protein levels, which was presumed to be a result of improved stability and 
reduced endogenous ERK degradation. These mice were also more resilient to ischemia/reperfusion induced 
apoptosis than control mice (Lips et al., 2004). Therefore, increased ERK expression during stabilization can 
be considered as a mechanism of preconditioning to subsequent ischemic insults.  
- ISCHEMIA 
At the end of a 20 min ischemic insult, GRT supplementation resulted in decreased ERK1 and 2 expression 
(Figure 5.28C, Figure 5.29C), and decreased ERK2 activation compared to HCD (Figure 5.29B, Table 5.5). 
However, when considering the relative ERK1/ERK2 ratio, GRT supplementation significantly increased 
activation in both control and HCD (Figure 5.30A) and increased the expression ratio in HCD (Figure 5.30B, 
Table 5.5). In a study done by Yang and colleagues (2011) they investigated the effect of 30 min myocardial 
ischemia on isolated rat hearts at two different temperatures. The authors found infarct size to be greatly 
reduced at 35°C (mean infarct size of 15.6%), which had consistently higher ERK activation compared to 
38.5°C (mean infarct size of 34.4%), reducing ERK activation. Therefore, ERK activation during ischemia 
rather than reperfusion was found to be a crucial indicator of cardioprotection. In contrast, but done in a 
separate organ system, another study performed by Lu and colleagues (2007) induced spinal cord ischemia 
for 5 min in rats before restoring blood flow. In control rats, ERK1 and 2 were activated, corresponding to the 
abundant microglial formation at the infarcted area and increased IL-1β expression. Whereas receiving 
MEK1/2 inhibitor, U0126, completely inhibited ERK1/2 activation, resulting in significantly lower microglial 
activation, IL-1β levels and improved neuronal survival and functional performance. Therefore, ERK1 and 2 
inhibition resulted in reduced inflammatory reactions and cytokine production, which can be beneficial to post 
ischemia-reperfusion injury.  
- REPERFUSION 
During early reperfusion, GRT supplementation significantly increased ERK2 activation in controls 
(Figure 5.29B), while decreasing ERK1 activation in HCD (Figure 5.28B, Table 5.5). Considering the above-
mentioned studies this could indicate a pro-survival response in controls and a more anti-inflammatory 
response in HCD. The ERK1/ERK2 activation were also significantly decreased by GRT supplementation in 
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both controls and HCD (Figure 5.30A) showing GRT’s identical response on ERK signaling albeit towards 
producing different cellular responses. In late reperfusion, GRT supplementation furthermore decreased ERK2 
expression and the ERK2 activation/expression ratio in HCD (Figure 5.29C+A) – indicating a reduction in 
stress and therefore ERK activation, while in controls also decreasing ERK1/2 expression but increasing ERK1 
activation and ERK2 activation/expression ratio – indicating a sustained pro-survival effect.  
6.5.4 Stress 
• JNK 1/2  
JNKs, or stress-activated protein kinase, form part of the death receptor-initiated extrinsic pathways, as well 
as the mitochondrial intrinsic apoptotic pathways. JNKs lead to apoptosis through upregulating pro-apoptotic 
genes via specific transcription factors or modulating mitochondrial pro- and anti-apoptotic proteins by kinase 
action (Dhanasekaran & Reddy, 2011). JNK1, and not JNK2, has been indicated as essential for tumor 
necrosis factor alpha (TNFα)-induced c-Jun kinase activation, c-Jun expression, and apoptosis (Liu et al., 
2004). TNFα activates JNK1, but not JNK2. However, JNK2 can still influence JNK1 activity through upstream 
kinases. JNK activation does not significantly increase during myocardial ischemia in human coronary artery 
bypass surgery (Talmor et al., 2000) however subsequent JNK activation significantly contributes to myocardial 
I/R-I in heart transplantations (Vassalli et al., 2012).  
- ISCHEMIA 
In the present study, we also found no significant changes JNK1 and JNK2 activation prior to reperfusion 
(Figure 5.31, Figure 5.32, Table 5.5). Interestingly, during stabilization, GRT supplementation increased JNK2 
expression in controls, but not HCD (Figure 5.32C). The meaning hereof is uncertain and could potentially just 
indicate the overall health of the cells or serve as a form of preconditioning – having the capacity to defend 
against potential increases in stress.  
- REPERFUSION 
In early reperfusion, HCD had significantly decreased JNK1 expression and activation, compared to controls 
(Figure 5.31B+C, Table 5.5). Concurringly, even though HCD increased JNK2 expression, it also significantly 
decreased JNK2 activation, resulting in a decrease of JNK2 activation/expression compared to controls 
(Figure 5.32A, Table 5.5). This is strange, as at face value this would infer that HCD had less inflammatory 
markers, such as TNFα, and less oxidative stress, through ROS, to stimulate JNK activation, and is also less 
prone to apoptosis. GRT supplementation, decreased JNK2 activation even further in HCD. However, during 
late reperfusion, HCD had significantly increased JNK1 and JNK2 activation levels (Figure 5.31B, 
Figure 5.32B) and increased JNK1 and JNK2 activation/expression compared to controls (Figure 5.31A, 
Figure 5.32A), indicative that the bulk of apoptosis would only occur later into reperfusion. Once again, GRT 
supplementation decreased JNK2 in this late stage (Figure 5.32B) and thereby potentially prevented more 
pro-apoptotic signaling. Taken together, it would appear as though HCD has a slower response to increasing 
stress brought upon by reperfusion compared to controls, and perhaps first need to express more JNK to 
meaningfully respond to the new stress stimulus. Considering that these hearts had worse function, it would 
also indicate a preoccupation with handling the new influx of stress, rather than focusing on maintaining 
functional parameters. Considering GRT in controls, during early reperfusion, JNK1 activation was significantly 
increased (Figure 5.31B). This was also the case for both JNK1 activation and activation/expression ratio in 
late reperfusion (Figure 5.31A, Figure 5.31B). This is difficult to explain given the prior argument that HCD 
delayed JNK expression and subsequent activation, whereas now, GRT resulted in elevated JNK activation – 
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given that these hearts performed mechanistically better, and had similar infarct sizes, I would argue that it’s 
not reflective of apoptosis per se, but rather reflects on the responsiveness of control animals’ susceptibility to 
treatment. JNK-dependent signaling results in ROS generation, mitochondrial dysfunction and cardiomyocyte 
apoptosis (Chambers et al., 2013). Higher ROS generation would result in a greater need for endogenous 
antioxidant systems to maintain a positive balance of antioxidants to oxidants – and vice versa. And since GRT 
is abundant in polyphenols, known for their strong antioxidant capacity, 6 weeks treatment could have instilled 
quite a reservoir of antioxidants in membranes of the myocardium. Therefore, JNK could potentially be 
activated by upstream signaling to counter the high amounts of antioxidants present in the myocardium.  
6.5.5 Inflammation 
• p38 MAPK  
p38 MAPKs are a class of serine/threonine protein kinases which relays extracellular stress signals to the cell 
nucleus and thereby induce adaptive intracellular responses. It can be thought of as an ‘emergency switch’ 
that results in activation of transcription factors, cytokines and surface receptors (Korb et al., 2006). p38 
activation is especially prominent step in chronic inflammation (Korb et al., 2006). Therefore, p38 inhibition is 
regarded as a promising target to manage inflammatory diseases. Furthermore, T2D is associated with 
hyperglycemia, chronic inflammation, and high plasma levels of FFAs, all capable of activating p38 (Liu & Cao, 
2009). This is also confirmed by our findings that p38 activation was significantly increased in HCD compared 
to controls prior to ischemia (Figure 5.33B), which also led to an increased p38 activation/expression ratio 
(Figure 5.33A, Table 5.6). This elevation in p38 activation in HCD could also be attenuated by GRT 
supplementation (Figure 5.33B+C) and would infer that GRT had an anti-inflammatory effect prior to ischemia. 
In a study by Ku and colleagues (2015), they showed that aspalathin and nothofagin treatment in both high-
glucose induced inflammation in human umbilical vein endothelial cells and mice suppressed ROS and NFB 
(a cytokine production signal and proinflammatory marker). Furthermore, it has been demonstrated that hearts 
from transgenic mice with a dominant-negative p38-alpha mutant were significantly protected from ischemia 
reperfusion injury and had smaller infarct size compared to controls (Lips et al., 2004). In another study done 
by Chai and colleagues (2008) rats were fasted overnight and hearts investigated for 30 min regional ischemia-
reperfusion injury with an insulin infusion starting 10 min prior to ischemia. Insulin had no cardioprotective 
effect by itself, however, when co-administered with a p38 inhibitor 10 min prior to ischemia or 5 min prior to 
reperfusion, a considerable decrease in infarct size was detected. Therefore, this inhibitory mechanism 
induced by GRT could potentially have been a form of preconditioning and thereby cardioprotective to 
subsequent I/R-I.  
- ISCHEMIA/REPERFUSION 
There were no differences between HCD and control p38 expression or activation during ischemia and early 
reperfusion, however upon later reperfusion, p38 expression was significantly decreased in HCD compared to 
controls (Figure 5.33C, Table 5.6). GRT supplementation in controls led to significant elevation in p38 
expression during ischemia (Figure 5.33C), and increased p38 activation in early reperfusion (Figure 5.33B), 
while also decreasing p38 expression in HCD during early reperfusion (Figure 5.33B). It has been shown that 
non-selective p38 activation through anisomycin prior to 25 min of global ischemia can precondition the rat 
heart against reperfusion injury (Lochner et al., 2003) while attenuation of p38 after extended reperfusion can 
be considered a prerequisite for improved recovery and reduced infarct size. However, these findings early 
into reperfusion are novel and as such hard to definitively explain the mechanism. Most studies on isolated rat 
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hearts subjected to 30 min ischemia and 30 min reperfusion only sampled protein signaling at the end of 
reperfusion, whereby significant left ventricular dysfunction, together with increased p38 and JNK activation 
was observed (Kumar et al., 2004; Milano et al., 2007). Furthermore, in a study by Surinkaew and colleagues 
(2013) using adult wistar rats subjected to 30 min regional ischemia followed by 120 min reperfusion, they 
found that p38 inhibition before or during ischemia was beneficial, however when given at the onset of 
reperfusion, hearts presented with decreased ventricular tachycardia/ventricular fibrillation and increased heat 
shock protein 27 activation. Therefore, timing of p38 inhibition and relative activation prior to ischemia is 
essential to confer cardioprotection. However, from the findings of the current study, it is still uncertain what 
the role of p38 activation is prior to ischemia. 
6.5.6 Autophagy 
• LC3 
LC3 (microtubule-associated protein 1 light chain 3) is a mediator in the autophagic process. The formation of 
the autophagosome is initiated by PI3K, Beclin 1 and two ubiquitin-like conjugation systems resulting in Atg5-
12 and LC3 formation (Yang & Klionsky, 2010). Once LC3 is converted from its cytoplasmic form, LC3-I (18 
kDa), to the autophagosome-bound form, LC3-II (16 kDa), autophagy is activated (Walczak et al., 2017). 
Therefore, the LC3-II/LC3-I ratio is considered an important indicator of autophagy (Kadowaki & Karim, 2009). 
During autophagy, injured protein and organelles are enzymatically digested to supply energy and provide 
substrates for repairing organelles important in cell homeostasis (Yang & Klionsky, 2010). However, excessive 
autophagy can also induce irreversible cell atrophy resulting in autophagic cell death, or by inducing apoptosis 
and necrosis (Maiuri et al., 2007). Autophagy have been shown to be upregulated in response to I/R-I (Dai et 
al., 2017), however the degree of upregulation and timing of autophagy remains a mystery. In the present 
study HCD had more LC3-I and II during stabilization compared to controls (Figure 5.34B+C, Table 5.6) 
indicating higher levels of autophagy. Furthermore, GRT supplementation increased autophagic flux in 
controls, but not in HCD (Figure 5.34A) – potentially because autophagy had already been upregulated.  
- ISCHEMIA 
Ischemia presented with the lowest autophagy activity in all 4 groups, with both HCD and GRT supplemented 
controls also experiencing a significant decrease from baseline autophagy levels (Figure 5.34A, Table 5.6). It 
has been shown in rabbit hearts exposed to 20 min of ischemia that autophagy remained fairly dormant, as 
though the cell was in a hibernative state (Decker & Wildenthal, 1980). 
- REPERFUSION 
Early into reperfusion, HCD had upregulated LC3-I and II and compared to controls (Figure 5.34B+C). GRT 
supplementation further increased autophagy in HCD, while suppressing autophagy in controls 
(Figure 5.34A). As reperfusion progressed, HCD had decreased LC3-II content compared to controls 
(Figure 5.34B). GRT supplementation also reduced autophagy in controls, but not in HCD – as these groups 
already had lowered autophagy (Figure 5.34B). In all 4 groups autophagy was gradually increased and peaked 
at the end of reperfusion – with HCD having an initial burst during early reperfusion, but then slowing down 
upregulation of autophagy (Figure 5.34A). Continueing with the rabbit study described above, autophagy was 
shown to be extensively upregulated following reperfusion, with a certain subgroup also showing signs of 
necrotic damage (Decker & Wildenthal, 1980). Furthermore, severe stress, such as prolonged I/R-I can result 
in excessive and long-term autophagic upregulation which results in cell death and digestion of essential 
organelles and proteins (Gustafsson & Gottlieb, 2009). Given the functional and infarct cardioprotection 
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conferred by GRT in this study, the pattern of gradually increasing autophagy seems most beneficial to 
preserving cell integrity, whereas sudden increases in autophagy can become detrimental – as was found in 
the HCD groups. GRT has not been investigated for its role in autophagy before. However, one of its 
polyphenols, quercetin has shown to extensively induce autophagy and promote cell death in cancer cells 
through inhibition of proteasomal activity and mTOR signaling (Klappan et al., 2012). Furthermore, various 
other polyphenols, such as resveratrol, catechin, silibinin and curcumin (Hasima & Ozpolat, 2014; Pallauf & 
Rimbach, 2013) have shown to regulate autophagy through Beclin-1 dependent and independent pathways, 
and could implicate GRT to have similar action. These observations warrant further elucidation.  
6.5.7 Auxiliary Metabolic Regulation 
• GSK3β 
GSK3β plays a key role in deactivating glycogen synthase (resulting in lower blood glucose utilization), gene 
regulation (inducing apoptosis) (Meares & Jope, 2007) and GSK3β inactivation significantly inhibits the mPTP 
opening in response to increases of ROS and calcium overload (Ghaderi et al., 2017b). It is distributed 
throughout the cell, and once activated, translocates from the cytoplasm to the cellular membrane or 
mitochondria (Bijur & Jope, 2003). It can be deactivated (inhibited) through phosphorylation by various pro-
survival pathways, including p38, PI3K and AMPK (Ghaderi et al., 2017b), making it a central but complex role 
player in cell survival (Mnatsakanyan et al., 2017). GSK3β expression and phosphorylation has been shown 
to be upregulated in skeletal muscle of T2D (Nikoulina et al., 2000) and in adipose tissue of obese diabetic 
mice (Eldar-Finkelman et al., 1999). This tendency was observed in our present study, as pre-ischemia HCD 
elevated the GSK3β phosphorylation/expression ratio compared to controls (Figure 5.35A, Table 5.6), 
whereas GRT supplementation in HCD reduced GSK3β activation and expression (Figure 5.35B+C). To date, 
no other study has investigated the effect of GRT or its polyphenols on GSK3β signaling. There was however 
one unrelated study that reported rutin to have a pro-apoptotic effect in adherent leukemic cells which was 
correlated with a decrease in GSK3β phosphorylation (Bourogaa et al., 2011). 
- ISCHEMIA/REPERFUSION 
From ischemia, HCD had significantly less GSK3β activation (and therefore less inhibition) compared to 
controls, persisting until early reperfusion (up to 3 times less GSK3β phosphorylation), and only reached similar 
levels to controls towards the end of reperfusion (Figure 5.35A+B, Table 5.6). The determinant role of GSK3β 
inhibition is to suppress the mPTP opening post ischemia. Most research indicate that GSK3β inhibition leads 
to inhibition of apoptosis and thereby reduce the damage caused by myocardial I/R-I (Huisamen & Lochner, 
2010). For instance, in a study done by Wagner and colleagues (2010) open chest rats subjected to a 30 min 
regional ischemia protocol and receiving post-conditioning by three 30 s cycles of reperfusion and occlusion 
at the start of reperfusion had significantly smaller infarct size and 2.3 times higher phosphorylation of GSK3β 
than controls. However, in another study done by Skyschally and colleagues (2008), performing an 
ischemia/reperfusion protocol on pigs, by subjecting them to 90 min of regional ischemia, followed by 120 min 
of reperfusion, a group receiving 6 cycles of 20/20 sec reperfusion/occlusion upon reperfusion presented with 
the greatest reduction infarct size without any correlating with GSK3β phosphorylation levels post-ischemia. 
These discrepancies point to the complex role of GSK3β in ischemia/reperfusion and how apparently animal 
and model specific its signaling can be. Given that HCD had less GSK3β activation compared to controls at a 
time when it was more critical, yet had worse functional recovery and infarct size, it would more strongly 
indicate the importance of GSK3β inhibition upon reperfusion. Also, during late reperfusion, GRT significantly 
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increased GSK3β expression, albeit having no difference in GSK3β activation (Figure 5.35B+C, Table 5.6). 
This is in accordance with our argument, that GSK3β inhibition upon reperfusion is a significant determinant 
of heart resilience to potential cardiac events, which would lift the inhibition on AMPK (Suzuki et al., 2013) and 
consequently increase AS160 and GLUT4 translocation improving glucose clearance.  
• ATM 
ATM kinase is considered one of the master regulators of signaling networks, with over 490 substrates 
(Matsuoka et al., 2007). ATM is activated in response to oxidative stress, hypoxia and insulin, giving rise to 
ATM-dependent activation of autophagy through AMPK (Li, Luo, et al., 2017) or insulin-stimulated PKB 
activation leading to AS160 phosphorylation and subsequent glucose uptake (Viniegra et al., 2005). These are 
but a few of the mechanisms of importance to choosing ATM as a potential signal to investigate in elucidating 
GRT action. In the present study, there were no significant differences in ATM expression or activation prior 
to ischemia between either of the 4 groups (Figure 5.36).  
- ISCHEMIA 
During ischemia, ATM activation was significantly increased in HCD compared to controls (Figure 5.36B, 
Table 5.6), resulting in insulin-independent mechanism preference (AMPK activation) above insulin-
dependence (PKB inactivation), albeit without resulting in elevated autophagy or AS160 activation. GRT 
supplementation increased ATM activation in controls, but not in HCD – potentially due to the elevated 
mitochondrial OxPhos resulting in increased ROS production. This mechanism did however also result in 
increased AMPK activation and AS160 activation, potentially increasing glucose utilization during ischemia (as 
described in Section 6.5.2). It has been shown previously in our labs that ATM inhibitors given to HCD animals 
just prior to 30 min ischemia resulted in improved cardiac function 5 min into reperfusion, but the 
cardioprotection was lost after 10 min of reperfusion (Espach, 2017). It was also shown that ATM inhibition 
attenuated downstream insulin-signaling, but PKB activation could still be stimulated in the presence of insulin 
alone.  
- REPERFUSION 
Both during early and late reperfusion, HCD decreased ATM activation compared to controls (Figure 5.36B). 
ATM downregulation in HCD also resulted in decreased PKB and AMPK activation and ultimately a decreased 
AS160 activation, inferring that these hearts were significantly less dependent on glucose metabolism during 
reperfusion. This is also in line with our findings on HCD hearts having upregulated β-oxidation preference 
(discussed in Section 6.6.3). Given that autophagy was upregulated in these hearts as evidenced by increased 
LC3-II:-I ratio yet absent of increased AMPK, would furthermore implicate an AMPK-independent mechanism 
of autophagy at work. GRT supplementation in controls also led to decreased ATM expression and ATM 
activation (Figure 5.36B+C) in both early and late reperfusion, which culminated in less PKB activation and 
less autophagy during late reperfusion (mechanism unknown but ATM-dependent). Since these hearts 
performed functionally better and had better resilience to infarct size development we propose a mechanism 
as described by Xie and colleagues (2015): Acute and excessive ROS production has shown to activate ATM 
which promotes cardiomyocyte apoptosis, whereas treatment with antioxidant agents can significantly inhibit 
ATM activation and attenuate cardiomyocyte apoptosis and contractile dysfunction (Yoshida et al., 2009). 
Therefore, GRT could potentially have deterred both autophagic and apoptotic cell death through strong 
antioxidant action alleviating increased ROS-induced cell damage. Surprisingly, we found that throughout all 
the perfusion time points investigated, GRT supplementation had no effect on ATM expression or activation in 
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HCD animals - although it has been shown previously in a study done by Espach (2017) that drugs aimed at 
activating or inhibiting ATM in HCD hearts had no effect on ATM expression or activation. It remains unclear 
why ATM signaling is so difficult to manipulate in a pre-diabetic rat heart.  
6.6 MITOCHONDRIAL FUNCTION AND MITOPHAGY IN GLOBAL ISCHEMIA -
REPERFUSION INJURY 
Obesity is known to increase myocardial infarction susceptibility and worsen the outcome following an ischemic 
event (Zhu et al., 2014). This has also been verified in numerous animal models (Andres et al., 2016; Kamau, 
2018; Kleindienst et al., 2016). It is still unknown whether mitochondrial dysfunction is the reason for metabolic 
impairment or the result thereof, however it is certain that there’s an association in various tissues including 
pancreas, liver, skeletal muscle and adipose tissue (Bhatti et al., 2017). Dysfunctional mitochondria are a 
common feature in metabolic diseases implicating impairment of mitochondrial quality control, which entail 
dysregulation of fission, fusion, mitophagy and mitochondrial biogenesis (Gottlieb & Thomas, 2017).  
 
Our last aim was to determine the effect of 6 weeks of GRT treatment on potential myocardial mitochondrial 
dysfunction parameters induced by both a 16-week HCD and a 20 min global ischemia reperfusion protocol. 
Sub-sarcolemmal mitochondria were isolated and polarographically evaluated for respiration and ADP 
conversion to ATP through the activity of the ETC chain in the presence of glutamate (as a carbohydrate-rich 
substrate) or palmitate (as a FA-rich substrate) to determine OxPhos substrate preference and efficiency, 
before subjecting the isolated samples to an additional 20 min anoxia reoxygenation protocol to assess 
mitochondrial dysfunction and OxPhos recovery. Furthermore, we focused on the role of mitophagy which 
plays a critical role in degrading and recycling dysfunctional mitochondria to restore energy homeostasis. As 
discussed in Section 2.3.2, mitophagy occurs through either Parkin-dependent or independent pathways, and 
proceed by first recognizing damaged mitochondria, and then inducing autophagy (Ding & Yin, 2012). 
Following the loss of Δψm, PINK1 accumulates on the damaged mitochondria, promoting Parkin activation 
which then ubiquinates p62, the link between damaged mitochondria and LC3-II attached to the expanding 
phagophore - destined to engulf the mitochondria and fuse with a lysosome for degradation (Song et al., 2015). 
Independent of parkin, BNIP3L located on the outer membrane of mitochondria can also link to LC3-II to initiate 
the same aforementioned degradation (Novak et al., 2010).  
6.6.1 Stabilization 
OxPhos plays an important role in the supply of energy for the continuously contracting myocardium (Gnaiger, 
2014). As the severity of metabolic disorders such as T2D and obesity increase, the capacity of mitochondria 
to retain normal functioning also decline (Bhatti et al., 2017). During stabilization, OxPhos rates were not 
significantly different between HCD and controls (Figure 5.39, Figure 5.41, Table 5.7), even though HCD had 
worse heart function compared to controls. Previously in our laboratory it was found that hearts from obese 
rats  harvested at baseline (prior to perfusion) and after stabilization on the perfusion rig, did not present with 
significantly different OxPhos rates compared to controls (Nduhirabandi, 2014) even with varying function. 
Furthermore, it has been shown in early obese and insulin-resistant humans that these conditions do not 
always present with mitochondrial dysfunction (Samocha-Bonet et al., 2012). HCD did however show improved 
OxPhos rate 3 efficiency in a FA compared to carbohydrate medium (Figure 5.39, Figure 5.41). It has been 
shown in previous studies that high-sucrose diet fed rats presented with significantly elevated β-oxidation prior 
to ischemia which also resulted in poorer heart recovery post-ischemia (Gonsolin et al., 2007). However, this 
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phenomenon can be a double-edged sword. Firstly, increased FA OxPhos as a result of high circulating FA 
present in conditions such as obesity and diabetes increases oxidative stress and mitochondrial alterations 
and functions, including mitochondrial uncoupling which increases the risk for the mPTP opening and ultimate 
cell death (Rial et al., 2010). Paradoxically, activating uncoupling proteins are often therapeutic targets in 
obesity and diabetes as they also result in reducing the accumulation of FA in the mitochondria and ultimately 
attenuate FA-oxidation (Busiello et al., 2015). As the HCD heart had worse contractile function pre-ischemia, 
we propose the former: that β-oxidation prior to ischemia results in worse cardiac outcome. The initial signals, 
PINK1 or BNIP3L accumulation on the outer membrane of damaged mitochondria initiates the first step in 
responding to stress. In the present study after 30 min of stabilizing hearts on a perfusion rig and isolating 
mitochondria, there were no significant differences in PINK1 levels between either of the 4 groups 
(Figure 5.45, Table 5.11), while HCD animals presented with increased Parkin levels (Figure 5.46). It has 
been shown in PINK1-deficient mice that Parkin can be recruited to damaged mitochondria in the absence of 
PINK1 (Kubli et al., 2015). As LC3-II levels remained the same between the 4 groups (Figure 5.49) it could be 
possible that Parkin-activation was the initial step or priming of the HCD mitochondria to subsequent 
degradation to follow. Additionally, HCD also had significantly reduced mitochondrial BNIP3L levels (Figure 
5.48), pointing towards Parkin being a more preferred method to induce degradation during low-stress. GRT 
supplementation in both controls and HCD rats resulted in increased mitochondrial uncoupling (evidenced by 
a decrease in ADP/O ratio) in the glutamate medium, and also in GRT treated controls in the FA medium. 
Mitochondrial OxPhos is not perfectly coupled to ATP synthesis as part of the energy liberated from the 
oxidation of energy substrates is lost as both heat and proton reuptake in to the matrix, called proton leak 
(Mookerjee et al., 2010). This is postulated to account for up to 30% of the resting metabolic rate and can be 
induced through inducing mitochondrial uncoupling. This can be protective in conditions favouring ROS 
production, including obesity and diabetes (Busiello et al., 2015). Furthermore, GRT supplementation resulted 
in a decrease in Parkin, p62 and BNIP3L in mitochondria from control rats while having no effect in HCD 
(Figure 5.46, Figure 5.47, Figure 5.48), implicating these hearts to be the least prone to mitophagy during 
this time point. The discrepancies seen here in the mitophagy signaling confirms the similar OxPhos rates 
noted and also indicates that, during stabilization, no significant mitochondrial dysfunction is present in HCD 
hearts. Following an anoxic insult, mitochondria from HCD rats had improved %RR in a carbohydrate medium 
and poorer %RR in a FA medium compared to controls, while GRT supplementation improved %RR in the FA 
medium (Figure 5.44). Interestingly, it was shown before that mitochondria obtained from T2D patient hearts 
presented with impairments in both FA substrate (palmitoyl-L-carnitine) and carbohydrate substrate 
(glutamate) respiration, together with less endogenous antioxidant (glutathione) and increased ROS 
production (greater H2O2 emission release) (Anderson et al., 2009). Epidemiological studies have revealed a 
direct link between high dietary polyphenol intake and ameliorated cellular damage as a consequence of 
improved radical scavenging and combatting dysfunctional free radical producing enzymes (Hussain et al., 
2016; Losada-Barreiro & Bravo-Díaz, 2017; Pandey & Rizvi, 2009). Rooibos is known to have radical 
scavenging properties therefore GRT may also be beneficial in maintaining oxidative homeostasis during 
mitochondrial OxPhos. In previous studies, fermented and unfermented rooibos infusions given to rats for 10 
weeks, with hydroperoxide induced oxidative stress in the final 2 weeks, showed restoration of liver antioxidant 
capacity without negatively impacting lipid peroxidation or liver enzymes (Canda et al., 2014). It is therefore 
possible in the present study that GRT played a role in attenuating ROS-induced damage in anoxia-
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compromised mitochondria. Also, of interest, this 20 min anoxia period used in investigating mitochondrial 
functional recovery proved to be more robust at inducing mitochondrial dysfunction than the global ischemia 
protocol discussed in the next section – which once again shows the discrepancies between investigating 
mitochondria in isolation compared to its in vivo environment.  
6.6.2 Ischemia 
When coronary arteries are occluded for 15-20 sec, anaerobic glycolysis takes over metabolism as the only 
available supplier of new high-energy phosphates (Frank et al., 2012). This is good enough to take care of all 
basic cardiomyocyte energy demands. However, as ischemia is extended to 5 min and beyond, all reserve 
energy phosphates are depleted and the heart undergoes a phenomenon called rigor-contracture (heart 
shivering) (Stowe, 1999). Due to the high quantity of mitochondria in cardiomyocytes, the heart is extremely 
susceptible to hypoxic and ischemic conditions (Ghaderi et al., 2017b). Mitochondria is essential in reactive 
oxygen homeostasis (Bratic & Trifunovic, 2010) and contains various ATP-dependent antioxidant defences 
which are necessary as it can produce up to 12 different types of ROS released as by-products in the ETC - 
and scavenge additional ROS originating from the extramitochondrial environment (Mailloux, 2018). In 
response to time-dependent ischemia, cardiac tissue is primed for reperfusion injury which induces free radical 
release from the mitochondria (Eltzschig & Eckle, 2011). In the present study, after 20 min of global ischemia, 
there were no difference in OxPhos rates between mitochondria isolated from hearts of control rats compared 
to HCD in either of the mediums (Table 5.8). However, mitochondria from the HCD diet rats did show elevated 
OxPhos S4 in FA compared to carbohydrate medium (Figure 5.41), potentially showing higher oxygen 
consumption without elevated ATP production, further implicating uncoupling and poorer OxPhos potential. It 
has been shown that increased cardiac FA oxidation is particularly prevalent in conditions such as ischemic 
heart disease and T2D, while simultaneously impairing glucose oxidation (Fillmore et al., 2014). All the more, 
GRT supplementation in HCD also showed increased mitochondrial preference for FA-oxidation compared to 
carbohydrates (Figure 5.39, Figure 5.41). Given the possibility that GRT can scavenge against ROS-induced 
damage, increased OxPhos can potentially be sustained without causing adverse cell damage. For instance, 
in a study performed on primary leukemia cells it has been shown that upregulated OxPhos can produce anti-
oxidant measures independent of upregulated ROS (Khan et al., 2016). Therefore, it is plausible that 
supplementation with GRT increases residual antioxidant capacity capable of ameliorating high OxPhos cell 
damage. This argument is also strengthened by the upregulation of OxPhos S3 witnessed in GRT 
supplementation of control rats in mitochondria incubated in both FA and carbohydrate mediums but not in 
HCD (Figure 5.39), which could indicate a potential ceiling effect reached in the mitochondria from the HCD 
rats. The upregulated OxPhos rates in a carbohydrate medium in GRT treated controls is also in line with the 
findings that AS160 was upregulated during ischemia, thereby implying increased glucose oxidation rates. 
Curiously, GRT supplementation in controls significantly increased mitophagy through upregulation of 
mitochondrial PINK1, p62 and BNIP3L levels (potentially removing defective mitochondria, thereby decreasing 
ROS production and enabling nominal OxPhos rates to continue), while having no effect in HCD – which were 
arguably already elevated (Figure 5.45, Figure 5.47, Figure 5.48, Table 5.11). Myocardial mitochondria from 
HCD rats had significantly elevated PINK1, similar Parkin and p62 levels, and decreased LC3-II levels 
compared to controls (Figure 5.45 - 5.47). Furthermore, p62 levels were significantly elevated in all groups 
(except GRT treated HCD) compared to pre-ischemia (Figure 5.48). From these findings it is evident that 
mitophagy is upregulated in both HCD and after treatment with GRT. Clearance of defective mitochondria is 
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essential to preserve optimal function in heart cells, as the failure to do so will result in additive oxidative 
damage brought upon by ROS-producing mitochondria (Gottlieb et al., 2011), and recall that even phagophore 
formation, essential in mitophagy, is an ATP-dependent process (Abounit et al., 2012). This is also in 
accordance with the OxPhos rates described during ischemia, as both HCD and GRT treatment in controls 
resulted in elevated OxPhos levels – for better or worse, as persistent higher levels of OxPhos is also related 
to higher ROS-by-products (Zhang et al., 2017). Therefore, mitochondrial ROS production and detoxification 
is tightly balanced. When glucose-stimulated ROS production is not matched by glucose-stimulated ROS 
scavenging systems, a toxic cycle ensues leading to cell death (Liemburg-Apers et al., 2015). It has been 
shown in hyperglycemia-induced human umbilical vein endothelial cells that treatment with rooibos extracts 
resulted in increased catalase and SOD activity, which dose-dependently reduced intracellular ROS 
(Waisundara & Hoon, 2015). This substantiates the argument that GRT may also act as ROS scavenger. 
Furthermore, high glucose treatment in cardiac H9c2 cells caused downregulation of Prkag1 (a gene coding 
for AMPK and involved in mitophagy (Ross et al., 2016)) which could be reversed by aspalathin treatment 
(Johnson et al., 2017). Thus, increasing mitochondrial OxPhos without the capacity to effectively scavenge 
added ROS and a growing decline in substrate availability induced by ischemia would potentially start to trigger 
cell death mechanisms in HCD. 
 Early Reperfusion 
Upon reperfusion, mitochondrial OxPhos return to pre-ischemic levels within seconds, while contraction is still 
lagging, known as myocardial stunning (Kloner & Jennings, 2001). Stunned myocardium has more oxygen 
supply than the slow rate of contraction requires, and therefore decreased mechanical efficiency (Frank et al., 
2012). Early into cardiac reperfusion, both mitochondrial ROS production and increased Ca2+ concentrations 
in the matrix result in the mPTP opening, resulting in a major loss of nucleotides and the release of pro-
apoptotic factors, such as cytochrome c (Di Lisa et al., 2003) into the cytoplasm, upregulating apoptosis and 
further aggravating I/R-I (Zhou, Prather, et al., 2018). Oxidative damage is also induced to the mitochondrial 
respiratory chain, mitochondrial metabolic enzymes and mitochondrial membrane structure resulting in more 
free radical production (Zorov et al., 2014). The fate of cardiomyocytes is dictated by the amount of oxidative 
damage induced, particularly to mitochondria (Kurian et al., 2016). Presently, in early reperfusion, mitochondria 
from HCD still presented with significantly elevated OxPhos rates in a FA medium and showed a preference 
for palmitate over glutamate in respiration (Figure 5.38-41, Table 5.9), which is characteristic of T2D and 
ischemic heart disease as described during ischemia. Alternatively, it has also been shown that high-fat diet-
induced insulin resistant and obese mice presented  with improved mitochondrial OxPhos (Gupte et al., 2013). 
These mice, showing similar high circulating FA as present in our HCD rats (Appendix A8, Table A3) also 
showed improved insulin sensitivity in cardiac tissue, even though systemic insulin resistance was established. 
As discussed under insulin-dependent PKB signaling (Section 6.5.1) it is possible, that in the present study 
our animals also presented with insulin-sensitive cardiac tissue, even while presenting with systemic insulin 
resistance (Section 6.3.2). Considering that JNK1/2 activation was initially downregulated in early reperfusion 
(Section 6.5.4) GRT supplementation in HCD downregulated OxPhos in both mediums but retained greater 
OxPhos efficiency in palmitate compared to glutamate. This is also in line with the elevated AMPK levels 
induced by GRT supplementation in HCD during early reperfusion (Section 6.5.2). AMPK has been shown to 
accelerate FA-oxidation with the degree of activation dependent on the duration of ischemia (Zordoky et al., 
2014). GRT had no significant effect on OxPhos in controls during early reperfusion, potentially because 
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OxPhos was not dysfunctional in controls. In early reperfusion, Parkin was significantly elevated in all groups 
compared to pre-reperfusion (Figure 5.46, Table 5.11), while untreated and treated HCD animals also 
presented with increased LC3-II levels compared to control counterparts (Figure 5.49). PINK1 and p62 
remained similar between all 4 groups. Taken together this would indicate an elevation in mitophagy during 
early reperfusion, with the highest levels recorded in both the treated and untreated HCD animals. This could 
potentially indicate higher oxidative stress from dysfunctional mitochondria in need of recycling in accordance 
with I/R-I induced ROS (Zorov et al., 2014). Interestingly, both untreated HCD and GRT supplemented controls 
(the two groups described during ischemia to have elevated mitophagy) presented with markedly reduced p62 
levels compared to the end of ischemia, signifying an initial downregulation of mitophagy at the onset of 
reperfusion. GRT supplementation in HCD also led to a significant increase in Parkin levels, furthermore 
implicating preference of Parkin-dependent mitophagy in early reperfusion, as opposed to BNIP3L, which 
showed no significance. 
6.6.3 Late Reperfusion 
In late reperfusion, diet had no significant effect on OxPhos as there were no differences between HCD and 
controls (Table 5.10). HCD hearts retained greater OxPhos effiency (elevated coupling) in palmitate compared 
to glutamate (Figure 5.37). Furthermore, at this late stage, GRT supplementation only had a significant effect 
in controls which resulted in decreased OxPhos rates and RCI in both mediums throughout the protocol, which 
could potentially infer that cellular homeostasis was restored in this GRT treated group first, followed by 
controls.  
 
Towards late reperfusion, mitochondria from HCD rats also had significantly increased p62 levels compared 
to controls, while p62 and BNIP3L levels was still higher compared to pre-ischemia. It has been shown in a 
control mouse model that 45 min ischemia followed by 0 – 24 h of reperfusion led to progressive increases in 
FUNDC1 (an alternative mitophagy pathway), correlating with infarct size,  till at least 3h post reperfusion 
(Zhou et al., 2018). Therefore, it could also be inferred that following 30 min of reperfusion, the amount of 
damage incurred would still be increasing and the role of mitophagy as a whole remains essential – albeit 
varying in specificity for which autophagy pathway. Parkin and BNIP3L was significantly reduced towards late 
reperfusion in controls while GRT supplementation further decreased Parkin, BNIP3L and p62 levels. The 
severe reduction in mitophagy in these animals and the low infarct size, together with better functional recovery 
all point to the increased robustness of these hearts to endure a 20 min global ischemic insult. Inversely, this 
also point to the heightened susceptibility of insulin-resistant obese rats to I/R-I damage and subsequent 
mitochondrial dysfunction during late reperfusion. Mitochondria-bound LC3-II, used as steady state mitophagy 
indicator, also remained significantly elevated in GRT supplemented HCD since ischemia. 
6.7 SUMMARY OF FINDINGS 
• Insulin-resistant model 
Young control rats administered a high-caloric diet for 16 weeks compared to a normal rat chow diet presented 
with in an average 24% higher daily food intake and 37% lower water intake, resulting in 8% higher body 
weight, 69% higher visceral fat, 10% increased fasting blood glucose, 44% higher fasting blood insulin and 
elevated blood lipids – and collectively deemed pre-diabetic. This manifested in a 15% poorer heart function 
when stabilized, and a 26% poorer heart function after a 20 min ischemic period, and 14% poorer heart 
recovery compared to controls indicating cardiac dysfunction. In response to a 35-min regional ischemia, 60 
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min reperfusion protocol the hearts from pre-diabetic rats also had a 113% greater infarct size (meaning a 
more than doubling in non-viable heart tissue) showing a severe lack of cardioprotection. Furthermore, 
mitochondria isolated from pre-diabetic hearts did not yet show mitochondrial dysfunction but did show 
elevated OxPhos in a FA medium compared to a carbohydrate medium, showing a greater reliance on β-
oxidation. Prior to ischemia (Figure 6.1), these hearts showed a decreased dependence on insulin-
independent AMPK, had increased inflammation through upregulated p38, and presented with an increase in 
mitophagy through Parkin (less reliant on BNIP3) and autophagy through LC3 signaling. Following 20 min of 
ischemia (Figure 6.2), mitochondrial dysfunction was still not present, but the elevated β-oxidation rates 
remained. Insulin-independent AMPK was upregulated together with ATM while insulin-dependent PKB was 
downregulated together with GSK3β phosphorylation. Mitophagy was also upregulated through PINK1 and 
p62, but autophagy in general was low as LC3 remained low, plausibly because mitophagy is an energy-
dependent process and substrates needed for efficient mitophagy are not abundant in ischemia. Upon 
reperfusion (Figure 6.3), nearly all protective signals were downregulated including AMPK, PKB, AS160, 
GSK3β and ATM. Mitophagy was also highly upregulated via increased Parkin, p62 and LC3. Surprisingly, 
these hearts had a greater mitochondrial OxPhos capacity early into reperfusion – which would implicate either 
efficient mitophagy or elevated ischemia-induced stress. The reasoning for improved mitophagy relates to 
maintaining the energy demand required to combat I/R-I induction of ROS and Ca2+ influx (which would all be 
aimed at destroying the Δψm) through upregulating antioxidant systems and efficiently restoring ion channel 
activity (possibly due to high substrate availability in energy-rich foods and high sustained activity levels 
(Menshikova et al., 2006)). To the contrary, higher stress induced by ischemia requires more energy intensive 
OxPhos resulting in substrate exhaustion and subsequent ROS production, which could trigger not only the 
increased mitophagy levels witnessed, but also result in cell death (as seen from the increased infarct size). It 
was shown towards late reperfusion that hearts from pre-diabetic rats had lower ERK1/2 activation, and 
therefore less protection against prolonged reperfusion damage, while also retaining elevated β-oxidation. 
However, mitochondrial dysfunction seemed to improve towards late reperfusion as there was no significant 
difference in OxPhos potential between mitochondria from HCD and controls.  
• GRT in insulin-resistant model 
Administration of potentially cardioprotective, “hypoglycemic”, antioxidant-rich GRT treatment for 6 weeks to 
rats at risk for developing pre-diabetes (10 weeks of HCD at commencement of GRT treatment, followed by 
an additional 6 weeks of HCD), resulted in no change in biometric parameters (e.g. equal daily food and water 
intake compared to HCD, no difference in body weight or visceral fat, no difference in fasting blood glucose or 
insulin levels). However, isolated hearts had a 10 bpm lower heart rate and 12% improved heart function when 
stabilized, a 23% better heart function after a 20 min ischemic period, implicating GRT as a potent cardiotonic. 
Furthermore, in response to a 35-min regional ischemia, 60 min reperfusion protocol the hearts from pre-
diabetic rats also had a 62% reduction in infarct size (meaning half the non-viable heart tissue compared to 
the untreated pre-diabetic rats), implicating GRT as a potent cardioprotective agent. Prior to ischemia 
(Figure 6.1), these hearts showed a decreased dependence on insulin-dependent PKB together with 
decreased glucose uptake through AS160 (which also corrolated with a higher mitochondrial uncoupling and 
preference for OxPhos in FA compared to glucose) and presented with decreased GSK3β inhibition but had 
decreased inflammation evident by downregulated p38, confirming GRT’s previously reported anti-
inflammatory effects. No significant effects on mitophagy were recorded prior to reperfusion. After 20 min of 
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ischemia (Figure 6.2), insulin-independent AMPK was downregulated together with ERK1/2 signaling and 
autophagy through downregulated LC3. Once reperfusion was initiated (Figure 6.3), insulin-independent 
AMPK and mitophagy through Parkin was upregulated, while the stress markers JNK1/2 and inflammatory 
markers p38 was significantly decreased, further showing GRT’s effect on reducing oxidative stress and 
inflammation. Surprisingly also ERK1/2 and LC3 were decreased compared to the HCD. OxPhos prior to 
reperfusion remained similar to HCD, however upon reperfusion OxPhos was significantly reduced in GRT 
treated rats, while a preference for FA was still maintained over carbohydrates. Towards late reperfusion 
insulin-dependent PKB signaling was also attenuated.  
• GRT in insulin-sensitive model 
Administration of potentially cardioprotective, “hypoglycemic”, antioxidant-rich GRT treatment for 6 weeks to  
control rats (10 weeks of standard rat chow at commencement of GRT treatment, followed by an additional 6 
weeks of standard rat chow), resulted in no change in biometric parameters (e.g. equal daily food and water 
intake compared to HCD, no difference in body weight or visceral fat, no difference in fasting blood glucose or 
insulin levels). However, isolated hearts had a 9 bpm lower heart rate and 10% improved heart function when 
stabilized, a 7% better heart function after a 20 min ischemic period, implicating GRT as a cardiotonic even in 
rats absent of CVD. However, in response to a 35-min regional ischemia, 60 min reperfusion protocol the 
hearts from GRT treated control rats presented with no additional infarct size reduction, potentially indicating 
that control rats absent of CVD are already optimally protected. Prior to ischemia (Figure 6.1), these hearts 
showed an increase in both insulin-dependent PKB and insulin-independent AMPK signaling but presented 
with decreased glucose uptake through AS160 (and elevated mitochondrial uncoupling resulting in reduced 
metabolic rate) – potentially explaining why GRT treatment did not have a hypoglycemic effect.  GRT 
supplemented controls presented with elevated ERK1/2 activation, which can be considered preconditioning 
against I/R-I, however in the present study it did not confer additional cardioprotection. GRT treatment in 
controls resulted in a potential upregulation in mitophagy as evidenced by an observed increase in 
mitochondria-bound LC3. However, since all the specific mitophagy proteins investigated were downregulated 
(BNIP3L, Parkin, p62) this would indicate either an AMPK-dependent or additional unknown mechanism. After 
20 min of ischemia (Figure 6.2), insulin-independent AMPK was upregulated together with AS160 (potentially 
indicating an increase in glucose oxidation during ischemia which could be beneficial in maintaining cell 
housekeeping and ATP production). This allowed mitophagy to remain upregulated as increased PINK1, p62 
and BNIP3L was also found. However, LC3-II remained extremely low in both GRT treated and untreated 
controls compared to HCD counterparts, thereby implicating a reduction in, albeit more efficient mitophagy. 
Once reperfusion was initiated (Figure 6.3), ATM and ATM-dependent PKB activation were both 
downregulated, whereas pro-survival signals such as ERK1/2 was upregulated, however stress signals, 
JNK1/2 and inflammatory markers, p38 were also upregulated which is an opposite profile as was seen in the 
GRT treated pre-diabetic rats.  For JNK1/2 it is argued that the presence of antioxidants conferred by the GRT 
treatment resulted in an elevated propensity to deal with stress-induced damage, and even though these 
hearts presented with high stress, it is more indicative of the stress-response signaling than the subsequent 
damage to be incurred. Regarding the p38, a marker of inflammation, we pose that since p38 had been 
upregulated since stabilization, GRT was able to act as a preconditioning agent against subsequent 
inflammatory-induced damage, and thereby still be cardiotonic, as was seen from increased heart function, 
and cardioprotective, as seen from no additional infarct size increases. GRT supplemented controls did not 
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show significant difference in mitochondrial function, arguably because control rats did not have dysfunctional 
mitochondria induced by a 20 min global ischemia insults. The known mitophagy markers investigated, 
BNIP3L, Parkin and p62 were all downregulated, even though LC3-II was once again upregulated pointing to 
a separate mechanism of mitophagy being retained in late reperfusion. 
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Figure 6.1 Cardioprotective signaling during stabilization. Effect of: HCD (red arrow); GRT in control (green arrow); GRT in HCD (blue arrow).   
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Figure 6.2 Cardioprotective signaling during ischemia. Effect of: HCD (red arrow); GRT in control (green arrow); GRT in HCD (blue arrow).   
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
168 
    
 
Figure 6.3 Cardioprotective signaling during reperfusion. Effect of: HCD (red arrow); GRT in control (green arrow); GRT in HCD (blue arrow).  
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6.8 STUDY LIMITATIONS 
The rats used in the study were housed in a controlled environment without exposure to toxins, environmental 
hazards, and related factors that would further exacerbate obesity and insulin resistance in humans (Murea et 
al., 2012).  We also recognize using male only rats is a limitation to extrapolation of the results. For the 
purposes of the research question it was decided not to double the sample size, cost and effort required in 
using female subjects with potential confounding endocrine function on CVD progression (Rice et al., 2014).  
 
As described in Section 4.3.2.3. in the current study, a rat age of 22 weeks equates to approximately 13 
human years and is therefore not yet fully-grown. This does not consider the development of cellular ageing 
of the rat being studied potentially resulting in decreased scientific validity. In most studies, rodents under the 
age of 20 weeks are often used to limit cost of maintenance and allow data comparability with a historical 
database of rodent studies (Jackson et al., 2017). Therefore, the use of older animals may be beneficial and 
would increase scientific rigour accelerating translation of therapies to humans. However, since obesity and 
its comorbidities are becoming a growing concern especially in younger children (Section 1.3.4.1.) it remains 
important to investigate the therapeutic reversibility of early risk factors.  
 
It has been shown that performing identical protocols on different species result in significantly different 
outcomes, as demonstrated in isolated heart perfusions from rabbits, hamsters, ferrets, gerbils, rats, mice and 
guinea pigs (Galinanes & Hearse, 1990). Furthermore, different strains of the same species have also been 
shown to have significantly different outcomes in response to I/R-I (Barnabei et al., 2010) which can be a 
serious experimental limitation and need to be considered. 
 
In the past, mitochondrial oxidative capacity used to be a measure of the maximal mitochondrial enzyme 
activities (Lanza & Nair, 2009). This approach assumed that the activity or expression of one enzyme 
accurately reflects the overall function of the mitochondrion and could thus be indicative of OxPhos. 
Nevertheless, it led to the development of a technique to measure oxygen consumption in isolated 
mitochondria and was first established 60 years ago (Chance & Williams, 1956). Different substrates were 
used to measure mitochondrial function in response to different energy states, favouring electron flow through 
specific mitochondrial complexes and coupling oxygen consumption to ATP production (Lanza & Nair, 2009). 
The limitations of this technique include exposure of mitochondria to non-physiological conditions, such that:  
• isolated mitochondria in vitro are subject to oxygen levels way above physiological oxygen 
concentrations in vivo.  
• substrate and ADP concentrations are also added in saturating quantities which far exceed its inherent 
microcellular environment (Lanza & Nair, 2009).  
Nevertheless, isolating mitochondria allowed for detailed OxPhos capacity determination without confounding 
factors such as blood flow, oxygen and substrate delivery or mitochondrial density volume (Lanza & Nair, 
2009). 
 
There is an ongoing debate regarding the probability of observed direct antioxidant activities in vivo, since 
supra-physiological concentrations (100–400 μM) of polyphenols were often used in vitro tests determining 
their antioxidant properties (Goszcz et al., 2015). Furthermore, the low bioavailability (~1 μM) of phenolic 
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compounds seriously questions their ability to engage in direct antioxidant potential in the in vivo scenario.  
Presently, we did not measure antioxidant capacity in the blood and only inferred that some of the 
cardioprotective effects observed is plausibly due to antioxidant effects of GRT. Furthermore, an argument 
has been put forth that the antioxidant activity of polyphenols could be irrelevant to their protective effects – to 
the contrast it is reasoned to be due to their toxic effect which upregulate endogenous antioxidant systems 
properties (Goszcz et al., 2015). This analogy can be thought of in the same manner as how bouts of exercise 
preconditions the body to handle subsequent exercise ‘insults’ (van Vilsteren et al., 2005). To verify either an 
elevated anti- or pro-oxidant state, blood samples would need to be analysed for TBARS, total and reduced 
glutathione (GSH + GSSG), glutathione peroxidase activity and SOD, as well as urine samples analysed for 
ascorbic and uric acid.  
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CHAPTER 7 
CONCLUSION AND FUTURE RESEARCH 
 
Ancient wisdom withstanding the test of time:  
Hippocrates asserted in ~400 BC: “Let food be thy medicine and medicine be thy food.”  
Ezekiel’s vision in ~580 BC on heavenly trees: “Their fruit will be for food, and their leaves for healing.”   
 
Therefore, it is up to modern day researchers and physicians to figure out the dosing, duration of treatment 
and contra-indications when used in conjunction with other medications.  
 
In the present study we aimed to answer three questions: 
1. What is the effect of 6-weeks of high-dose Afriplex GRT treatment on heart function pre- and post-ischemia 
in a pre-diabetic Wistar rat model? 
In establishing our pre-diabetic model, we found that 16 weeks of high-caloric diet feeding resulted in significant 
increases in body weight, body fat, elevated fasting serum triglycerides, glucose and insulin levels, worse 
glucose tolerance and elevated HOMA-IR - inferring insulin resistance. Furthermore, the elevated risk for CVD 
imposed on these rats also resulted in increased heart mass, worse heart function and recovery post-ischemia, 
and increased infarct sizes. Without significantly affecting any of the biometric parameters, GRT treatment for 
6 weeks improved heart function pre- and post-ischemia, improved heart recovery post-ischemia and 
significantly reduced infarct size. Furthermore, GRT treatment lowered heart rate pre-ischemia, while 
improving cardiac contractility, showing additional cardiotonic properties. 
 
2. How does this relate to cardioprotection following an ischemic event? 
Mechanistically, we found that GRT treatment pre-conditioned the pre-diabetic hearts to I/R-I by inhibition of 
GSK3β, sustaining anti-inflammatory (↓p38 activation), and switched metabolism to insulin-independent (↓PKB 
activation) and glucose-independent (↓AS160 activation) mechanisms. Early into reperfusion, GRT’s anti-
inflammatory effect was still evident (↓p38 and ERK1/2 activation), while also improving resilience to oxidative 
stress (↓JNK activation) and favouring insulin-independent mechanism (↑AMPK and ↓PKB activation).  
 
3. How does GRT treatment effect mitochondrial function in I/R-I? 
In the present study, pre-diabetic hearts did not present with significant mitochondrial dysfunction prior to 
reperfusion, but  retained greater reliance on β-oxidation, indicative of FA accumulation in the heart and an 
independent indicator for poorer cardiac recovery post ischemia (Fillmore et al., 2014). These hearts also had 
elevated mitophagy through a Parkin mediated mechanism (and less reliant on BNIP3L) and autophagy 
through LC3 signaling. GRT treatment did not significantly alter the preference for β-oxidation, but did result in 
mitochondrial uncoupling, leading to a reduction in OxPhos, thereby reducing basal metabolic rate – and 
ultimately less ROS production (Mookerjee et al., 2010). GRT did not significantly alter mitophagy prior to 
reperfusion. Early into reperfusion, pre-diabetic rats presented with elevated OxPhos, increasing ROS 
production and plausibly one of the greatest contributors to the cell death that caused the severely increased 
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infarct size. GRT treatment was able to inhibit OxPhos, thereby preventing additional ROS-induced cell death, 
and reducing infarct size. Mitophagy was also highly upregulated via increased Parkin, p62 and LC3. 
 
Surprisingly in the present study, GRT did not have a hypoglycemic effect, neither played a role in resensitizing 
insulin signaling. One limitation to this regard was addressed, in that previous studies showed a dose-specific 
hypoglycemic effect that could only be sustained for 6 hours maximum and dissipated with increasing dosages 
of GRE (Muller et al., 2012). This could mean the high-aspalathin content in the present daily GRT extract 
supplemented could have potentially overwhelmed the pancreas, or insulin-sensitive tissues and transport 
mechanisms and thereby nullify the beneficial hypoglycemic effects. To test this hypothesis, future studies 
would need to use varying daily dosages ranging from 10-60 mg GRT/kg BW to potentially investigate this 
claim. Furthermore, GRE has presented with strong α-glucosidase inhibitory effects leading to reduced blood 
glucose elevations after a meal (Miller et al., 2018). This mechanism of managing hyperglycemia would 
encourage multiple GRT dosages (or dissolving the GRT in water) to be administered throughout the day in 
hyperphagia high-caloric-induced pre-diabetic rats. 
 
Second only to revascularization, ischemic preconditioning remains the most effective cardioprotective 
intervention to reduce I/R-I (Cohen & Downey, 2015). Currently, in patients with coronary occlusion and acute 
myocardial infarction, the coronary artery is opened and the damaged ischemic myocardium reperfused. It is 
important to understand why cardioprotective agents has mostly failed to provide the theoretical relief for I/R-I 
and become an effective therapy. A multi-target hypothesis has been suggested by (Rossello & Yellon, 2018). 
Future research should not solely focus on improving the potency of RISK pathway kinases, but also study the 
compounding effect of combination therapies to maximize cellular survival. 
 
Making sense of the mitophagy results in the present study posed to be quite challenging. For the interpretation 
of results to be sensible there must be certain trends that can be appreciated. If, however, one sees various 
up and down phenomenas at play regardless of how these hearts were perfused before isolation of 
mitochondria it readily implicates mitochondrial dynamics as more complex than initially realized. Mitochondria 
are independent organelles with one goal in mind: produce energy through OxPhos. To maintain a favourable 
work environment, it can undergo structural changes, mitophagy, fission, fusion and biogenesis. Thus, at any 
given time a ‘colony’ of mitochondria can be in either of these states depending on the need for energy 
production and the need for cell survival. To reach more certainty on the cellular mechanisms involved during 
different pathological states one would need to investigate all these phenomena together – as aiming at simply 
one could result in tunnel vision, and worse: being stuck in the tunnel while the train is approaching. To clarify, 
the train is the investigative need to understand signalling dynamics; the tunnel is using either a sniper or a 
shotgun to investigate signalling phenomena. It is recommended that one rather use surveillance and 
exhaustively follow the flux of each protein at multiple time points following the onset of reperfusion. 
Regardless, this study has improved our understanding of the complexity of mitochondrial dynamics in I/R-I in 
response to both high-caloric diets and phytochemical therapy.  
 
  
Stellenbosch University  https://scholar.sun.ac.za
173 
    
In conclusion, I will sign off with my answer to the question: What did I learn from doing this study? 
 
Firstly, excessive sugar intake is bad for the heart (as inferred by the nutritional make-up of the current diet 
used to induce pre-diabetes). Not only does it result in declining function and poor recovery after an ischemic 
event, it can also cause irreversible damage to the heart (the shear magnitude of infarcted tissue present 
following an ischemic event). This necessitates the need to exercise self-control when considering and 
partaking in overindulgence of sweet treats. The human body is an amazing machine, and it will serve you well 
initially. But when ignorance continuously wins the battle against symptomatic gluttony, and sound wisdom 
such as everything in moderation is downplayed, a harsh reality of primary medication dependence, and 
secondary side-effects awaits.  
 
Secondly, rooibos has a future in primary health care. The reasoning is as follow: rooibos can be a harsh plant 
to cultivate evident from its preference to only grow in its indigenous scorched earth climate. Somehow this 
results in unique polyphenols capable of scavenging stress and inflammation (primarily to the benefit of the 
rooibos plant itself). This resistance can be transferred when rooibos phytochemicals are consumed in 
adequate concentrations which makes it especially beneficial to alleviate stress induced by our modern 
lifestyles. In the present study we have shown the cardioprotective benefit of high rooibos intake, through a 
commercial product called Afriplex GRT, which aids in bridging the gap between the pre-diabetic heart and a 
normal healthy heart. Surprisingly, rooibos also lowered resting heart - a proven favourable indicator of 
cardiovascular health. This is on par with cardio-exercise which is arguably the best cardiopreserving therapy. 
Even though exercise raises heart rate initially, its benefit is a result of lowering resting heart rate and thereby 
lowering the overall strain placed on the heart in the long run. Moreover, the one trait that all centenarians 
have in common is a well-preserved heart molded by a peaceful life. Therefore, rooibos is not only beneficial 
to protect the heart against impending cardiac risk, but also confers a soothing or calming effect which is 
synonymous with longevity. As the findings in this study has only been confirmed in a pre-diabetic rat model, 
it remains to be determined what the potential benefits of Afriplex GRT will be in humans. However, as a 
personal inference in the meantime, if you had to snack on something… feel free to make it a cup of rooibos. 
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A1) TRANSMISSION AND 3D SCANNING ELECTRON MICROSCOPY OF MITOCHONDRIA IN CARDIOMYOPATHY PATIENT 
 
Figure A1 Scanning electron micrographs showing cardiac mitochondrial colonies (1), shapes and sizes (2), irregular shapes (3) and huge 
fused mitochondria (4). From Kanzaki et al. (2010).
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A2) MITOCHONDRIA ONLY PRESENT IN OOCYTE POST FERTILIZATION 
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A3) AFRIPLEX GREEN ROOIBOS EXTRACT COMPOSITIONAL ANALYSIS 
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A4) STANDARD RAT CHOW DIET COMPOSITION 
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A5) HIGH-CALORIC DIET COMPOSITION 
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A6) WESTERN BLOT WORK FLOW AND NORMALIZATION 
 
 
Figure A3 Western blotting work-flow and normalization. C1: 30 min stabilized control. Lanes 
1 and 2: 30 min young control stabilized; Lanes 3 and 4: C1; Lanes 5 – 9: Control samples; Lanes 
10 – 14: Control + GRT samples; Lanes 15-19: HCD samples; Lanes 20-24: HCD + GRT samples.
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A7) SUMMARY OF MITOCHONDRIAL FUNCTIONAL PARAMETERS IN GLUTAMATE AND PALMITATE 
Table A1 Summary of mitochondrial functional parameters in glutamate and palmitate 







CONTROL+GRT HCD HCD+GRT CONTROL CONTROL+GRT HCD HCD+GRT 
MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  
ADP/O 
Ratio 
S 2.53±0.08  2.17±0.11 (*) ↓ 2.33±0.12  1.97±0.13 (p=0.066) ↓ 
2.76±0.01  2.37±0.05 (***) ↓ 2.58±0.10  2.47±0.13  
I 2.29±0.14  2.33±0.11  2.45±0.07  2.08±0.11  2.65±0.09  2.61±0.09  2.78±0.26  2.46±0.07 (p=0.065)  
ER 2.61±0.20  2.36±0.06 
  
2.41±0.06  2.32±0.05  2.73±0.09  2.90±0.17  2.89±0.23  3.05±0.09 ()  
LR 2.53±0.15  2.51±0.09 
  




S 297.05±38.14  291.69±25.95  248.28±42.51  277.34±19.18  313.35±13.09  358.92±12.71 (*) ↑ 
341.21±40.39  300.17±30.5  




243.54±27.88  245.96±26.73  318.09±5 (p=0.053) ↑ 
299.76±13.65  309.65±16.6  
ER 344.98±25.52  331.69±32.08  392.34±10.44  275.61±37.77 (*) ↓ 
368.84±10.77  332.43±19.7  446.68±26.38 (*) ↑ 
297.88±26.53 
(**) ↓ 
LR 305.2±19.03  227.09±14.49 
(*) ↓ 
239.86±41.91  198.77±24.39  314.9±6.51  259.76±6.34 (***) ↓ 







  64.53±8.99 (*) ↓ 59.97±2.65  88.8±4.04 
 
81.23±2.7  89.38±11.59  66.67±2.76 ↓ 
I 
46.31±5.19 
 69.51±5.36 (*) 
 ↑ 64.44±3.64 (*) ↑ 61.93±5.34  65.76±4.98 
 





















  62.19±10.13  63.11±4.3  76.45±4.3 
 




S 255.55±41.43  329.59±27.05  278.34±36.14  341.11±40.51  419.64±22.56 
() 
 447.65±8.24  274.1±44 (*) ↓ 392.13±17.28 (p=0.053) ↑ 
I 200.52±33.7  314.7±26.3 (*) ↑ 311.04±31.57 (*) ↑ 
290.24±34.22  263.71±54.28  351.38±24.87  372.89±20.83  288.58±56.1  
ER 370.92±26.63  367.22±41.69  396.25±26.27  298.89±43.83  399.15±32.34  372.33±26.46  468.71±9.81 (p=0.098)  
352.65±26.72 
(**) ↓ 
LR 383.46±35.35  277.88±26.39 
(*) ↓ 
298.6±41.07  272.72±27.87  416.2±9.56  356.74±5.42 (**) ↓ 
369.11±49.77  362.97±29.17  
S: Stabilization; I: Ischemia; ER: Early Reperfusion; LR: Late Reperfusion; HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance 
compared to Control, HCD significance compared to Control, HCD + GRT significance compared to HCD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Table A2 Summary of mitochondrial functional parameters in glutamate and palmitate (Continued) 







CONTROL+GRT HCD HCD+GRT CONTROL CONTROL+GRT HCD HCD+GRT 
MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  MEAN±SEM  
%Respiratory 
Recovery 




126.16±19.14  133.45±2.06 
() 
 125.17±2.72  89.14±21.44 (*) ↓ 
134.67±10.32 
(*) ↑ 
I 108.72±5.45  112.08±5.9  113.93±3.58  120.21±8.27  100.2±12.02  110.71±8.42  124.36±5.16  114.63±7.15  
ER 107.87±3.2  110.35±4.8 
  
100.87±5.41  108.08±4.16  116.73±2.7  112.21±5.98  106.47±6.77  119.15±3.21  
LR 125.5±8.54  121.98±6.28 
  
132.05±20.52  139.1±7.17  132.23±2.2  137.63±3.11  148.62±9.72  137.62±5.37  
RCI 
S 3.17±0.25  3.47±0.26 
  
3.93±0.71  4.62±0.26  3.55±0.19  4.46±0.28 (*) ↑ 3.84±0.16  4.53±0.47  
I 3.9±0.26  4.09±0.28 
  
4.21±0.26  3.94±0.33  3.72±0.21  3.69±0.25  3.94±0.12  3.87±0.32  
ER 4.71±0.26  4.84±0.65 
  
5.06±0.29  4.46±0.6  4.24±0.15  3.95±0.22  4.21±0.23  3.95±0.42  
LR 5.05±0.45  3.84±0.34 
(p=0.065) ↓ 




S 659.17±130.65  586.83±72.7 
  
579.11±106.35  542.43±43.67  758.4±92.18  774.06±78.77 ↑ 879.23±101.5 
() 
 739.55±76.02  
I 355±37.38  653.83±58.72 
(**) ↑ 
523.16±83.35  441.14±38.77  578.04±106.03  830.26±36.8 (p=0.075) ↑ 
780.28±97.22  724.49±41.41 
() 
 
ER 894.89±85.29  781.07±74.34  943.19±28.14  641.21±92.55 (*) ↓ 
1007.01±51.39  953.78±44.92  1276.93±70.55 
() (*) 
↑ 913.69±92.23 (*) ↓ 
LR 760.98±24.93  635.21±79.29  511.31±73.96 (*) ↓ 
446.09±63.35  853.09±38.38  717.37±47.61 (p=0.059) ↓ 








117.6±7.29  211.31±25.73  184.18±13.59  230.25±29.53 
() 
 163.9±8.02  
I 112.19±10.48  163.28±18.76 
(p=0.053) ↑ 






ER 197.63±31.44  169.41±21.9  189.11±12.17  147.76±16.14 (p=0.078) ↓ 









141.4±22.77  207.62±16.25  221.91±10.18  196.57±32.9  183.94±19.98  
S: Stabilization; I: Ischemia; ER: Early Reperfusion; LR: Late Reperfusion; HCD: High-caloric diet, GRT: Afriplex green rooibos extract; Control + GRT significance 
compared to Control, HCD significance compared to Control, HCD + GRT significance compared to HCD; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ⧫p<0.05 
(Palmitate vs Glutamate in Control), p<0.05 (Palmitate vs Glutamate in HCD), p<0.05 (Palmitate vs Glutamate in HCD + GRT) 
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A8) UNDISCLOSED TOTAL LIPID FATTY ACID CONTENT 
Table A3 Fasting Serum Total Lipid Fatty Acid Content  
Chemical Name Common Name Control 
(n = 8) 
Control + GRT 
(n = 8) 
HCD 
(n = 8) 
HCD + GRT 
(n = 8) 
Monounsaturated fatty acids (MUFAs) 
n-7 Series 
C16:1 n-7 PTA Palmitoleic acid 1.927±0.273 1.974±0.333    1.99±0.253    3.221±0.646  
C18:1 n-7 VA Vaccenic acid 2.45±0.161 2.767±0.133    2.35±0.162    3.375±0.341 (*) ↑ 
n-9 Series 
C18:1 n-9 OA Oleic acid 12.158±1.133 10.623±0.451    18.725±0.513 (***) ↑   19.196±0.251  
C20:1 n-9 GA Gadoleic acid 0.236±0.011 0.269±0.022    0.264±0.015    0.299±0.027  
C22:1 n-9 EA Erucic acid 0.003±0.003 0.028±0.011    0.027±0.007 (*) ↑   0.023±0.005  
C24:1 n-9 NA Nervonic acid 0.282±0.017 0.276±0.034    0.25±0.018    0.204±0.018  
  111111111111111 111111111111111 111 111111111111111 111 111111111111111 111 
Polyunsaturated fatty acids (PUFAs) 
n-3 Series 
C18:3 n-3 ALA Alpha-linolenic acid 0.957±0.076 1.197±0.14    0.583±0.042 (***) ↓   0.654±0.067  
C20:3 n-3 ETA Eicosatrienoic acid 0.017±0.008 0.027±0.008    0.026±0.006    0.025±0.006  
C20:5 n-3 EPA Eicosapentaenoic acid 2.612±0.521 4.31±0.455 (*) ↑   1.873±0.121    2.133±0.161  
C22:5 n-3 DPA Docosapentaenoic acid 1.187±0.1 1.923±0.137 (***) ↑   1.227±0.067    1.393±0.123  
C22:6 n-3 DHA Docosahexaenoic acid 3.464±0.354 4.605±0.159 (*) ↑   4.182±0.214    4.312±0.303  
n-6 Series 
C18:2 n-6 LA Linoleic acid 22.06±1.105 22.734±0.507    17.829±0.498 (**) ↓   16.288±0.577  
C18:3 n-6 GLA Gamma linolenic acid 0.634±0.029 0.322±0.016 (****) ↓   0.288±0.012 (***) ↓   0.277±0.017  
C20:2 n-6 EDA Eicosadienoic acid 0.313±0.021 0.297±0.007    0.206±0.01 (***) ↓   0.203±0.013  
C20:3 n-6 DGLA Dihomo-gamma-linolenic acid 0.718±0.051 0.73±0.024    1.101±0.057 (***) ↑   1.121±0.045  
C20:4 n-6 AA Arachidonic acid 16.607±0.655 17.077±1.079    12.194±0.748 (***) ↓   10.441±0.671  
C22:2 n-6 DDA Docosadienoic acid 0±0 0.01±0.01    0.013±0.013    0±0  
C22:4 n-6 ADA Adrenic acid 0.254±0.05 0.201±0.008    0.207±0.012    0.188±0.013  
C22:5 n-6 DPA Docosapentaenoic acid 0.109±0.018 0.098±0.03    0.142±0.011    0.109±0.012  
         
Saturated fatty acid 
         
C12:0 LA Lauric acid 0.024±0.007 0.022±0.007    1.355±0.258 (***) ↑   1.319±0.097  
C14:0 MA Myristic acid 0±0 0.722±0.126 (***) ↑   2.403±0.287 (***) ↑   3.09±0.258  
C16:0 PA Palmitic acid 20.382±0.571 17.899±0.386 (**) ↓   19.899±0.165    19.685±0.452  
C17:0 HAD Heptadecanoic acid 0.583±0.039 0.564±0.017    0.346±0.022 (***) ↓   0.365±0.023  
C18:0 SA Stearic acid 12.279±0.455 10.666±0.45 (*) ↓   11.83±0.191    11.466±0.144  
C20:0 ARA Arachidic acid 0.168±0.009 0.167±0.021    0.187±0.018    0.198±0.009  
C22:0 BA Behenic acid 0.168±0.011 0.148±0.01    0.176±0.007    0.146±0.008 (*) ↓ 
C24:0 LGA Lignoceric acid 0.407±0.022 0.342±0.028    0.326±0.013 (**) ↓   0.27±0.018 (*) ↓ 
           
Calculations 
        
Total Saturated Fatty Acids 34.011±0.937 30.53±0.48 (**) ↓   36.522±0.543 (*) ↑   36.54±0.405  
Total n-7-MUFA 4.378±0.425 4.742±0.449    4.339±0.392    6.596±0.984  
Total n-9-MUFA 12.68±1.122 11.196±0.459    19.265±0.51 (***) ↑   19.721±0.257  
Total Monounsaturated Fatty Acids 17.058±1.51 15.938±0.842    23.605±0.801 (**) ↑   26.317±1.034  
Total Polyunsaturated Fatty Acids 48.932±1.797 53.532±0.982 (*) ↑   39.873±1.163 (***) ↓   37.143±1.131  
Total n-6-PUFA 40.695±1.159 41.47±1.403    31.981±1.241 (***) ↓   28.626±1.108  
Total n-3-PUFA 8.237±0.956 12.062±0.809 (**) ↑   7.892±0.366    8.517±0.602  
PUFA/SFA Ratio 1.451±0.077 1.758±0.05 (**)    1.096±0.047 ↓   1.018±0.036  
Total n-6/Total n-3 Ratio 5.355±0.565 3.61±0.385 (*) ↓   4.139±0.319 ↓   3.491±0.294  
GLA:LA 0.029±0.002 0.014±0.001 (***) ↓   0.016±0.001 (***) ↓   0.017±0.002  
DGLA:GLA 1.13±0.054 2.278±0.052 (***) ↑   3.926±0.381 (***) ↑   4.111±0.174  
DGLA:LA 0.034±0.004 0.032±0.002    0.062±0.003 (***) ↑   0.07±0.005  
AA:DGLA 23.838±1.691 23.488±1.551    11.193±0.734 (***) ↓   9.505±0.835  
AA:LA 0.766±0.046 0.75±0.043    0.68±0.025    0.639±0.029  
n-6DPA:DHA 0.036±0.008 0.022±0.008    0.035±0.004    0.026±0.002  
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